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Total Synthesis of Aflastatin A 
Abstract 
 The syntheses of aflastatin A (1) and its C3–C48 degradation fragment (2) are 
described. The syntheses feature several complex diastereoselective fragment couplings, 
including a C35–C36 anti-Felkin-selective boron-mediated oxygenated aldol reaction, a C15–
C16 Felkin-selective trityl-catalyzed Mukaiyama aldol reaction, and a C26–C27 chelate-
controlled aldol reaction involving soft enolization with magnesium. 
 Careful comparison of the spectroscopic data for the synthetic aflastatin A C3–C48 
degradation fragment (2) to that reported by the isolation group revealed a structural 
misassignment in the lactol region of the naturally derived degradation product. The cause of 
the mismatch was initially believed to be stereochemical in origin. Ultimately, the data 
reported for the naturally derived aflastatin A C3–C48 degradation lactol (2, R = H) was 
attributed to its derivative lactol trideuteriomethyl ether (R = CD3). 
 Further, the absolute configurations of six stereogenic centers (C8, C9 and C28–C31) 
in aflastatin A (1) were formally revised by the isolation group prior to completion of its total 
synthesis. The synthesis of the aflastatin A C3–C48 lactol trideuteriomethyl ether and its 
spectroscopic match to the naturally derived C3–C48 degradation fragment confirm the 
stereochemical revision. 
 The synthesis of a degradation product containing the tetramic acid and two 
overlapping stereocenters (C4 and C6) was also achieved. Its spectroscopic match to the 
corresponding naturally derived degradation fragment verified the absolute configuration of 
 iv 
the aflastatin A C5' stereocenter. When combined with previous degradation fragment 
syntheses, and eventually the total synthesis of aflastatin A, the revised stereochemical 
assignment of aflastatin A was fully affirmed. 
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Chapter 
1 
Introduction to Aflastatin A 
I. Aflatoxins 
The aflatoxins represent a group of mycotoxins produced by fungi of the Aspergillus 
genus (Figure 1.1).1 Aflatoxins produced by strains of A. flavus and A. parasiticus regularly 
contaminate food and feedstock derived from infected corn, cotton, grain and peanut crops.2 
Contamination of agricultural commodities is problematic because aflatoxins exhibit potent 
toxicity and carcinogenicity in mammals.3 Limiting the amount of aflatoxin that enters our 
food supply is important for protecting human and animal health while minimizing economic 
loss.4 As an example, aflatoxin levels are regulated within the United States by the Food and 
Drug Administration (FDA), and must not exceed 20 parts-per-billion in food destined for 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(1)  Goldblatt, L., Ed. Aflatoxin, Scientific Background, Control, and Implications; Academic Press, New York, 
NY, 1969. 
(2)  (a) Detroy, R.W.; Lillehoj, E.B.; Ciegler, A. Aflatoxin and Related Compounds. In Microbial Toxins: 
Fungal Toxins; Ciegler, A., Kadis, S., Ajl, S.J., Eds.; Academic Press: New York, 1971; Vol. 6, pp 3–178; 
(b) Diener, U.L.; Cole, R.J.; Sanders, T.H.; Payne, G.A.; Lee, L.S.; Klich, M.A. Annu. Rev. Phytopathol. 
1987, 25, 249–270. 
(3)  (a) Squire, R.A. Science 1981, 214, 877–880; (b) Eaton, D.L., Groopman, J.D., Eds.; The Toxicology of 
Aflatoxins: Human Health, Veterinary, and Agricultural Significance; Academic Press: San Diego, CA, 
1994; (c) Newberne, P.M.; Butler, W.H. Cancer Res. 1969, 29, 236–250. 
(4) (a) Payne, G.A. Process of Contamination by Aflatoxin-Producing Fungi and Their Impact on Crops. In 
Mycotoxins in Agriculture and Food Safety; Sinha, K.K., Bhatnagar, D., Eds.; Marcel Dekker: New York, 
1998; pp 279–306. (b) Bennett, J.W.; Klich, M. Clin. Microbiol. Rev. 2003, 16, 497–516. 
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human consumption.5 
 
Figure 1.1. Representative aflatoxins. 
Few methods exist for protecting agricultural products from aflatoxin contamination. 
Traditionally, fungicides have been used to control the propagation of aflatoxigenic fungi, but 
they are often toxic to mammals, and provoke the emergence and pervasion of resistant strains. 
More recently, non-aflatoxigenic strains of A. flavus were developed to displace aflatoxin-
producing strains from crop fields, but application timing, cost, and overall effectiveness of 
this technology are limiting.6 
Alternatively, specific inhibitors of aflatoxin biosynthesis that lack fungicidal activity 
are desirable.7 Since aflatoxins do not appear to be essential for fungal growth and viability, it 
should be possible to inhibit their synthesis without selecting for resistant strains. Aflatoxin 
production inhibitors should also provide new insight into the mechanism and regulation of 
aflatoxin biosynthesis by fungi on the molecular level. Study in this area should aid the 
development of more effective and economically practical means of minimizing aflatoxin 
contamination.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(5) U.S. Food and Drug Administration. Action Levels for Aflatoxins in Animal Feeds. Compliance Policy 
Guide, Sec. 683.100, 1979 (revised 1994). 
(6)  (a) Dorner, J.W.; Lamb, M.C. Mycotoxin Res. 2006, 22, 33–38; (b) Cotty, P.J. Phytopathology 1994, 84, 
1270–1277. 
(7)  (a) Zaika, L.L.; Buchanan, R.L. J. Food Prot. 1987, 50, 691–708; (b) Wheeler, M.H.; Bhatnagar, D. Pestic. 
Biochem. Physiol. 1995, 52, 109–115; (c) Wheeler, M.H.; Bhatnagar, D.; Rojas, M.G. Pestic. Biochem. 
Physiol. 1989, 35, 315–320; (d) Dutton, M.F.; Anderson, M.S. J. Food Prot. 1980, 43, 381–384. 
O
O
O
O O
OMe
Aflatoxin B1
O
O
O
O
OMe
Aflatoxin G1
O
O
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II. Isolation and Biological Activity 
Aflastatin A (AsA, 1) was discovered during a screen of microbial metabolites that 
specifically targeted aflatoxin production in A. parasiticus (Figure 1.2).8 AsA was isolated by 
Sakuda and coworkers from the mycelial extract of the bacterium Streptomyces sp. MRI142, 
which in turn was isolated from a soil sample collected in Zushi-shi, Kanagawa prefecture, 
Japan. Similarly, blasticidin A (BcA, 2) was isolated by Fukunaga, Yonehara and their 
respective coworkers from the soil bacterium Streptomyces griseochromogenes.9 BcA was 
initially reported to show antifungal activity towards the rice blast pathogen Pyricularia 
oryzae. Later, Sakuda and coworkers reevaluated BcA as an inhibitor of aflatoxin production 
after noticing homologous physicochemical properties between it and AsA.10 
 
Figure 1.2. Structures of aflastatin A (1) and blasticidin A (2). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(8) (a) Sakuda, S.; Ono, M.; Furihata, K.; Nakayama, J.; Suzuki, A.; Isogai, A. J. Am. Chem. Soc. 1996, 118, 
7855–7856; (b) Ono, M.; Sakuda, S.; Suzuki, A.; Isogai, A. J. Antibiotics 1997, 50, 111–118; (c) Ono, M.; 
Suzuki, A.; Isogai, A.; Sakuda, S. Production Aflastatin A from Streptomyces sp., A Pharmaceutical 
Composition and Methods of Use. U.S. Patent 5,773,263, June 30, 1998. 
(9)  (a) Fukunaga, K.; Misato, T.; Ishii, I.; Asakawa, M. Bull. Agric. Chem. Soc. Jpn. 1955, 19, 181–188; (b) 
Kōno, Y.; Takeuchi, S.; Yonehara, H. J. Antibiotics 1968, 21, 433–438. 
(10)  (a) Sakuda, S.; Ono, M.; Ikeda, H.; Inagaki, Y.; Nakayama, J.; Suzuki, A.; Isogai, A. Tetrahedron Lett. 
1997, 38, 7399–7402; (b) Sakuda, S.; Ono, M.; Ikeda, H.; Nakamura, T.; Inagaki, Y.; Kawachi, R.; 
Nakayama, J.; Suzuki, A.; Isogai, A.; Nagasawa, H. J. Antibiotics 2000, 53, 1265–1271. (c) Ono, M.; 
Suzuki, A.; Isogai, A.; Sakuda, S. Aflatoxin Contamination Inhibitor and Aflatoxin Contamination-
Inhibiting Method. U.S. Patent 6,121,310, September 19, 2000. 
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Owing to their similar chemical properties, AsA and BcA exhibit comparable 
biological activities.11 AsA and BcA inhibit production of both aflatoxin B and G groups by A. 
parasiticus (IC50 = 0.07 and 0.04 µM, respectively) without significantly affecting fungal 
growth. They also reduce production of the pentaketide-derived melanin in the fungus 
Colletotrichum lagenarium. 12  Biological assays reveal that AsA and BcA suppress the 
expression of enzymes (i.e. PKS1) and a regulatory protein (AflR) involved in early steps of 
the biosyntheses of aflatoxin and melanin,13 but exact molecular targets for these natural 
products have yet to be identified. Collectively, AsA and BcA exhibit antibiotic activity 
against various fungi, bacteria and yeast. Independently, AsA inhibits propagation of 
subcutaneously transplanted mouse adenocarcinoma,8c whereas BcA suppresses ribosomal 
protein synthesis in the yeast Saccharomyces cerevisiae.14 
III. Structure Elucidation 
Aflastatin A is a 3-acyltetramic acid natural product that bears a highly oxygenated 
and long alkyl chain.8a It contains 29 stereogenic centers, one stereodefined (E) alkene (C2–
C3), a six-membered lactol (C33–C37), and is capped by a D-alanine-based tetramic acid 
moiety (N1’–C6’) that is subject to both rotameric and tautomeric equilibria. As a polyketide, 
AsA bears hydroxyl groups at several unexpected positions (C8, C28, C30, C34, and C36), 
but this unusual oxidation pattern can be explained by the incorporation of five glycolic acid 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(11) Sakuda, S. Mycotoxins 2010, 60, 79–86. 
(12)  Okamoto, S.; Sakurada, M.; Kubo, Y.; Tsuji, G.; Fujii, I.; Ebizuka, Y.; Ono, M.; Nagasawa, H.; Sakuda, S. 
Microbiology 2001, 147, 2623–2628. 
(13)  (a) Kondo, T.; Sakurada, M.; Okamoto, S.; Ono, M.; Tsukigi, H.; Suzuki, A.; Nagasawa, H.; Sakuda, S. J. 
Antibiotics 2001, 54, 650–657; (b) Sakuda, S. Mycotoxins 2002, 52, 153–159; (c) Sakuda, S.; Kondo, T.; 
Yoshinari, T.; Nagasawa, H. Mycotoxins 2003, Suppl. 3, 99–105; (d) Yoshinari, T.; Akiyama, T.; 
Nakamura, K.; Kondo, T.; Takahashi, Y.; Muraoka, Y.; Nonomura, Y.; Nagasawa, H.; Sakuda, S. 
Microbiology 2007, 153, 2774–2780. 
(14)  Yoshinari, T.; Noda, Y.; Yoda, K.; Sezaki, H.; Nagasawa, H.; Sakuda, S. J. Antibiotics 2010, 63, 309–314. 
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subunits during its biosynthesis.15 
Sakuda and coworkers first reported preliminary structural information for AsA in 
concert with its isolation.8a They used a combination of spectroscopic and degradation 
experiments to elucidate its molecular formula, structural connectivity, and relative 
stereochemistry in the C33–C37 lactol region. The same group later assigned the complete 
relative and absolute stereochemistry of AsA as represented by structure 3 (Figure 1.3).16 
They ultimately corrected the configuration of six stereogenic centers (C8, C9 and C28–C31), 
which will be discussed in due course. 
 
Figure 1.3. Initial structural assignment of aflastatin A (AsA). 
The initial stereochemical assignment of AsA (3) relied upon its chemical degradation 
and spectroscopic analyses of the resultant fragments (Scheme 1.1). The absolute 
configurations of the smallest degradation fragments were determined as follows: N-methyl-
D-alanine (6) by Marfey’s method, β-hydroxyacid 11 by comparison of its optical rotation 
data to literature value, and both dibenzoate 7 and tribenzoate 10 by comparison of their 
respective circular dichroism spectra and optical rotation values to data obtained from 
authentic samples. The relative stereochemistry of the C9–C27 and C3–C48 degradation 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(15)  Ono, M.; Sakuda, S.; Ikeda, H.; Furihata, K.; Nakayama, J.; Suzuki, A.; Isogai, A. J. Antibiotics 1998, 51, 
1019–1028. 
(16)  Ikeda, H.; Matsumori, N.; Ono, M.; Suzuki, A.; Isogai, A.; Nagasawa, H.; Sakuda, S. J. Org. Chem. 2000, 
65, 438–444. 
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fragments 9 and 8, respectively, was elucidated by J-based configuration analysis17 and partly 
supplemented with ROE correlation data. The absolute and relative configurations of the 
degradation fragments were then connected to provide a complete stereochemical depiction of 
AsA. 
Scheme 1.1. Degradation of aflastatin A (4). 
 
Reagents and conditions: (a) NaIO4; NaBH4; (b) NaIO4; (c) HCl (aq.); (d) O3; Me2S; (e) LiAlH4; (f) BzCN, 
nBu3N; (g) HCl, MeOH; (h) O3; NaBH4; (i) Ac2O, py, DMAP; (j) NaOMe; Dowex-50W (H+); (k) NaIO4; 
NaBH4; (l) Ac2O, py, DMAP; (m) NaOMe; (n) HCl, MeOH; (o) NaIO4; (p) NaBH4; (q) HCl (aq.); (r) BzCl, py, 
DMAP; (s) NaIO4. 
The relative stereochemistry of C9–C27 degradation fragment 9 was reinforced by 
[13C]acetonide analysis,18 and its absolute configuration elucidated by Mosher ester analysis19 
(Scheme 1.2).20 First, pentaacetonide 12 and tetraacetonide 14 were synthesized and analyzed 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(17)  Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. J. Org. Chem. 1999, 64, 866–876. 
(18) Rychnovsky, S.D.; Rogers, B.N.; Richardson, T.I. Acc. Chem. Res. 1998, 31, 9–17. 
(19)  Dale, J.A.; Mosher, H.S. J. Am. Chem. Soc. 1973, 95, 512–519. 
(20)  Sakuda, S.; Ikeda, H.; Nakamura, T.; Nagasawa, H. Biosci. Biotechnol. Biochem. 2004, 68, 407–412. 
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to establish 1,3-syn diol relationships across the entire C9–C27 region. Second, the MTPA 
esters of carbinol 13 were prepared to determine the absolute configuration at C13. Taken 
together, these derivations provided additional support for the initial absolute configuration 
assignment of C3–C48 degradation fragment 8, and therefore AsA. 
Scheme 1.2. Derivitization of AsA C9–C27 degradation fragment 9. 
 
Reagents and conditions: (a) 2,2-dimethoxypropane, CSA, acetone, rt; Et3N; (b) TrCl, py, DMAP, MeCN, rt; (c) 
Me2C(OMe)2, p-TsOH, DMF, rt; Et3N. 
IV. Stereochemical Revision 
Aflastatin A attracted the attention of the Kishi group during their development of a 
universal NMR database as a tool for the stereochemical assignment of acyclic regions of 
natural products.21 The structural array of contiguous carbinols seen in the C27–C31 region of 
AsA was particularly suited for comparison with their library of 1,2,3,4,5-pentaols. Kishi and 
coworkers observed that each pentaol diastereomer exhibited a distinct spectroscopic profile. 
Specifically, comparison of their spin-coupling profiles to the reported data (Figure 1.4A) 
compelled them to suggest that the relative stereochemistry in the C27–C31 pentaol region of 
AsA degradation fragment 8 be revised from syn/syn/syn/syn (Figure 1.4B) to 
anti/syn/syn/syn (Figure 1.4C). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(21)  (a) Kobayashi, Y.; Tan, C.-H.; Kishi, Y. Helv. Chim. Acta 2000, 83, 2562–2571; (b) Higashibayashi, S.; 
Czechtizky, W.; Kobayashi, Y.; Kishi, Y. J. Am. Chem. Soc. 2003, 125, 14379–14393. 
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Figure 1.4. Spin-coupling constant comparison of the C27–C31 pentaol region of AsA 
degradation fragment 8 (A) to Kishi's database pentaols (B,C). 
 Somewhat concurrently, Sakuda and coworkers deciphered the structure of blasticidin 
A (BcA). 22  As with AsA, they used a combination of spectroscopic and degradation 
experiments to elucidate its relative and absolute stereochemistry. Unlike AsA, however, they 
took greater caution in assigning stereochemistry to the C8–C9 diol and C25–C29 pentaol 
regions, as purposefully left ambiguous in structure 15 (Scheme 1.3). 
Scheme 1.3. Degradation of blasticidin A (15) to C3–C47 fragment 16. 
 
Reagents and conditions: (a) HCl, MeOH; (b) O3; NaBH4; (c) Ac2O, py, DMAP; (d) NaOMe; Dowex-50W (H+). 
Sakuda and coworkers relied on BcA C3–C47 degradation fragment 16 to determine 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(22)  Sakuda, S.; Ikeda, H.; Nakamura, T.; Kawachi, R.; Kondo, T.; Ono, M.; Sakurada, M.; Inagaki, H.; Ito, R.; 
Nagasawa, H. J. Antibiotics 2000, 53, 1378–1384. 
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the absolute configuration of these positions.23 They used J-based configuration analysis17 in 
combination with the NMR database method21 to assign the relative configurations from C23–
C25 as syn, and C25–C29 as anti/syn/syn/syn. Less expected was that they assigned the 
absolute configurations of C8 and C9 to be opposite those proposed for AsA. During their 
analysis, they discovered that in the C8–C9 diol region, the spin-coupling profile of BcA 
degradation fragment 16 (Figure 1.5A) was very similar to that of AsA fragment 8. Such 
spectral similarity allowed them to correct a coupling constant value (3JH-9,H-10) attributed 
previously to AsA fragment 8 (Figure 1.5B), and prompted them to revise their previous 
assignments for C8 and C9 in AsA. Ultimately, Sakuda and coworkers revised the 
configuration of six stereogenic centers (C8, C9 and C28–C31) in AsA to match the 
corresponding stereocenters in BcA. 
 
Figure 1.5. Stereochemical assignment of the C8–C9 diol region of BcA degradation 
fragment 16 (A) and revision of AsA fragment 8 (B). 
To support their assignment of the C8–C11 region of BcA (and reassignment of AsA), 
Sakuda and coworkers synthesized four model diastereomers 17a–d (Figure 1.6A).23 Among 
the models, only the coupling constant values observed for syn/syn diastereomer 17a and the 
C8–C10 region of BcA degradation fragment 16 were comparable.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(23)  (a) Sakuda, S.; Matsumori, N.; Furihata, K.; Nagasawa, H. Tetrahedron Lett. 2007, 48, 2527–2531; (b) 
Sakuda, S.; Yoshinari, T.; Nakamura, K.; Akiyama, T.; Takahashi, Y.; Muraoka, Y.; Nonomura, Y.; 
Nagasawa, H. Mycotoxins 2006, Suppl. 4, 135–140. 
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Figure 1.6. Sakuda’s (A) and Evans’ (B) models for the C8–C9 diol region of AsA and BcA. 
Nevertheless, the NMR databases suggest that interactions between structural motifs 
that are two (but potentially four) carbons away are significant.21 Because our group had been 
actively pursuing the synthesis of AsA since its initial stereochemical assignment, we desired 
stronger evidence for the reassignment of C8 and C9 and synthesized the corresponding C3–
C15 model diastereomers 18a–d (Figure 1.6B).24  The syn/syn diastereomer (18a) provided 
not only the closest spectral match, but also assurance that redirecting future synthesis efforts 
toward revised structures 1 and 19 was appropriate (Figure 1.7). 
 
Figure 1.7. Revised structural assignment of AsA (1) and C3–C48 degradation fragment 19. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(24)  Young, J.M. Studies Toward the Synthesis of Aflastatin A. Ph.D. Thesis, Harvard University, 2008. 
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V. Synthesis Achievements Made Prior to the Stereochemical Revision 
The Evans group has a long-standing interest in the use of aldol reactions for the 
construction of polyacetate and polypropionate natural products. We selected aflastatin A (3) 
as a synthesis target due to the challenges posed by its densely oxygenated structure. We were 
attracted by the opportunity to develop aldol chemistry for the construction of natural 
products containing contiguous polyols. Despite uncertainty surrounding the initial 
stereochemical assignment, our laboratory made enduring advances toward the synthesis of 
AsA prior to the stereochemical revision. These include the developments of: (1) an anti-
Felkin-selective C35–C36 oxygenated aldol reaction, (2) a Felkin-selective C18–C19 anti 
aldol reaction and its application to the synthesis of C9–C27 degradation fragment 9, and (3) a 
Felkin-selective C15–C16 Mukaiyama aldol reaction. 
A. The C35–C36 Oxygenated Aldol Reaction25 
The C33–C37 lactol region of AsA presented us the opportunity to investigate 
diastereoselective construction of the C33–C36 anti/syn/anti tetraol by aldol reaction of an 
oxygenated enolate.26 Concerns over controlling enolate geometry, enolization regioselectivity, 
and aldehyde facial selectivity were abated by the discovery of a highly selective C35–C36 
oxygenated aldol reaction (Scheme 1.4). We observed exclusive formation of desired 
anti/syn/anti aldol adduct 23 by linking together the α- and β-oxygens of model aldehyde 20 
with an acetonide protecting group. We propose that anti-Felkin addition of the more reactive 
(E) enolate27 of ketone 21 to this aldehyde is favored and proceeds via Zimmerman-Traxler28 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(25)  This section represents the culminative work of Drs. Frank Glorius, Jing Zhang, and Jason D. Burch. 
(26)  (a) Glorius, F. Development of α-Oxygenated Aldol Methodology and Progress Towards the Synthesis of 
Aflastatin A. Postdoctoral Report, Harvard University, 2001; (b) Evans, D.A.; Glorius, F.; Burch, J.D. Org. 
Lett. 2005, 7, 3331–3335. 
(27)  Evans, D.A.; Nelson, J.V.; Vogel, E.; Taber, T.R. J. Am. Chem. Soc. 1981, 103, 3099–3111. 
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transition state 22. By contrast, we anticipate that the Felkin rotamer of aldehyde 20 
destabilizes transition state 24 by introducing nonbonding interactions between the aldehyde 
side chain and the incoming enolate nucleophile. 
Scheme 1.4. The C35–C36 oxygenated aldol reaction. 
 
Ultimately, we determined that aldol diastereoselectivity was strongly dependent upon 
protecting group identity. As applied to the synthesis of AsA, installation of an acetonide 
protecting group at C33/C34 would be essential for anti-Felkin-selective C35–C36 bond 
formation. Upon satisfying this requirement, we successfully applied the oxygenated aldol 
reaction to the syntheses of AsA lactol region subunits 27 (eq 1)29 and 29 (eq 2).26b,30 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(28)  Zimmerman, H.E.; Traxler, M.D. J. Am. Chem. Soc. 1957, 79, 1920–1923. 
(29)  Zhang, J. Studies Toward the Total Synthesis of (–)-Aflastatin A. Postdoctoral Report, Harvard University, 
2003. 
(30)  Burch, J.D. Complex Aldol Reactions for Polyketide Synthesis: I. Total Synthesis of Callipeltoside A. II. 
Synthesis of the C27–C48 Subunit of Aflastatin A. Ph.D. Thesis, Harvard University, 2005. 
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 Recently, Ramana and coworkers reported an alternative approach to constructing the 
AsA lactol region. 31  Their syntheses featured the palladium-mediated 6-endo-dig 
cycloisomerization of alkynones directly obtained from the oxidation of alkynols 30 and 33 
(Scheme 1.5). They then installed the requisite stereochemistry at C33 and C34 via face-
selective hydroboration of intermediate dihydropyrans 31 and 34. Their efforts ultimately led 
to the construction of lactol methyl ethers 32 and 35, respectively. 
Scheme 1.5. Ramana’s syntheses of the AsA lactol region. 
 
Reagents and conditions: (a) IBX, EtOAc, reflux; (b) Pd(OAc)2, MeOH, rt, 54% (31, 2 steps), 53% (34, 2 steps); 
(c) BH3•Me2S, THF, 0 °C; H2O2, NaOH (aq.), rt; (d) Ac2O, py, CH2Cl2, rt, 65% (32, 2 steps), 61% (35, 2 steps). 
B. The C18–C19 Aldol Reaction and Synthesis of the C9–C27 Degradation Fragment32 
 Soon after Kishi and coworkers questioned the initial stereochemical assignment of 
AsA,21b the Evans group prioritized confirmation of the relative and absolute stereochemistry 
of C9–C27 degradation fragment 9 by chemical synthesis. Our strategy was based on the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(31)  (a) Narute, S.B.; Kiran, N.C.; Ramana, C.V. Org. Biomol. Chem. 2011, 9, 5469–5475; (b) Narute, S.B.; 
Ramana, C.V. Tetrahedron 2013, 69, 1830–1840. 
(32)  This section represents the culminative work of Drs. William C. Trenkle and Jing Zhang. 
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Felkin-selective anti aldol addition of ethyl ketone 37 to α,β-syn-aldehyde 36 (Scheme 1.6).33 
Despite the non-reinforcing relationship between vicinal substituents on the aldehyde,34 Felkin 
adduct 39 is still formed with high diastereoselection due to the inherent Felkin bias of the 
preformed (E) enolate.33b As seen in transition state 40, formation of undesired anti-Felkin 
product 41 is disfavored due to a syn pentane interaction that develops during C–C bond 
formation. 
Scheme 1.6. Precedent for the C18–C19 anti aldol reaction. 
 
 Our group then successfully applied this anti aldol reaction to the synthesis of AsA 
C9–C27 degradation fragment 9.29,35 Addition of the (E) enolate of ethyl ketone 42 to 
aldehyde 43 provided the desired anti adduct 44 and its C18 epimer in moderate yield and 
excellent Felkin diastereoselectivity (Scheme 1.7). The undesired diastereomer arose from 
unfortunate epimerization of the major product under the reaction conditions. We then 
converted aldol adduct 44 to degradation fragment 9 and its derivative peracetate, compared 
their analytical data with authentic samples,15,16 and concluded that Sakuda and coworkers had 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(33)  (a) Dart, M.J. Diastereoselective Aldol Addition Reactions. Ph.D. Thesis, Harvard University, 1995; (b) 
Evans, D.A.; Dart, M.J.; Duffy, J.L.; Rieger, D.L. J. Am. Chem. Soc. 1995, 117, 9073–9074. 
(34)  Evans, D.A.; Dart, M.J.; Duffy, J.L.; Yang, M.G. J. Am. Chem. Soc. 1996, 118, 4322–4343. 
(35)  Evans, D.A.; Trenkle, W.C.; Zhang, J.; Burch, J.D. Org. Lett. 2005, 7, 3335–3338. 
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correctly assigned the relative and absolute stereochemistry of the AsA C9–C27 degradation 
fragment 9. 
Scheme 1.7. Synthesis of AsA C9–C27 degradation fragment 9. 
 
 More recently, Robles and McDonald reported an alternative approach to constructing 
the pentaacetonide derivative of AsA degradation fragment 9. 36  Their strategy for the 
synthesis of the C9–C27 polyketide region relied on iterative additions of lithium acetylides 
to epoxides, followed by regio- and stereoselective functionalization of the resultant internal 
alkynes (Scheme 1.8). Their efforts resulted in the modular synthesis of pentaacetonide 51, 
which matched original spectral data provided by the isolation group. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(36)  (a) Robles, O.; McDonald, F.E. Org. Lett. 2008, 10, 1811–1814; (b) Robles-Resendiz, O. Modular 
Synthesis of Polyketide Natural Products: Synthesis of the C9–C27 Degradation Product of Aflastatin A 
and Total Synthesis of Fostriecin. Ph.D. Thesis, Emory University, 2009. 
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Scheme 1.8. McDonald’s synthesis of AsA C9–C27 degradation fragment 51. 
 
C. The C15–C16 Mukaiyama Aldol Reaction37 
The C18–C19 aldol reaction was key to providing us access to degradation fragment 9 
and verification of its structural assignment. Nevertheless, we desired a more convergent 
fragment coupling for the synthesis of AsA, and found recourse in a Felkin-selective C15–
C16 Mukaiyama aldol reaction. Our approach was based on the trityl-catalyzed38 addition of 
enolsilane 53 to syn aldehyde 52 to selectively form Felkin aldol adduct 54 despite non-
reinforcing α,β-stereoinduction (Scheme 1.9).34 We propose that sterically demanding Lewis 
acids such as the trityl cation increase the influence of the α-methyl stereocenter by 
promoting addition through antiperiplanar transition state 56, 39 perhaps with an altered 
nucleophile trajectory.40 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(37)  This section represents the culminative work of Drs. William C. Trenkle, Jing Zhang, and Joseph M. 
Young. 
(38) (a) Mukaiyama, T.; Kobayashi, S.; Murakami, M. Chem. Lett. 1984, 13, 1759–1762; (b) Denmark, S.E.; 
Chen, C.-T. Tetrahedron Lett. 1994, 35, 4327–4330.  
(39)  Heathcock, C.H.; Walker, M.A. J. Org. Chem. 1991, 56, 5747–5750 and references therein. 
(40)  Heathcock, C.H.; Flippin, L.A. J. Am. Chem. Soc. 1983, 105, 1667–1668. 
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Scheme 1.9. Precedent for the C15–C16 Mukaiyama aldol reaction. 
 
Our initial attempts at the trityl-catalyzed C15–C16 Mukaiyama aldol addition of 
enolsilane 58 to aldehyde 57 were met with decomposition (eq 3).41 We later identified that 
the likely origin of decomposition was the C27 PMB ether of enolsilane 58.24 Since the trityl 
cation is known to oxidize unhindered PMB ethers via hydride abstraction,42 new aldol 
coupling partners were designed to exclude this protecting group. Ultimately, addition of 
enolsilane 61 to aldehyde 60 provided the desired Felkin aldol adduct 62 as a single C15 
diastereomer (eq 4). This result demonstrated that construction of the AsA C3–C26 
polyketide region could be achieved with greater convergence and efficiency. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(41)  Trenkle, W.C. Progress Towards the Synthesis of Aflastatin A. Postdoctoral Report, Harvard University, 
2002. 
(42)  For examples, see: (a) Fujioka, H.; Sawama, Y.; Kotoku, N.; Ohnaka, T.; Okitsu, T.; Murata, N.; Kubo, O.; 
Li, R.; Kita, Y. Chem. Eur. J. 2007, 13, 10225–10238; (b) Yadav, V.K.; Agrawal, D. Chem. Commun. 
2007, 5232–5234; (c) Doddi, V.R.; Kokatla, H.P.; Pal, A.P.J.; Basak, R.K.; Vankar, Y.D. Eur. J. Org. 
Chem. 2008, 5731–5739. 
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Shortly after our discovery of a competent C15–C16 Mukaiyama aldol reaction, 
Sakuda and coworkers revised the initial stereochemical assignment of AsA.23 In response, we 
prioritized the synthesis of C3–C48 degradation fragment 19 as a means of confirming the 
relative and absolute stereochemistry of AsA. Although the structural reassignment required 
us to revisit our synthesis plans, we were confident in the structural identity of the C9–C27 
region, and could use both the C35–C36 oxygenated aldol and C15–C16 Mukaiyama aldol 
reactions in our future synthesis efforts. Our synthesis of AsA C3–C48 degradation fragment 
19 will be discussed in Chapter 2. 
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Chapter 
2 
Synthesis of the C3–C48 Degradation Fragment of 
Aflastatin A 
 
I. Synthesis Plans Involving C28–C29 Bond Formation 
The structure of aflastatin A (AsA) presented our group the opportunity to develop 
aldol chemistry for the construction of its densely oxygenated C27–C31 and C33–C37 regions. 
In addition to developing an anti-Felkin-selective C35–C36 oxygenated aldol reaction, our 
group targeted the C27–C31 pentaol as a site for major fragment coupling. Initially, our 
retrosynthesis plan hinged on the development of a C28–C29 oxygenated aldol reaction, but 
was later transformed by the discovery of a C26–C27 chelate-controlled aldol addition. 
A. Initial Structure of Aflastatin A1 
Our first retrosynthesis plan for the initial structure of AsA (1) involved disconnection 
at C2–C3 to produce tetramic acid derivative 2 (Scheme 2.1).2  We planned to install the 
tetramic acid by a Horner-Wadsworth-Emmons reaction3 as late in the synthesis as possible 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(1)  This section represents the culminative work of Dr. William C. Trenkle and Dr. Jing Zhang. 
(2)  Trenkle, W.C. Progress Towards the Synthesis of Aflastatin A. Postdoctoral Report, Harvard University, 
2002. 
(3)  (a) Horner, L.; Hoffman, H.; Wippel, H.G.; Klahre, G. Chem. Ber. 1959, 92, 2499–2505; (b) Wadsworth, 
W.S., Jr.; Emmons, W.D. J. Am. Chem. Soc. 1961, 83, 1733–1738. 
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because we expected that the C5’ stereocenter would be readily epimerizable.4 Having 
removed this base-sensitive moiety, we next focused on an aldol-based assemblage of the C3–
C48 polyketide backbone. For the major fragment coupling, we decided to investigate the 
double-stereodifferentiating syn aldol addition of ketone 4 to dialdehyde synthon 3 as a means 
of forming the C28–C29 bond. 
Scheme 2.1. First retrosynthesis plan for structure 1. 
 
 At the time, double-stereodifferentiating syn aldol additions of α’-oxygenated ketones 
to α-oxygenated aldehydes were undocumented. Although syn aldol reactions of chiral α’-
oxygenated ketones with achiral aldehydes were known to favor the formation of 1,3-syn 
products,5 the effect of introducing a second stereocontrol element at the aldehyde’s α-
position was not well understood. As per the polar Felkin-Anh model,6 we predicted that the 
aldehyde α-alkoxy stereocenter at C27 would establish a matched relationship with the C31 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(4)  Royles, B.J.L. Chem. Rev. 1995, 95, 1981–2001 and references therein. 
(5)  (a) Masamune, S.; Choy, W.; Kerdesky, F.A.J.; Imperiali, B. J. Am. Chem. Soc. 1981, 103, 1566–1568; (b) 
Marco, J.A.; Carda, M.; Falomir, E.; Palomo, C.; Oiarbide, M.; Ortiz, J.A.; Linden, A. Tetrahedron Lett. 
1999, 40, 1065–1068; (c) Carda, M.; Murga, J.; Falomir, E.; González, F.; Marco, J.A. Tetrahedron 2000, 
56, 677–683. 
(6)  (a) Chérest, M.; Felkin, H.; Prudent, N. Tetrahedron Lett. 1968, 9, 2199–2204; (b) Anh, N.T.; Eisenstein, 
O. Nouv. J. Chim. 1977, 1, 61–70; (c) Anh, N.T. Top. Curr. Chem. 1980, 88, 145–162. 
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stereocenter of (Z) enolate 6. Aldol reaction via transition state 7 would effect 
diastereoselective C28–C29 bond formation, and thereby lead to the desired syn/syn/syn 
adduct 8 (Scheme 2.2). We envisioned that transition state 7 would be favored since it 
features hyperconjugative stabilization of the forming C28–C29 bond, dipole-dipole 
minimization between the C31 α'-alkoxy stereocenter and the transforming enolate, and 
minimization of nonbonding interactions between the reacting partners. 
Scheme 2.2. Proposed C28–C29 oxygenated aldol reaction. 
 
Model studies of the C28–C29 oxygenated aldol reaction were then performed to 
evaluate our stereochemical prediction.7 Our desires to control enolization regioselectivity and 
produce geometrically-defined (Z) enolates of general structure 6 were satisfied by reports of 
chlorodicyclohexylborane-mediated syn aldol additions of ketones bearing both chelating 
alkyl and bulky silyl protecting groups at their α’-oxygen position (C31).8 Disappointingly, 
reaction of ketone 9 with aldehyde 10 under these conditions proceeded poorly in both yield 
and diastereoselectivity (eq 1). Boron-mediated enolization of advanced C29–C48 ketone 12 
was also attempted, but reactivity – and similarly poor levels of diastereoselection – was 
observed only upon formation of the corresponding lithium enolates (eq 2). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(7)  Zhang, J. Studies Toward the Total Synthesis of (–)-Aflastatin A. Postdoctoral Report, Harvard University, 
2003. 
(8)  Murga, J.; Falomir, E.; Carda, M.; González, Marco, J.A. Org. Lett. 2001, 3, 901–904. 
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During the course of these studies, related work in the Evans group demonstrated that 
the modified Cornforth model provides a more accurate description of enolate additions to α-
alkoxy aldehydes than the polar Felkin-Anh model.9 Shortly thereafter, Marco, Carda and 
coworkers reported double-stereodifferentiating boron aldol reactions of an erythulose-
derived α,α’-dioxygenated ketone with both enantiomeric series of α-oxygenated aldehydes 
15 (Scheme 2.3).10 Addition of (Z) boron enolate 14 to aldehydes 15 having the same relative 
stereochemistry required for the C28–C29 aldol reaction produced a complex mixture of aldol 
adducts 17, thus agreeing with our model studies. Reaction of the same chiral enolate with 
enantiomeric aldehyde ent-15 established a matched stereorelationship between these reacting 
partners and resulted in the formation of anti/syn/syn aldol adducts 19 in high yield and 
excellent diastereoselectivity.  
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(9)  (a) Evans, D.A.; Siska, S.J.; Cee, V.J. Angew. Chem., Int Ed. 2003, 42, 1761–1765; (b) Siska, S.J. 
Construction of Polyhydroxylated Stereoarrays Using the Aldol Reaction. Ph.D. Thesis, Harvard 
University, 2005. 
(10)  (a) Marco, J.A.; Carda, M.; Díaz-Oltra, S.; Murga, J.; Falomir, E.; Roeper, H. J. Org. Chem. 2003, 68, 
8577–8582; (b) Díaz-Oltra, S.; Murga, J.; Falomir, E.; Carda, M.; Peris, G.; Marco, J.A. J. Org. Chem. 
2005, 70, 8130–8139. 
Cy2BCl, Et3N;
aldehyde 10
40%, dr ~ 1:1:1:1
RO
12, R = TBS
O
31
RO
C9H1939
OR
O
RO
H OMe
OTMS
OR
35 RO
13, R = TBS,
     R' = PMB
O
23
RO
C9H1939
OR
O
RO
H OMe
OTMS
OR
35R'OOO
MeMe
OH
29
28
LiHMDS, –78 °C;
aldehyde 10
(2)
30%, dr ~ 1:1:1:1
OBn
9
O
31
OBn
OBn
OBn
11, R = PMB
O
23
OBnOROO
MeMe
OH
29
28 (1)
OBn
OBn
35 OBn
OBn
OBn
35
27
O
OPMBOO
23
H
10
MeMe
	   23 
Scheme 2.3. Double stereodifferentiating aldol reactions that support the Cornforth model. 
 
B. Revised Structure of Aflastatin A11 
Overall, these experiments provided support for the modified Cornforth model in aldol 
additions of substituted enolates to α-oxygenated aldehydes. As a result, we deemed that 
proposed transition state 7 (Scheme 2.2) was likely invalid, and realized that relying upon a 
C28–C29 oxygenated aldol reaction for construction of the initially proposed structure of AsA 
(1) was untenable. Fortunately, the stereochemical revision of the C27–C31 pentaol region of 
AsA12 provided us an opportunity to revisit this disconnection as an alternative to the C26–
C27 aldol chemistry that will be described in due course. One of our retrosynthesis plans for 
AsA C3–C48 degradation fragment 2013 involved disconnection at C28–C29 to produce 
aldehyde 21 and the C31-epimer 22 of the original ketone fragment (Scheme 2.4).14 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(11)  The synthesis of C27–C31 pentaol derivative 25 (vide infra) was performed by the author in collaboration 
with Dr. Joseph M. Young and Dr. Egmont Kattnig. 
(12)  (a) Higashibayashi, S.; Czechtizky, W.; Kobayashi, Y.; Kishi, Y. J. Am. Chem. Soc. 2003, 125, 14379–
14393; (b) Sakuda, S.; Matsumori, N.; Furihata, K.; Nagasawa, H. Tetrahedron Lett. 2007, 48, 2527–2531; 
(c) Sakuda, S.; Yoshinari, T.; Nakamura, K.; Akiyama, T.; Takahashi, Y.; Muraoka, Y.; Nonomura, Y.; 
Nagasawa, H. Mycotoxins 2006, Suppl. 4, 135–140. 
(13)  Ikeda, H.; Matsumori, N.; Ono, M.; Suzuki, A.; Isogai, A.; Nagasawa, H.; Sakuda, S. J. Org. Chem. 2000, 
65, 438–444. 
(14)  Young, J.M. Studies Toward the Synthesis of Aflastatin A. Ph.D. Thesis, Harvard University, 2008. 
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Scheme 2.4. C28–C29 aldol-based retrosynthesis plan for C3–C48 degradation fragment 20. 
 
Synthesis of the AsA C27–C31 anti/syn/syn/syn pentaol region by this double-
stereodifferentiating aldol strategy required selection of protecting groups that did not 
interfere with reactivity or diastereoselectivity. Previous experiments revealed that sterically 
encumbered ketones (such as 12, eq 2) resist enolization by chlorodicyclohexylborane,7 and 
that bulky aldehydes display limited reactivity with simple boron enolates.15 We alleviated 
these concerns by tying back both the C27 and C31 stereocenters as their respective 1,3-syn 
acetonides. Gratifyingly, the model reaction of the dicyclohexylboron enolate of α-silyloxy 
ketone 24 with aldehyde 23 produced the desired aldol adduct with high levels of conversion 
and diastereoselection (eq 3). The intermediate β-hydroxy ketone was subsequently reduced 
with diisobutylalane16 to afford the desired pentaol derivative 25 in good overall yield. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(15)  Burch, J.D. Complex Aldol Reactions for Polyketide Synthesis: I. Total Synthesis of Callipeltoside A. II. 
Synthesis of the C27–C48 Subunit of Aflastatin A. Ph.D. Thesis, Harvard University, 2005. 
(16)  Kiyooka, S.; Kuroda, H.; Shimasaki, Y. Tetrahedron Lett. 1986, 27, 3009–3012. 
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This result demonstrated the potential of oxygenated enolate chemistry in constructing 
the C27–C31 pentaol region of AsA. As a major fragment coupling, however, we noted that 
the C28–C29 aldol addition was limited by both the relative stoichiometry and protecting 
group requirements of its reacting partners. We therefore refocused our efforts on the 
development and implementation of a C26–C27 chelate-controlled aldol addition. 
II. Synthesis Plans Involving C26–C27 Bond Formation 
A. Initial Structure of Aflastatin A17 
 As experimental support for the modified Cornforth model grew, our group began to 
explore other possibilities for major fragment coupling within the C27–C31 pentaol region. 
Our second retrosynthesis plan for the initial structure of AsA (1) abandoned the idea of a 
C28–C29 oxygenated aldol reaction and instead focused on forming the C26–C27 bond by 
boron-mediated aldol addition of methyl ketone 26 to poly-hydroxylated aldehyde synthon 27 
(Scheme 2.5).15 
Scheme 2.5. Second retrosynthesis plan for structure 1. 
 
 The newly proposed disconnection at C26–C27 was borne out of our group's 
systematic study of methyl ketone aldol additions to α,β-bisoxygenated aldehydes under 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(17)  This section represents the culminative work of Drs. Victor J. Cee, Sarah J. Siska, and Jason D. Burch. 
HO
1
OH
27
HO
C9H1939
OH
OH
HO
Me Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
7
3
11 15 2319
Me
OH
NMe
O
O
Me
2' O
HO
H OH
OH
OH
35
HO
27
OH
31
HO
C9H1939
OH
O
HO
H OH
OH
OH
35
2 26
Me Me
Me
O
OH
OH
Me Me Me
OH OH OH OH OH OH OH
Me Me
73 11 15 2319H
O
26
boron-mediated
aldol addition
H
O
OH
27
	   26 
nonchelating conditions.18 We observed synthetically useful levels of diastereoselectivity for 
the desired 1,2-syn aldol adducts 30 when enolboranes were added to syn aldehyde 28, in 
which both α- and β-oxygen substituents were protected as TBS ethers (eq 4). 
 
 This reaction was then extended to model substrates that possessed the full 
oxygenation pattern present in the C28–C31 region of AsA. Aldol addition of 9-BBN enolate 
30 derived from isobutyl methyl ketone to aldehyde 31 afforded the desired 1,2-syn adduct 
with slightly diminished diastereoselection (eq 5).15 Notably, the size of the protecting groups 
on C30 and C31 was minimized (benzoates were selected instead of TBS ethers) to ensure 
reactivity. 
 
 To our surprise, reaction of the same enolborane with fully elaborated C27–C48 
aldehyde 33 proceeded with inverted diastereoselectivity (eq 6), even though the first point of 
difference between aldehydes 31 and 33 occurred at C33.15 This experiment showed that 
formation of the C33–C37 lactol prior to major fragment coupling could have an adverse 
effect on reaction diastereoselectivity. As a result, future synthesis plans centered upon C26–
C27 bond formation as the major fragment coupling would involve additions to the open-
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(18)  Evans, D.A.; Cee, V.J.; Siska, S.J. J. Am. Chem. Soc. 2006, 126, 9433–9441. 
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chain form of the C27–C48 lactol region. Lactol formation would then be delayed until a later 
stage in the synthesis, such as global deprotection. 
 
B. Revised Structure of Aflastatin A19 
 As before, the stereochemical revision of the C27–C31 pentaol region of AsA 
provided us an opportunity to modify our major fragment coupling strategy. However, before 
completing the total synthesis of AsA, we sought to confirm its stereochemical reassignment12 
by way of C3–C48 degradation fragment 20.13 We envisioned polyol 20 to arise from the 
diastereoselective aldol addition of C3–C26 ketone 35 to C27–C48 aldehyde 36 (Scheme 
2.6).14,20 Aldehyde 36, possessing both α- and β-oxygenation, offered us the possibility of 
using chelation control21 to establish the stereocenter at C27 with high diastereoselection. We 
expected that nucleophilic addition to a six-membered chelate would afford the desired 1,3-
anti relationship. Since silyl ethers generally disfavor chelation,22,23 we planned to induce 
chelation between the carbonyl and β-benzyloxy substituent (at C29) by protecting the C28 
carbinol as its silyl ether. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(19)  This section represents the culminative work of Drs. Victor J. Cee, and Egmont Kattnig. Dr. Kattnig is 
credited with the discovery and development of the chelate-controlled/soft enolization-based C26–C27 
aldol reaction (vide infra). 
(20)  Kattnig, E. An Aldol Approach Toward Aflastatin A – Synthesis of the C3–C48 Polyol. Postdoctoral Report, 
Harvard University, 2011. 
(21)  (a) Reetz, M.T. Angew. Chem. 1984, 96, 542–555; Angew. Chem., Int. Ed. 1984, 23, 556–569; (b) Reetz, 
M.T. Acc. Chem. Res. 1993, 26, 462–468 and references therein. 
(22)  Keck, G.E.; Boden, E.P. Tetrahedron Lett. 1984, 25, 265–268. 
(23)  For exceptions, see: a) Evans, D.A.; Allison, B.D.; Yang, M.G.; Masse, C.E. J. Am. Chem. Soc. 2001, 123, 
10840–10852; b) Stanton, G.R.; Kauffman, M.C.; Walsh, P.J. Org. Lett. 2012, 14, 3368–3371 and 
references therein. 
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Scheme 2.6. C26–C27 aldol-based retrosynthesis plan for C3–C48 degradation fragment 20. 
 
 In developing this strategy, we were encouraged by our earlier systematic study24 of 
methyl ketone Mukaiyama aldol additions25 to α,β-bisoxygenated aldehydes under chelating 
conditions.26 For these experiments, magnesium(II) iodide was chosen as the Lewis acid 
because it was known to chelate heteroatom-substituted aldehydes and promote highly 
diastereoselective Mukaiyama aldol reactions.27 Gratifyingly, enolsilane additions to syn α-
silyloxy, β-alkoxy aldehyde 37 in the presence of freshly prepared MgI2 proceeded in high 
yield to afford the desired 1,3-anti products 39 as single diastereomers (Scheme 2.7).28 The 
observed selectivity is consistent with 1,3-chelate model 38, whereby nucleophilic addition to 
the carbonyl occurs preferentially from the less sterically hindered face of the six-membered 
chelate. In this model, the two stereocenters of the syn diastereomer are reinforcing, as aldol 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(24)  Cee, V.J. I. Asymmetric Induction in Heteroatom-Substituted Aldehydes. II. Total Synthesis of (+)-
Casuarine. Ph.D. Thesis, Harvard University, 2003. 
(25)  (a) Mukaiyama, T.; Narasaka, K.; Banno, K. Chem. Lett 1973, 1011–1014; (b) Mukaiyama, T.; Banno, K.; 
Narasaka, K. J. Am. Chem. Soc. 1974, 96, 7503–7509; (c) Mukaiyama, T. Angew. Chem. 2004, 116, 5708–
5733; Angew. Chem., Int. Ed. 2000, 43, 5590–5614. 
(26)  For the analogous study under nonchelating conditions, see: Ref. 18. 
(27)  For an example, see: Corey, E.J.; Li, W.; Reichard, G.A. J. Am. Chem. Soc. 1998, 120, 2330–2336. 
(28)  The stereochemistry of the newly formed stereogenic center was determined by Mosher ester analysis. See: 
(a) Dale, J.A.; Mosher, H.S. J. Am. Chem. Soc. 1973, 95, 512–519; (b) Hoye, T.R.; Jeffrey, C.S.; Shao, F. 
Nat. Protoc. 2007, 2, 2451–2458. 
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addition to the Re face of aldehyde 37 is blocked by both the α-silyloxy and β-alkyl 
substituents.23a Having realized the feasibility of using a chelate-controlled Mukaiyama aldol 
addition to form the C26–C27 bond, we opted to investigate the coupling of more complex 
substrates. 
Scheme 2.7. Precedent for C26–C27 chelate-controlled aldol addition. 
 
 Our model studies began with the further elaboration of aldehyde fragment 37 (eq 7). 
The influence of additional oxygen-based stereocenters (and therefore protecting groups) at 
C30 and C31 on the diastereoselectivity of the fragment coupling was unknown. Aldehyde 40 
was chosen as a suitable model since it featured the first four stereocenters (C28–C31) present 
in subunit 36, while maintaining the requisite α-silyloxy and β-alkoxy substituents at C28 and 
C29, respectively. In an effort to minimize any potential steric effects on aldehyde reactivity, 
we also protected the neighboring stereocenters (C30 and C31) as benzyl ethers. Addition of 
the enolsilane derived from 3-methyl-2-butanone to aldehyde 40 in the presence of MgI2 
again produced the desired aldol adduct 41 in good yield and excellent diastereoselectivity, 
but we noted that freshly prepared MgBr2•OEt2 was more efficient at promoting this 
reaction.29 In either experiment, the remote benzyloxy substituents at C30 and C31 did not 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(29)  For another example in which MgBr2•OEt2 was found to be superior to MgI2, see: Evans, D.A.; Kvœrnø, 
L.; Dunn, T.B.; Beauchemin, A.; Raymer, B.; Mulder, J.A.; Olhava, E.J.; Juhl, M.; Kagechika, K.; Favor, 
D.A. J. Am. Chem. Soc. 2008, 130, 16295–16309. 
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significantly diminish the 1,3-anti diastereoselectivity of the aldol addition, and ultimately 
provided us a viable protecting group strategy for the C28–C31 stereotetrad during the key 
fragment coupling. 
 
 Our model studies continued with an investigation into the reactivity of model 
enolsilane 42 which incorporates the C23 carbinol of ketone fragment 35 protected as its silyl 
ether (Scheme 2.8). Magnesium-promoted aldol addition of enolsilane 42 to aldehyde 40 
proceeded with excellent 1,3-anti diastereoselectivity, but unexpectedly resulted in 
elimination of the C23 silyloxy substituent to produce enone 44. Formation of this undesired 
elimination product might be explained by the intermediacy of oxocarbenium ion 43.25 When 
silylation of the nascent C27 oxyanion is slowed by steric hindrance,30 we propose that this 
alkoxide may instead abstract a proton from C24, ultimately resulting in departure of the 
vicinal silyloxy group. Further inspection of our previous reactions (eq 7) revealed the 
formation of enolsilane 45 prior to workup, presumably via an analogous deprotonation 
pathway.31 When various attempts to prevent elimination by facilitating silyl transfer or 
quenching magnesium aldolate 43 in situ were unsuccessful, we found recourse in soft 
enolization. 
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(30)  Intermolecular silyl transfer may be operative. For examples, see: Carreira, E.M.; Singer, R.A.; 
Tetrahedron Lett. 1994, 35, 4323; Denmark, S.E.; Chen, C.-T. Tetrahedron Lett. 1994, 35, 4327. 
(31)  Our group noted the formation of similar byproducts during the synthesis of azaspiracid. See: Dunn, T.B. 
Synthesis of the C21–C40 Fragment of Azaspiracid-1. Ph.D. Thesis, Harvard University, 2005. 
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Scheme 2.8. Model C26–C27 Mukaiyama aldol reaction. 
 
 Soft enolization32 is a powerful method for generating metal enolates under mild 
conditions. Our lab has previously demonstrated33 that enolizable carbonyl compounds may 
be deprotonated by weak trialkylamine bases in the presence of suitable magnesium(II)-based 
Lewis acids to enable highly efficient C–C bond-forming reactions. Excited by the prospect of 
maintaining aldehyde facial selectivity while suppressing the formation of undesired enone 44, 
we imagined assembling polyol 20 by way of a chelate-controlled aldol reaction involving 
soft enolization with MgBr2•OEt2.34 Albeit promising, the reversible nature of soft enolization 
with magnesium raised new concerns about enolate regioselectivity, substrate dimerization, 
and aldehyde epimerization. Fortunately, addition of ketone 46a (1.1 equiv) to aldehyde 47 
(1.0 equiv) in the presence of MgBr2•OEt2 (4.0 equiv) and Hünig base (2.0 equiv) produced 
the desired aldol adduct 49a in modest yield and excellent diastereoselectivity (Scheme 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(32)  For the earliest examples of magnesium-based soft enolization, see: (a) Rathke, M.W.; Cowan, P.J.; J. Org. 
Chem. 1985, 50, 2622–2624; (b) Rathke, M.W.; Nowak, M. J. Org. Chem. 1985, 50, 2624–2626; (c) 
Tirpak, R.E.; Olsen, R.S.; Rathke, M.W. J. Org. Chem. 1985, 50, 4877–4879; (d) Olsen, R.S.; Fataftah, 
Z.A.; Rathke, M.W. Synth. Commun. 1986, 16, 1133–1139. 
(33) Evans, D.A.; Tedrow, J.S.; Shaw, J.T.; Downey, C.W. J. Am. Chem. Soc. 2002, 124, 392–393; (b) Evans, 
D.A.; Downey, C.W.; Shaw, J.T.; Tedrow, J.S. Org. Lett. 2002, 4, 1127–1130. 
(34)  For previous examples of direct aldol additions involving soft enolization with MgBr2•OEt2, see: (a) Wei, 
H.-X.; Li, K.; Zhang, Q.; Jasoni, R.L.; Hu, J.; Paré, P.W. Helv. Chim. Acta 2004, 87, 2354–2358; (b) Yost, 
J.M.; Zhou, G.; Coltart, D.M. Org. Lett. 2006, 8, 1503–1506; (c) Zhou, G.; Yost, J.M.; Coltart, D.M. 
Synthesis 2007, 478–482; (d) Yost, J.M.; Alfie, R.J.; Tarsis, E.M.; Chong, I.; Coltart, D.M. Chem. Commun. 
2011, 47, 571–572. 
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2.9).28,35 In contrast to the Mukaiyama aldol example (Scheme 2.8), only a trace amount of 
enone byproduct was formed under these soft enolization conditions. We propose that 
elimination of the C23 silyloxy substituent is disfavored due to the stability of intermediate 
magnesium aldolate complex 48. Furthermore, use of a bulky amine base curtailed aldehyde 
epimerization36 while enforcing a desirable level of enolate regioselection. 
Scheme 2.9. Model C26–C27 soft enolization-based aldol reaction. 
 
 Despite using nearly equimolar amounts of substrate, ketone dimerization37 posed a 
formidable challenge to improving reaction yield. We envisioned disfavoring this pathway by 
enlarging the C23 silyloxy substituent (OTPS, OTIPS > OTBS), and consequently observed 
increased yields of aldol adducts 49b and 49c (eq 8). During the course of our optimization 
studies, we also noted that increasing the size of the trialkylamine base to PMP (1,2,2,5,5-
pentamethylpiperidine) appeared to completely suppress aldehyde epimerization. As before, 
we used excess base (2.0 equiv) and Lewis acid (4.0 equiv) to reach high conversions over 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(35)  Reformatsky-type aldol addition of the corresponding a-bromoketone to aldehyde 47 in the presence of 
SmI2 in THF at –78 °C also produced the desired aldol adduct 49a in 85% yield but with slightly 
diminished diastereoselectivity (dr = 90:10). See: Ref. 20. 
(36)  In the absence of ketone 46a, less than 10% epimerization of aldehyde 47 was observed after 0.5 h under 
the same reaction conditions. 
(37)  In the absence of aldehyde 47, complete ketone dimerization was observed within 10 min under the 
reaction conditions defined in Scheme 2.9. 
MgBr2•OEt2,
EtN(iPr)2
45%, dr = 95:05
Me
O
46a
CH2Cl2, 0 °C
BnO
TBSO
23
OBnO
TBSO
27
OBn
Me31
Me
H
OBnOH
TBSO
27
OBn49a
O
1,3-anti
MeBnO 31
TBSO Me(workup)OBnO
TBSO
27
OBn48
MeBnO 31
TBSO Me
LnX
Mg
O
2321
26
47
	   33 
short reaction times (ca. 6 min at –5 °C),38 then rapidly quenched the mixtures to avoid 
decomposition of the desired aldol adducts. 
 
 Now confident in our ability to construct the C26–C27 bond of polyol 20 using a 
merged chelate-controlled/soft enolization-based aldol approach, we turned our attention to 
the syntheses of subunits 35 and 36 (Scheme 2.6). 
III. Synthesis of the C3–C26 Ketone39 
 Our synthesis plan for C3–C26 ketone fragment 50 was inspired by the Felkin-
selective C15–C16 Mukaiyama aldol reaction that we discovered before the structural 
revision (Scheme 2.10).14 We envisioned that trityl-catalyzed40 addition of the enolsilane of 
ketone 52 to aldehyde 51 would selectively form the corresponding Felkin aldol adduct 
despite non-reinforcing α,β-stereoinduction.41 We anticipated that the same strategy could be 
used to assemble C16–C26 ketone 52 from aldehyde 55 and Chan's diene42 (56). Finally, we 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(38)  Temperatures lower than –5 °C significantly limited conversion, even after extended reaction times. 
(39)  This section represents the culminative work of Drs. William C. Trenkle, Jing Zhang, Joseph M. Young, 
and Peter H. Fuller. 
(40) (a) Mukaiyama, T.; Kobayashi, S.; Murakami, M. Chem. Lett. 1984, 13, 1759–1762; (b) Denmark, S.E.; 
Chen, C.-T. Tetrahedron Lett. 1994, 35, 4327–4330.  
(41) Evans, D.A.; Dart, M.J.; Duffy, J.L.; Yang, M.G. J. Am. Chem. Soc. 1996, 118, 4322–4343. 
(42)  (a) Chan, T.-H.; Brownbridge, P. J. Chem. Soc., Chem. Commun. 1979, 578–579; (b) Brownbridge, P.; 
Chan, T.-H.; Brook, M.A.; Kang, G.J. Can. J. Chem. 1983, 61, 688–693. 
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expected that chelate-controlled addition43 of the alkyllithium derivative of iodide 53 to α-
alkoxy aldehyde 55 would set the 1,2-syn diol relationship seen in C3–C15 aldehyde 51. 
Scheme 2.10. Retrosynthesis plan for C3–C26 ketone 50. 
 
A. Synthesis of the C3–C15 Aldehyde 
 Our synthesis of C3–C15 aldehyde synthon 51 began with the preparation of C3–C7 
iodide 53 44  (Scheme 2.11). The copper-catalyzed, enantioselective hetero-Diels–Alder 
reaction45 of enol ether 5746 and α-ketoester 5847 produced the desired cycloadduct with 
excellent enantio- and diastereoselection. Substrate-controlled hydrogenation of dihydropyran 
60 then afforded the corresponding 1,3-syn dimethyl product as a single diastereomer. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(43)  (a) Cram, D.J.; Abd Elhafez, F.A. J. Am. Chem. Soc. 1952, 74, 5828–5835; (b) Cram, D.J.; Kopecky, K.R. 
J. Am. Chem. Soc. 1959, 81, 2748–2755; (c) Cram, D.J.; Leitereg, T.H. J. Am. Chem. Soc. 1968, 90, 4019–
4026. 
(44)  The synthesis of C3–C7 iodide 53 was previously achieved in 7 steps via a pair of auxiliary-controlled 
enolate alkylations. See: Vong, B.G.; Abraham, S.; Xiang, A.X.; Theodorakis, E.A. Org. Lett. 2003, 5, 
1617–1620. 
(45)  (a) Evans, D.A.; Olhava, E.J.; Johnson, J.S.; Janey, J.M. Angew. Chem., Int. Ed. 1998, 37, 3372–3375; (b) 
Evans, D.A.; Johnson, J.S.; Olhava, E.J. J. Am. Chem. Soc. 2000, 122, 1635–1649. 
(46)  Prepared in one step by isomerization of allyl ethyl ether. See: Ref. 31 and references cited therein. 
(47)  Prepared in one step by mono-addition of isopropenylmagnesium bromide to diethyl oxalate. See: (a) Ref. 
31; (b) Rambaud, M.; Bakasse, M.; Duguay, G.; Villieras, J. Synthesis 1988, 564–566. 
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Reduction of ethyl ester 61 and iodination of the resultant primary carbinol proceeded in good 
yield. Ring fragmentation of iodide 62 was then induced by lithium-halogen exchange to 
provide acyclic enol 63.48 Benzylation, ozonolysis with reductive workup, and iodination 
ultimately provided C3–C7 iodide 53 in good overall yield and 11 total steps from 
commercially available material. 
Scheme 2.11. Synthesis of C3–C7 iodide 53. 
 
Reagents and conditions: (a) (S,S)-59, 3 Å MS, Et2O, –78 °C, 96% ee, dr = 98:02; (b) H2, Pd/C, EtOAc, rt, dr > 
95:05, 78% (2 steps); (c) Et3SiH, BF•OEt2, CH2Cl2, –10 °C to 0 °C; (d) LiAlH4, Et2O, 0 °C; (e) PPh3, I2, 
imidazole, MeCN, PhH, 55 °C, 70% (3 steps); (f) t-BuLi, Et2O, –78 °C; (g) BnBr, NaH, DMF, 0 °C; (h) O3, 
Na2CO3, Sudan III, EtOH, CH2Cl2, –78 °C; NaBH4, –78 °C to rt, 75% (3 steps); (i) PPh3, I2, imidazole, CH2Cl2, 
0 °C to rt, 85%. 
 Our synthesis of the C3–C15 aldehyde continued with the preparation of C8–C15 
aldehyde 54 (Scheme 2.12). The syn aldol reaction of cinnamaldehyde (65) and oxazolidinone 
66 produced the desired adduct in very good yield and excellent diastereoselectivity.49 
Benzylation of the C9 carbinol and net reduction of imide 67 to its corresponding aldehyde 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(48)  The catalytic, enantioselective synthesis of ent-63 was previously developed by our group and applied to 
the synthesis of (+)-azaspiracid-1. See: (a) Evans, D.A.; Dunn, T.B.; Kvœrnø, L.; Beauchemin, A.; Raymer, 
B.; Olhava, E.J.; Mulder, J.A.; Juhl, M.; Kagechika, K.; Favor, D.A. Angew. Chem., Int. Ed. 2007, 46, 
4698–4703; (b) Ref. 29.; (c). Ref. 31. 
(49) Evans, D.A.; Bartroli, J.; Shih, T.L. J. Am. Chem. Soc. 1981, 103, 2127–2129. 
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proceeded in very good yield. Boron-mediated aldol addition of β-ketoimide 6950 to aldehyde 
68 was immediately followed by silylation of the nascent C11 carbinol to produce adduct 70 
in good yield and excellent diastereoselectivity. Diastereoselective reduction of the C13 
carbonyl with zinc borohydride gave the desired anti/anti/syn C11–C14 stereotetrad with 
excellent selectivity.51 Transamidation of the intermediate imide, acetonide formation, and 
ozonolysis of styryl derivative 71 completed the synthesis of C8–C15 aldehyde 54 in 11 linear 
steps and very good overall yield. 
Scheme 2.12. Synthesis of C8–C15 aldehyde 54. 
 
Reagents and conditions: (a) Bu2BOTf, Et3N, CH2Cl2, –78 °C to 0 °C, dr > 95:05, 86%; (b) Me(MeO)NH•HCl, 
AlMe3, THF, –78 °C, 87%; (c) BnBr, NaH, DMF, –10 °C, 99%; (d) LiAlH4, Et2O, 0 °C to rt, 93%; (e) Cy2BCl, 
EtNMe2, Et2O, –78 °C, dr > 95:05; (f) TESOTf, 2,6-lut., CH2Cl2, –78 °C, 75% (2 steps); (g) Zn(BH4)2, Et2O, 
CH2Cl2, –55 °C to –25 °C, 59%; (h) Me(MeO)NH•HCl, AlMe3, THF, –78 °C to 0 °C, 80%; (i) AcOH, THF, 
H2O, rt; (j) Me2C(OMe)2, PPTS, CH2Cl2, rt, 91% (2 steps); (k) O3, py, Sudan III, EtOH, CH2Cl2, –78 °C; Me2S, –
78 °C to rt, 92%. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(50) Evans, D.A.; Ng, H.P.; Clark, J.S.; Rieger, D.L. Tetrahedron 1992, 48, 2127–2142. 
(51)  (a) Halstead, D.P. Total Syntheses of Miyakolide & Discodermolide. Ph.D. Thesis, Harvard University, 
1998; (b) Nakata, T.; Oishi, T. Tetrahedron Lett. 1980, 21, 1641–1644; (c) Nakata, T.; Oishi, T. Acc. Chem. 
Res. 1984, 17, 338–344. 
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 Our synthesis of C3–C15 aldehyde 74 concluded with union of the C3–C7 and C8–
C15 fragments (Scheme 2.13).52 Chelate-controlled addition of alkyllithium 72 to α-alkoxy 
aldehyde 54 yielded the desired 1,2-syn diol derivative 73 as a single diastereomer in very 
good yield. Silylation of the C8 carbinol and reduction of the Weinreb amide produced C3–
C15 aldehyde 74 in excellent yield and overall convergency (14 longest linear steps, 25 
overall). 
Scheme 2.13. Synthesis of C3–C15 aldehyde 74. 
 
Reagents and conditions: (a) t-BuLi, Et2O, pentane, –78 °C; (b) MgBr2•OEt2, CH2Cl2, –78 °C, dr > 95:05, 86%; 
(c) TBSOTf, 2,6-lut., CH2Cl2, –78 °C to 0 °C, 97%; (d) LiAlH4, Et2O, 0 °C, 97%. 
B. Syntheses of the C16–C26 Enolsilane and C3–C26 Ketone 
 Our synthesis of C3–C26 ketone synthon 50 continued with the preparation of the 
enolsilane of C16–C26 ketone synthon 5253 via C16–C21 aldehyde 5554 (Scheme 2.14). Syn 
aldol reaction55 of methacrolein (75) and oxazolidinone 66 was followed by silylation of the 
nascent C19 carbinol to produce adduct 76 in very good yield and excellent 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(52)  This reaction sequence was performed by Dr. Peter H. Fuller. The synthesis of the corresponding C3 TBS 
ether of C3–C15 aldehyde 74 was achieved by Dr. Joseph M. Young. See: Ref. 14. 
(53)  The synthesis of C16–C26 enolsilane 83 (vide infra) was previously achieved by Dr. Joseph M. Young in 
13 steps via a pair of auxiliary-controlled aldol reactions. See: Ref 14. 
(54)  The synthesis of C16–C21 aldehyde 55 in 7 steps from methyl (S)-(+)-3-hydroxy-2-methylpropionate was 
previously reported. See: Mínguez, J.M.; Kim, S.-Y.; Giuliano, K.A.; Balachandran, R.; Madiraju, C.; Day, 
B.W.; Curran, D.P. Bioorg. Med. Chem. 2003, 11, 3335–3357. 
(55)  Evans, D.A.; Fitch, D.M. J. Org. Chem. 1997, 62, 454–455. 
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diastereoselectivity. Substrate-controlled hydroboration 56  selectively established the C18 
methyl stereocenter and afforded γ-lactone 77 in very good yield upon oxidative workup. 
Oxidative ring opening, C16–C17 olefination, and reduction of Weinreb amide 78 gave 
aldehyde 55 in good overall yield. 
Scheme 2.14. Synthesis of C16–C21 aldehyde 55. 
 
Reagents and conditions: (a) Bu2BOTf, EtN(iPr)2, –78 °C to 0 °C, dr > 95:05, 88%; (b) TBSOTf, 2,6-lut., 
CH2Cl2, –78 °C to –20 °C, 98%; (c) 9-BBN, THF, 0 °C; aq H2O2, pH 7 buffer, EtOH, 0°C to rt; cat. KOt-Bu, 
THF, 0 °C to rt, dr = 95:05, 84%; (d) Me(MeO)NH•HCl, AlMe3, THF, –40 °C to 0 °C; (e) SO3•Py, EtN(iPr)2, 
DMSO, CH2Cl2, –30 °C to 0 °C; (f) Ph3PPMeBr, NaHMDS, THF, –78 °C to 0 °C, 74% (3 steps); (g) DIBALH, 
CH2Cl2, –78 °C, 77%. 
 The synthesis of C16–C26 enolsilane 83 57  continued with the trityl-catalyzed40 
addition of Chan's diene42 (56) to C16–C21 aldehyde 55 to form Felkin aldol adduct 79 in 
very good yield and excellent diastereoselectivity (Scheme 2.15). Prasad 1,3-syn reduction58 
was followed by cerium-mediated conversion of ester 80 to its corresponding allylsilane59 and 
global desilylation to produce triol 81 in good yield. Selective protection of the C23 carbinol 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(56)  (a) Still, W.C.; Barrish, J.C. J. Am. Chem. Soc. 1983, 105, 2487–2489; (b) Midland, M.M.; Kwon, Y.C. J. 
Am. Chem. Soc. 1983, 105, 3725–3727. 
(57)  The synthesis of C16–C26 enolsilane 83 from methyl ester 80 was designed in collaboration with Dr. Peter 
H. Fuller, and executed by Dr. Fuller. 
(58)  Chen, K.-M.; Hardtmann, G.E.; Prasad, K.; Repič, O; Shapiro, M.J. Tetrahedron Lett. 1987, 28, 155–158. 
(59)  (a) Anderson, M.B.; Fuchs, P.L. Synth. Commun. 1987, 17, 621–635; (b) Narayanan, B.A.; Bunnelle, W.H. 
Tetrahedron Lett. 1987, 28, 6261–6264; (c) Lee, T.V.; Channon, J.A.; Cregg, C.; Porter, J.R.; Roden, F.S.; 
Yeoh, H.T.-L. Tetrahedron 1989, 45, 5877–5886; (d) Bunnelle, W.H.; Narayanan, B.A. Org. Synth. 1990, 
69, 89–92; Org. Synth. 1993, Coll. Vol. 8, 602–605. 
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as its triisopropylsilyl ether, 1,3-syn acetonide formation and Wacker oxidation60 of the C16–
C17 alkene produced methyl ketone 82 in good overall yield and 15 linear steps. The 
synthesis was capped by formation of enolsilane 83 in preparation for the C15–C16 
Mukaiyama aldol reaction. 
Scheme 2.15. Synthesis of C16–C26 enolsilane 83. 
 
Reagents and conditions: (a) Ph3PCPF6 (5 mol%), CH2Cl2, –78 °C; PPTS, MeOH, 0 °C to rt, dr > 95:05, 84%; 
(b) Et2BOMe, NaBH4, THF, MeOH, –78 °C to –50 °C; aq H2O2, pH 7 buffer, MeOH, –50 °C to rt, dr > 95:05, 
87%; (c) TMSOTf, 2,6-lut., CH2Cl2, –78 °C to rt; (d) TMSCH2MgBr, CeCl3, THF, Et2O, –78 °C to rt; (e) HF•py, 
CH2Cl2, 0 °C to rt, 76% (3 steps); (f) TIPSCl, imidazole, DMF, rt to 45 °C, 91%; (g) Me2C(OMe)2, PPTS, 
acetone, rt, 93%; (h) PdCl2(quinox), AgSbF6, aq t-BuOOH, CH2Cl2, 0 °C to rt, 86%; (i) TMSOTf, Et3N, CH2Cl2, 
–78 °C to –20 °C, 99%. 
 Our synthesis of C3–C26 ketone 85 concluded with merging of the C3–C15 and C16–
C26 fragments (Scheme 2.16). Encouraged by results obtained before the structural revision, 
the trityl-catalyzed40 addition of enolsilane 83 to aldehyde 74 proceeded in similar fashion to 
produce the desired Felkin aldol adduct 84 as a single C15 diastereomer in very good yield. 
Prasad 1,3-syn reduction58 was followed by acetonide formation and ozonolysis to provide 
C3–C26 ketone 85 in good overall yield and 20 linear steps. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(60)  Michel, B.W.; Camelio, A.M.; Cornell, C.N.; Sigman, M.S. J. Am. Chem. Soc. 2009, 131, 6076–6077. 
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Scheme 2.16. Synthesis of C3–C26 ketone 85. 
 
Reagents and conditions: (a) Ph3PCPF6 (3 x 10 mol%), CH2Cl2, –78 °C; PPTS, MeOH, 0 °C, dr > 95:05, 84%; 
(b) Et2BOMe, NaBH4, THF, MeOH, –78 °C to –20 °C; aq H2O2, pH 7 buffer, MeOH, –20 °C to rt, dr > 95:05, 
87%; (c) Me2C(OMe)2, PPTS, acetone, rt, 85%; (d) O3, py, EtOH, CH2Cl2, –78 °C; Me2S, –78 °C to rt, 81%. 
IV. Synthesis of the C27–C48 Aldehyde61 
 Our synthesis plan for C27–C48 aldehyde fragment 86 was designed to take advantage 
of the anti-Felkin selective α-oxygenated aldol reaction developed specifically for the C33–
C36 stereochemical array (Scheme 2.17).62  We presumed that the intervening structural 
revision would have minimal impact on reaction diastereoselectivity, and therefore decided to 
target the same C35–C36 aldol bond disconnection. This act produced C36–C48 ketone 88 
and C27–C35 aldehyde 87, the latter of which could be accessed stereoselectively from C27–
C31 aldehyde 91 via a series of allylation, ring-closing metathesis and dihydroxylation steps. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(61)  The synthesis of C27–C48 aldehyde 117 was designed and performed by the author in collaboration with 
Dr. Egmont Kattnig. 
(62)  (a) Glorius, F. Development of α-Oxygenated Aldol Methodology and Progress Towards the Synthesis of 
Aflastatin A. Postdoctoral Report, Harvard University, 2001; (b) Evans, D.A.; Glorius, F.; Burch, J.D. Org. 
Lett. 2005, 7, 3331–3335. 
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Scheme 2.17. Retrosynthesis plan for C27–C48 aldehyde 86. 
 
 Two syntheses of C36–C48 ketone 88 were achieved before the structural revision 
(Scheme 2.18). The first route62a featured the copper-catalyzed, enantioselective aldol addition 
of silylketene acetal 93 to benzyloxy acetaldehyde (92). 63  The resulting absolute 
stereochemistry of the C37 carbinol was then relayed to C39 by Evans-Tishchenko 1,3-anti 
reduction,64 and ultimately produced gram-scale quantities of ketone 88 in 9 steps, 46% 
overall yield and 98% ee. A shorter, second route65 was based upon the enantioselective 
methallylation66 of decanal, providing the desired fragment in 6 steps, 36% unoptimized 
overall yield and 96% ee. 
 Our synthesis of the C27–C48 aldehyde began with the preparation of C27–C31 
aldehyde 91 from methyl α-D-(+)-glucopyranoside (99) (Scheme 2.19). Regioselective 
dibenzylation,67 iodination68 and silylation produced pyranoside 101 in good overall yield. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(63)  (a) Evans, D.A.; Murry, J.A.; Kozlowski, M.C. J. Am. Chem. Soc. 1996, 118, 5814–5815; (b) Evans, D.A.; 
Kozlowski, M.C.; Murry, J.A.; Burgey, C.S.; Campos, K.R.; Connell, B.T.; Staples, R.J. J. Am. Chem. Soc. 
1999, 121, 669–685; (c) Allison, B.D. Chelate Control: A Pivotal Design Element in Asymmetric Synthesis. 
Ph.D. Thesis, Harvard University, 2001. 
(64)  Evans, D.A.; Hoveyda, A.H. J. Am. Chem. Soc. 1990, 112, 6447–6449. 
(65)  Thaisrivongs, D.A. Synthesis of the C5'–C2 and C36–C48 Subunits of Aflastatin A. A.B. Thesis, Harvard 
University, 2007. 
(66)  (a) Keck, G.E.; Tarbet, K.H.; Geraci, L.S. J. Am. Chem. Soc. 1993, 115, 8467–8468; (b) Keck, G.E.; 
Krishnamurthy, D.; Grier, M.C. J. Org. Chem. 1993, 58, 6543–6544; (c) Keck, G.E.; Krishnamurthy, D. 
Org. Synth. 1998, 75, 12–18. 
(67)  Français, A.; Urban, D.; Beau, J.-M. Angew. Chem., Int. Ed. 2007, 46, 8662–8665. 
OBn
31
OR
C9H1939
OR
H
O
R3SiO RO
OR
OR
OR
OR
O
35
86
27
36
oxygenated
aldol addition OBn
31
OR
C9H1939
OTBS
RO
R3SiO RO
O
OTBS
O
O
O
35
88
27 H
Me
Me
87
BnO
31
O
TBSO
TBSO BnO
27 H
91
30
OBn
31
O
RO
R3SiO RO
27
1,2-synchelate-
controlled
addition OBn
31
O
RO
R3SiO RO
27
89
O
O
O
Me
Me
33
34
O
RCM
90
32
	   42 
Zinc-mediated fragmentation69 and in situ reduction produced an intermediate enol that was 
silylated and oxidatively cleaved, ultimately furnishing C27–C31 aldehyde 91 in eight steps 
and 52% overall yield. 
Scheme 2.18. Previous syntheses of C36–C48 ketone 88. 
 
Reagents and conditions: (a) (S,S)-94, CH2Cl2, –78 °C; aq HCl, THF, rt, 93%, 98% ee; (b) Me(MeO)NH•HCl, 
AlMe3, THF, –15 °C to rt, 97%; (c) Pd/C, H2, EtOAc, rt, 98%; (d) TBSCl, imidazole, THF, CH2Cl2, 0 °C, 92%; 
(e) C9H19MgBr, THF, 0 °C to rt, 66%; (f) SmI2, iPrCHO, THF, –10 °C, dr > 99:01, 91%; (g) TBSOTf, 2,6-lut., 
CH2Cl2, 0 °C, 99%; (h) DIBALH, PhMe, –78 °C, 97%; SO3•Py, Et3N, DMSO, CH2Cl2, –55 °C to 0 °C, 98%; (j) 
(S)-(–)-1,1'-bi-2-naphthol, Ti(OiPr)4, 4 Å MS, CH2Cl2, –78 °C to –20 °C, 74%, 96% ee; (k) TBSCl, imidazole, 
DMF, rt, 83%; (l) O3, py, CH2Cl2, MeOH, –78 °C; Me2S, –78 °C to rt, quant.; (m) LDA, THF; TMSCl, Et3N, –
78 °C to rt; (n) m-CPBA, NaHCO3, CH2Cl2, 0 °C to rt; aq HCl, THF, H2O, rt; (o) TBSCl, imidazole, DMF, rt to 
50 °C, 58% (3 steps). 
Scheme 2.19. Synthesis of C27–C31 aldehyde 91. 
 
Reagents and conditions: (a) TMSCl, py, CH2Cl2, 0 °C to rt, quant.; (b) PhCHO, Cu(OTf)2, CH2Cl2, MeCN; 
Et3SiH, 0 °C to rt; (c) BH3•THF, Cu(OTf)2, 82% (2 steps); (d) PPh3, I2, imidazole, PhMe, MeCN, rt, 97%; (e) 
TBSCl, imidazole, CH2Cl2, 0 °C to rt, quant.; (f) Zn, THF, H2O, ))), 45 °C; NaBH4, 0 °C, 88%; (g) TBSCl, 
imidazole, CH2Cl2, 0 °C to rt, 92%; (h) O3, py, CH2Cl2, MeOH, –78 °C; PPh3, –78 °C to rt, 94%. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(68)  (a) Garegg, P.J.; Samuellson, B. J. Chem. Soc., Perkin Trans. I. 1980, 2866–2869; (b) Garegg, P.J.; 
Johansson, R.; Ortega, C.; Samuellson, B. J. Chem. Soc., Perkin Trans. I. 1982, 681–683. 
(69)  Skaanderup, P.R.; Hyldtoft, L.; Madsen, R. Monatsh. Chem. 2002, 133, 467–472. 
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 Our synthesis of the C27–C48 aldehyde continued with the stereoselective allylation 
of syn α,β-bisalkoxy aldehyde 91 (Scheme 2.20). Although both α- and β-oxygen 
substituents were available for chelation,70 the rate of reaction of allylmagnesium bromide 
with the five-membered chelate43 was significantly faster,71 producing homoallylic alcohol 
102 in 96% yield and excellent diastereoselectivity (dr ≥ 93:07). We observed that the nature 
of the nucleophile20,24 and distal carbinol protecting groups (at C27 and C28)20 were important 
for maintaining excellent diastereoselection. 
Scheme 2.20. Synthesis of C27–C35 aldehyde 106. 
 
Reagents and conditions: (a) MgBr2•OEt2, allylMgBr, CH2Cl2, Et2O, PhMe, –78 °C, 96%, dr ≥ 93:07; (b) acrylic 
pivalic anhydride, EtN(iPr)2, DMAP, THF, PhH, rt, 94%; (c) (Ph3P)2Cl2Ru=CHPh, PhH, 65 °C, 92%; (d) RuCl3, 
CeCl3•7H2O, NaIO4, EtOAc, MeCN, H2O, 0 °C, dr ≥ 95:05; (e) Me2C(OMe)2, PPTS, acetone, 30 °C, 69% (2 
steps); (f) LiBH4, THF, H2O, 0 °C to rt; (g) PivCl, py, 0 °C to rt, 78% (2 steps); (h) BnBr, NaH, nBu4NI, THF, 
0 °C to rt, 92%; (i) HF•py, py, THF, 0 °C to rt, 85%; (j) TESOTf, 2,6-lut., CH2Cl2, 0 °C, 91%; (k) DIBALH, 
CH2Cl2, PhMe, –78 °C, 90%; (l) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C, 95%. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(70)  The possibility of bicyclic chelates involving the aldehyde carbonyl and both oxygen substituents cannot be 
ruled out. See: (a) Charette, A.B.; Mellon C.; Rouillard, L.; Malenfant, E. Pure Appl. Chem. 1992, 64, 
1925–1931; (b) Charette, A.B.; Mellon C.; Rouillard, L.; Malenfant, E. Synlett 1993, 81–82. 
(71)  For examples that suggest five-membered magnesium chelates react much faster than six-membered 
chelates, see: (a) Frye, S.V.; Eliel, E.L.; Cloux, R. J. Am. Chem. Soc. 1987, 109, 1862–1863; (b) Williams, 
D.R.; Klingler, F.D. Tetrahedron Lett. 1987, 28, 869–872; (c) Keck, G.E.; Andrus, M.B.; Romer, D.R. J. 
Org. Chem. 1991, 56, 417–420; (d) Burgess, K.; Chaplin, D.A. Tetrahedron Lett. 1992, 33, 6077–6080. 
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 Acryloylation72 of the nascent C31 carbinol, and ring-closing metathesis73 of the 
intermediate diene then furnished unsaturated lactone 103. Stereoselective dihydroxylation74,75 
and acetonide formation produced lactone 104 as a single diastereomer. Reduction to the diol, 
selective protection of the primary carbinol, and benzylation yielded pivalate ester 105. Silyl 
protecting group exchange at C27 was necessary at this stage because selective removal of the 
TBS ether76 after C35–C36 aldol coupling would later prove difficult. Reductive removal of 
the ester and Parikh-Doering oxidation77 ultimately provided C27–C35 aldehyde 106 in 12 
steps and 27% overall yield from aldehyde 91. 
 With scalable routes to C36–C48 ketone 88 and C27–C35 aldehyde 106 in hand, the 
synthesis of the C27–C48 fragment was nearly complete. At this juncture, it was unclear how 
the revised stereochemistry (C28–C31) of aldehyde 106 would influence the 
diastereoselectivity of our planned C35–C36 aldol reaction. Addition of the corresponding (E) 
enolate of ketone 88 to this aldehyde produced the desired anti-Felkin product 107 in fairly 
good isolated yield but with unexpectedly diminished diastereoselection (Scheme 2.21, eq 9). 
A similar result was observed for an aldehyde (108) having the same relative configuration 
between C31 and C33 (Scheme 2.21, eq 10).20 Both examples deviated from the good yields 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(72)  Tanaka, A.; Suzuki, H.; Yamashita, K. Agric. Biol. Chem. 1989, 53, 2253–2256. 
(73)  Schwab, P.; France, M.B.; Ziller, J.W.; Grubbs, R.H. Angew. Chem. 1995, 107, 2179–2181; Angew. Chem., 
Int. Ed. 1995, 34, 2039–2041. 
(74)  (a) Plietker, B.; Niggemann, M. J. Org. Chem. 2005, 70, 2402–2405; (b) Plietker, B. Synthesis 2005, 2453–
2472. 
(75)  For examples of the diastereoselective dihydroxylation of related α,β-unsaturated δ-lactones using Upjohn 
conditions (OsO4, NMO), see: (a) Ghosh, A.K.; Kim, J.-H. Tetrahedron Lett. 2003, 44, 3967–3969; (b) 
Ramachandran, P.V.; Prabhudas, B.; Chandra, J.S.; Reddy, M.V.R. J. Org. Chem. 2004, 69, 6294–6304; 
(c) Bhaket, P.; Stauffer, C.S.; Datta, A. J. Org. Chem. 2004, 69, 8594–8601. 
(76)  Selective desilylation of the C27 carbinol was achieved under specific buffered conditions. See: Hu, T.; 
Takenaka, N.; Panek, J.S. J. Am. Chem. Soc. 2002, 124, 12806–12815. 
(77)  Parikh, J.R.; Doering, W.v.E. J. Am. Chem. Soc. 1967, 89, 5505–5507. 
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and excellent diastereoselectivities obtained prior to the C28–C31 stereochemical revision 
(Scheme 2.21, eqs 11,12).7,15 
Scheme 2.21. C35–C36 oxygenated aldol reactions. 
 
Reagents and conditions: (a) ketone 88, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 106, pentane, PhMe, –
78 °C to –20 °C, 66%, dr = 86:14; (b) ketone 88, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 108, pentane, 
PhMe, –78 °C to –20 °C, 65%, dr = 84:16; (c) ketone 88, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 110, 
pentane, PhMe, –78 °C to –20 °C, 73%, dr > 95:05; (d) ketone 88, Cy2BCl, Me2NEt, pentane, 0 °C to rt; 
aldehyde 112, pentane, –78 °C to –20 °C, 81%, dr > 95:05. 
 The reduced diastereoselection for the anti-Felkin product may be attributed to the 
inversion of relative configuration between the C31 and C33 carbinol stereocenters. When 
these stereocenters exist in a 1,3-anti relationship, anti-Felkin transition state 114 benefits 
both from dipole-dipole minimization and extension of the aldehyde's alkyl chain away from 
the reaction center (Figure 2.1A). When this relationship is inverted, the transition states 
(115–117) that lead to desired anti-Felkin products 107 and 109 become destabilized by 
unfavorable steric and/or electrostatic interactions, regardless of C31–C32 rotational isomer 
(Figure 2.1B). 
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Figure 2.1. C35–C36 oxygenated aldol anti-Felkin transition state possibilities. 
 Our synthesis of C27–C48 aldehyde 118 was completed in short order (Scheme 2.22). 
Silylation of aldol adduct 107 was followed by selective deprotection and oxidation77 at C27. 
This sequence provided C27–C48 fragment 118 in good overall yield and 24 linear steps. 
Scheme 2.22. Synthesis of C27–C48 aldehyde 118. 
 
Reagents and conditions: (a) TESOTf, 2,6-lut., CH2Cl2, 0 °C, 87%; (b) PPTS, CH2Cl2, MeOH, 0 °C to rt, quant.; 
(c) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C, 87%. 
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V. Synthesis of the C3–C48 Degradation Fragment78 
 Having completed the syntheses of both the C3–C26 and C27–C48 fragments, we 
ventured forward with the key aldol coupling (Scheme 2.23).20 Satisfyingly, chelate-
controlled addition of ketone 85 to aldehyde 118 under our soft enolization conditions 
delivered the desired β-hydroxy ketone 119 with excellent diastereoselection.28 We reduced 
the aldol adduct under Prasad's conditions58 to afford the corresponding 1,3-syn diol in good 
yield. Both steps were completely chemoselective and eliminated the need to mask the C37 
carbonyl. To conclude the synthesis of the target structure, the intermediate diol was subjected 
to a two-step deprotection sequence. We found that removal of the acetonide and silyl 
protecting groups was best achieved with hexafluorosilicic acid,79 but noted that removal of 
the C36 TBS ether was particularly troublesome and limited yield. Deprotection over longer 
reaction times, with larger excess reagent, or with resubjection of incompletely deprotected 
material to the original reaction conditions increased overall conversion at the cost of 
decomposition. Ultimately, the remaining benzyl ethers were cleaved to unveil C3–C48 
degradation fragment 20 in modest overall yield and 28 linear steps. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(78)  The synthesis of C3–C48 degradation fragment 20 was first performed by Dr. Egmont Kattnig in 
collaboration with Dr. Peter H. Fuller and the author. 
(79)  (a) Pilcher, A.S.; Hill, D.K.; Shimshock, S.J.; Waltermire, R.E.; DeShong, P. J. Org. Chem. 1992, 57, 
2492–2495; (b) Pilcher, A.S.; Shimshock, S.J. J. Org. Chem. 1993, 58, 5130–5134. 
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Scheme 2.23. Synthesis of C3–C48 degradation fragment 20. 
 
Reagents and conditions: (a) MgBr2•OEt2, PMP, CH2Cl2, –5 °C, 60%, dr = 95:05; (b) Et2BOMe, NaBH4, THF, 
MeOH, –78 °C to –55 °C; aq H2O2, pH 7 buffer, MeOH, 0 °C to rt; pinacol, MeOH, 50 °C, 68%, dr = 95:05; (c) 
aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt; (d) H2, Pd black, dioxane, H2O, rt, 35% (2 steps). 
 Careful comparison of our NMR spectroscopic data for C3–C48 degradation fragment 
20 to that reported by the isolation group for the naturally derived degradation product 
revealed a structural misassignment.20 To our surprise, the chemical shifts of the reassigned 
stereocenters (C8, C9, C28–C31) were in reasonable agreement with our data, but significant 
differences were observed in the C33–C39 lactol (hemiketal) region. The solution to this 
structural curiosity and our structural reassignment of naturally derived degradation product 
20 will be discussed in Chapter 3. 
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VI. Graphical Summary 
Synthesis of C27–C31 Lactone 104 
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Synthesis of C27–C48 Aldehyde 118 
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Chapter 
3 
Structural Revision of the C3–C48 Degradation Fragment 
of Aflastatin A 
 
I. Development of a Model for the C27–C48 Lactol Region1 
 We anticipated that synthesis of C3–C48 degradation fragment 1 and comparison of 
its NMR spectroscopic data to that reported by the isolation group2 would corroborate the 
stereochemical revision of aflastatin A (AsA).2b,3 Despite favorable agreement between our 
data4 and the chemical shifts of the reassigned stereocenters in the C8–C9 diol and C27–C31 
pentaol regions, we became disappointed when significant differences appeared in the region 
loosely bound by C33 and C39 (Figure 3.1). 
 Our analysis revealed a structural misassignment in the lactol region of naturally 
derived degradation fragment 1.4 Since the isolation group reported mass spectrometry data 
for this molecule,2a we believed the correct structure to be an isomer of C53H106O22. We could 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(1)  A model for the C27–C48 lactol region was developed by Dr. Egmont Kattnig in collaboration with Dr. 
Peter H. Fuller and the author. 
(2)  (a) Ikeda, H.; Matsumori, N.; Ono, M.; Suzuki, A.; Isogai, A.; Nagasawa, H.; Sakuda, S. J. Org. Chem. 
2000, 65, 438–444; (b) Sakuda, S.; Matsumori, N.; Furihata, K.; Nagasawa, H. Tetrahedron Lett. 2007, 48, 
2527–2531. 
(3)  Higashibayashi, S.; Czechtizky, W.; Kobayashi, Y.; Kishi, Y. J. Am. Chem. Soc. 2003, 125, 14379–14393. 
(4)  Kattnig, E. An Aldol Approach Toward Aflastatin A – Synthesis of the C3–C48 Polyol. Postdoctoral Report, 
Harvard University, 2011. 
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not rule out the possibility of constitutional isomerism, but the body of two-dimensional NMR, 
degradation and isotopic labeling experiments conducted by Sakuda and coworkers2,5 strongly 
suggested that the structural problem was stereochemical in origin. 
 
Figure 3.1. NMR data comparisons of synthetic to naturally derived degradation fragment 1. 
 We further analyzed the available data to better confine the suspected stereochemical 
misassignment to the C33–C39 region. At first we used Kishi's NMR database of 1,3,5,7-
tetraols6 to deduce the absolute configuration of the C27 stereocenter (Table 3.1).4 To begin, 
the absolute configurations of the C23 and C25 stereocenters had previously been established 
by Mosher ester and [13C]acetonide analyses,5c as well as the independent chemical syntheses 
of the AsA C9–C27 degradation fragment and its derivatives.7 We anticipated that the 
chemical shifts of the C23 and C25 carbon atoms would largely depend upon 1,3-
stereochemical relationships within the C21–C27 tetraol region, and be negligibly influenced 
by the surrounding polypropionate and pentaol regions. Comparison of the corresponding 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(5) (a) Sakuda, S.; Ono, M.; Furihata, K.; Nakayama, J.; Suzuki, A.; Isogai, A. J. Am. Chem. Soc. 1996, 118, 
7855–7856; (b) Ono, M.; Sakuda, S.; Ikeda, H.; Furihata, K.; Nakayama, J.; Suzuki, A.; Isogai, A. J. 
Antibiotics 1998, 51, 1019–1028; (c) Sakuda, S.; Ikeda, H.; Nakamura, T.; Nagasawa, H. Biosci. 
Biotechnol. Biochem. 2004, 68, 407–412. 
(6)  Kobayashi, Y.; Tan, C.-H.; Kishi, Y. Helv. Chim. Acta 2000, 83, 2562–2571. 
(7)  (a) Evans, D.A.; Trenkle, W.C.; Zhang, J.; Burch, J.D. Org. Lett. 2005, 7, 3335–3338; (b) Robles, O.; 
McDonald, F.E. Org. Lett. 2008, 10, 1811–1814. 
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values for AsA to Kishi's tetraols revealed a syn/syn/syn stereoarray. Additionally, the 
chemical shifts of C23 and C25 for the naturally derived2 and synthetic4 C3–C48 degradation 
fragments (1) were all within 0.6 ppm of each other, suggesting like syn/syn relationships 
about each carbon. If a syn/syn/anti stereochemical relationship existed in this region, we 
expected that the chemical shift of C25 would be approximately 69 ppm, or roughly 2 ppm 
lesser than C23.8 Since the absolute configurations of the C23 and C25 stereocenters were 
known, and the relative 1,3-syn relationship between C25 and C27 duly established, our 
analysis supported Sakuda's assignment for the C27 stereocenter. 
Table 3.1. Chemical shift analysis of the C21–C27 1,3,5,7-tetraol region.a 
 
a All chemical shifts (δ) are reported in ppm. b Measured in DMSO-d6. c Measured in pyridine-d5. d Value 
misreported. e Values misassigned. 
 We then compared the spectroscopic profiles of the C27–C31 pentaol regions of 
naturally derived2 and synthetic4 C3–C48 degradation fragments 1 (Table 3.2). Their vicinal 
proton-proton spin-coupling profiles were similar and suggested that the relative 
stereochemistry in this region be assigned as anti/syn/syn/syn, according to Kishi's NMR 
database of 1,2,3,4,5-pentaols.3 We did note that the C30 carbon atoms differed in chemical 
shift by 1.2 ppm, but suspected that such disagreement was an artifact of some stereochemical 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(8)  We assumed that our distribution of chemical shifts in pyridine-d5 would be similar to those observed by 
Kishi and coworkers in DMSO-d6 and methanol-d4. We did not expect intramolecular interactions (i.e. 
hydrogen-bonding networks) to significantly impact our analysis. 
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anomaly in the C33–C39 region.9 In the end, we trusted the coupling constant analysis and 
relayed the absolute stereochemistry of the C27 carbinol through the C27–C31 pentaol region, 
thereby supporting Sakuda's stereochemical revision of the C28–C31 stereocenters. 
Table 3.2. Data analysis of the C27–C31 pentaol region.a 
 
a All coupling constants (3JH,H) are reported in Hertz (Hz). b All chemical shifts (δ) are reported in ppm.                
c Measured in pyridine-d5. d Values reassigned in 2007. 
 The preceding analyses (Tables 3.1 and 3.2) allowed us to relay the absolute 
configurations of C23 and C25 to C27 and eventually the entire C27–C31 pentaol region. As 
such, we limited the potential stereochemical problem to the C33–C39 region wherein the 
largest contiguous spectral discrepancies existed. 
 We next developed a model for the C33–C39 region to help us solve the structural 
curiosity.4 The model needed to be large enough so that the site of truncation would not affect 
the chemical shifts of the stereocenters in question. The NMR databases demonstrated that 
interactions between structural motifs connected directly (α) or with one bridging carbon (β) 
were significant.6 Although the influence of structural motifs located outside this "self-
contained box" was often negligible, the effects of the γ- and δ-positions on chemical shift 
profiles were recognizable in some cases.3 When applied to the C33–C39 region, we 
identified a self-contained box spanning from C29 to C43. Fortunately, our model studies did 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(9)  Medium coupling constant values (3JH,H and 2JC,H) were observed by Sakuda and coworkers about the C29–
C30 bond. Due to uncertainty in their J-based configuration analysis and our C30 chemical shift 
comparison, we could not fully exclude the possibility of an anti/syn/anti/syn relationship in this region. 
Protons Sakuda 1c
7.5
3.0
5.0
3.0
H27–H28
H28–H29
H29–H30
H30–H31
Evans 1c
7.0
2.5
5.5
2.5
R R
OHOH OH
27
anti/syn/syn/syn
Carbon Sakuda 1c
72.2d
76.2d
71.5
75.4
70.9
C27
C28
C29
C30
C31
Evans 1c
72.3
76.1
71.4
74.2
71.0
Coupling Constant Analysisa Chemical Shift Analysisb
OH OH
31
	   55 
not require consumption of advanced intermediate C3–C26 ketone. Rather, we quickly 
accessed C27–C48 lactol region model 3a from an intermediate used in the synthesis of C3–
C48 degradation fragment 1 (Scheme 3.1). 
Scheme 3.1. Synthesis of model C27–C48 lactol 3a. 
 
Reagents and conditions: (a) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt; (b) H2, Pd black, dioxane, H2O, rt, 44% (2 
steps). 
 As hoped, the chemical shifts for model lactol 3a and synthetic C3–C48 degradation 
fragment 1 were in good agreement, except at those positions (C27–C29) closest to the site of 
truncation (Figure 3.2).4 It followed that similar discrepancies in spectral data for the C33–
C39 region were seen between naturally derived2 C3–C48 degradation 1 and the truncated 
C27–C48 polyol 3a.  
 
Figure 3.2. NMR data comparisons of model C27–C48 lactol 3a to synthetic C3–C48 
degradation fragment 1. 
 As such, we determined that diastereomers of truncated polyol 3a could serve as 
suitable models of the lactol region in our future studies toward the stereochemical revision of 
AsA. Ideally, once a spectral match was obtained, we could parlay our work on that model 
diastereomer into the synthesis of a revised C27–C48 aldehyde fragment. 
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II. Syntheses of the epi-C39 and epi-C33–C37 Lactols 
 We revisited the chemical shift discrepancies between synthetic4 and naturally 
derived2 degradation fragments 1 and were intrigued that the largest numerical differences 
occurred from C36–C39 in the carbon spectra, and at H33, H38 and H39 in the proton spectra. 
These observations prompted us to question the stereochemical relationships between the 
C27–C31 pentaol region and the C33–C37 lactol, as well as the C33–C37 lactol and the 
isolated C39 stereocenter.  
 The absolute configurations at C39 and C33 of AsA were determined by optical 
rotation analyses of small degradation fragments 410 and 5, respectively (Figure 3.3).2a We 
noticed that the J-based configuration analysis11 used to link the absolute configurations of 
C31 and C33 before the stereochemical revision of AsA was later discarded.2b With this in 
mind, we decided to check the validity of the optical rotation data through chemical syntheses 
of epi-C39 and epi-C33–C37 lactol regions 3b and 3c, respectively. The latter diastereomer 
was designed to be epimeric at C33 and by necessity throughout the entire C33–C37 region in 
order to preserve the relative stereochemistry within the lactol ring, as supported by published 
coupling constant and NOE data.5a,b 
 
Figure 3.3. Design of model C27–C48 lactols 3b and 3c to probe optical rotation data. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(10)  Vining, L.C.; Taber, W.A. Can. J. Chem. 1962, 40, 1579–1584. 
(11)  Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. J. Org. Chem. 1999, 64, 866–876. 
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A. Synthesis of the epi-C39 Lactol12 
 The first truncated polyol that we targeted was the C39 epimer (3b). Our synthesis 
plan for this diastereomer targeted the same C35–C36 aldol bond disconnection,13 except that 
enantiomeric ketone ent-7 would be added to common aldehyde intermediate 6 (Scheme 3.2). 
Scheme 3.2. Synthesis plan for epi-C39 lactol 3b. 
 
 We took this opportunity to further improve the synthesis of the C36–C48 ketone 
(Scheme 3.3).14 Our route featured the iridium-catalyzed transfer hydrogenative allylation15 of 
1-decanol to give homoallylic carbinol ent-8 in very good yield and excellent enantioselection. 
Silylation and dihydroxylation16 afforded diol ent-9. Regioselective silylation and Parikh-
Doering oxidation17 then gave α-silyloxyketone ent-7 in five steps and good overall yield. 
Scheme 3.3. Synthesis of C36–C48 ketone ent-7. 
 
Reagents and conditions: (a) [Ir(cod)Cl]2 (2.5 mol%), (R)-(+)-BINAP, Cs2CO3, m-NO2BzOH, THF, 100 °C, 81%, 
95% ee; (b) TBSCl, imidazole, DMF, 0 °C to rt; (c) RuCl3, CeCl3•7H2O, NaIO4, EtOAc, MeCN, H2O, 0 °C, dr ~ 
1:1, 84% (2 steps); (d) TBSCl, imidazole, DMF, 0 °C to rt, 93%; (e) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –10 °C 
to 10 °C, 85%. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(12)  The synthesis of epi-C39 lactol 3b was achieved by the author in collaboration with Drs. Egmont Kattnig 
and Peter H. Fuller. 
(13)  (a) Glorius, F. Development of α-Oxygenated Aldol Methodology and Progress Towards the Synthesis of 
Aflastatin A. Postdoctoral Report, Harvard University, 2001; (b) Evans, D.A.; Glorius, F.; Burch, J.D. Org. 
Lett. 2005, 7, 3331–3335. 
(14)  This reaction sequence was designed and performed by Dr. Peter H. Fuller. 
(15)  Kim, I.S.; Ngai, M.-Y.; Krische, M.J. J. Am. Chem. Soc. 2008, 130, 14891–14899. 
(16)  (a) Plietker, B.; Niggemann, M. J. Org. Chem. 2005, 70, 2402–2405; (b) Plietker, B. Synthesis 2005, 2453–
2472. 
(17)  Parikh, J.R.; Doering, W.v.E. J. Am. Chem. Soc. 1967, 89, 5505–5507. 
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 With C27–C35 aldehyde 10 in hand,4 the synthesis of epi-C39 lactol 3b was three 
steps from completion (Scheme 3.4). Addition of the corresponding (E) enolate of ketone ent-
7 to aldehyde 10 produced the desired anti-Felkin product 11 in poor isolated yield18 but with 
a similar level of diastereoselection previously observed en route to lactol 3a (dr = 84:16). 
The inverted stereochemistry (C39) at the β'-position of ketone ent-7 had a minimal impact on 
C35–C36 aldol reaction diastereoselectivity. Ultimately, removal of the acetonide, silyl and 
benzyl protecting groups provided epi-C39 lactol 3b in serviceable yield. 
Scheme 3.4. Synthesis of epi-C39 lactol 3b. 
 
Reagents and conditions: (a) ketone ent-7, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 10, PhMe, –78 °C to –
25 °C, 16%, dr ~ 77:23; (b) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt, 50%; (b) H2, Pd black, dioxane, H2O, rt. 
B. Synthesis of the epi-C33–C37 Lactol19 
 The second truncated polyol that we targeted was the C33–C37 epimer (3c). Our 
synthesis plan for this diastereomer again targeted the C35–C36 aldol bond disconnection13 
because inversion of the entire lactol preserved the anti/syn/anti relationship required for this 
transform (Scheme 3.5). Additionally, we expected the diastereoselectivity of this reaction to 
be restored to the excellent levels seen before the revision since the relative configuration 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(18)  The quality of the chlorodicyclohexylborane used in this reaction was questionable. For the best results, we 
distilled Cy2BCl at least once every 3 months and stored it under argon in a Schlenck flask at –20 °C. 
(19)  The synthesis of epi-C33–C37 lactol 3c was achieved by the author in collaboration with Drs. Egmont 
Kattnig and Peter H. Fuller. 
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between the C31 and C33 carbinol stereocenters was again 1,3-anti.13b,20 The C27–C35 
fragment 14 would in turn be assembled via the double stereodifferentiating syn aldol addition 
of α,α'-bisoxygenated ketone 1521 to β-oxygenated aldehyde 16. We expected excellent 
diastereoselection due to the matched relationship between the ketone α'-stereocenter and the 
aldehyde β-stereocenter. Dipole-dipole minimization within both ketone22 and aldehyde23 
would determine their respective facial selectivities, and bond formation would occur on each 
reactant's less sterically hindered face. 
Scheme 3.5. Synthesis plan for epi-C33–C37 lactol 3c. 
 
 We took this opportunity to modify the protecting group scheme of the C36–C48 
ketone. We finally decided to protect the C36 carbinol as its TES ether24 rather than its TBS 
ether because removal of the latter protecting group during our previous fragment and model 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(20)  (a) Zhang, J. Studies Toward the Total Synthesis of (–)-Aflastatin A. Postdoctoral Report, Harvard 
University, 2003; (b) Burch, J.D. Complex Aldol Reactions for Polyketide Synthesis: I. Total Synthesis of 
Callipeltoside A. II. Synthesis of the C27–C48 Subunit of Aflastatin A. Ph.D. Thesis, Harvard University, 
2005. 
(21)  Chlorodicyclohexylboron-mediated aldol reactions of α-triethylsilyloxyketone 15 were known to produce 
syn products via the corresponding (Z) enolate. See: (a) Marco, J.A.; Carda, M.; Falomir, E.; Palomo, C.; 
Oiarbide, M.; Ortiz, J.A.; Linden, A. Tetrahedron Lett. 1999, 40, 1065–1068; (b) Carda, M.; Murga, J.; 
Falomir, E.; González, F.; Marco, J.A. Tetrahedron 2000, 56, 677–683; (c) Ribes, C.; Falomir, E.; Carda, 
M.; Marco, J.A. Org. Lett. 2007, 9, 77–80. 
(22)  (a) Masamune, S.; Choy, W.; Kerdesky, F.A.J.; Imperiali, B. J. Am. Chem. Soc. 1981, 103, 1566–1568; (b) 
Heathcock, C.H.; Arseniyadis, S. Tetrahedron Lett. 1985, 26, 6009–6012; (c) Bernardi, A.; Capelli, A.M.; 
Comotti, A.; Gennari, C.; Gardner, M.; Goodman, J.M. Paterson, I. Tetrahedron 1991, 47, 3471–3484. 
(23) Evans, D.A.; Dart, M.J.; Duffy, J.L.; Yang, M.G. J. Am. Chem. Soc. 1996, 118, 4322–4343. 
(24)  Boron-mediated aldol reactions of α-triethylsilyloxyketones were known. For examples, see: Ref. 21. 
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syntheses was difficult.4 The synthesis of C36–C48 ketone 13 (Scheme 3.6) was achieved in 
similar fashion to its pseudo-enantiomer ent-7 (Scheme 3.3). As a point of difference, 
regioselective triethylsilylation of diol 9 and oxidation17 of the intermediate C37 carbinol gave 
C36–C48 ketone 13 in five steps and good overall yield. 
Scheme 3.6. Synthesis of C36–C48 ketone 13. 
 
Reagents and conditions: (a) [Ir(cod)Cl]2 (2.5 mol%), (S)-(+)-BINAP, Cs2CO3, m-NO2BzOH, THF, 100 °C, 72%, 
≥ 90% ee; (b) TBSCl, imidazole, DMF, 0 °C to rt, 90%; (c) RuCl3, CeCl3•7H2O, NaIO4, EtOAc, MeCN, H2O, 
0 °C, dr ~ 1:1, 73%; (d) TESCl, EtN(iPr)2, CH2Cl2, –60 °C to –20 °C, 90%; (e) SO3•Py, EtN(iPr)2, DMSO, 
CH2Cl2, –30 °C to –20 °C, 99%. 
 The synthesis of epi-C33–C37 lactol 3c began with the preparation of ketone 15 in six 
steps from L-ascorbic acid,25 and aldehyde 16 in five steps from (–)-2,3-O-isopropylidene-D-
erythronolactone26 (Scheme 3.7). Addition of the (Z) boron enolate derived from ketone 15 to 
aldehyde 16 provided adduct in good yield with excellent diastereoselection. 27  Prasad 
reduction,28,29 protecting group manipulation, and oxidation17 provided aldehyde 19 in good 
overall yield. As expected, anti aldol addition of ketone 13 to this aldehyde provided adduct 
20 as a single diastereomer in good overall yield. Ultimately, the now standard two-step 
deprotection sequence yielded epi-C33–C37 lactol 3c. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(25)  Marco, J.A.; Carda, M.; González, F.; Rodríguez, S.; Murga, J. Liebigs Ann. Chem. 1996, 1801–1810. 
(26)  For steps related to the synthesis of aldehyde 16, see: (a) Choi, W.J.; Park, J.G.; Yoo, S.J.; Kim, H.O.; 
Moon, H.R.; Chun, M.W.; Jung, Y.H.; Jeong, L.S. J. Org. Chem. 2001, 66, 6490–6494; (b) Pirrung, 
F.O.H.; Hiemstra, H.; Speckamp, W.N.; Kaptein, B.; Schoemaker, H.E. Synthesis 1995, 458–472; (c) 
Brown, H.C.; Mandal, A.K.; Kulkarni, S.U. J. Org. Chem. 1977, 42, 1392–1398; (d) Kang, S.-K.; Jung, K.-
Y.; Chung, J.-U.; Namkoong, E.-Y.; Kim, T.-H. J. Org. Chem. 1995, 60, 4678–4679. 
(27)  The stereochemistry of the newly formed stereogenic center was determined by Mosher ester analysis. See: 
(a) Dale, J.A.; Mosher, H.S. J. Am. Chem. Soc. 1973, 95, 512–519; (b) Hoye, T.R.; Jeffrey, C.S.; Shao, F. 
Nat. Protoc. 2007, 2, 2451–2458. 
(28)  Chen, K.-M.; Hardtmann, G.E.; Prasad, K.; Repič, O; Shapiro, M.J. Tetrahedron Lett. 1987, 28, 155–158. 
(29) The stereochemistry of the newly formed stereogenic center was determined by [13C]acetonide analysis. 
See: Rychnovsky, S.D.; Rogers, B.N.; Richardson, T.I. Acc. Chem. Res. 1998, 31, 9–17. 
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Scheme 3.7. Synthesis of epi-C33–C37 lactol 3c. 
 
Reagents and conditions: (a) Cy2BCl, Et3N, Et2O, –78 °C to 0 °C, dr ≥ 95:05, 78% (2 steps); (b) Et2BOMe, 
NaBH4, THF, MeOH, –78 °C to 0 °C; aq H2O2, pH 7 buffer, MeOH, 0 °C to rt, 92%, dr ≥ 95:05; (c) CsF, THF, 
70 °C; BnBr, NaH, nBu4NI, 0 °C to rt, 72%; (d) DDQ, CH2Cl2, pH 7 buffer, 0 °C, no hν, 81%; (e) SO3•Py, 
EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C; (f) ketone 13, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 19, 
Et2O, –78 °C to –25 °C, dr ≥ 95:05, 56% (3 steps); (g) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt; (h) H2, Pd black, 
dioxane, H2O, rt. 
 After completing the syntheses of lactols 3b and 3c, we once again compared 
spectroscopic data. Coupling constant analysis (3JH31–H32) revealed that the stereochemical 
relationship between C31 and the lactol was correct in diastereomers 3a and 3b, but not epi-
C33–C37 lactol 3c (Table 3.3). As expected, the degradation fragments and model lactols all 
exhibited similar spin-coupling profiles around the C33–C37 lactol. 
Table 3.3. Coupling constant analysis of the C31–C36 region.a 
 
a All coupling constants (3JH,H) are reported in Hertz (Hz). b Measured in pyridine-d5. c Measured in methanol-d4. 
d Measured in DMSO-d6. 
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 Chemical shift analysis in the C38–C39 region was not as conclusive (Table 3.4). We 
were hard pressed to explain the relative positional flip of the H38 protons throughout the 
series. Ultimately, we surmised that the absolute configurations at both C33 and C39 were 
assigned properly.30 
Table 3.4. Chemical shift analysis of the C38–C39 region. 
 
a All chemical shifts (δ) are reported in ppm. b Measured in pyridine-d5. c Observed peak a doublet of doublets 
having two large coupling constants. d Observed peak a doublet of doublets having one large and one small 
coupling constant. 
III. Syntheses of Three Diastereomeric epi-C36 Lactols 
 Having substantiated the stereochemical assignments at C33 and C39 with our own 
data, we refocused on the remaining structural ambiguities in the lactol region. We reasoned 
that due to conformational and anomeric effects, the configuration at C33 should control C37, 
thus leaving three stereocenters (C34–C36) in question (Figure 3.4A). Now limited to eight 
possible diastereomers, we scrutinized the published spectra for further guidance. Out of all 
the peaks associated with the C34–C36 triol, one distinct doublet of doublets (dd) was 
identified in the 1H-NMR spectrum (Figure 3.4B).2a Assuming a chair conformation, the 
requirement that a proton within the lactol ring exhibit one large (L) and one small (S) 
coupling constant (or be anti and gauche to vicinal protons, respectively) reduced the field to 
four diastereomers (Figure 3.4C), one of which was the originally assigned structure (3a). Our 
highest priority became the synthesis of a structure (3d) that agreed with the proposed 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(30) The corresponding C31 and C37 stereocenters of blasticidin A were assigned the same absolute 
configuration. See: (a) Sakuda, S.; Ono, M.; Ikeda, H.; Inagaki, Y.; Nakayama, J.; Suzuki, A.; Isogai, A. 
Tetrahedron Lett. 1997, 38, 7399–7402; (b) Sakuda, S.; Ono, M.; Ikeda, H.; Nakamura, T.; Inagaki, Y.; 
Kawachi, R.; Nakayama, J.; Suzuki, A.; Isogai, A.; Nagasawa, H. J. Antibiotics 2000, 53, 1265–1271. 
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assignment of this peak to H35 (Figure 3.4D). Should we suspect that the two-dimensional 
NMR correlation data had been misinterpreted and the peak actually corresponds to H34, both 
structures 3e and 3g would become viable synthesis candidates. We were open to this 
possibility because a similar error may have led to the correction (and formal swap) of 
chemical shift data sets for C27 and C28 when the stereochemical revision was reported.2b 
 
Figure 3.4. Design of model C27–C48 lactols 3d, 3e and 3g to probe two-dimensional NMR 
correlation data. Abbreviations: d = doublet, t = triplet, S = having a small J value(s), L = 
having a large J value(s). 
A. Synthesis of the epi-C34,C36 Lactol31  
 Under this rationale, we first targeted the synthesis of epi-C34,C36 lactol 3d. Since the 
relative stereochemistry of the C33–C36 tetraol region was changed, we could no longer form 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(31)  The synthesis of epi-C34,C36 lactol 3d was achieved by Dr. Peter H. Fuller in collaboration with the 
author. 
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the C35–C36 bond by anti-Felkin-selective oxygenated aldol addition.13 Instead, we tried to 
form this bond by the Cornforth-selective syn aldol addition32 of ketone 13 to aldehyde 21, 
but these efforts were stymied by an unexpected reversal in enolate regioselectivity33 (eq 1). 
 
 We then modified our synthesis plan such that the assembly of the C33–C36 
syn/anti/syn tetraol relied on the diastereoselective syn dihydroxylation16 of enone 24 
according to Kishi's empirical rule34 (Scheme 3.8). The C35–C36 bond of enone 24 would in 
turn be formed by the Horner-Wadsworth-Emmons reaction35 of β-ketophosphonate 26 and 
aldehyde 25. Then, given the success of our newly developed chelate-controlled aldol reaction, 
we anticipated applying our soft-enolization based method4 to the formation of the C32–C33 
bond via 1,2-chelate-controlled addition of ketone 27 to aldehyde 28. Based upon the Cram 
chelate model,36 we expected excellent selectivity for the desired 1,2-syn diastereomer via 
exclusive formation of five-membered chelate 29 and nucleophilic addition to the less 
sterically hindered face. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(32) (a) Cornforth, J.W.; Cornforth, R.H.; Mathew, K.K. J. Chem. Soc. 1959, 112–127; (b) Evans, D.A.; Siska, 
S.J.; Cee, V.J. Angew. Chem., Int Ed. 2003, 42, 1761–1765; (c) Cee, V.J. I. Asymmetric Induction in 
Heteroatom-Substituted Aldehydes. II. Total Synthesis of (+)-Casuarine. Ph.D. Thesis, Harvard University, 
2003. 
(33) Products resulting from α'-enolization were not observed in earlier chlorodicyclohexylboron-mediated 
aldol additions of C36–C48 ketones. See: Ref. 13. 
(34) (a) Cha, J.K.; Christ, W.J.; Kishi, Y. Tetrahedron Lett. 1983, 24, 3943–3946; (b) Cha, J.K.; Christ, W.J.; 
Kishi, Y. Tetrahedron 1984, 40, 2247–2255. 
(35)  (a) Horner, L.; Hoffman, H.; Wippel, H.G.; Klahre, G. Chem. Ber. 1959, 92, 2499–2505; (b) Wadsworth, 
W.S., Jr.; Emmons, W.D. J. Am. Chem. Soc. 1961, 83, 1733–1738. 
(36)  (a) Cram, D.J.; Abd Elhafez, F.A. J. Am. Chem. Soc. 1952, 74, 5828–5835; (b) Cram, D.J.; Kopecky, K.R. 
J. Am. Chem. Soc. 1959, 81, 2748–2755; (c) Cram, D.J.; Leitereg, T.H. J. Am. Chem. Soc. 1968, 90, 4019–
4026. 
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Scheme 3.8. Synthesis plan for epi-C34,C36 lactol 3d. 
 
 The synthesis of lactol 3d began with the preparation of ketone 27 in eight steps from 
methyl α-D-(+)-glucopyranoside, 37  aldehyde 28 in six steps from glycidol, 38  and β-
ketophosphonate 26 in three steps from diol 9 (Scheme 3.9).39 1,2-Chelation-controlled 
addition of ketone 27 to aldehyde 28 under soft enolization conditions proceeded with 
excellent diastereoselection. Prasad reduction28 of the intermediate adduct to diol 30, 
acetonide formation, desilylation and oxidation17 at C35 yielded aldehyde 32. Barium 
hydroxide-mediated addition40 of phosphonate 26 to this aldehyde provided (E) enone 33 as a 
single isomer in good overall yield. As predicted by Kishi's empirical rule,34 dihydroxylation16 
provided the desired 1,2-syn diol 34 in good yield and diastereoselection. Finally, the standard 
deprotection sequence gave epi-C34,C36 lactol 3d. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(37)  The synthesis of the C27–C31 aldehyde precursor to ketone 27 will be discussed in due course. 
(38)  (a) Kolakowski, R.V.; Williams, L.J. Tetrahedron Lett. 2007, 48, 4761–4764; (b) Furrow, M.E.; Schaus, 
S.E.; Jacobsen, E.N. J. Org. Chem. 1998, 63, 6776–6777. 
(39)  For an analogous synthesis of a structurally related β-ketophosphonate, see: Traoré, M.; Maynadier, M.; 
Souard, F.; Choisnard, L.; Vial, H.; Wong, Y.-S. J. Org. Chem. 2011, 76, 1409–1417. 
(40)  (a) Alvarez Ibarra, C.; Arias, S.; Fernández, M.J.; Sinisterra, J.V. J. Chem. Soc., Perkin Trans. II 1989, 
503–508; (b) Paterson, I.; Yeung, K.-S.; Smaill, J.B. Synlett 1993, 774–776. 
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Scheme 3.9. Synthesis of epi-C34,C36 lactol 3d. 
 
Reagents and conditions: (a) MgBr2•OEt2, PMP, CH2Cl2, –5 °C, dr ≥ 95:05; (b) Et2BOMe, NaBH4, THF, MeOH, 
–78 °C to 0 °C; aq H2O2, NaOH, MeOH, 0 °C to rt, dr ≥ 95:05, 56% (2 steps); (c) Me2C(OMe)2, PPTS, acetone, 
rt, quant.; (d) Et3N•HF, THF, 0 °C to rt, 95%; (e) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C; (f) 
Ba(OH)2, THF, H2O, 0 °C to 10 °C, 65% (2 steps); (g) RuCl3, CeCl3•7H2O, NaIO4, EtOAc, MeCN, H2O, 0 °C, 
76%, dr ≥ 90:10; (h) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt, ~70%; (i) H2, Pd black, dioxane, H2O, rt. 
 After completing the synthesis of lactol 3d, we were initially disappointed by how 
poorly its spectroscopic data matched that of polyol 1. Upon further analysis, we did observe 
a favorable exchange of the H38 resonances, most likely resulting from the inverted 
configuration at C36, and decided this effect deserved further investigation. Accordingly, we 
prioritized the synthesis of epi-C35,C36 lactol 3e over that of epi-C35 lactol 3g. 
B. Synthesis of the epi-C35,C36 Lactol41  
 Somewhat serendipitously, a precursor to epi-C35,C36 lactol 3e had already been 
isolated as the minor (Felkin) diastereomer in the earlier anti aldol addition of ketone 7 to 
aldehyde 35 (Scheme 3.10). Two-step global deprotection of this aldol product provided epi-
C35,C36 lactol 3e. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(41)  The synthesis of epi-C35,C36 lactol 3e was achieved by the author in collaboration with Dr. Peter H. Fuller. 
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Scheme 3.10. Synthesis of epi-C35,C36 lactol 3e. 
 
Reagents and conditions: (a) ketone 7, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 35, PhMe, –78 °C to –
20 °C, 66%, dr = 14:86; (b) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt, 53%; (c) H2, Pd black, dioxane, H2O, rt. 
 Comparison of the spectroscopic data for lactol 3e with naturally derived2 degradation 
polyol 1 produced the best chemical shift match to date for the methylene protons at C32 and 
C38 while maintaining the same beneficial interchange of H38 resonances that were observed 
for lactol 3d. The excellent overlay of these diagnostic peaks suggested that the relative 
stereochemistries in lactol 3e between the C34 stereocenter and the C27–C31 pentaol region, 
and the C36 stereocenter and the isolated C39 stereocenter, were correct. Disappointingly, 
much of the spectroscopic data within the lactol ring itself still exhibited poor overlay. We 
hypothesized that this could be rectified by inverting the stereochemistry at C35 to its 
originally assigned configuration (Figure 3.5). In doing so, we discredited a coupling constant 
that was assigned to this region (3JH-35,H-36 = 3 Hz).5a The possibility that a coupling constant 
had been measured incorrectly was not so unreasonable since the correction of one value   
(3JH-9,H-10) by the isolation group led to the stereochemical revision of the AsA C8–C9 diol 
region.2b Unfortunately, this possibility was also inconsistent with our previous spectral 
analysis, namely the assumption that a doublet of doublets (having one small J value of about 
3 Hz) corresponds to either H34 or H35. Out of both desperation and curiosity, we proceeded 
anyway with the synthesis of lactol 3f. 
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Figure 3.5. Design of epi-C36 lactol 3f to probe the H35–H36 coupling constant. 
C. Synthesis of the epi-C36 Lactol42  
 Our synthesis plan for epi-C36 lactol 3f relied on the formation of the C36–C37 and 
C32–C33 bonds by a series of chelation-controlled additions (Scheme 3.11). We began with 
formation of the C36–C37 bond via 1,2-chelate-controlled addition of the organomagnesiate 
of vinyl bromide 39 to α-benzyloxy aldehyde 38.43 Based upon the Cram chelate model,36 we 
expected excellent selectivity for the desired 1,2-syn diastereomer via exclusive formation of 
a five-membered chelate. Similarly, we expected that addition of ketone 27 to the six-
membered chelate of aldehyde 40 would afford the desired 1,3-anti relationship in C27–C36 
fragment 38. 
Scheme 3.11. Synthesis plan for epi-C36 lactol 3f. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(42)  The synthesis of epi-C36 lactol 3f was achieved by the author in collaboration with Dr. Peter H. Fuller. 
(43)  For similar chelation-controlled additions of vinylmagnesium reagents, see: (a) Heathcock, C.H.; 
McLaughlin, M.; Medina, J.; Hubbs, J.L.; Wallace, G.A.; Scott, R.; Claffey, M.M.; Hayes, C.J.; Ott, G.R. J. 
Am. Chem. Soc. 2003, 125, 12844–12849; (b) Terrell, L.R. The Total Synthesis of the Assigned Structure of 
Amphidinolide A. Ph.D. Thesis, Michigan State University, 2001. 
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 The synthesis of lactol 3f began with the preparation of aldehyde 40 in five steps from 
cinnamaldehyde44 (Scheme 3.12). 1,3-Chelation-controlled addition of ketone 27 to aldehyde 
40 under soft enolization conditions4 proceeded with excellent diastereoselection. Prasad 
reduction28 of the intermediate adduct furnished diol 41. Acetonide formation, desilylation 
and oxidation17 at C36 yielded aldehyde 43. Addition of the magnesiated carbanion of vinyl 
bromide 3945 to this aldehyde provided the desired 1,2-syn adduct as a single diastereomer in 
very good overall yield. Silylation and ozonolysis were followed by the standard deprotection 
sequence to give epi-C36 lactol 3f. 
Scheme 3.12. Synthesis of epi-C36 lactol 3f. 
 
Reagents and conditions: (a) MgBr2•OEt2, PMP, CH2Cl2, –5 °C, dr ≥ 94:06; (b) Et2BOMe, NaBH4, THF, MeOH, 
–78 °C to 0 °C; aq H2O2, pH 7 buffer, MeOH, 0 °C to rt, dr ≥ 95:05; (c) Me2C(OMe)2, PPTS, acetone, rt; (d) 
PPTS, CH2Cl2, MeOH, 0 °C to rt, 73% (4 steps); (e) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C; (f) 
bromide 39, t-BuLi, Et2O, pentane, –78 °C; MgBr2•OEt2, Et2O, PhH, –78 °C to 0 °C; aldehyde 43, CH2Cl2, –
78 °C to 0 °C, dr ≥ 95:05, 85% (2 steps); (g) TESCl, imidazole, nBu4NI, DMF, 0 °C to 60 °C, 73%; (h) O3, py, 
CH2Cl2, MeOH, –78 °C; PPh3, –78 °C to rt, 58%; (i) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt, 61%; (c) H2, Pd black, 
dioxane, H2O, rt. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(44)  Evans, D.A.; Cee, V.J.; Siska, S.J. J. Am. Chem. Soc. 2006, 128, 9433–9441.  
(45)  Vinyl bromide 39 may be prepared in two steps from decanal. See: Zhang, Z.; Huang, J.; Ma, B.; Kishi, Y. 
Org. Lett. 2008, 10, 3073–3076. 
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 Comparison of the spectroscopic data for lactol 3f with naturally derived2 degradation 
polyol 1 produced a better chemical shift match than lactol 3e for the H32 methylene protons, 
but an unexpectedly greater mismatch for the H38 protons (Table 3.5). Full comparison of the 
three diastereomeric epi-C36 lactols indicated that the absolute configuration of C34 in lactols 
3e and 3f (as originally assigned) was correct. Unfortunately, chemical shift analysis of the 
C38 protons was not conclusive regarding the relationship between the C36 and C39 
stereocenters. Although we observed a beneficial interchange of H38 resonances across the 
series, we could never achieve a full spectroscopic profile match for the lactol region of 
naturally derived2 degradation fragment 1. At this point in our search, we judged that we had 
exhausted all reasonable stereochemical possibilities and decided to discontinue the syntheses 
of more C27–C48 lactol diastereomers. 
Table 3.5. Chemical shift analysis of C32 and C38 for epi-C36 lactols 3d–f.a,b 
 
a All chemical shifts (δ) are reported in ppm. b Measured in pyridine-d5. 
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IV. A Solution to the Structural Problem46 
 Despite achieving the syntheses of model C27–C48 lactol 3a and five of its 
diastereomers (3b–3f), we were left without a suitable spectroscopic match for naturally 
derived2 C3–C48 degradation product (née "lactol") 1. Prior comparisons of proton chemical 
shift data left the relationship between the C33–C37 lactol and the isolated C39 stereocenter 
unclear, so we shifted focus to the chemical shift of the C37 lactol carbon. 
 Having believed the structural issue to be stereochemical in origin for so long, we 
were delighted to realize that our data for the C37 lactol carbon of model C27–C48 lactol 3a 
closely matched that reported for the C35 lactol carbon of the structurally related blasticidin A 
(BcA) C3–C47 degradation lactol 47 (Table 3.6).47 Generally speaking, the chemical shift of 
the C37 carbon in all model C27–C48 diastereomers more closely matched that of the BcA 
C35 lactol carbon than the C37 carbon of naturally derived2 AsA C3–C48 degradation 
product 1. Furthermore, literature data for the C37 carbon of naturally derived AsA 
degradation product 1 closely matched that reported for the BcA degradation lactol methyl 
ether 48.47,48 
 These observations prompted us to formally convert model C27–C48 lactol 3a to its 
lactol methyl ether 51a (Scheme 3.13). The synthesis of model C27–C48 lactol methyl ether 
51a was accomplished in four steps from aldol adduct 49. Removal of the acetonide and silyl 
protecting groups was interrupted to ease the subsequent purification of lactol methyl ether 50. 
Cleavage of the C36 TBS ether was followed by debenzylation to give lactol methyl ether 51a. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(46)  The solution to the structural problem was discovered by the author in collaboration with Dr. Peter H. 
Fuller. 
(47)  Sakuda, S.; Ikeda, H.; Nakamura, T.; Kawachi, R.; Kondo, T.; Ono, M.; Sakurada, M.; Inagaki, H.; Ito, R.; 
Nagasawa, H. J. Antibiotics 2000, 53, 1378–1384. 
(48)  For a complete comparison of tabulated spectral data for naturally derived and synthetic AsA C3–C48 
degradation lactols 1, see: Appendix 1. 
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Table 3.6. Chemical shift analysis of AsA C37 (BcA C35) for lactols and lactol methyl 
ethers.a 
 
a Measured in pyridine-d5. b Average δ = 100.2 ppm. c Later corrected to δ = 100.1 ppm.  
Scheme 3.13. Syntheses of model C27–C48 lactol methyl ethers 51a and 51b. 
 
Reagents and conditions: (a) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt, 50%; (b) PPTS, CH2Cl2, MeOH, rt, 63%; (c) 
nBu4NF, THF, 0 °C; TMSOMe; (d) H2, Pd black, dioxane, H2O, rt; (e) Dowex 50x8 (H+), CD3OD, rt. 
 The chemical shift of the C37 carbon of model C27–C48 lactol methyl ether 51a 
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(Table 3.7). We then became curious why the resonances belonging to the newly incorporated 
methyl group were absent from their NMR spectra of naturally derived degradation product 1. 
We hypothesized that during the course of their NMR spectroscopic studies,2a the isolation 
group dissolved AsA degradation lactol methyl ether 46a in methanol-d4 and inadvertently 
exchanged the methyl ether for its trideuteriomethyl ether (46b). To substantiate this proposal, 
we converted model lactol methyl ether 51a to trideuteriomethyl ether 51b in the presence of 
trace acid (Dowex) (Scheme 3.13). 
Table 3.7. Chemical shift analysis of AsA C37 for model lactol 3a, lactol methyl ethers 51a 
and 51b, and degradation fragment 1.a 
 
a Measured in pyridine-d5. 
 As expected, the chemical shift of the C37 carbon of model lactol trideuteriomethyl 
ether 51b correlated nicely with that reported for naturally derived AsA C3–C48 degradation 
product 1 (Table 3.7). In fact, model lactol ethers 51a and 51b were spectroscopically 
indistinct with the exception of the obvious resonances. Furthermore, the spectroscopic data 
for lactol trideuteriomethyl ether 51b provided us the best profile match for naturally derived 
degradation fragment 1 in the C27–C48 lactol region (Figure 3.6). The only data point that 
concerned us was the chemical shift of C36, but resolution of this difference between the two 
structures will be discussed in due course. 
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Figure 3.6. NMR data comparison of naturally derived C3–C48 degradation lactol 1 to model 
C27–C48 lactol trideuteriomethyl ether 51b. 
V. Syntheses of the C3–C48 Degradation Fragments 
 Now confident that we had found a solution to our structural problem, we pursued the 
syntheses of AsA C3–C48 degradation lactol methyl ether 46a and its trideuteriomethyl ether 
analogue (46b). Rather than retrace the route we had originally used to synthesize C3–C48 
degradation lactol 1, we decided to modify our synthesis plan for C27–C48 aldehyde 52 
(Scheme 3.14). We began with the usual C35–C36 aldol bond disconnection13 to produce 
C27–C35 aldehyde 6 and C36–C48 ketone 13. In this iteration, we decided to install a 
triethylsilyl ether at the C36 carbinol position of ketone 13,24 as we had in the synthesis of 
epi-C33–C37 lactol 3c, to facilitate global deprotection. Then, given the success of our newly 
developed 1,3-chelate-controlled aldol reaction, we anticipated extending our soft enolization-
based method4 to the formation of the C31–C32 bond via 1,2-chelate-controlled addition of 
ketone 54 to aldehyde 53. Based upon the Cram chelate model,36 we expected excellent 
selectivity for the desired 1,2-syn diastereomer via exclusive formation of five-membered 
chelate 55 and nucleophilic addition to the less sterically hindered face. 
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Scheme 3.14. Synthesis plan for C3–C48 degradation fragment 46a. 
 
 The synthesis of C27–C35 aldehyde 5349 commenced with the glycolate aldol addition 
of oxazolidinone 5750 to aldehyde 56,51 which afforded the desired syn adduct 58 in good 
yield and excellent diastereoselectivity (Scheme 3.15). Silylation and net reduction afforded 
α-benzyloxyaldehyde 53 in good overall yield. Chelate-controlled addition of C32–C35 
ketone 5452 to this C27–C31 aldehyde under our soft enolization conditions delivered the 
desired β-hydroxy ketone 59 on multigram scale.53 As before, our magnesium-promoted aldol 
process was found to exhibit exceptionally high asymmetric induction.27,54 Diastereoselective 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(49)  The synthesis of C27–C35 aldehyde 67 was first achieved by Dr. Egmont Kattnig using a chelation-
controlled/soft enolization-based approach. The synthesis of C27–C48 aldehyde 71 from redesigned C36–
C48 ketone 13 was then completed by the author in collaboration with Dr. Peter H. Fuller (vide infra). 
(50)  Evans, D.A.; Gage, J.R.; Leighton, J.L.; Kim, A.S. J. Org. Chem. 1992, 57, 1961–1963. 
(51)  Aldehyde 56 was prepared in two steps from L-gulonic acid γ-lactone. See: Hubschwerlen, C.; Specklin, J.-
L.; Higelin, J. Org. Synth. 1995, 72, 1–5. 
(52)  Ketone 54 was prepared in six steps from L-serine. See: Hirth, G.; Walther, W. Helv. Chim. Acta 1985, 68, 
1863–1871. 
(53)  Chelate-controlled Mukaiyama aldol addition of the corresponding enolsilane of ketone 54 to aldehyde 53 
was again unsuccessful. 
(54)  To make a more efficient synthesis, we would prefer to protect the C29 oxygen as its benzyl ether, but 
reaction of the corresponding aldehyde with ketone 54 under our soft enolization conditions produced an 
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carbonyl reduction55 was followed by desilylation to produce triol 60. Installation of the 
C33,C34 acetonide to produce the fully protected C27–C35 fragment 61 required three 
protecting group manipulations: PMP acetal formation,56 dibenzylation, and acetal exchange. 
Scheme 3.15. Synthesis of C27–C35 fragment 61. 
 
Reagents and conditions: (a) (nBu)2BOTf, Et3N, PhMe, –78 °C to –40 °C, dr > 95:05, 70%; (b) TESCl, 
imidazole, DMF, rt, 84%; (c) LiBH4, H2O, THF, 0 °C to rt, 92%; (d) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –40 °C 
to –10 °C, 93%; (e) MgBr2•OEt2, PMP, CH2Cl2, –5 °C, dr = 97:03, 72%; (f) Zn(BH4)2, CH2Cl2, Et2O, –78 °C, dr 
= 93:07, 86%; (g) PPTS, CH2Cl2, MeOH, 0 °C, 68%; (h) DDQ, 4 Å MS, CH2Cl2, 0 °C, 83%; (i) BnBr, NaH, 
nBu4NI, THF, 0 °C to rt, 88%; (j) Me2C(OMe)2, PPTS, acetone, 55 °C, 95%. 
 Alternatively, the fully protected C27–C35 fragment 61 may be accessed from 
dibenzylglucopyranoside 6257 in twelve steps (Scheme 3.16). Iodination,58 zinc-mediated 
fragmentation,59 in situ reduction, and protection of the resultant 1,2-diol produced acetonide 
63 in good overall yield. Ozonolysis and stereoselective allylation of the resultant syn α,β-
bisalkoxy aldehyde produced homoallylic alcohol 64 in moderate yield. We also observed a 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
unfavorable mixture of diastereomers (dr = 49:51), whereas allylmagnesium bromide addition produced 
homoallylic carbinol 64 in very good diastereoselectivity (dr = 89:11) (vide infra). 
(55)  Oishi, T.; Nakata, T. Acc. Chem. Res. 1984, 17, 338–344 and references therein. 
(56)  Oikawa, Y.; Nishi, T.; Yonemitsu, O. Tetrahedron Lett. 1983, 24, 4037–4040. 
(57)  Français, A.; Urban, D.; Beau, J.-M. Angew. Chem., Int. Ed. 2007, 46, 8662–8665. 
(58)  (a) Garegg, P.J.; Samuellson, B. J. Chem. Soc., Perkin Trans. I. 1980, 2866–2869; (b) Garegg, P.J.; 
Johansson, R.; Ortega, C.; Samuellson, B. J. Chem. Soc., Perkin Trans. I. 1982, 681–683. 
(59)  Skaanderup, P.R.; Hyldtoft, L.; Madsen, R. Monatsh. Chem. 2002, 133, 467–472. 
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diminished level of diastereoselection (dr = 89:11) when compared to our previous synthesis 
in which the aldehyde substrate had silyl protecting groups at C27 and C28. Acryloylation60 of 
the nascent C31 carbinol, and ring-closing metathesis61  of the intermediate diene then 
furnished unsaturated lactone 65. Stereoselective dihydroxylation62,63 and acetonide formation 
produced lactone 66 as a single diastereomer. Reduction to the diol, selective protection of the 
primary carbinol, and benzylation yielded common intermediate 61. Desilylation and 
oxidation17 of the resultant carbinol ultimately provided C27–C35 aldehyde 67. 
Scheme 3.16. Alternative synthesis of C27–C35 aldehyde 67. 
 
Reagents and conditions: (a) PPh3, I2, imidazole, PhMe, MeCN, rt, 97%; (b) Zn, THF, H2O, ))), 45 °C; NaBH4, 
0 °C, 78%; (c) Me2C(OMe)2, PPTS, acetone, rt, 90%; (d) O3, py, CH2Cl2, MeOH, –78 °C; PPh3, –78 °C to rt; (e) 
MgBr2•OEt2, allylMgBr, CH2Cl2, Et2O, –78 °C to –40 °C, dr = 89:11, 56% (2 steps); (f) acrylic pivalic anhydride, 
EtN(iPr)2, DMAP, THF, PhH, rt, 80%; (g) (Ph3P)2Cl2Ru=CHPh (4 x 5 mol%), PhH, 65 °C, 89%; (h) RuCl3, 
CeCl3•7H2O, NaIO4, EtOAc, MeCN, H2O, 0 °C, 85%, dr ≥ 95:05; (i) Me2C(OMe)2, PPTS, acetone, 30 °C, 78%; 
(j) LiBH4, H2O, THF, 0 °C to rt, quant.; (k) TBDPSCl, imidazole, DMF, 0 °C, 95%; (l) BnBr, NaH, nBu4NI, 
DMF, –20 °C, 95%; (m) nBu4NF, THF, 0 °C, quant.; (n) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C, 
96%. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(60)  Tanaka, A.; Suzuki, H.; Yamashita, K. Agric. Biol. Chem. 1989, 53, 2253–2256. 
(61)  Schwab, P.; France, M.B.; Ziller, J.W.; Grubbs, R.H. Angew. Chem. 1995, 107, 2179–2181; Angew. Chem., 
Int. Ed. 1995, 34, 2039–2041. 
(62)  (a) Plietker, B.; Niggemann, M. J. Org. Chem. 2005, 70, 2402–2405; (b) Plietker, B. Synthesis 2005, 2453–
2472. 
(63)  For examples of the diastereoselective dihydroxylation of related α,β-unsaturated δ-lactones using Upjohn 
conditions (OsO4, NMO), see: (a) Ghosh, A.K.; Kim, J.-H. Tetrahedron Lett. 2003, 44, 3967–3969; (b) 
Ramachandran, P.V.; Prabhudas, B.; Chandra, J.S.; Reddy, M.V.R. J. Org. Chem. 2004, 69, 6294–6304; 
(c) Bhaket, P.; Stauffer, C.S.; Datta, A. J. Org. Chem. 2004, 69, 8594–8601. 
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Scheme 3.17. Synthesis of C27–C48 aldehyde 71. 
 
Reagents and conditions: (a) ketone 13, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 67, Et2O, –78 °C to –
25 °C, dr = 91:09, 77%; (b) TESOTf, 2,6-lutidine, CH2Cl2, 0 °C; TMSOTf; aq H2SO4, 88%; (c) AcCl, 2,4,6-
collidine, CH2Cl2, –78 °C to 0 °C, 98%; (d) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 74%; (e) DIBALH, CH2Cl2, –
78 °C, 84%; (f) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C, 95%. 
 Having completed the syntheses of both the C3–C26 and C27–C48 fragments, we 
ventured forward with the key aldol coupling (Scheme 3.18). 64  Satisfyingly, chelate-
controlled addition of ketone 72 to aldehyde 71 under our soft enolization conditions4 
delivered the desired β-hydroxy ketone with excellent diastereoselection. We immediately 
reduced the aldol adduct65 under Prasad's conditions28 to afford 1,3-syn diol 73 as a single 
diastereomer in good overall yield. Both steps were completely chemoselective and 
eliminated the need to mask the C37 carbonyl. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(64)  The syntheses of the C3–C48 degradation fragments were achieved by the author in collaboration with Dr. 
Peter H. Fuller. 
(65)  We observed that the intermediate aldol adduct is subject to retro-aldolization on silica gel. For higher 
overall yields of diol 73, we performed the aldol addition and reduction in tandem before purification. 
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Scheme 3.18. Synthesis of C3–C48 degradation fragments 1, 46a, and 46b. 
 
Reagents and conditions: (a) MgBr2•OEt2, PMP, CH2Cl2, –5 °C, dr = 95:05; (b) Et2BOMe, NaBH4, THF, MeOH, 
–78 °C to –55 °C; aq H2O2, aq NaOH, MeOH, 0 °C, dr ≥ 95:05, 70% (2 steps); (c) aq H2SiF6, MeCN, CH2Cl2, 
0 °C to rt, 58%; (d) H2, Pd black, dioxane, H2O, rt, 53%; (e) Dowex 50x8 (H+), MeOH, 30 °C, 39%; (f) H2, Pd 
black, dioxane, H2O, rt, 74%; (g) Dowex 50x8 (H+), CD3OD, rt, 79%. 
 We concluded the synthesis of C3–C48 degradation lactol methyl ether 46a in three 
steps from diol 73. As before, removal of the acetonide and silyl protecting groups was best 
achieved with hexafluorosilicic acid.66 We obtained pentabenzyl ether 74 in higher yield and 
purity than previously due to the increased lability of the C36 triethylsilyl ether. The nascent 
lactol was then converted to its lactol methyl ether, and the remaining benzyl ethers cleaved to 
unveil C3–C48 degradation lactol methyl ether 46a in modest yield. Transetherification of 
lactol methyl ether 46a was performed in the presence of methanol-d4 and trace acid (Dowex) 
to afford C3–C48 trideuteriomethyl ether 46b in good yield. Finally, we achieved our second 
synthesis of C3–C48 degradation fragment 1 in two steps and better overall yield from 
pentabenzyl ether 74 via the standard two-step deprotection sequence.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(66)  (a) Pilcher, A.S.; Hill, D.K.; Shimshock, S.J.; Waltermire, R.E.; DeShong, P. J. Org. Chem. 1992, 57, 
2492–2495; (b) Pilcher, A.S.; Shimshock, S.J. J. Org. Chem. 1993, 58, 5130–5134. 
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VI. Spectroscopic Analysis of the C3–C48 Degradation Fragments67 
 Upon completion of the syntheses of degradation fragments 1, 46a, and 46b (Figure 
3.7), we proceeded with their full spectroscopic analysis. Our data for lactol trideuteriomethyl 
ether 46b correlated nicely with those tabulated for naturally derived2 degradation product 1. 
All chemical shift values in the proton and carbon spectra were within 0.03 ppm and 0.2 ppm 
of each other, respectively, with one caveat. In conjunction with the stereochemical revision 
of AsA, the chemical shift of C25 of naturally derived degradation product 1 was revised 
from 73.1 ppm to 71.1 ppm.2b However, our data for model C27–C48 lactol trideuteriomethyl 
ether 46b indicated that the value of 73.1 ppm should be assigned to C36. As a result, we 
believe the chemical shift value of 71.5 ppm originally reported for C36 should instead be 
revised to 71.1 ppm. Then, the carbon data for these two atoms, as well as the proton data for 
H25 and H36, should be switched. We believe this error resulted from misinterpretation of 
two-dimensional NMR correlation (i.e. COSY, HMQC, and HMBC) data,2a as the proton 
signals are very close in chemical shift. Our proposed correction is supported by the 
corresponding data for BcA C3–C47 degradation lactol methyl ether 48.47 Upon making this 
correction, we make two important conclusions: 
1) The data reported by the isolation group for naturally derived AsA C3–C48 degradation 
lactol 1 should in fact be attributed to its derivative lactol trideuteriomethyl ether 46b; and 
2) Our synthesis of lactol trideuteriomethyl ether 46b and its spectroscopic match to naturally 
derived C3–C48 degradation fragment 1 confirm the revised stereochemical assignment of 
AsA. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(67)  The spectroscopic analysis of C3–C48 degradation lactol 1 was first performed by Dr. Egmont Kattnig and 
later revised by the author.  The spectroscopic analyses of C3–C48 degradation lactol methyl ethers 46a 
and 46b were performed by the author in collaboration with Dr. Peter H. Fuller. 
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Figure 3.7. Structures of AsA model lactol 3a, model lactol methyl ethers 51a and 51b, C3–
C48 degradation fragments 1, 46a, and 46b, and BcA C3–C47 degradation fragments 47 and 
48. 
 In continuation of our analysis, the data for trideuteriomethyl ether 46b and lactol 
methyl ether 46a were spectroscopically indistinct with the exception of the obvious 
resonances. By extension, our data for lactol methyl ether 46a also matched naturally derived2 
degradation product 1 apart from the resonances belonging to the methyl group. We 
hypothesized that during the course of their NMR spectroscopic studies, the isolation group 
dissolved degradation fragment 46a (née 1) in methanol-d4 and inadvertently exchanged the 
methyl ether for its trideuteriomethyl ether 46b in the presence of trace acid.68 Our hypothesis 
is reasonable because structural elucidation of the corresponding AsA C9–C27 degradation 
fragment was conducted in methanol-d4 or a mixture of methanol-d4 and pyridine-d5. 
Unfortunately, we have no evidence that C3–C48 degradation lactol methyl ether 46a was 
ever dissolved in methanol-d4 because the NMR spectra are reported in pyridine-d5. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(68)  In our hands, simple filtration of model C27–C48 lactol methyl ether 51a through Dowex 50x8 (H+) resin 
and dissolution in methanol-d4 resulted in little to no ether exchange (<10% conversion to lactol 
trideuteriomethyl ether 51b by 1H-NMR over one week at room temperature). 
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 We explicitly propose that the isolation group synthesized lactol trideuteriomethyl 
ether 46b by transetherification of lactol methyl ether 46a, which we noted is experimentally 
more facile in the presence of trace acid (Dowex) than the ketalization of parent lactol 1. As a 
result, we suspect that the isolation group did not synthesize aflastatin A C3–C48 degradation 
lactol 1 as reported. Our notion is supported by inconsistencies between experimental 
procedures disclosed for the degradations of AsA and BcA to their respective lactols 1 and 47. 
In the case of AsA, the last reported chemical step is the saponification of the peracetate of 
lactol 1, followed by neutralization of the crude product mixture by passing it through an 
acidic Dowex column. In the case of BcA, saponification was performed on the peracetate of 
lactol methyl ether 48, and hydrolysis of lactol methyl ether 48 to its parent lactol 47 required 
an extra step, namely exposure to strong aqueous acid. We expect that the hydrolysis of AsA 
C3–C48 degradation lactol methyl ether 46a to its corresponding lactol 1 requires similar 
acidic conditions. In the end, we suspect that lactol trideuteriomethyl ether 46b was mistaken 
for lactol 1 upon acquisition of NMR spectra that lacked resonances corresponding to the 
proper product, lactol methyl ether 46a. 
 The NMR data that we present for AsA C3–C48 degradation product 1 is the first to 
be reported for this structure. Our second synthesis of this structure allowed us to revise our 
own chemical shift data for the C37 carbon from 101.2 ppm to 100.1 ppm, thus bringing it 
into excellent agreement with model C27–C48 lactol 3a and BcA C3–C47 degradation lactol 
47 (Table 3.6). Overall, our NMR data for AsA C3–C48 degradation lactol 1 may best be 
described as a rough overlay of the C3–C27 and C40–C48 regions of naturally derived AsA 
C3–C48 degradation fragment 46a (née 1) and the C20–C41 (or C22–C43 by AsA 
numbering) region of BcA C3–C47 degradation lactol 47 (Appendix 1, Tables 7 and 8). As 
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such, we are confident that our data for AsA C3–C48 degradation product 1 is correct and not 
attributable to any other structure. 
 As final proof of structure, the high-resolution mass spectrometry (HRMS) data that 
we measured for AsA C3–C48 degradation lactol 1 predicts the correct molecular formula, 
C53H106O22. Although this result was expected, we could not explain Sakuda's matching 
HRMS data for naturally derived degradation fragment 1, which we structurally reassigned as 
lactol trideuteriomethyl ether 46b. Looking to resolve this issue, we scrutinized their 
published spectra for any recognizable amount of lactol 1, but only observed a lopsided 
mixture of lactol trideuteriomethyl and lactol methyl ethers 46b and 46a, respectively.69 We 
then tested the possibility that HRMS data for lactol 1 could be obtained from such a mixture. 
We succeeded, but were unable to reproduce the accuracy of the isolation group's 
measurement.70 
 At the conclusion of our spectroscopic analyses, we had successfully revised the 
structure of the naturally derived AsA C3–C48 degradation fragment from lactol 1 to its lactol 
trideuteriomethyl ether derivative 46b. We believe that the misassignment of this fragment 
provided us the opportunity to test structural curiosities while displaying the true power of 
chemical synthesis. In particular, our accumulated work involving soft enolization with 
magnesium clearly demonstrated the reliability of our chelate-controlled aldol method in 
complex settings, as well as its potential applicability to the large-scale production of chiral 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(69)  The tabulated NMR data for degradation product 1 (Ref. 2a) is devoid of resonances corresponding to the 
methyl group of lactol methyl ether 46a. However, these resonances appear to be attenuated in the 
published spectra. Therefore, spectral analysis was presumably completed on some mixture of lactol 
methyl and lactol triodeuteriomethyl ethers 46a and 46b, respectively. 
(70)  High-resolution mass spectrometry (HRMS) data corresponding to lactol 1 (m/z calcd for C53H106NaO22 
[M+Na]+: 1117.7068) may be obtained from a sample containing lactol methyl ether 46a (TOF, found: 
1117.7279) or lactol trideuteriomethyl ether 46b (TOF, found: 1117.7353). As such, we believe it possible 
that MS data corresponding to degradation lactol 1 (Ref. 2a) may be obtained from a mixture of lactol 
methyl ether 46a and its derivative lactol trideuteriomethyl ether 46b. 
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building blocks for stereoselective organic synthesis. Now, with the syntheses of the AsA 
degradation fragments behind us, and the structural revision duly confirmed, we were ready to 
tackle the synthesis of the natural product. Our work toward the installation of the tetramic 
acid and the completion of the total synthesis of aflastatin A will be discussed in Chapter 4. 
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VII. Graphical Summary 
Synthesis of C27–C35 Aldehyde 67 
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Synthesis of C3–C48 Degradation Fragment 1 
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Synthesis of C3–C48 Degradation Fragments 46a and 46b 
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VIII. Experimental Section 
General Information  
Reactions in anhydrous solvents were carried out in glassware that was flame-dried or 
oven-dried. Unless noted, reactions were magnetically stirred and conducted under an 
atmosphere of nitrogen or argon. Air-sensitive reagents and solutions were transferred via 
syringe or cannula, and were introduced to reaction vessels through rubber septa. Reactions 
conducted below ambient temperature were cooled by external baths: dry ice/acetone for –78 
°C to –5 °C, sodium chloride/ice water for –5 °C, and ice water for 0 °C. Reactions requiring 
more than 8 h at temperatures between –55 °C and 0 °C were chilled using an immersion 
cooler. Reactions conducted above ambient temperature were heated by a silicone oil bath. 
Analytical thin layer chromatography (TLC) was performed on EMD Reagent silica gel 60 
F254 plates (210–270 µm layer thickness). Visualization was accomplished with ultraviolet 
light (254 nm) followed by heating after staining the plate with ceric ammonium molybdate or 
potassium permanganate solution. Extraction and chromatography solvents were reagent 
grade or HLPC grade, and were used without further purification. Brine solution refers to a 
saturated aqueous solution of sodium chloride. Product purification was performed by flash 
column chromatography71 using Sorbent Technologies, Whatman, or Dynamic Adsorbents 
silica gel (32–63 µm, 230–400 mesh). Reversed-phase chromatography was performed using 
a Teledyne Isco CombiFlash® Rf 200 UV/Vis purification system and RediSep® Rf Gold C18 
column (5.5 g, 20–40 µm). 
Materials  
Tetrahydrofuran, diethyl ether, toluene, and dichloromethane employed as reaction 
solvents were dried by passage through a column of activated alumina under an argon 
atmosphere.72 Benzene, acetonitrile, and pentane employed as reaction solvent were distilled 
from calcium hydride prior to use. Methanol was distilled from magnesium methoxide prior 
to use. EMD DriSolv dimethyl sulfoxide and N,N-dimethylformamide were used without 
further purification. Triethylamine, Hünig’s base, 2,6-lutidine, pyridine, dimethylethylamine, 
diisopropylamine, hexamethyldisilazane, and chlorotrimethylsilane were distilled from 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(71)  Still, W.C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
(72)  Pangborn, A.B.; Giardello, M.A.; Grubbs, R.H.; Rosen, R.K.; Timmers, F.J. Organometallics 1996, 15, 
1518–1520. 
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calcium hydride prior to use. Organolithium reagents (e.g. n-butyllithium, t-butyllithium, 
methyllithium) were purchased from commercial suppliers and were titrated prior to use using 
2-butanol with 1,10-phenanthroline as indicator.73 Grignard reagents were titrated using I2 in 
THF. Dicyclohexylchloroborane was distilled under reduced pressure and stored under argon 
in a Schlenk flask. Trimethylsilyl, triethylsilyl, and t-butyldimethylsilyl 
trifluoromethanesulfonates, as well as boron trifluoride diethyl etherate were distilled from 
calcium hydride and stored under argon in Schlenk flasks. Benzyl bromide was purified by 
passage through a column of activated neutral alumina. Me(MeO)NH•HCl was dried 
azeotropically with benzene immediately prior to use. 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) was recrystallized from benzene and chloroform and stored under argon 
at –20 °C in a foil-wrapped vial. (R)-(–)- and (S)-(+)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chlorides were purchased from the Sigma-Aldrich Chemical 
Company, and their absolute configurations were confirmed by optical rotation. Chloroform-d 
and benzene-d6 were stored over 4Å molecular sieves.74 Other reagents were purified, if 
necessary, according to the published methods.75 
Analytical Information 
Unless otherwise stated, all isolated and characterized compounds were >95% pure as 
judged by 1H-NMR spectroscopic analysis. 1H-NMR spectra were recorded at room 
temperature on an Agilent DD2 600 spectrometer (600 MHz), a Varian Inova 600 
spectrometer (600 MHz), a Varian Inova 500 spectrometer (500 MHz), or a Mercury 400 
spectrometer (400 MHz). 1H-NMR data are reported in the following format: chemical shift 
(multiplicity, coupling constant(s), integration, proton assignment). Chemical shifts are 
reported in parts per million (ppm) from tetramethylsilane (δ scale) with the residual solvent 
resonance as internal standard (7.26 ppm for CDCl3, 7.15 for C6D6, 3.30 for CD3OD, and 7.55 
pm for the middle peak of C5D5N). Multiplicity is abbreviated as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent. Proton assignments 
are referenced to the aflastatin A numbering system, and were made with the aid of 2D-COSY 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(73)  Watson, S.C.; Eastham, J.F. J. Organomet. Chem. 1967, 9, 165–168. 
(74)  (a) Burfield, D.R.; Gan, G.H.; Smithers, R.H. J. Appl. Chem. & Biotechnol. 1978, 28, 23–30. (b) Burfield, 
D.R.; Goh, E.H.; Ong, E.H.; Smithers, R.H. Gazz. Chim. Ital. 1983, 113, 841–843. 
(75)  Armarego, W.L.F.; Chai, C.L.L. Purification of Laboratory Chemicals, 6th Ed. Butterworth-Heinemann: 
Oxford, 2009. 
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experiments. NOEs were measured by 2D-NOESY experiments or pulsed-field-gradient 
assisted 1D NOE experiments. 
13C-NMR spectra were recorded at room temperature on a Varian Inova 500 
spectrometer (125 MHz), or a Mercury 400 spectrometer (100 MHz) with broadband proton 
decoupling. Chemical shifts are reported in ppm from tetramethylsilane (δ scale) with the 
residual solvent resonance as internal standard (77.0 ppm for CDCl3, 128.0 for C6D6, 49.0 for 
CD3OD, and 135.5 pm for the middle peak of C5D5N). Carbon assignments are referenced to 
the aflastatin A numbering system, and were made with the aid of 2D-HSQC experiments. 
Infrared spectra were recorded as thin films on NaCl plates using a Perkin Elmer 1600 
series FT-IR spectrometer at a resolution of 4 cm–1. Optical rotations were measured on a 
Jasco P-2000 series digital polarimeter with a sodium lamp, and are reported as [α] DT (°C)  XX° 
(c (g/100 mL), solvent). High-resolution mass spectra were obtained on Agilent 6210 TOF or 
Bruker micrOTOF-Q II spectrometers at Harvard University’s Small Molecule Mass 
Spectrometry Facility or Laukien-Purcell Instrumentation Center, respectively. 
 
Spectroscopic Data for Model C27–C48 Lactols and Lactol Methyl Ethers 
 
Aflastatin A Model C27–C48 Lactol (3a). White solid; [α] D23  +12.8° (c = 0.50, CH3OH); IR 
(neat) 3428 (br), 1638 cm–1; 1H-NMR (600 MHz, pyridine-d5) δ 7.06 (br s, 1H, one of –OH), 
6.80–5.80 (br s, 8H, eight of –OH), 5.00 (app dt, J = 7.0, 7.0, 2.0 Hz, 1H, C31-H), 4.95 (br s, 
1H, one of –OH), 4.89 (app dt, J = 10.0, 10.0, 3.0 Hz, 1H, C33-H), 4.79 (dd, J = 9.5, 3.0 Hz, 
1H, C35-H), 4.76 (m, 1H, C39-H), 4.72 (dd, J = 4.5, 3.5 Hz, 1H, C29-H), 4.62–4.59 (m, 2H, C28-
H and C30-H), 4.50 (d, J = 3.0 Hz, 1H, C36-H), 4.41 (app t, J = 9.5, 9.5 Hz, 1H, C34-H), 4.35–
4.30 (m, 2H, C27-H2), 3.22 (ddd, J = 13.2, 8.0, 3.0 Hz, 1H, one of C32-H), 2.75 (dd, J = 14.4, 
1.8 Hz, 1H, one of C38-H), 2.58 (ddd, J = 13.2, 10.0, 7.0 Hz, 1H, one of C32-H), 2.15 (dd, J = 
14.4, 10.9 Hz, 1H, one of C38-H), 1.68–1.61 (m, 1H, one of C40-H), 1.56–1.45 (m, 2H, one of 
C40-H and one of C41-H), 1.39–1.34 (m, 1H, one of C41-H), 1.30–1.13 (m, 12H, C42–47-H2), 
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0.83 (t, J = 7.2 Hz, 3H, C48-H3); 13C-NMR (125 MHz, pyridine-d5) δ 100.2 (C37), 75.2 (C36), 
73.8 (C34), 73.7 (C30), 73.5 (C29), 72.9 (C28 and C35), 71.6 (C31 and C33), 69.0 (C39), 
64.6 (C27), 42.6 (C38), 39.6 (C40), 37.5 (C32), 32.1 (C46), 30.1 (C43 or C44), 29.9 (C43 or 
C44), 29.8 (C42), 29.6 (C45), 25.8 (C41), 22.9 (C47), 14.3 (C48); HRMS (ESI-TOF) m/z 
calcd for C22H44NaO11 [M+Na]+: 507.2776, found: 507.2788. 
 
epi-C39 Model C27–C48 Lactol (3b). White solid; 1H-NMR (600 MHz, pyridine-d5) δ 6.84 
(br s, 1H, one of –OH), 6.55 (br s, 2H, two of –OH), 6.44–6.22 (br m, 3H, three of –OH), 
6.14 (br s, 1H, one of –OH), 5.98 (br s, 2H, two of –OH), 5.87 (br s, 1H, one of –OH), 4.88 
(dd, J = 9.2, 2.8 Hz, 1H, C35-H), 4.87 (app dt, J = 9.4, 9.4, 2.6 Hz, 1H, C33-H), 4.83 (m, J = 
7.3, 4.1 Hz, 1H, C31-H), 4.59 (d, J = 2.8 Hz, 1H, C36-H), 4.59 (m, 1H, C39-H), 4.56 (dd, J = 
3.8, 3.2 Hz, 1H, C29-H), 4.54 (m, J = 3.5 Hz, 1H, C28-H), 4.43 (m, 1H, C30-H), 4.41 (app t, J = 
9.1 Hz, 1H, C34-H), 4.34–4.28 (m, J = 5.4, 4.5 Hz, 2H, C27-H2), 3.07 (ddd, J = 14.2, 4.1, 3.4 
Hz, 1H, one of C32-H), 2.62 (dd, J = 14.2 Hz, 1H, one of C38-H), 2.53 (ddd, J = 14.2, 8.8, 7.9 
Hz, 1H, one of C32-H), 2.48 (dd, J = 14.2, 10.1 Hz, 1H, one of C38-H), 1.77–1.73 (m, 1H, one 
of C40-H), 1.62–1.56 (m, 2H, one of C40-H and one of C41-H), 1.47–1.42 (m, 1H, one of C41-
H), 1.27–1.11 (m, 12H, C42–47-H2), 0.82 (t, J = 7.2 Hz, 3H, C48-H3); 13C-NMR (125 MHz, 
pyridine-d5) δ 100.3 (C37), 74.8 (C30), 74.2 (C36), 74.1 (C28), 73.3 (C29), 73.1 (C35), 72.93 
(C33), 72.87 (C34), 72.4 (C31), 67.6 (C39), 64.6 (C27), 45.3 (C38), 39.1 (C40), 37.3 (C32), 
32.1 (C46), 30.04 (C43 or C44), 29.99 (C43 or C44), 29.8 (C42), 29.6 (C45), 26.2 (C41), 22.9 
(C47), 14.3 (C48); 1H-NMR (600 MHz, CD3OD) δ 4.01 (ddd, J = 7.3, 5.5, 3.1 Hz, 1H, C31-
H), 3.94 (m, 1H, C39-H), 3.85 (dd, J = 9.5, 3.4 Hz, 1H, C35-H), 3.83 (ddd, J = 9.7, 9.5, 2.7 Hz, 
1H, C33-H), 3.79 (m, J = 3.4 Hz, 1H, C28-H), 3.74 (dd, J = 4.7, 3.4 Hz, 1H, C29-H), 3.68 (d, J 
= 3.4 Hz, 1H, C36-H), 3.67–3.61 (m, 2H, C27-H2), 3.63 (dd, J = 4.7, 3.1 Hz, 1H, C30-H), 3.42 
(dd, J = 9.5, 9.4 Hz, 1H, C34-H), 2.17 (ddd, J = 14.4, 5.5, 2.7 Hz, 1H, one of C32-H), 1.88 (dd, 
J = 14.5, 1.9 Hz, 1H, one of C38-H), 1.78 (dd, J = 14.6, 10.0 Hz, 1H, one of C38-H), 1.73 (ddd, 
J = 14.4, 9.5, 7.3 Hz, 1H, one of C32-H), 1.50–1.23 (m, 16H, C40–47-H2), 0.89 (t, J = 7.0 Hz, 
3H, C48-H3). 
HO
OH
3127
HO 35
OH
C9H19
OH
O 39H OH
HO
OH
OH
3b
HO
	   92 
 
epi-C33–C37 Model C27–C48 Lactol (3c). White solid; 1H-NMR (600 MHz, pyridine-d5) δ 
8.03 (br s, 1H, one of C37–OH), 6.90 (br s, 1H, one of –OH), 6.51 (br s, 2H, two of –OH), 
6.44–6.21 (br m, 3H, three of –OH), 6.12–6.01 (br m, 3H, three of –OH), 5.04 (ddd, J = 9.4, 
9.2, 2.8 Hz, 1H, C33-H), 4.91–4.90 (m, 2H, C30-H and C31-H), 4.64 (dd, J = 3.7, 3.2 Hz, 1H, 
C29-H), 4.58 (d, J = 2.6 Hz, 1H, C36-H), 4.58–4.54 (m, 2H, C28-H and C39-H), 4.38 (m, J = 
9.4, 9.1 Hz, 1H, C34-H), 4.35–4.26 (m, 3H, C27-H2 and C35-H), 3.11 (m, J = 2.6 Hz, 1H, one of 
C32-H), 2.70 (dd, J = 13.2 Hz, 1H, one of C38-H), 2.38 (dd, J = 14.2, 10.3 Hz, 1H, one of C38-
H), 2.32 (m, J = 11.8, 9.2 Hz, 1H, one of C32-H), 1.76–1.72 (m, 1H, one of C40-H), 1.62–1.56 
(m, 2H, one of C40-H and one of C41-H), 1.48–1.41 (m, 1H, one of C41-H), 1.26–1.05 (m, 12H, 
C42–47-H2), 0.82 (t, J = 7.2 Hz, 3H, C48-H3); 13C-NMR (125 MHz, pyridine-d5) δ 100.2 (C37), 
76.1 (C35), 74.03 (C29), 73.99 (C36), 73.3 (C30), 73.2 (C28), 73.0 (C34), 71.1 (C33), 69.9 
(C31), 67.9 (C39), 64.6 (C27), 44.8 (C38), 39.0 (C40), 38.5 (C32), 32.1 (C46), 30.04 (C43 or 
C44), 29.99 (C43 or C44), 29.8 (C42), 29.6 (C45), 26.2 (C41), 22.9 (C47), 14.3 (C48); 1H-
NMR (600 MHz, CD3OD) δ 3.97 (ddd, J = 10.3, 3.5, 3.1 Hz, 1H, C31-H), 3.94 (m, 1H, C39-
H), 3.88 (dd, J = 9.5, 3.4 Hz, 1H, C35-H), 3.87 (ddd, J = 9.7, 9.7, 2.8 Hz, 1H, C33-H), 3.78 
(ddd, J = 6.2, 5.0, 3.5 Hz, 1H, C28-H), 3.73 (dd, J = 4.5, 3.5 Hz, 1H, C29-H), 3.70 (d, J = 3.4 
Hz, 1H, C36-H), 3.66 (d, J = 11.1, 5.0 Hz, 1H, one of C27-H), 3.63 (d, J = 11.1, 6.2 Hz, 1H, 
one of C27-H), 3.57 (dd, J = 4.2, 4.0 Hz, 1H, C30-H), 3.40 (dd, J = 9.7, 9.5 Hz, 1H, C34-H), 
2.15 (ddd, J = 14.4, 10.0, 2.6 Hz, 1H, one of C32-H), 1.93 (dd, J = 14.6, 1.9 Hz, 1H, one of 
C38-H), 1.75 (dd, J = 14.6, 10.0 Hz, 1H, one of C38-H), 1.61 (ddd, J = 14.4, 9.8, 2.9 Hz, 1H, 
one of C32-H), 1.50–1.38 (m, 2H, C40-H2), 1.37–1.23 (m, 14H, C41–47-H2), 0.89 (t, J = 7.1 Hz, 
3H, C48-H3). 
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epi-C34,C36 Model C27–C48 Lactol (3d). White solid; 1H-NMR (600 MHz, pyridine-d5) δ 
7.46 (br s, 1H, one of –OH), 6.96 (br s, 1H, one of –OH), 6.54 (br s, 1H, one of –OH), 6.38–
6.28 (br m, 2H, two of –OH), 6.25–6.12 (br m, 4H, four of –OH), 5.07 (ddd, J = 7.5, 6.9 Hz, 
1H, C33-H), 4.85 (m, 1H, C31-H), 4.69 (m, 1H, C39-H), 4.68 (dd, J = 3.4, 3.2 Hz, 1H, C30-H), 
4.59 (m, J = 3.5 Hz, 1H, C28-H), 4.56 (dd, J = 10.1, 3.1 Hz, 1H, C35-H), 4.48 (m, 1H, C29-H), 
4.44 (m, 1H, C34-H), 4.38 (d, J = 9.7 Hz, 1H, C36-H), 4.35–4.29 (m, 2H, C27-H2), 2.96 (ddd, J 
= 13.5, 8.1, 7.9 Hz, 1H, one of C32-H), 2.69 (ddd, J = 13.4, 6.7, 5.9 Hz, 1H, one of C32-H), 
2.64 (dd, J = 14.1, 11.3 Hz, 1H, one of C38-H), 2.04 (dd, J = 13.9 Hz, 1H, one of C38-H), 
1.64–1.59 (m, 1H, one of C40-H), 1.51–1.42 (m, 2H, one of C40-H and one of C41-H), 1.38–
1.31 (m, 1H, one of C41-H), 1.26–1.11 (m, 12H, C42–47-H2), 0.82 (t, J = 7.1 Hz, 3H, C48-H3); 
13C-NMR (125 MHz, pyridine-d5) δ 100.1 (C37), 74.3 (C36), 74.2 (C29), 73.9 (C28), 73.5 
(C30), 72.5 (C35), 72.1 (C34), 70.6 (C31), 69.3 (C33), 68.2 (C39), 64.5 (C27), 43.8 (C38), 
39.2 (C40), 35.7 (C32), 32.0 (C46), 30.0 (C43 or C44), 29.9 (C43 or C44), 29.8 (C42), 29.5 
(C45), 25.8 (C41), 22.9 (C47), 14.2 (C48).  
 
epi-C35,C36 Model C27–C48 Lactol (3e). White solid; 1H-NMR (600 MHz, pyridine-d5) δ 
7.52 (br s, 1H, one of –OH), 7.32 (br s, 1H, one of –OH), 7.07 (br s, 1H, one of –OH), 6.47–
6.37 (br m, 4H, four of –OH), 6.09–6.03 (br m, 3H, three of –OH), 4.96–4.90 (m, J = 9.8, 3.4 
Hz, 2H, C31-H and C33-H), 4.74–4.66 (m, 2H, C29-H and C35-H), 4.62–4.55 (m, 2H, C28-H and 
C39-H), 4.55–4.49 (m, 1H, C30-H), 4.37–4.28 (m, 2H, C27-H2), 3.92–3.89 (m, 1H, C36-H), 3.86 
(m, J = 8.6 Hz, 1H, C34-H), 3.09 (ddd, J = 14.2, 5.9, 3.4 Hz, 1H, one of C32-H), 2.51 (ddd, J = 
14.1, 9.8, 7.1 Hz, 1H, one of C32-H), 2.45 (dd, J = 14.3, 10.5 Hz, 1H, one of C38-H), 2.16 (dd, 
J = 14.2 Hz, 1H, one of C38-H), 1.69–1.64 (m, 1H, one of C40-H), 1.60–1.47 (m, 2H, one of 
C40-H and one of C41-H), 1.46–1.39 (m, 1H, one of C41-H), 1.26–1.11 (m, 12H, C42–47-H2), 
0.82 (t, J = 7.2 Hz, 3H, C48-H3); 13C-NMR (125 MHz, pyridine-d5) δ 100.8 (C37), 74.4 (C35), 
74.00 (C30), 73.95 (C28), 73.5 (C29), 73.1 (C34), 71.8 (C36), 71.6 (C31), 67.8 (C39), 67.3 
(C33), 64.6 (C27), 45.7 (C38), 38.9 (C40), 37.2 (C32), 32.1 (C46), 30.1 (C43 or C44), 29.9 
(C43 or C44), 29.8 (C42), 29.6 (C45), 26.0 (C41), 22.9 (C47), 14.3 (C48); 1H-NMR (600 
HO
OH
3127
HO 35
OH
C9H19
OH
O 39H OH
HO
OH
OH
3e
HO
	   94 
MHz, CD3OD) δ 4.07 (ddd, J = 6.7, 6.6, 2.7 Hz, 1H, C31-H), 4.03 (ddd, J = 9.8, 9.8, 3.1 Hz, 
1H, C33-H), 4.03–3.98 (m, 1H, C39-H), 4.01 (dd, J = 3.1, 2.9 Hz, 1H, C35-H), 3.79 (ddd, J = 
6.3, 5.1, 3.1 Hz, 1H, C28-H), 3.78–3.75 (m, 1H, C30-H), 3.68 (dd, J = 5.0, 2.7 Hz, 1H, C29-H), 
3.67–3.62 (m, 2H, C27-H2), 3.34 (d, J = 3.1 Hz, 1H, C36-H), 3.28 (dd, J = 9.8, 2.9 Hz, 1H, C34-
H), 2.21 (ddd, J = 14.1, 6.7, 3.1 Hz, 1H, one of C32-H), 1.86 (dd, J = 14.6, 10.4 Hz, 1H, one 
of C38-H), 1.70 (ddd, J = 14.2, 9.7, 6.6 Hz, 1H, one of C32-H), 1.67 (dd, J = 14.5, 1.8 Hz, 1H, 
one of C38-H), 1.45–1.22 (m, 16H, C40–47-H2), 0.90 (t, J = 7.0 Hz, 3H, C48-H3). 
 
epi-C36 Model C27–C48 Lactol (3f). White solid; 1H-NMR (600 MHz, pyridine-d5) δ 7.53 
(br s, 1H, one of –OH), 6.99–6.96 (br m, J = 4.2, 4.0 Hz, 2H, two of –OH), 6.84 (br s, 1H, 
one of –OH), 6.58 (br s, 1H, one of –OH), 6.53–6.49 (br s, 2H, two of –OH), 6.10–6.05 (br 
m, 2H, two of –OH), 5.98 (br d, J = 4.0 Hz, 1H, one of –OH), 4.95 (m, 1H, C31-H), 4.90 (ddd, 
J = 9.8, 9.7, 3.1 Hz, 1H, C33-H), 4.72–4.66 (m, 2H, C29-H and C39-H), 4.61–4.56 (m, J = 9.8, 
7.6 Hz, 3H, C28-H, C30-H and C35-H), 4.34–4.28 (m, 2H, C27-H2), 3.94 (ddd, J = 9.8, 9.2, 3.6 
Hz, 1H, C34-H), 3.91 (dd, J = 8.2, 7.8 Hz, 1H, C36-H), 3.21 (ddd, J = 13.8, 7.0, 3.4 Hz, 1H, 
one of C32-H), 2.67 (dd, J = 14.2, 11.1 Hz, 1H, one of C38-H), 2.51 (ddd, J = 13.8, 10.0, 6.6 
Hz, 1H, one of C32-H), 2.06 (dd, J = 12.9 Hz, 1H, one of C38-H), 1.66–1.60 (m, 1H, one of 
C40-H), 1.54–1.46 (m, 2H, one of C40-H and one of C41-H), 1.42–1.34 (m, 1H, one of C41-H), 
1.26–1.11 (m, 12H, C42–47-H2), 0.82 (t, J = 7.2 Hz, 3H, C48-H3); 13C-NMR (125 MHz, 
pyridine-d5) δ 99.8 (C37), 77.8 (C36), 77.1 (C34), 75.8 (C29), 73.8 (C30), 73.6 (C28), 73.1 
(C35), 71.5 (C31), 70.7 (C33), 68.3 (C39), 64.5 (C27), 43.8 (C38), 39.2 (C40), 37.6 (C32), 
32.0 (C46), 30.1 (C43 or C44), 29.9 (C43 or C44), 29.8 (C42), 29.5 (C45), 25.8 (C41), 22.9 
(C47), 14.2 (C48); 1H-NMR (600 MHz, CD3OD) δ 4.08–4.02 (m, J = 8.3, 6.3, 2.3 Hz, 2H, 
C31-H and C39-H), 3.89 (ddd, J = 10.0, 9.8, 2.9 Hz, 1H, C33-H), 3.79–3.76 (m, J = 5.1, 3.1 Hz, 
2H, C28-H and C29-H), 3.68–3.62 (m, J = 8.2, 6.1 Hz, 2H, C27-H2), 3.67 (dd, J = 5.1, 2.5 Hz, 
1H, C30-H), 3.58 (app t, J = 9.2 Hz, 1H, C35-H), 3.10 (d, J = 9.4 Hz, 1H, C36-H), 3.09 (app t, J 
= 9.4 Hz, 1H, C34-H), 2.23 (ddd, J = 13.9, 7.5, 2.9 Hz, 1H, one of C32-H), 1.93 (dd, J = 14.5, 
10.8 Hz, 1H, one of C38-H), 1.66 (ddd, J = 13.9, 10.1, 6.3 Hz, 1H, one of C32-H), 1.62 (dd, J = 
HO
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14.4, 1.9 Hz, 1H, one of C38-H), 1.48–1.24 (m, 16H, C40–47-H2), 0.89 (t, J = 7.0 Hz, 3H, C48-
H3). 
 
Aflastatin A Model C27–C48 Lactol Methyl Ether (51a). White solid; [α] D24  +19.8° (c = 
0.30, CH3OH); IR (neat) 3362 (br), 2926, 2855, 1456, 1377, 1206, 1102, 1063 cm–1; 1H-NMR 
(600 MHz, pyridine-d5) δ 6.87 (br s, 1H, one of –OH), 6.48 (br s, 2H, two of –OH), 6.42–5.99 
(br m, 6H, six of –OH), 4.94 (m, J = 6.2, 2.9 Hz, 1H, C31-H), 4.70–4.66 (m, J = 3.6 Hz, 2H, 
C29-H and C36-H), 4.65 (ddd, J = 5.6, 5.1, 3.5 Hz, 1H, C28-H), 4.58 (dd, J = 9.3, 3.6 Hz, 1H, 
C35-H), 4.52 (dd, J = 3.5, 3.4 Hz, 1H, C30-H), 4.38–4.32 (m, J = 10.8, 4.5 Hz, 2H, C27-H2), 
4.33 (app t, J = 9.1 Hz, 1H, C34-H), 4.26 (app dt, J = 9.2, 9.2, 2.8 Hz, 1H, C33-H), 4.22–4.17 
(m, J = 7.3, 5.0 Hz, 1H, C39-H), 3.37 (s, 3H, C56-H3), 3.20 (ddd, J = 14.2, 6.4, 2.7 Hz, 1H, one 
of C32-H), 2.50 (ddd, J = 14.6, 8.9, 5.9 Hz, 1H, one of C32-H), 2.46 (dd, J = 15.1, 9.3 Hz, 1H, 
one of C38-H), 2.23 (app d, J = 14.9 Hz, 1H, one of C38-H), 1.71–1.64 (m, 1H, one of C40-H), 
1.63–1.53 (m, 2H, one of C40-H and one of C41-H), 1.52–1.43 (m, 1H, one of C41-H), 1.32–
1.14 (m, 12H, C42–47-H2), 0.82 (t, J = 7.0 Hz, 3H, C48-H3); 13C-NMR (125 MHz, pyridine-d5) δ 
103.3 (C37), 74.3 (C30), 73.9 (C28), 73.6 (C29), 73.1 (C36), 72.8 (C33), 72.7 (C35), 72.4 
(C34), 71.3 (C31), 67.0 (C39), 64.7 (C27), 47.9 (C56), 39.42 (C38 or C40), 39.36 (C38 or 
C40), 37.5 (C32), 32.1 (C46), 30.03 (C43 or C44), 29.97 (C43 or C44), 29.8 (C42), 29.5 
(C45), 26.0 (C41), 22.9 (C47), 14.2 (C48); HRMS (ESI-TOF) m/z calcd for C23H46NaO11 
[M+Na]+: 521.2932, found: 521.2926. 
 
Aflastatin A Model C27–C48 Lactol Trideuteriomethyl Ether (51b). White solid; [α] D24  
+22.9° (c = 0.38, CH3OH); IR (neat) 3365 (br), 2926, 2855, 2072, 1456, 1418, 1260, 1207, 
1114, 1062 cm–1; 1H-NMR (600 MHz, pyridine-d5) δ 6.13 (br s, 9H, nine of –OH), 4.94 (app 
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dt, J = 6.2, 6.2, 3.2 Hz, 1H, C31-H), 4.70–4.66 (m, J = 3.6 Hz, 2H, C29-H and C36-H), 4.65 
(ddd, J = 5.7, 5.3 Hz, 1H, C28-H), 4.58 (dd, J = 9.2, 3.7 Hz, 1H, C35-H), 4.52 (dd, J = 3.8, 3.4 
Hz, 1H, C30-H), 4.38–4.32 (m, J = 10.8, 5.3 Hz, 2H, C27-H2), 4.33 (app t, J = 9.5 Hz, 1H, C34-
H), 4.26 (app dt, J = 9.2, 9.2, 2.6 Hz, 1H, C33-H), 4.21–4.17 (m, J = 5.9 Hz, 1H, C39-H), 3.20 
(ddd, J = 14.1, 6.4, 2.8 Hz, 1H, one of C32-H), 2.50 (ddd, J = 14.6, 8.7, 5.9 Hz, 1H, one of C32-
H), 2.46 (dd, J = 15.3, 9.3 Hz, 1H, one of C38-H), 2.22 (app d, J = 14.9 Hz, 1H, one of C38-H), 
1.71–1.64 (m, 1H, one of C40-H), 1.63–1.53 (m, 2H, one of C40-H and one of C41-H), 1.52–
1.43 (m, 1H, one of C41-H), 1.32–1.14 (m, 12H, C42–47-H2), 0.82 (t, J = 7.0 Hz, 3H, C48-H3); 
13C-NMR (125 MHz, pyridine-d5) δ 103.3 (C37), 74.3 (C30), 73.9 (C28), 73.6 (C29), 73.1 
(C36), 72.8 (C33), 72.6 (C35), 72.4 (C34), 71.3 (C31), 66.9 (C39), 64.6 (C27), 39.42 (C38 or 
C40), 39.36 (C38 or C40), 37.5 (C32), 32.1 (C46), 30.03 (C43 or C44), 29.97 (C43 or C44), 
29.8 (C42), 29.5 (C45), 26.0 (C41), 22.9 (C47), 14.2 (C48); HRMS (ESI-TOF) m/z calcd for 
C23H43D3NaO11 [M+Na]+: 524.3121, found: 524.3100. 
 
Synthesis of the C27–C35 Aldehyde 
 
(2S,3R,4R,5S,6S)-4,5-Bis(benzyloxy)-6-(iodomethyl)-2-methoxytetrahydro-2H-pyran-3-ol 
(78). To a solution of diol 62 (9.8 g, 26 mmol, 1.0 equiv), imidazole (5.4 g, 79 mmol, 3.0 
equiv), and triphenylphosphine (10.7 g, 40.7 mmol, 1.55 equiv) in 2:1 PhMe/MeCN (131 mL, 
0.2 M wrt 62) at rt was added iodine (10 g, 39 mmol, 1.5 equiv) in three portions. The 
reaction mixture was stirred at rt for 3 h, quenched with brine (100 mL), and then diluted with 
H2O (10 mL) and Et2O (50 mL). The layers were separated and the aqueous layer extracted 
with Et2O (3 x 100 mL). The combined organic extracts were dried over Na2SO4 with added 
hexanes, filtered and concentrated. Column chromatography (gradient elution, 5:1 → 4:1 → 
3:1 hexanes/EtOAc) afforded iodide 78 (12.3 g, 97% yield) as a white solid. [α]
€ 
D
25  +95.4° (c = 
2.3, CH2Cl2); IR (neat) 3424 (br), 3029, 2924, 1497, 1453, 1399, 1361, 1325, 1214, 1192, 
1140, 1087, 1046, 733, 696 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.39–7.30 (m, 10H, ArH), 
4.95 (d, J = 11.0 Hz, 1H, one of –OCH2Ph), 4.94 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.84 
OHO
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(d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.78 (d, J = 3.8 Hz, 1H, C27-H), 4.72 (d, J = 11.0 Hz, 
1H, one of –OCH2Ph), 3.80 (dd, J = 9.2, 8.9 Hz, 1H, C29-H), 3.71 (ddd, J = 8.8, 8.6, 3.8 Hz, 
1H, C28-H), 3.51 (dd, J = 10.5, 2.6 Hz, 1H, one of C32-H), 3.48 (ddd, J = 9.1, 6.4, 2.6 Hz, 1H, 
C31-H), 3.48 (s, 3H, –OCH3), 3.36 (dd, J = 9.2, 8.9 Hz, 1H, C30-H), 3.32 (dd, J = 10.5, 6.3 Hz, 
1H, one of C32-H), 2.16 (d, J = 8.6 Hz, 1H, C28-OH); 13C-NMR (125 MHz, CDCl3) δ 138.4, 
137.9, 128.5, 128.5, 127.9, 127.9, 127.8, 99.3, 82.8, 81.2, 75.4, 75.3, 73.1, 69.7, 55.5, 7.3; 
HRMS (ESI-TOF) m/z calcd for C21H25INaO5 [M+Na]+: 507.06389, found: 507.06416. 
 
((2S,3R,4R)-3,4-Bis(benzyloxy)hex-5-ene-1,2-diol (79). To a solution of iodide 78 (1.1 g, 2.2 
mmol, 1.0 equiv) in 4:1 THF/H2O (22 mL, 0.1 M wrt 78) at rt was added preactivated zinc 
dust76 (1.4 g, 22 mmol, 10 equiv). The reaction mixture was sonicated at 40–45 °C for 4 h, 
then cooled to 0 °C and charged with sodium borohydride (0.17 g, 4.4 mmol, 2.0 equiv) in 
three portions. The resulting suspension was stirred at 0 °C for 2 h, slowly quenched with 1 M 
NaHSO4 (15 mL), diluted with Et2O (15 mL), warmed to rt, and filtered through Celite. The 
filter cake was rinsed with Et2O (3 x 10 mL) and sat. aq NH4Cl (3 x 10 mL). The layers were 
separated and the aqueous layer extracted with Et2O (3 x 50 mL). The combined organic 
extracts were dried over Na2SO4 with added hexanes, filtered and concentrated. Column 
chromatography (gradient elution, 2:1 → 3:2 → 1:1 hexanes/EtOAc) afforded diol 79 (0.56 g, 
78% yield) as a clear, colorless oil. [α]
€ 
D
25  +7.6° (c = 0.66, CH2Cl2); IR (neat) 3419 (br), 3064, 
3031, 2934, 2877, 1497, 1455, 1403, 1351, 1209, 1066, 1028, 998, 931, 870, 736, 699 cm–1; 
1H-NMR (600 MHz, C6D6) δ 7.27 (m, 2H, two of ArH), 7.22 (m, 2H, two of ArH), 7.17–7.12 
(m, 4H, four of ArH), 7.08 (m, 2H, two of ArH), 5.78 (ddd, J = 17.4, 10.4, 7.3 Hz, 1H, C31-
H), 5.24 (d, J = 17.4 Hz, 1H, one of C32-H), 5.11 (d, J = 10.4 Hz, 1H, one of C32-H), 4.75 (d, J 
= 11.3 Hz, 1H, one of –OCH2Ph), 4.49 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.43 (d, J = 
11.3 Hz, 1H, one of –OCH2Ph), 4.22 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.11 (dd, J = 7.3, 
6.4 Hz, 1H, C30-H), 3.76 (dddd, J = 7.6, 5.4, 5.4, 3.4 Hz, 1H, C28-H), 3.55–3.47 (m, J = 11.1, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(76)  Hyldtoft, L.; Madsen, R. J. Am. Chem. Soc. 2000, 122, 8444–8452. 
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7.8, 5.4, 4.8 Hz, 2H, C27-H2), 3.45 (dd, J = 6.4, 3.4 Hz, 1H, C29-H), 2.41 (d, J = 7.6 Hz, 1H, 
C28-OH), 1.86 (dd, J = 7.8, 4.8 Hz, 1H, C27-OH); 13C-NMR (125 MHz, C6D6) δ 138.9, 138.9, 
135.6, 128.6, 128.6, 128.3, 128.1, 127.9, 127.7, 118.9, 82.1, 81.6, 74.8, 71.4, 70.9, 64.3; 
HRMS (ESI-TOF) m/z calcd for C20H24NaO4 [M+Na]+: 351.15668, found: 351.15697. 
 
(S)-4-((1S,2R)-1,2-Bis(benzyloxy)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (63). To a 
solution of diol 79 (2.7 g, 8.1 mmol, 1.0 equiv) in 2:1 acetone/2,2-dimethoxypropane (81 mL, 
0.1 M wrt 79) at rt was added PPTS (10 mg, 41 µmol, 0.005 equiv). The reaction mixture was 
stirred at rt for 10 h, quenched with a small spatula tip full of NaHCO3 (s), stirred vigorously 
for an additional 15 min, and filtered through Celite. The filter cake was rinsed with EtOAc 
(40 mL total), and the filtrate concentrated. Column chromatography (gradient elution, 4% → 
6% → 8% EtOAc in hexanes) afforded acetonide 63 (2.7 g, 90% yield) as a clear, colorless 
oil. [α]
€ 
D
24  –25.3° (c = 2.1, CH2Cl2); IR (neat) 3065, 3031, 2985, 2873, 1497, 1455, 1380, 
1252, 1213, 1070, 1001, 930, 861, 736, 698 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.35–7.26 
(m, 10H, ArH), 5.90 (ddd, J = 17.4, 10.4, 7.0 Hz, 1H, C31-H), 5.33 (d, J = 17.4 Hz, 1H, one of 
C32-H), 5.31 (d, J = 10.4 Hz, 1H, one of C32-H), 4.79 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 
4.76 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.60 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.34 
(d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.27 (ddd, J = 7.8, 6.4, 6.4 Hz, 1H, C28-H), 3.93 (dd, J 
= 6.7, 5.1 Hz, 1H, C30-H), 3.82 (dd, J = 8.2, 6.3 Hz, 1H, one of C27-H), 3.65 (dd, J = 8.1, 8.1, 
1H, one of C27-H), 3.45 (dd, J = 6.6, 4.8 Hz, 1H, C29-H), 1.40 (s, 3H, one of CH3), 1.35 (s, 
3H, one of CH3); 13C-NMR (125 MHz, CDCl3) δ 138.6, 138.1, 134.9, 128.3, 128.2, 128.2, 
128.1, 128.0, 127.8, 127.6, 127.4, 118.4, 108.7, 81.3, 80.5, 76.8, 74.0, 70.6, 65.9, 26.6, 25.7; 
HRMS (ESI-TOF) m/z calcd for C23H28NaO4 [M+Na]+: 391.18798, found: 391.18848. 
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(2S,3R)-2,3-Bis(benzyloxy)-3-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)propanal (80). To a 
solution of alkene 63 (0.55 g, 1.5 mmol, 1.0 equiv) in 1:1 CH2Cl2/MeOH (30 mL, 0.05 M wrt 
63) at –78 °C was added pyridine (1.2 mL, 15 mmol, 10 equiv). The reaction mixture was 
bubbled with ozone until it turned blue, purged with oxygen until the color faded, quenched 
dropwise with a solution of triphenylphosphine (0.47 g, 1.8 mmol, 1.2 equiv) in 1:1 
CH2Cl2/MeOH (7.4 mL, 0.24 M wrt PPh3), slowly warmed to rt o/n (16 h total stir time), and 
then diluted with 1 M aq NaHSO4 (40 mL) and brine (5 mL). The layers were separated and 
the aqueous layer extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated. A sufficient quantity of crude aldehyde 80 was 
purified by column chromatography (4:1 hexanes/EtOAc) for characterization. [α]
€ 
D
24  –30.9° 
(c = 6.4, CH2Cl2); IR (neat) 3032, 2987, 2936, 2874, 1732 (s), 1498, 1455, 1371, 1255, 1211, 
1152 1077, 850, 739, 699 cm–1; 1H-NMR (600 MHz, C6D6) δ 9.70 (d, J = 1.2 Hz, 1H, C31-H), 
7.25 (m, 2H, two of ArH), 7.17–7.05 (m, 8H, eight of ArH), 4.56 (d, J = 11.6 Hz, 1H, one of 
–OCH2Ph), 4.52 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.50 (d, J = 11.6 Hz, 1H, one of –
OCH2Ph), 4.40 (ddd, J = 7.2, 6.7, 5.4 Hz, 1H, C28-H), 4.15 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 3.69 (dd, J = 4.5, 1.3 Hz, 1H, C30-H), 3.69 (dd, J = 8.2, 6.6 Hz, 1H, one of C27-H), 
3.61 (dd, J = 8.3, 7.2 Hz, 1H, one of C27-H), 3.45 (dd, J = 5.4, 4.5 Hz, 1H, C29-H), 1.38 (s, 
3H, one of CH3), 1.24 (s, 3H, one of CH3); 13C-NMR (125 MHz, C6D6) δ 201.0, 138.5, 137.7, 
128.6, 128.5, 128.3, 128.2, 128.2, 127.9, 127.8, 109.7, 83.0, 79.9, 76.3, 73.7, 73.1, 65.8, 26.5, 
25.7; HRMS (ESI-TOF) m/z calcd for C22H26NaO5 [M+Na]+: 393.16725, found: 393.16666. 
 
(1R,2R,3S)-1,2-Bis(benzyloxy)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)hex-5-en-3-ol (64). 
To a solution of crude aldehyde 80 (theoretical 0.55 g, 1.5 mmol, 1.0 equiv) in CH2Cl2 (30 
mL, 0.05 M wrt 80) at 0 °C was added freshly prepared77 MgBr2•OEt2 (1.5 g, 6.0 mmol, 4.0 
equiv). The resulting suspension was stirred at 0 °C for 5 min, cooled to –78 °C, and then 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(77)  Peterson, S. Studies Toward the Synthesis of Amphidinol 3. Ph.D. Thesis, Harvard University, 2006. 
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charged dropwise with a freshly prepared78 solution of allylmagnesium bromide in Et2O (5.3 
mL, 0.42 M, 2.2 mmol, 1.5 equiv). The reaction mixture was stirred at –78 °C for 2.5 h, 
slowly warmed to –40 °C over 30 min, then briefly warmed to 0 °C and quenched with sat. aq 
NH4Cl (30 mL). The biphasic mixture was diluted with H2O (5 mL) and CH2Cl2 (30 mL) and 
warmed to rt. The layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 40 
mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The 
residue was analyzed by 1H-NMR spectroscopy to assess reaction diastereoselectivity (d.r. = 
89:11). Column chromatography (gradient elution, 16% → 18% → 20% EtOAc in hexanes) 
afforded homoallylic carbinol 64 (0.35 g, 56% yield, two steps) as a clear, colorless oil. [α]
€ 
D
25  
–18.9° (c = 1.4, CH2Cl2); IR (neat) 3477 (br), 3065, 3031, 2984, 2935, 1641, 1497, 1454, 
1371, 1249, 1211, 1068, 916, 858, 736, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.36–7.29 
(m, 8H, eight of ArH), 7.27 (m, 2H, two of ArH), 5.77 (dddd, J = 17.1, 10.3, 7.0, 7.0 Hz, 1H, 
C33-H), 5.07 (d, J = 10.3 Hz, 1H, one of C33a-H), 5.03 (dd, J = 17.1, 1.5 Hz, 1H, one of C33a-
H), 4.68 (d, J = 12.4 Hz, 1H, one of –OCH2Ph), 4.66 (d, J = 12.3 Hz, 1H, one of –OCH2Ph), 
4.64 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.52 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.44 
(ddd, J = 6.7, 6.7, 5.6 Hz, 1H, C28-H), 3.95 (dd, J = 8.1, 6.7 Hz, 1H, one of C27-H), 3.90 
(dddd, J = 7.6, 7.0, 5.4, 2.2 Hz, 1H, C31-H), 3.78 (dd, J = 7.8, 7.8 Hz, 1H, one of C27-H), 3.55 
(dd, J = 5.3, 5.3 Hz, 1H, C29-H), 3.46 (dd, J = 5.3, 2.2 Hz, 1H, C30-H), 2.60 (d, J = 6.9 Hz, 
1H, C28-OH), 2.31 (ddd, J = 14.2, 7.2, 7.0 Hz, 1H, one of C32-H), 2.23 (ddd, J = 14.1, 6.9, 6.3 
Hz, 1H, one of C32-H), 1.44 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3); 13C-NMR (125 
MHz, CDCl3) δ 138.2, 137.8, 134.9, 128.5, 128.4, 128.3, 128.1, 128.0, 127.7, 117.4, 109.0, 
79.5, 77.8, 76.0, 73.9, 73.9, 69.2, 66.0, 39.0, 26.5, 25.6; HRMS (ESI-TOF) m/z calcd for 
C25H33O5 [M+H]+: 413.2323, found: 413.2330. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(78)  Benson, R.E.; McKusick, B.C. Org. Synth. 1958, 38, 78–84. 
OBn
64
OBn
31O
O
27
Me Me
OH OBn
81
OBn
31O
O
27
Me Me
O
O
33a
34a
	   101 
(1R,2R,3S)-1,2-Bis(benzyloxy)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)hex-5-en-3-yl 
acrylate (81). To a solution of homoallylic carbinol 64 (1.6 g, 4.0 mmol, 1.0 equiv) in THF 
(20 mL, 0.2 M wrt 64) at room temperature was added EtN(iPr)2 (2.1 mL, 12 mmol, 3.0 
equiv), DMAP (0.12 g, 0.99 mmol, 0.25 equiv), and a freshly prepared solution of acrylic 
pivalic anhydride in PhH (6.0 mL, 2.0 M, 12 mmol, 3.0 equiv). The resulting suspension was 
stirred at room temperature for 7 h, then charged with additional EtN(iPr)2 (2.1 mL, 12 mmol, 
3.0 equiv), DMAP (0.12 g, 0.99 mmol, 0.25 equiv), and acrylic pivalic anhydride (6.0 mL, 2.0 
M in PhH, 12 mmol, 3.0 equiv). The reaction mixture was stirred for an additional 12 h, 
quenched with sat. aq NaHCO3 (35 mL), and diluted with Et2O (35 mL) and H2O (5 mL). The 
layers were separated and the aqueous layer extracted with Et2O (2 x 60 mL). The combined 
organic extracts were dried over Na2SO4 with added hexanes, filtered and concentrated. 
Column chromatography (gradient elution, 6% → 8% → 10% EtOAc in hexanes) afforded 
acrylate ester 81 (1.48 g, 80% yield) as a clear, colorless oil. [α]
€ 
D
25  –19.3° (c = 1.3, CH2Cl2); 
IR (neat) 3066, 3032, 2985, 2892, 1730 (s), 1640, 1497, 1455, 1405, 1371, 1260, 1195, 1064 
(br), 987, 919, 853, 808, 736, 698 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.35–7.27 (m, 10H, 
ArH), 6.42 (dd, J = 17.3, 1.2 Hz, 1H, one of C34a-H), 6.14 (dd, J = 17.3, 10.4 Hz, 1H, C34-H), 
5.83 (dd, J = 10.4, 1.2 Hz, 1H, one of C34a-H), 5.67 (dddd, J = 17.1, 10.1, 7.0, 7.0 Hz, 1H, C33-
H), 5.32 (ddd, J = 7.3, 5.2, 4.9 Hz, 1H, C31-H), 5.02 (dd, J = 10.1, 1.5 Hz, 1H, one of C33a-H), 
4.99 (dd, J = 17.1, 1.5 Hz, 1H, one of C33a-H), 4.74 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 
4.72 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.64 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.58 
(d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.26 (ddd, J = 6.4, 6.4, 6.4 Hz, 1H, C28-H), 3.86 (dd, J 
= 8.3, 6.5 Hz, 1H, one of C27-H), 3.73 (dd, J = 7.9, 7.6 Hz, 1H, one of C27-H), 3.65 (dd, J = 
5.0, 4.8 Hz, 1H, C30-H), 3.51 (dd, J = 5.4, 5.4 Hz, 1H, C29-H), 2.46 (dddd, J = 14.3, 6.6, 5.6, 
1.0 Hz, 1H, one of C32-H), 2.32 (ddd, J = 14.6, 7.5, 7.2 Hz, 1H, one of C32-H), 1.43 (s, 3H, 
one of CH3), 1.34 (s, 3H, one of CH3); 13C-NMR (125 MHz, CDCl3) δ 165.5, 138.2, 137.9, 
133.5, 131.1, 128.4, 128.4, 128.3, 128.2, 128.1, 127.8, 127.7, 117.9, 109.0, 78.6, 78.0, 76.4, 
74.0, 73.9, 72.5, 65.8, 35.4, 26.5, 25.6; HRMS (ESI-TOF) m/z calcd for C28H34NaO6 [M+Na]+: 
489.2248, found: 489.2229. 
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(S)-6-((1R,2R)-1,2-Bis(benzyloxy)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5,6-
dihydro-2H-pyran-2-one (65). To a degassed solution of diene 81 (0.28 g, 0.60 mmol, 1.0 
equiv) in PhH (40 mL, 0.015 M wrt 81) at room temperature was added ruthenium catalyst 90 
(0.025 g, 0.030 mmol, 0.05 equiv). The reaction mixture was purged with argon for 5 min, 
stirred at 65 °C for 12 h, then recharged with additional catalyst (0.025 g, 0.030 mmol, 0.05 
equiv) at this time and approximately every 7 h twice after (total catalyst 90 added: 0.2 
equiv). The reaction mixture was stirred at 65 °C for an additional 12 h, cooled to room 
temperature, concentrated to half volume, diluted with 2:1 hexanes/EtOAc (50 mL) and 
filtered through a silica gel plug (4 cm). The filter cake was rinsed with 2:1 hexanes/EtOAc 
(200 mL), and the filtrate concentrated. Column chromatography (gradient elution, 4:1 → 3:1 
→ 5:2 hexanes/EtOAc) afforded lactone 65 (0.23 g, 89% yield) as a dark brown oil 
contaminated with ruthenium-based impurities (<5%). A sufficient quantity of this material 
was repurified by column chromatography to produce a clear, colorless oil for 
characterization. [α]
€ 
D
25  –91.0° (c = 1.2, CH2Cl2); IR (neat) 3064, 3031, 2986, 2935, 2881, 
1732 (s), 1498, 1455, 1381, 1248, 1213, 1157, 1116, 1064, 893, 851, 816, 740, 700 cm–1; 1H-
NMR (600 MHz, CDCl3) δ 7.36–7.28 (m, 10H, ArH), 6.79 (ddd, J = 9.7, 6.3, 2.3 Hz, 1H, C33-
H), 5.97 (ddd, J = 9.7, 2.8, 0.7 Hz, 1H, C34-H), 4.75 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 
4.73 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.71 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.71 
(ddd, J = 12.2, 4.2, 3.8 Hz, 1H, C31-H), 4.67 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.39 
(ddd, J = 6.9, 6.7, 5.1 Hz, 1H, C28-H), 3.90 (dd, J = 8.2, 6.6 Hz, 1H, one of C27-H), 3.79 (dd, J 
= 8.2, 7.0 Hz, 1H, one of C27-H), 3.72 (dd, J = 5.3, 5.3 Hz, 1H, C29-H), 3.61 (dd, J = 5.3, 4.2 
Hz, 1H, C30-H), 2.51 (dddd, J = 18.3, 12.2, 2.6, 2.5 Hz, 1H, one of C32-H), 2.08 (dddd, J = 
18.5, 6.2, 3.8, 0.9 Hz, 1H, one of C32-H), 1.45 (s, 3H, one of CH3), 1.35 (s, 3H, one of CH3); 
13C-NMR (125 MHz, CDCl3) δ 163.7, 145.5, 138.1, 137.6, 128.4, 128.4, 128.3, 128.1, 128.0, 
127.8, 120.8, 109.2, 79.1, 78.0, 77.8, 76.3, 74.6, 74.2, 65.7, 26.5, 25.8, 25.6; HRMS (ESI-
TOF) m/z calcd for C26H30NaO6 [M+Na]+: 461.1935, found: 461.1937. 
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(3R,4R,6S)-6-((1R,2R)-1,2-Bis(benzyloxy)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-
3,4-dihydroxytetrahydro-2H-pyran-2-one (82). To a bright yellow suspension of NaIO4 
(0.17 g, 0.80 mmol, 1.5 equiv) and CeCl3•7H2O (0.020 g, 0.053 mmol, 0.1 equiv) in deionized 
H2O (0.53 mL, 1.5 M wrt NaIO4) at 0 °C was added EtOAc (0.66 mL, 1.2 M wrt NaIO4), 
MeCN (0.80 mL, 1.0 M wrt NaIO4), and an aqueous solution of RuCl3 (27 µL, 0.1 M, 2.7 
µmol, 0.005 equiv). The bilayer suspension was stirred at 0 °C for 5 min, then charged slowly 
dropwise with a solution of unsaturated lactone 65 (0.23 g, 0.53 mmol, 1.0 equiv) in EtOAc 
(1.1 mL, 0.5 M wrt 65) over 1 min (with 2 x 0.27 mL rinses). The reaction mixture was 
vigorously stirred at 0 °C for 1.5 h, charged with Na2SO4 (0.53 g), then filtered through 
Na2SO4 with EtOAc rinses (50 mL total) into a flask containing sat. aq Na2SO3 (10 mL) and 
brine (10 mL). The layers were separated and the aqueous layer extracted with EtOAc (2 x 50 
mL). The combined organic extracts were dried over Na2SO4 with added hexanes (150 mL) 
and filtered through a silica gel plug (4 cm). The filter cake was rinsed with 1:1 
hexanes/EtOAc (300 mL), and the filtrate concentrated and azeotroped with PhH (2 x 5 mL) 
to afford crude diol 82 (0.21 g, 85% yield) as a solid of mixed white and brown coloration due 
to contamination with ruthenium-based impurities (<5%). The crude product was analyzed by 
1H-NMR spectroscopy to assess reaction diastereoselectivity (d.r. ≥ 95:05).  [α]
€ 
D
24  –12.1° (c = 
1.0, CH2Cl2); IR (neat) 3442 (br), 3064, 3030, 2965, 2934, 1745 (s), 1455, 1371, 1214, 1124, 
1062, 854, 741, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.36–7.24 (m, 10H, ArH), 5.03 
(ddd, J = 11.4, 4.1, 2.2 Hz, 1H, C31-H), 4.80 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.78 (d, J 
= 11.6 Hz, 1H, one of –OCH2Ph), 4.70 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.53 (d, J = 
11.6 Hz, 1H, one of –OCH2Ph), 4.38 (ddd, J = 6.7, 6.6, 4.5 Hz, 1H, C28-H), 4.29 (m, 1H, C33-
H), 4.05 (dd, J = 2.9, 1.0 Hz, 1H, C34-H), 3.99 (dd, J = 8.2, 6.6 Hz, 1H, one of C27-H), 3.87 
(dd, J = 8.2, 6.9 Hz, 1H, one of C27-H), 3.82 (dd, J = 6.7, 4.5 Hz, 1H, C29-H), 3.57 (dd, J = 
6.9, 2.3 Hz, 1H, C30-H), 3.38 (d, J = 1.0 Hz, 1H, C34-OH), 2.69 (dd, J = 2.1, 1.2 Hz, 1H, C33-
OH), 2.12 (dddd, J = 14.4, 11.4, 2.1, 2.1 Hz, 1H, one of C32-H), 1.99 (ddd, J = 14.5, 4.2, 4.2 
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Hz, 1H, one of C32-H), 1.45 (s, 3H, one of CH3), 1.36 (s, 3H, one of CH3); 13C-NMR (125 
MHz, CDCl3) δ 173.7, 138.2, 137.4, 128.5, 128.4, 128.1, 128.1, 127.9, 127.7, 109.1, 80.0, 
78.2, 76.9, 76.2, 74.8, 74.7, 70.4, 66.1, 65.5, 29.8, 26.5, 25.6; HRMS (ESI-TOF) m/z calcd for 
C26H32NaO8 [M+Na]+: 495.1989, found: 495.1999. 
 
(3aR,6S,7aR)-6-((1R,2R)-1,2-Bis(benzyloxy)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-
2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyran-4(6H)-one (66). To a solution of diol 
82 (0.75 g, 1.6 mmol, 1.0 equiv) in 2:1 acetone/2,2-dimethoxypropane (32 mL, 0.05 M wrt 
82) at rt was added PPTS (40 mg, 0.16 mmol, 0.1 equiv). The reaction mixture was stirred at 
30 °C for 15 h, quenched with a large spatula tip full of NaHCO3 (s), stirred vigorously for an 
additional 15 min, and filtered through Celite. The filter cake was rinsed with EtOAc (40 mL 
total), and the filtrate concentrated. Column chromatography (gradient elution, 16% → 18% 
→ 20% EtOAc in hexanes) afforded acetonide 66 (0.63 g, 78% yield) as a white solid. [α]
€ 
D
25  
+6.5° (c = 1.1, CH2Cl2); IR (neat) 3031, 2987, 2936, 1751 (s), 1497, 1456, 1377, 1266, 1211, 
1159, 1119, 1061, 919, 852, 738, 700 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.35–7.26 (m, 
10H, ArH), 4.92 (ddd, J = 10.4, 2.2, 2.1 Hz, 1H, C31-H), 4.76 (d, J = 11.4 Hz, 1H, one of –
OCH2Ph), 4.74 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.69 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.57 (m, J = 9.7, 2.8 Hz, 1H, C33-H), 4.56 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 
4.53 (dd, J = 6.9, 1.0 Hz, 1H, C34-H), 4.35 (ddd, J = 6.4, 6.3, 4.8 Hz, 1H, C28-H), 3.97 (dd, J = 
7.3, 6.4 Hz, 1H, one of C27-H), 3.84 (dd, J = 7.3, 7.3 Hz, 1H, one of C27-H), 3.78 (dd, J = 5.9, 
5.0 Hz, 1H, C29-H), 3.61 (dd, J = 6.2, 3.2 Hz, 1H, C30-H), 2.99 (ddd, J = 15.1, 10.3, 3.1 Hz, 
1H, one of C32-H), 1.88 (ddd, J = 15.1, 2.1, 1.8 Hz, 1H, one of C32-H), 1.48 (s, 3H, one of 
CH3), 1.44 (s, 3H, one of CH3), 1.35 (s, 3H, one of CH3), 1.33 (s, 3H, one of CH3); 13C-NMR 
(125 MHz, CDCl3) δ 167.8, 138.1, 137.5, 128.5, 128.4, 128.2, 128.0, 127.9, 127.7, 110.6, 
109.0, 80.1, 78.1, 76.1, 74.9, 74.6, 74.5, 72.9, 71.7, 65.5, 30.9, 26.5, 26.0, 25.6, 24.0; HRMS 
(ESI-TOF) m/z calcd for C29H36KO8 [M+K]+: 551.2042, found: 551.2039. 
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(2S,3R,4R)-3,4-Bis(benzyloxy)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-((4R,5S)-5-
(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butan-2-ol (83). To a solution of lactone 
66 (0.64 g, 1.3 mmol, 1.0 equiv) in THF (13 mL, 0.10 M wrt 66) at 0 °C was added H2O (36 
µL, 2.0 mmol, 1.6 equiv) and LiBH4 (0.041 g, 1.9 mmol, 1.5 equiv). The reaction mixture was 
slowly warmed to rt o/n (16 h total stir time), then recooled to 0 °C, quenched with 1 M aq 
NaOH (15 mL), stirred vigorously at rt for 0.5 h, and diluted with Et2O (15 mL). The layers 
were separated and the organic layer washed sequentially with H2O and brine (10 mL each). 
The combined aqueous layers were extracted with Et2O (2 x 15 mL), and the combined 
organic extracts were dried over Na2SO4 with added hexanes, filtered and concentrated. 
Column chromatography (gradient elution, 2:1 → 1:1 → 1:2 hexanes/EtOAc + 1% Et3N) 
afforded diol 83 (0.64 g, quant. yield) as a clear, colorless oil. [α]
€ 
D
23  –10.1° (c = 2.7, CH2Cl2); 
IR (neat) 3480 (br), 3064, 3031, 2986, 2935, 2879, 1497, 1456, 1371, 1251, 1216, 1161, 
1118, 1065, 892, 862, 737, 700 cm–1; 1H-NMR (600 MHz, C6D6) δ 7.38 (m, 2H, ArH), 7.23–
7.06 (m, 8H, ArH), 4.77 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.70 (d, J = 11.6 Hz, 1H, one 
of –OCH2Ph), 4.63 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.62 (ddd, J = 7.2, 6.6, 5.0 Hz, 1H, 
C28-H), 4.44 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.19 (dddd, J = 8.2, 4.2, 4.0, 3.4 Hz, 1H, 
C31-H), 4.07 (ddd, J = 10.0, 5.9, 4.1 Hz, 1H, C33-H), 3.95–3.90 (m, J = 8.2, 7.3, 6.6 Hz, 2H, 
C27-H2), 3.90 (m, J = 6.2, 3.1 Hz, 1H, C34-H), 3.82 (dd, J = 5.6, 5.1 Hz, 1H, C29-H), 3.60 (dd, 
J = 5.8, 3.0 Hz, 1H, C30-H), 3.45–3.38 (m, J = 11.3, 7.2, 6.2, 5.4, 4.7 Hz, 2H, C35-H2), 3.08 (d, 
J = 4.5 Hz, 1H, C31-OH), 1.98 (ddd, J = 14.1, 9.7, 8.5 Hz, 1H, one of C32-H), 1.94 (dd, J = 
7.2, 4.8 Hz, 1H, C35-OH), 1.55 (ddd, J = 14.1, 4.0, 4.0 Hz, 1H, one of C32-H), 1.52 (s, 3H, one 
of CH3), 1.37 (s, 3H, one of CH3), 1.33 (s, 3H, one of CH3), 1.19 (s, 3H, one of CH3); 13C-
NMR (125 MHz, C6D6) δ 139.3, 138.8, 128.6, 128.5, 128.5, 128.2, 128.0, 127.7, 109.1, 108.2, 
81.4, 79.1, 78.3, 77.4, 76.0, 74.5, 74.2, 70.0, 66.3, 61.6, 33.3, 28.1, 26.9, 26.0, 25.4; HRMS 
(ESI-TOF) m/z calcd for C29H41O8 [M+H]+: 517.2796, found: 517.2800. 
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(2S,3R,4R)-3,4-Bis(benzyloxy)-1-((4R,5S)-5-((tert-butyldiphenylsilyloxy)methyl)-2,2-
dimethyl-1,3-dioxolan-4-yl)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)butan-2-ol (84). To a 
solution of diol 83 (0.60 g, 1.2 mmol, 1.0 equiv) and imidazole (0.12 g, 1.7 mmol, 1.5 equiv) 
in DMF (5.8 mL, 0.20 M wrt 83) at 0 °C was added tert-butylchlorodiphenylsilane (0.33 mL, 
1.3 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 4 h, quenched with sat. aq 
NaHCO3 (15 mL), and diluted with 1:1 hexanes/Et2O (30 mL) and H2O (5 mL). The layers 
were separated and the aqueous layer extracted with 1:1 hexanes/Et2O (2 x 30 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated. Column 
chromatography (gradient elution, 12% → 16% → 20% EtOAc in hexanes) afforded silyl 
ether 84 (0.83 g, 95% yield) as a clear, colorless oil. [α]
€ 
D
24  –7.2° (c = 2.8, CH2Cl2); IR (neat) 
3522 (br), 3070, 3030, 2985, 2933, 2859, 1455, 1428, 1380, 1360, 1252, 1216, 1113, 1066, 
824, 738 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.71 (m, 5H, ArH), 7.49–7.29 (m, 15H, ArH), 
4.77 (d, J = 12.2 Hz, 1H, one of –OCH2Ph), 4.75 (d, J = 12.3 Hz, 1H, one of –OCH2Ph), 4.70 
(d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.57 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.50 (ddd, 
J = 6.9, 6.7, 5.7 Hz, 1H, C28-H), 4.23 (ddd, J = 10.8, 6.0, 2.3 Hz, 1H, C33-H), 4.15 (ddd, J = 
6.4, 6.3, 6.0 Hz, 1H, C34-H), 4.13 (m, J = 8.1, 3.4 Hz, 1H, C31-H), 3.97 (dd, J = 8.1, 6.6 Hz, 
1H, one of C27-H), 3.85 (dd, J = 7.8, 7.8 Hz, 1H, one of C27-H), 3.69 (dd, J = 5.4, 5.4 Hz, 1H, 
C29-H), 3.66 (dd, J = 10.8, 6.8 Hz, 1H, one of C35-H), 3.63 (dd, J = 10.7, 5.7 Hz, 1H, one of 
C35-H), 3.49 (dd, J = 5.4, 2.9 Hz, 1H, C30-H), 3.26 (d, J = 3.2 Hz, 1H, C31-OH), 1.87 (ddd, J = 
14.2, 10.8, 8.5 Hz, 1H, one of C32-H), 1.69 (ddd, J = 14.1, 3.2, 2.9 Hz, 1H, one of C32-
H), 1.49 (s, 3H, one of CH3), 1.42 (s, 3H, one of CH3), 1.41 (s, 3H, one of CH3), 1.35 (s, 3H, 
one of CH3), 1.10 (s, 9H, C(CH3)3); 13C-NMR (125 MHz, CDCl3) δ 138.5, 137.9, 135.6, 
135.5, 133.3, 133.1, 129.8, 129.8, 128.4, 128.3, 128.3, 128.0, 127.8, 127.7, 127.7, 127.6, 
108.8, 108.4, 80.6, 78.4, 78.0, 76.8, 76.4, 74.1, 74.0, 70.0, 65.9, 62.7, 32.8, 28.0, 26.8, 26.6, 
25.7, 25.4, 19.2; HRMS (ESI-TOF) m/z calcd for C45H58NaO8Si [M+Na]+: 777.3793, found: 
777.3797. 
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tert-Butyl(((4S,5R)-2,2-dimethyl-5-((2S,3R,4R)-2,3,4-tris(benzyloxy)-4-((S)-2,2-dimethyl-
1,3-dioxolan-4-yl)butyl)-1,3-dioxolan-4-yl)methoxy)diphenylsilane (61). To a solution of 
carbinol 84 (0.83 g, 1.1 mmol, 1.0 equiv) in DMF (5.5 mL, 0.20 M wrt 84) at –20 °C was 
added sodium hydride (0.13 g, 60 wt% mineral oil dispersion, 3.3 mmol, 3.0 equiv). The 
suspension was stirred at –20 °C for 15 min, then charged with benzyl bromide (0.20 mL, 1.6 
mmol, 1.5 equiv) and tetrabutylammonium iodide (0.041 g, 0.11 mmol, 0.1 equiv). The 
reaction mixture was stirred at –20 °C for 3 h, briefly warmed to 0 °C, then quenched with 
sat. aq NH4Cl (15 mL), and diluted with 1:1 hexanes/Et2O (40 mL) and H2O (5 mL). The 
layers were separated and the aqueous layer extracted with 1:1 hexanes/Et2O (2 x 30 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated. Column 
chromatography (gradient elution, 6% → 8% → 10% EtOAc in hexanes) afforded benzyl 
ether 61 (0.88 g, 95% yield) as a clear, colorless oil. [α]
€ 
D
25  +10.4° (c = 0.94, CH2Cl2); IR 
(neat) 3069, 3030, 2985, 2933, 2859, 1496, 1455, 1428, 1370, 1253, 1212, 1109, 1071, 823, 
739 cm–1; 1H-NMR (600 MHz, C6D6) δ 7.81–7.79 (m, 4H, ArH), 7.42 (m, J = 7.3 Hz, 2H, 
ArH), 7.30 (m, J = 7.2 Hz, 2H, ArH), 7.25 (m, J = 7.2 Hz, 2H, ArH), 7.22–7.04 (m, 15H, 
ArH), 4.98 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.83 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.70 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.65 (ddd, J = 7.0, 6.7, 6.7 Hz, 1H, 
C28-H), 4.58 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.54 (d, J = 11.4 Hz, 1H, one of –
OCH2Ph), 4.44 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.35 (ddd, J = 10.5, 6.4, 1.8 Hz, 1H, 
C33-H), 4.23 (ddd, J = 8.8, 3.7, 3.4 Hz, 1H, C31-H), 4.10 (ddd, J = 6.0, 6.0, 5.6 Hz, 1H, C34-H), 
3.96 (dd, J = 6.6, 4.2 Hz, 1H, C29-H), 3.91 (dd, J = 7.9, 7.6 Hz, 1H, one of C27-H), 3.86 (m, J 
= 4.1 Hz, 1H, C30-H), 3.85 (dd, J = 8.2, 6.4 Hz, 1H, one of C27-H), 3.82 (dd, J = 10.8, 6.3 Hz, 
1H, one of C35-H), 3.77 (dd, J = 10.7, 5.2 Hz, 1H, one of C35-H), 2.18 (ddd, J = 14.4, 7.1, 1.8 
Hz, 1H, one of C32-H), 1.94 (ddd, J = 14.5, 10.7, 3.4 Hz, 1H, one of C32-H), 1.51 (s, 3H, one 
of CH3), 1.44 (s, 3H, one of CH3), 1.34 (s, 3H, one of CH3), 1.27 (s, 3H, one of CH3), 1.16 (s, 
9H, C(CH3)3); 13C-NMR (125 MHz, C6D6) δ 139.7, 139.3, 139.2, 136.1, 136.0, 133.8, 133.7, 
130.1, 128.5, 128.5, 128.4, 128.3, 128.1, 127.9, 127.7, 127.7, 109.0, 108.0, 79.7, 79.3, 78.5, 
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78.4, 77.8, 74.1, 74.0, 73.7, 72.0, 66.3, 63.6, 29.6, 28.3, 27.1, 25.9, 25.5, 19.4; HRMS (ESI-
TOF) m/z calcd for C52H64O8Si [M+H]+: 845.4443, found: 845.4456. 
 
((4S,5R)-2,2-Dimethyl-5-((2S,3R,4R)-2,3,4-tris(benzyloxy)-4-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)butyl)-1,3-dioxolan-4-yl)methanol (85). To a solution of silyl ether 61 (0.88 
g, 1.0 mmol, 1.0 equiv) in THF (6.9 mL, 0.15 M wrt 61) at 0 °C was added dropwise a 
solution of tetrabutylammonium fluoride in THF (1.6 mL, 1.0 M, 1.6 mmol, 1.5 equiv). The 
reaction mixture was stirred at 0 °C for 8 h, slowly warmed to rt over 6 h, then quenched with 
sat. aq NaHCO3 (15 mL), and diluted with Et2O (35 mL) and H2O (5 mL). The layers were 
separated and the aqueous layer extracted with Et2O (2 x 35 mL). The combined organic 
extracts were dried over Na2SO4 with added hexanes, filtered and concentrated. Column 
chromatography (gradient elution, 4:1 → 2:1 hexanes/EtOAc + 1% Et3N) afforded carbinol 
85 (0.63 g, quant. yield) as a clear, colorless oil. [α]
€ 
D
24  +6.4° (c = 0.81, CH2Cl2); IR (neat) 
3478 (br), 3063, 3030, 2985, 2935, 2880, 1496, 1454, 1370, 1251, 1213, 1160, 1064, 916, 
855, 736 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.36–7.27 (m, 15H, ArH), 4.81 (d, J = 11.9 Hz, 
1H, one of –OCH2Ph), 4.75 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.69 (d, J = 11.9 Hz, 1H, 
one of –OCH2Ph), 4.65 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.57 (d, J = 11.6 Hz, 1H, one 
of –OCH2Ph), 4.55 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.23 (ddd, J = 7.2, 6.7, 6.7 Hz, 1H, 
C28-H), 4.01 (ddd, J = 10.1, 6.3, 2.9 Hz, 1H, C33-H), 3.84 (ddd, J = 6.2, 5.9, 4.2 Hz, 1H, C31-
H), 3.79 (ddd, J = 6.2, 5.9, 4.2 Hz, 1H, C34-H), 3.59 (dd, J = 6.7, 4.0 Hz, 1H, C29-H), 3.54 (dd, 
J = 7.9, 7.5 Hz, 1H, one of C27-H), 3.52 (dd, J = 5.9, 4.0 Hz, 1H, C30-H), 3.44 (dd, J = 8.1, 6.4 
Hz, 1H, one of C27-H), 3.31 (m, J = 11.3, 7.6, 7.2, 4.5, 4.4 Hz, 2H, C35-H2), 1.74 (dd, J = 7.8, 
4.5 Hz, 1H, C35-OH), 1.60 (ddd, J = 14.5, 6.4, 2.9 Hz, 1H, one of C32-H), 1.43 (s, 3H, one of 
CH3), 1.41 (s, 3H, one of CH3), 1.36 (ddd, J = 14.5, 10.1, 4.1 Hz, 1H, one of C32-H), 1.29 (s, 
3H, one of CH3), 1.29 (s, 3H, one of CH3); 13C-NMR (125 MHz, CDCl3) δ 138.6, 138.3, 
138.1, 129.0, 128.5, 128.4, 128.4, 128.3, 128.0, 127.8, 127.6, 108.8, 108.0, 77.8, 77.7, 77.7, 
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76.7, 73.8, 73.4, 72.8, 72.2, 65.6, 61.7, 28.6, 28.2, 26.7, 25.5, 25.4; HRMS (ESI-TOF) m/z 
calcd for C36H46NaO8 [M+Na]+: 629.3085, found: 629.3104. 
 
(4R,5R)-2,2-Dimethyl-5-((2S,3R,4R)-2,3,4-tris(benzyloxy)-4-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)butyl)-1,3-dioxolane-4-carbaldehyde (67). To a solution of carbinol 85 (0.12 
g, 0.19 mmol, 1.0 equiv) and EtN(iPr)2 (0.10 mL, 0.58 mmol, 3.0 equiv) in CH2Cl2 (0.55 mL, 
0.35 M wrt 85) and DMSO (0.22 mL, 0.88 M wrt 85) at –30 °C was added a solution of 
SO3•py (0.093 g, 0.58 mmol, 3.0 equiv) in DMSO (0.33 mL, 1.75 M wrt SO3•py). The 
reaction mixture was stirred between –30 °C and –20 °C for 1.5 h, then quenched with brine 
(20 mL), Et2O (60 mL) and H2O (2 mL). The layers were separated and the organic layer 
washed sequentially with 1 M aq NaHSO4 (20 mL), sat. aq NaHCO3 (20 mL), and 1:1 
H2O/brine (2 x 20 mL). The organic layer was then dried over Na2SO4 with added hexanes, 
filtered and concentrated to afford crude aldehyde 67 (0.11 g, 96% yield) as a clear, colorless 
oil that was used without further purification. [α]
€ 
D
25  +7.4° (c = 0.94, CH2Cl2); IR (neat) 3063, 
3030, 2986, 2934, 1734 (s), 1496, 1454, 1370, 1255, 1216, 1159, 1065, 858, 736, 699 cm–1; 
1H-NMR (600 MHz, CDCl3) δ 9.38 (d, J = 3.2 Hz, 1H, C35-H), 7.35–7.28 (m, 15H, ArH), 
4.80 (d, J = 12.0 Hz, 1H, one of –OCH2Ph), 4.75 (d, J = 12.0 Hz, 1H, one of –OCH2Ph), 4.72 
(d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.62 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.56 (d, J 
= 11.9 Hz, 1H, one of –OCH2Ph), 4.54 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.24 (ddd, J = 
7.2, 6.9, 6.9 Hz, 1H, C28-H), 4.19 (ddd, J = 10.0, 7.3, 2.8 Hz, 1H, C33-H), 3.88 (dd, J = 7.2, 
3.4 Hz, 1H, C34-H), 3.86 (ddd, J = 6.2, 6.2, 4.2 Hz, 1H, C31-H), 3.56 (dd, J = 7.0, 3.6 Hz, 1H, 
C29-H), 3.51 (dd, J = 7.9, 7.8 Hz, 1H, one of C27-H), 3.46 (dd, J = 6.2, 3.6 Hz, 1H, C30-H), 
3.42 (dd, J = 8.1, 6.4 Hz, 1H, one of C27-H), 1.75 (ddd, J = 14.6, 6.3, 2.8 Hz, 1H, one of C32-
H), 1.52 (s, 3H, one of CH3), 1.43 (s, 3H, one of CH3), 1.33 (s, 3H, one of CH3), 1.30 (s, 3H, 
one of CH3), 1.21 (ddd, J = 14.6, 10.1, 4.2 Hz, 1H, one of C32-H); 13C-NMR (125 MHz, 
CDCl3) δ 201.7, 138.4, 138.1, 138.0, 128.9, 128.7, 128.4, 128.4, 128.3, 128.3, 128.0, 127.8, 
127.8, 110.5, 108.9, 81.7, 77.9, 77.7, 77.4, 76.4, 74.4, 73.7, 73.3, 72.3, 65.6, 29.3, 27.6, 26.7, 
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25.5, 25.3; HRMS (ESI-TOF) m/z calcd for C36H44NaO8 [M+Na]+: 627.2928, found: 
627.2914. 
Synthesis of the C27–C48 Aldehyde 
 
(5S,8R)-5-((S)-((4S,5R)-2,2-Dimethyl-5-((2S,3R,4R)-2,3,4-tris(benzyloxy)-4-((S)-2,2-
dimethyl-1,3-dioxolan-4-yl)butyl)-1,3-dioxolan-4-yl)(hydroxy)methyl)-3,3-diethyl-
10,10,11,11-tetramethyl-8-nonyl-4,9-dioxa-3,10-disiladodecan-6-one (68). To a solution of 
ketone 13 (0.29 g, 0.62 mmol, 2.0 equiv) and EtNMe2 (0.14 mL, 1.2 mmol, 4.0 equiv) in 
pentane (3.1 mL, 0.2 M wrt 13) at 0 °C was added Cy2BCl (0.14 mL, 0.65 mmol, 2.1 equiv). 
The enolization mixture was stirred at 0 °C for 20 min, then stirred at rt for 15 h, then cooled 
to –78 °C and charged slowly dropwise with a solution of aldehyde 67 (0.19 g, 0.31 mmol, 
1.0 equiv) in Et2O (0.70 mL, 0.44 M wrt 67) over 1 min (with 0.30 mL rinse). The reaction 
mixture was stirred at –78 °C for 0.5 h, slowly warmed to –40 °C over 0.5 h, stirred at –40 °C 
for 4 h, slowly warmed to –25 °C over 2 h, stirred at –25 °C for 9 h, then quenched at 0 °C 
with aq pH 7 buffer (3 mL), MeOH (3 mL), Et2O (15 mL) and 30% aq H2O2 (1 mL). The 
biphasic mixture was stirred vigorously at 0 °C for 0.5 h, then at rt for 1 h. The layers were 
separated and the aqueous layer extracted with Et2O (2 x 15 mL). The combined organic 
extracts were washed with 10% aq Na2S2O3 (2 x 10 mL) and brine (10 mL), dried over 
Na2SO4 with added hexanes, filtered and concentrated. The residue was analyzed by 1H-NMR 
spectroscopy to assess reaction diastereoselectivity (d.r. = 91:09). Column chromatography 
(gradient elution, 5% → 6% EtOAc in hexanes) afforded aldol adduct 68 (0.26 g, 77% yield) 
as a clear, colorless oil. [α]
€ 
D
25  +0.2° (c = 1.7, CH2Cl2); IR (neat) 3567 (br), 3065, 3031, 2929, 
2856, 1721 (s), 1497, 1456, 1379, 1253, 1211, 1159, 1074, 836, 776, 733, 699 cm–1; 1H-NMR 
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(600 MHz, CDCl3) δ 7.35–7.26 (m, 15H, ArH), 4.82 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 
4.71 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.70 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.68 
(d, J = 12.0 Hz, 1H, one of –OCH2Ph), 4.60 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.53 (d, J 
= 11.6 Hz, 1H, one of –OCH2Ph), 4.23 (dddd, J = 6.2, 6.0, 5.4, 5.4 Hz, 1H, C39-H), 4.18 (ddd, 
J = 7.0, 6.9, 6.7 Hz, 1H, C28-H), 4.07 (m, J = 8.5, 7.6 Hz, 1H, C33-H), 4.03 (m, J = 7.3 Hz, 
1H, C34-H), 3.90 (m, J = 3.4 Hz, 1H, C31-H), 3.88 (d, J = 8.6 Hz, 1H, C36-H), 3.62 (dd, J = 
6.7, 4.0 Hz, 1H, C29-H), 3.57 (dd, J = 5.3, 4.1 Hz, 1H, C30-H), 3.53 (dd, J = 7.9, 7.8 Hz, 1H, 
one of C27-H), 3.42 (dd, J = 7.9, 6.7 Hz, 1H, one of C27-H), 3.37 (dd, J = 8.8, 8.8 Hz, 1H, C35-
H), 2.92 (dd, J = 18.5, 5.6 Hz, 1H, one of C38-H), 2.65 (dd, J = 18.4, 6.8 Hz, 1H, one of C38-
H), 2.13 (d, J = 8.9 Hz, 1H, C35-OH), 1.88 (ddd, J = 14.5, 10.4, 3.2 Hz, 1H, one of C32-H), 
1.74 (ddd, J = 14.5, 7.0, 1.8 Hz, 1H, one of C32-H), 1.53 (m, J = 5.0 Hz, 1H, one of C40-H), 
1.43 (s, 3H, one of CH3), 1.42–1.37 (m, 1H, one of C40-H), 1.40 (s, 3H, one of CH3), 1.36–
1.23 (m, 14H, C41–47-H2), 1.27 (s, 3H, one of CH3), 1.26 (s, 3H, one of CH3), 0.97 (t, J = 8.0 
Hz, 9H, –SiCH2CH3), 0.88 (s, 9H, C(CH3)3), 0.88 (t, J = 7.2 Hz, 3H, C48-H3), 0.64 (q, J = 7.9 
Hz, 6H, –SiCH2CH3), 0.09 (s, 3H, one of SiCH3), 0.06 (s, 3H, one of SiCH3); 13C-NMR (125 
MHz, CDCl3) δ 210.1, 138.8, 138.4, 138.2, 129.0, 128.3, 128.3, 128.3, 128.2, 127.9, 127.7, 
127.5, 108.7, 107.6, 78.7, 78.3, 77.8, 77.6, 76.9, 74.8, 73.8, 73.6, 72.9, 71.9, 71.1, 67.6, 65.5, 
45.8, 37.5, 31.9, 29.7, 29.6, 29.6, 29.3, 26.8, 26.7, 25.9, 25.5, 25.0, 24.3, 22.7, 18.0, 14.1, 6.7, 
4.7, –4.5, –4.7; HRMS (ESI-TOF) m/z calcd for C61H98NaO11Si2 [M+Na]+: 1085.6540, found: 
1085.6487. 
 
(5R,8S,9S)-9-((4R,5R)-2,2-Dimethyl-5-((2S,3R,4R,5S)-2,3,4-tris(benzyloxy)-5,6-
dihydroxyhexyl)-1,3-dioxolan-4-yl)-11,11-diethyl-2,2,3,3-tetramethyl-5-nonyl-8-
((triethylsilyl)oxy)-4,10-dioxa-3,11-disilatridecan-7-one (69). To a solution of carbinol 68 
(0.25 g, 0.24 mmol, 1.0 equiv) and 2,6-lutidine (0.16 mL, 1.4 mmol, 6.0 equiv) in CH2Cl2 (2.4 
mL, 0.1 M wrt 68) at 0 °C was added TESOTf (0.11 mL, 0.47 mmol, 2.0 equiv). The reaction 
mixture was stirred at 0 °C for 3 h, charged with TMSOTf (85 µL, 0.47 mmol, 2.0 equiv), 
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stirred at 0 °C for an additional 3 h, then quenched with 1 M aq H2SO4 (8 mL) and Et2O (8 
mL). The biphasic mixture was stirred vigorously at 0 °C for 0.5 h, then diluted with H2SO4 
(10 mL) and Et2O (30 mL), and the layers were separated. The organic layer was washed 
sequentially with sat. aq NaHCO3 and brine (10 mL each), dried over Na2SO4 with added 
hexanes, filtered and concentrated. Column chromatography (gradient elution, 4:1 → 3:1 
hexanes/EtOAc) afforded diol 69 (0.24 g, 88% yield) as a clear, colorless oil. [α] D26  +18.8° (c 
= 1.4, CH2Cl2); IR (neat) 3440 (br), 3065, 3032, 2955, 2929, 2878, 1712 (s), 1456, 1378, 
1250, 1220, 1100, 1061, 837, 775, 732, 699 cm–1; 1H-NMR (600 MHz, C6D6) δ 7.40 (m, J = 
7.9, 0.9 Hz, 2H, ArH), 7.35 (m, J = 7.9, 0.9 Hz, 2H, ArH), 7.23–7.07 (m, 11H, ArH), 4.76 (d, 
J = 11.6 Hz, 1H, one of –OCH2Ph), 4.74 (d, J = 12.3 Hz, 1H, one of –OCH2Ph), 4.68 (ddd, J 
= 11.9, 5.1, 2.8 Hz, 1H, C33-H), 4.62 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.58 (m, J = 5.9, 
5.9 Hz, 1H, C39-H), 4.56 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.52 (d, J = 11.6 Hz, 1H, one 
of –OCH2Ph), 4.49 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.30 (dd, J = 9.2, 5.1 Hz, 1H, C34-
H), 4.18 (ddd, J = 8.9, 4.5, 2.9 Hz, 1H, C31-H), 4.13 (dd, J = 9.2, 2.1 Hz, 1H, C35-H), 4.08 (dd, 
J = 7.2, 2.8 Hz, 1H, C30-H), 4.03 (d, J = 2.1 Hz, 1H, C36-H), 4.02 (dd, J = 7.2, 4.0 Hz, 1H, 
C29-H), 3.97 (m, J = 4.5, 4.2 Hz, 1H, C28-H), 3.71 (m, J = 10.8, 5.6 Hz, 1H, one of C27-H), 
3.67 (m, 1H, one of C27-H), 3.26 (dd, J = 19.5, 6.0 Hz, 1H, one of C38-H), 3.19 (dd, J = 19.5, 
6.0 Hz, 1H, one of C38-H), 2.89 (d, J = 5.1 Hz, 1H, C28-OH), 2.16 (ddd, J = 12.6, 12.3, 4.5 Hz, 
1H, one of C32-H), 2.06 (ddd, J = 12.7, 9.1, 2.8 Hz, 1H, one of C32-H), 1.78 (m, J = 5.6 Hz, 
1H, C27-OH), 1.76 (m, 1H, one of C40-H), 1.69 (m, 1H, one of C40-H), 1.60–1.51 (m, 2H, C41-
H2), 1.43 (s, 3H, one of CH3), 1.42–1.23 (m, 12H, C42–47-H2), 1.28 (s, 3H, one of CH3), 1.16 (t, 
J = 7.9 Hz, 9H, –SiCH2CH3), 1.03 (s, 9H, C(CH3)3), 0.96 (t, J = 8.0 Hz, 9H, –SiCH2CH3), 
0.92–0.80 (m, J = 8.1 Hz, 6H, –SiCH2CH3), 0.91 (t, J = 6.7 Hz, 3H, C48-H3), 0.62–0.52 (m, J 
= 8.1, 7.9 Hz, 6H, –SiCH2CH3), 0.22 (s, 3H, one of SiCH3), 0.21 (s, 3H, one of SiCH3); 13C-
NMR (125 MHz, C6D6) δ 211.6, 139.2, 139.0, 138.9, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 
128.1, 127.9, 127.6, 108.2, 79.5, 79.4, 79.3, 79.0, 76.4, 75.9, 74.7, 74.4, 74.3, 72.2, 72.0, 67.7, 
64.1, 49.1, 38.5, 30.6, 30.3, 30.1, 30.0, 29.8, 28.8, 26.1, 26.1, 25.6, 23.1, 18.3, 14.3, 7.3, 7.1, 
5.7, 5.0, –4.2, –4.4; HRMS (ESI-TOF) m/z calcd for C64H108NaO11Si3 [M+Na]+: 1159.7092, 
found: 1159.7053. 
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(2S,3R,4R,5S)-3,4,5-Tris(benzyloxy)-6-((4R,5R)-5-((5S,6S,9R)-3,3-diethyl-11,11,12,12-
tetramethyl-9-nonyl-7-oxo-6-((triethylsilyl)oxy)-4,10-dioxa-3,11-disilatridecan-5-yl)-2,2-
dimethyl-1,3-dioxolan-4-yl)-2-hydroxyhexyl acetate (86). To a solution of diol 69 (0.22 g, 
0.19 mmol, 1.0 equiv) and 2,4,6-collidine (51 µL, 0.38 mmol, 2.0 equiv) in CH2Cl2 (0.96 mL, 
0.2 M wrt 69) at –78 °C was added acetyl chloride (18 µL, 0.25 mmol, 1.3 equiv). The 
reaction mixture was stirred at –78 °C for 2 h, slowly warmed to 0 °C over 2 h, then quenched 
at 0 °C with 1 M aq H2SO4 (1 mL) and Et2O (1 mL). The biphasic mixture was stirred 
vigorously while warming to rt over 5 min, then diluted with H2SO4 (10 mL) and Et2O (40 
mL), and the layers were separated. The organic layer was washed with 1:1 sat. aq 
NaHCO3/brine (15 mL), dried over Na2SO4 with added hexanes, filtered and concentrated. 
Column chromatography (gradient elution, 12% → 14% → 16% EtOAc in hexanes) afforded 
acetate ester 86 (0.22 g, 98% yield) as a clear, colorless oil. [α] D26  +16.6° (c = 2.7, CH2Cl2); IR 
(neat) 3467 (br), 3064, 3032, 2930, 1743 (s), 1717 (s), 1458, 1375, 1247, 1096, 1062, 981, 
838, 733, 700 cm–1; 1H-NMR (600 MHz, C6D6) δ 7.38 (m, J = 7.5 Hz, 2H, ArH), 7.36 (m, J = 
7.3 Hz, 2H, ArH), 7.22–7.06 (m, 11H, ArH), 4.74 (d, J = 10.8 Hz, 1H, one of –OCH2Ph), 
4.74 (d, J = 12.4 Hz, 1H, one of –OCH2Ph), 4.67 (ddd, J = 12.0, 5.1, 2.8 Hz, 1H, C33-H), 4.64 
(d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.60 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.56 (m, J 
= 5.9, 5.7, 5.6 Hz, 1H, C39-H), 4.52 (d, J = 11.0 Hz, 1H, one of –OCH2Ph), 4.48 (d, J = 11.4 
Hz, 1H, one of –OCH2Ph), 4.36 (dd, J = 11.1, 6.9 Hz, 1H, one of C27-H), 4.29 (dd, J = 9.0, 
4.8 Hz, 1H, C34-H), 4.28 (dd, J = 11.3, 5.9 Hz, 1H, one of C27-H), 4.19 (m, J = 7.3, 7.0, 2.8 
Hz, 1H, C28-H), 4.17 (m, J = 8.8, 4.5 Hz, 1H, C31-H), 4.13 (dd, J = 9.4, 1.9 Hz, 1H, C35-H), 
4.11 (dd, J = 9.1, 2.6 Hz, 1H, C30-H), 4.03 (dd, J = 7.6, 2.6 Hz, 1H, C29-H), 4.02 (d, J = 1.9 
Hz, 1H, C36-H), 3.24 (dd, J = 19.5, 6.0 Hz, 1H, one of C38-H), 3.23 (dd, J = 19.5, 5.9 Hz, 1H, 
one of C38-H), 2.75 (d, J = 7.3 Hz, 1H, C28-OH), 2.18 (ddd, J = 12.6, 12.2, 4.5 Hz, 1H, one of 
C32-H), 2.08 (ddd, J = 12.7, 8.8, 2.5 Hz, 1H, one of C32-H), 1.74 (m, 1H, one of C40-H), 1.68 
(m, 1H, one of C40-H), 1.62 (s, 3H, COCH3), 1.60–1.50 (m, 2H, C41-H2), 1.42 (s, 3H, one of 
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CH3), 1.40–1.24 (m, 12H, C42–47-H2), 1.28 (s, 3H, one of CH3), 1.16 (t, J = 7.9 Hz, 9H, –
SiCH2CH3), 1.02 (s, 9H, C(CH3)3), 0.95 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.93–0.79 (m, J = 
7.9 Hz, 6H, –SiCH2CH3), 0.90 (t, J = 6.8 Hz, 3H, C48-H3), 0.60–0.53 (m, J = 8.1, 7.8 Hz, 6H, 
–SiCH2CH3), 0.21 (s, 3H, one of SiCH3), 0.20 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, 
C6D6) δ 211.6, 170.2, 139.2, 138.8, 138.7, 128.6, 128.5, 128.5, 128.4, 128.3, 127.9, 127.6, 
127.5, 108.2, 79.5, 79.3, 79.3, 79.1, 76.5, 75.9, 74.9, 74.4, 74.4, 71.9, 69.9, 67.7, 66.0, 49.1, 
38.4, 32.3, 30.4, 30.3, 30.1, 30.0, 29.8, 28.8, 26.1, 26.0, 25.6, 23.1, 20.4, 18.3, 14.3, 7.3, 7.1, 
5.7, 5.0, –4.2, –4.4; HRMS (ESI-TOF) m/z calcd for C66H110NaO12Si3 [M+Na]+: 1201.7197, 
found: 1201.7193.  
 
 (2S,3S,4R,5S)-3,4,5-Tris(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)-6-((4R,5R)-5-
((5S,6S,9R)-3,3-diethyl-11,11,12,12-tetramethyl-9-nonyl-7-oxo-6-((triethylsilyl)oxy)-4,10-
dioxa-3,11-disilatridecan-5-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)hexyl acetate (70). To a 
solution of carbinol 86 (0.22 g, 0.19 mmol, 1.0 equiv) and 2,6-lutidine (88 µL, 0.75 mmol, 4.0 
equiv) in CH2Cl2 (0.94 mL, 0.2 M wrt 86) at 0 °C was added TBSOTf (86 µL, 0.38 mmol, 2.0 
equiv). The reaction mixture was stirred at 0 °C for 4 h, slowly warmed to rt over 4 h, stirred 
at rt for 2 h, then quenched at 0 °C with sat. aq NaHCO3 (2 mL) and Et2O (1 mL). The 
biphasic mixture was stirred vigorously while warming to rt over 5 min, then diluted with 
H2O (10 mL) and Et2O (40 mL), and the layers were separated. The organic layer was washed 
sequentially with 1 M aq NaHSO4 and 1:1 sat. aq NaHCO3/brine (15 mL each), dried over 
Na2SO4 with added hexanes, filtered and concentrated. Column chromatography (gradient 
elution, 2% → 3% → 4% EtOAc in hexanes) afforded acetate ester 70 (0.18 g, 74% yield) as 
a clear, colorless oil. [α] D26  +10.4° (c = 2.8, CH2Cl2); IR (neat) 3066, 3032, 2930, 2857, 1745 
(s), 1714 (s), 1456, 1369, 1251, 1101, 1055, 1008, 979, 836, 777, 732, 698 cm–1; 1H-NMR 
(600 MHz, CDCl3) δ 7.35–7.15 (m, 15H, ArH), 4.77 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 
4.66 (d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.62 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.59 
(d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.56 (d, J = 11.3 Hz, 1H, one of –OCH2Ph), 4.45 (d, J 
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= 11.6 Hz, 1H, one of –OCH2Ph), 4.28 (dd, J = 11.3, 3.7 Hz, 1H, one of C27-H), 4.24 (ddd, J 
= 7.0, 6.7, 6.0 Hz, 1H, C33-H), 4.20 (dddd, J = 6.0, 5.9, 5.6, 5.4 Hz, 1H, C39-H), 4.10 (dd, J = 
11.3, 6.9 Hz, 1H, one of C27-H), 3.92 (m, J = 3.7 Hz, 1H, C28-H), 3.92 (m, J = 4.8 Hz, 1H, 
C31-H), 3.91 (dd, J = 5.1, 3.8 Hz, 1H, C29-H), 3.84 (dd, J = 5.1, 5.0 Hz, 1H, C30-H), 3.82 (dd, 
J = 8.9, 5.1 Hz, 1H, C34-H), 3.76 (dd, J = 9.1, 1.9 Hz, 1H, C35-H), 3.65 (d, J = 1.9 Hz, 1H, 
C36-H), 2.86 (dd, J = 19.6, 6.6 Hz, 1H, one of C38-H), 2.81 (dd, J = 19.6, 5.4 Hz, 1H, one of 
C38-H), 1.89 (m, 1H, one of C32-H), 1.89 (s, 3H, COCH3), 1.79 (m, J = 7.0, 6.0 Hz, 1H, one of 
C32-H), 1.46–1.20 (m, 16H, C40–47-H2), 1.39 (s, 3H, one of CH3), 1.24 (s, 3H, one of CH3), 
0.95 (t, J = 8.0 Hz, 9H, –SiCH2CH3), 0.86 (t, J = 7.2 Hz, 3H, C48-H3), 0.86 (s, 9H, one of 
C(CH3)3), 0.84 (s, 9H, one of C(CH3)3), 0.83 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.68–0.55 (m, J 
= 7.9, 7.8, 7.5 Hz, 6H, –SiCH2CH3), 0.48–0.40 (m, J = 8.1, 7.9 Hz, 6H, –SiCH2CH3), 0.06 (s, 
3H, one of SiCH3), 0.01 (s, 3H, one of SiCH3), –0.02 (s, 3H, one of SiCH3), –0.02 (s, 3H, one 
of SiCH3); 13C-NMR (100 MHz, CDCl3) δ 212.0, 170.7, 138.8, 138.6, 138.4, 128.3, 128.2, 
128.2, 128.1, 127.7, 127.5, 127.4, 127.3, 107.6, 78.7, 78.6, 78.5, 77.3, 76.1, 75.3, 73.9, 73.9, 
73.9, 71.3, 71.3, 67.3, 66.6, 48.7, 37.9, 31.9, 30.4, 29.8, 29.6, 29.6, 29.3, 28.7, 25.9, 25.9, 
25.8, 25.2, 22.7, 20.9, 18.1, 18.0, 14.1, 6.9, 6.8, 5.1, 4.5, –4.5, –4.5, –4.5, –4.7; HRMS (ESI-
TOF) m/z calcd for C72H124NaO12Si4 [M+Na]+: 1315.8062, found: 1315.8075. 
 
(5R,8S,9S)-9-((4R,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S)-2,3,4-tris(benzyloxy)-5-((tert-
butyldimethylsilyl)oxy)-6-hydroxyhexyl)-1,3-dioxolan-4-yl)-11,11-diethyl-2,2,3,3-
tetramethyl-5-nonyl-8-((triethylsilyl)oxy)-4,10-dioxa-3,11-disilatridecan-7-one (87). To a 
solution of acetate ester 70 (0.14 g, 0.11 mmol, 1.0 equiv) in CH2Cl2 (2.2 mL, 0.05 M wrt 70) 
at –78 °C was added dropwise a solution of DIBALH in PhMe (0.15 mL, 1.0 M, 0.15 mmol, 
1.4 equiv). The reaction mixture was stirred at –78 °C for 15 min, then quenched sequentially 
at –78 °C with EtOAc (0.15 mL), sat. aq Rochelle’s salt (5 mL), and CH2Cl2 (2 mL). The 
biphasic mixture was stirred vigorously at rt for 2 h, then diluted with H2O (10 mL) and 
CH2Cl2 (30 mL). The layers were separated and the aqueous layer extracted with CH2Cl2 (2 x 
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30 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. 
Column chromatography (gradient elution, 3% → 4% → 5% EtOAc in hexanes) afforded 
carbinol 87 (0.12 g, 84% yield) as a clear, colorless oil. [α] D25  +19.6° (c = 1.8, CH2Cl2); IR 
(neat) 3510 (br), 3065, 3031, 2930, 2857, 1711 (s), 1461, 1408, 1378, 1252, 1219, 1098, 
1061, 1008, 836, 776, 732, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.32–7.20 (m, 15H, 
ArH), 4.80 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.66 (m, 2H, –OCH2Ph), 4.63 (d, J = 11.7 
Hz, 1H, one of –OCH2Ph), 4.56 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.50 (d, J = 11.7 Hz, 
1H, one of –OCH2Ph), 4.28 (ddd, J = 11.1, 5.0, 3.1 Hz, 1H, C33-H), 4.22 (dddd, J = 6.0, 5.7, 
5.6, 5.4 Hz, 1H, C39-H), 3.98 (ddd, J = 4.1, 4.0, 3.5 Hz, 1H, C31-H), 3.92 (dd, J = 4.4, 4.0 Hz, 
1H, C30-H), 3.91 (dd, J = 6.0, 5.0 Hz, 1H, C29-H), 3.84 (m, J = 5.3, 5.0 Hz, 1H, C28-H), 3.84 
(dd, J = 8.8, 5.0 Hz, 1H, C34-H), 3.77 (dd, J = 8.9, 1.9 Hz, 1H, C35-H), 3.69 (ddd, J = 11.3, 
8.2, 3.1 Hz, 1H, one of C27-H), 3.67 (d, J = 1.9 Hz, 1H, C36-H), 3.56 (ddd, J = 11.4, 5.1, 4.7 
Hz, 1H, one of C27-H), 2.89 (dd, J = 19.6, 6.7 Hz, 1H, one of C38-H), 2.82 (dd, J = 19.6, 5.3 
Hz, 1H, one of C38-H), 1.78 (dd, J = 8.1, 4.7 Hz, 1H, C27-OH), 1.75 (ddd, J = 13.0, 11.1, 4.2 
Hz, 1H, one of C32-H), 1.71 (m, J = 13.0, 2.8 Hz, 1H, one of C32-H), 1.48–1.22 (m, 16H, C40–
47-H2), 1.42 (s, 3H, one of CH3), 1.26 (s, 3H, one of CH3), 0.97 (t, J = 7.9 Hz, 9H, –
SiCH2CH3), 0.89 (s, 9H, one of C(CH3)3), 0.88 (t, 3H, C48-H3), 0.87 (s, 9H, one of C(CH3)3), 
0.84 (t, J = 8.0 Hz, 9H, –SiCH2CH3), 0.70–0.57 (m, J = 7.8, 7.5, 7.3 Hz, 6H, –SiCH2CH3), 
0.43 (q, J = 7.9 Hz, 6H, –SiCH2CH3), 0.08 (s, 3H, one of SiCH3), 0.04 (s, 3H, one of SiCH3), 
0.01 (s, 3H, one of SiCH3), –0.01 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, CDCl3) δ 
211.9, 138.8, 138.6, 138.3, 128.4, 128.2, 128.2, 128.2, 128.0, 127.5, 127.4, 127.4, 127.3, 
107.7, 78.8, 78.6, 78.5, 77.5, 76.1, 75.3, 74.1, 73.9, 73.5, 73.3, 71.4, 67.3, 64.2, 48.7, 37.9, 
31.9, 30.4, 29.8, 29.6, 29.6, 29.3, 28.7, 26.0, 25.9, 25.9, 25.2, 22.7, 18.1, 18.0, 14.1, 6.9, 6.8, 
5.3, 5.1, 5.0, 4.5, –4.5, –4.5, –4.7, –4.7; HRMS (ESI-TOF) m/z calcd for C70H122NaO11Si4 
[M+Na]+: 1273.7956, found: 1273.7948. 
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(2R,3S,4R,5S)-3,4,5-Tris(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)-6-((4R,5R)-5-
((5S,6S,9R)-3,3-diethyl-11,11,12,12-tetramethyl-9-nonyl-7-oxo-6-((triethylsilyl)oxy)-4,10-
dioxa-3,11-disilatridecan-5-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)hexanal (71). To a solution 
of carbinol 87 (0.24 g, 0.19 mmol, 1.0 equiv) and EtN(iPr)2 (0.10 mL, 0.58 mmol, 3.0 equiv) 
in CH2Cl2 (0.55 mL, 0.35 M wrt 87) and DMSO (0.11 mL, 1.8 M wrt 87) at –30 °C was 
added a solution of SO3•py (0.092 g, 0.58 mmol, 3.0 equiv) in DMSO (0.44 mL, 1.3 M wrt 
SO3•py). The reaction mixture was stirred between –30 °C and –20 °C for 1.5 h, quenched 
with brine (15 mL), then diluted with Et2O (40 mL) and H2O (1 mL). The layers were 
separated and the organic layer washed sequentially with 1 M aq NaHSO4 (15 mL), sat. aq 
NaHCO3 (15 mL), and 1:1 H2O/brine (2 x 15 mL). The organic layer was then dried over 
Na2SO4 with added hexanes, filtered and concentrated. Column chromatography (gradient 
elution, 1% → 1.5% → 2% EtOAc in hexanes) afforded aldehyde 71 (0.23 g, 95% yield) as a 
clear, colorless oil. [α] D26  +11.9° (c = 2.2, CH2Cl2); IR (neat) 3066, 3031, 2927, 2872, 1731 
(s), 1714 (s), 1455, 1416, 1380, 1252, 1220, 1143, 1097, 1061, 1026, 979, 950, 894, 837, 777, 
729, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 9.74 (s, 1H, C27-H), 7.33–7.18 (m, 15H, ArH), 
4.68 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.63 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.61 
(d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.47 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.46 (d, J 
= 11.0 Hz, 1H, one of –OCH2Ph), 4.32 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.25 (dddd, J = 
5.7, 5.7, 5.7, 5.7 Hz, 1H, C39-H), 4.22 (ddd, J = 11.4, 5.0, 2.1 Hz, 1H, C33-H), 4.08 (dd, J = 
5.9, 3.7 Hz, 1H, C29-H), 3.97 (d, J = 5.7 Hz, 1H, C28-H), 3.88 (dd, J = 5.6, 3.7 Hz, 1H, C30-H), 
3.84 (dd, J = 9.1, 5.1 Hz, 1H, C34-H), 3.79 (m, 1H, C31-H), 3.78 (dd, J = 9.1, 2.0 Hz, 1H, C35-
H), 3.70 (d, J = 2.1 Hz, 1H, C36-H), 2.90 (dd, J = 19.6, 6.4 Hz, 1H, one of C38-H), 2.85 (dd, J 
= 19.6, 5.6 Hz, 1H, one of C38-H), 1.87 (ddd, J = 13.9, 3.7, 1.6 Hz, 1H, one of C32-H), 1.75 
(ddd, J = 13.8, 11.9, 5.0 Hz, 1H, one of C32-H), 1.48–1.27 (m, 16H, C40–47-H2), 1.41 (s, 3H, 
one of CH3), 1.27 (s, 3H, one of CH3), 0.97 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.89 (t, J = 7.0 
Hz, 3H, C48-H3), 0.88 (s, 9H, one of C(CH3)3), 0.88 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.88 (s, 
9H, one of C(CH3)3), 0.71–0.59 (m, J = 8.1, 7.9, 7.8 Hz, 6H, –SiCH2CH3), 0.43 (q, J = 7.9 Hz, 
6H, –SiCH2CH3), 0.09 (s, 3H, one of SiCH3), 0.06 (s, 3H, one of SiCH3), 0.02 (s, 3H, one of 
SiCH3), –0.10 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, CDCl3) δ 211.9, 200.6, 138.7, 
138.0, 137.7, 128.7, 128.6, 128.4, 128.3, 128.2, 128.0, 127.7, 127.5, 127.4, 107.6, 80.9, 78.8, 
78.4, 77.0, 76.9, 76.7, 75.3, 74.9, 73.7, 73.7, 72.1, 67.3, 48.7, 37.9, 31.9, 31.0, 29.8, 29.6, 
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29.6, 29.3, 28.6, 26.1, 25.9, 25.8, 25.2, 22.7, 18.3, 18.0, 14.1, 6.9, 6.8, 5.1, 4.5, –4.5, –4.6, –
4.7, –5.5; HRMS (ESI-TOF) m/z calcd for C70H120NaO11Si4 [M+Na]+: 1271.7800, found: 
1271.7846. 
Synthesis of the Aflastatin A C3–C48 Degradation Products 
Magnesium bromide diethyl etherate (MgBr2•OEt2).79 Magnesium turnings (99.98%) (2.3 
g, 95 mmol, 1.0 equiv) were added to a two-necked round-bottomed flask, equipped with a 
reflux condenser and a magnetic stir bar. Diethyl ether (150 mL) was added, followed by a 
small amount of 1,2-dibromoethane. After refluxing was initiated by external heating, the 
remaining 1,2-dibromoethane (8.2 mL, 95 mmol, 1.0 equiv) was added portion-wise such that 
a moderate reflux was maintained. After completion of the reaction, excess diethyl ether was 
removed under a stream of nitrogen, yielding a white paste. The surface of the paste was 
broken with a spatula and the residue further dried with a stream of nitrogen. This process was 
repeated until a white solid was obtained. The compound was stored under argon at room 
temperature. 
 
(5R,8S,9S)-9-((4R,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S,6S,8R,10R)-2,3,4-tris(benzyloxy)-11-
((4R,5S,6S)-6-((S)-1-((4S,6R)-6-((S)-1-((4R,5R,6R)-6-((2S,3R,4R,6R,8S)-3,9-
bis(benzyloxy)-4-((tert-butyldimethylsilyl)oxy)-6,8-dimethylnonan-2-yl)-2,2,5-trimethyl-
1,3-dioxan-4-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2,2,5-trimethyl-1,3-dioxan-4-
yl)-5-((tert-butyldimethylsilyl)oxy)-6,8-dihydroxy-10-((triisopropylsilyl)oxy)undecyl)-1,3-	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(79)  Harwood, L.M.; Manage, A.C.; Robin, S.; Hopes, S.F.G.; Watkin, D.J.; Williams, C.E. Synlett 1993, 777–
780. 
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dioxolan-4-yl)-11,11-diethyl-2,2,3,3-tetramethyl-5-nonyl-8-((triethylsilyl)oxy)-4,10-dioxa-
3,11-disilatridecan-7-one (73). To a solution of aldehyde 71 (0.23 g, 0.18 mmol, 1.0 equiv) 
and ketone 72 (0.24 g, 0.20 mmol, 1.1 equiv) in CH2Cl2 (1.3 mL, 0.14 M wrt 71) at –5 °C was 
added freshly prepared MgBr2•OEt2 (0.38 g, 1.5 mmol, 8.0 equiv). The resulting suspension 
was stirred at –5 °C for 10 min, then charged dropwise with 1,2,2,6,6-pentamethylpiperidine 
(83 µL, 0.46 mmol, 2.5 equiv). The reaction mixture was stirred at –5 °C for 7 min, then 
rapidly quenched with pre-chilled sat. aq NaHCO3 (3 mL). The biphasic mixture was stirred 
vigorously at rt for 10 min, then diluted with Et2O (30 mL), H2O (10 mL) and sat. aq NaHCO3 
(15 mL). The layers were separated and the aqueous layer extracted with CH2Cl2 (2 x 30 mL). 
The combined organic extracts were washed sequentially with sat. aq NH4Cl (2 x 20 mL) and 
brine (15 mL), dried over Na2SO4, filtered, concentrated and azeotroped with PhH (2 x 2 mL) 
to afford crude aldol adduct 88 as a clear, pale yellow oil that was used without further 
purification. 
To a solution of crude aldol adduct 88 (theoretical 0.44 g, 0.18 mmol, 1.0 equiv) in 4:1 
THF/MeOH (1.8 mL, 0.1 M wrt 88) at –78 °C was added dropwise a solution of 
diethylmethoxyborane in THF (0.20 mL, 1.0 M, 0.20 mmol, 1.1 equiv). The reaction mixture 
was stirred at –78 °C for 2.5 h, then charged with sodium borohydride (21 mg, 0.55 mmol, 3.0 
equiv) in one portion. The reaction mixture was slowly warmed to –55 °C over 0.5 h, stirred 
at –55 °C for 20 h, quenched with a pre-mixed mixture of 1 M aq NaOH (1 mL) and 30% aq 
H2O2 (0.4 mL), then diluted with 4:1 THF/MeOH (1 mL). The heterogeneous mixture was 
stirred vigorously at 0 °C for 1.5 h, then diluted with Et2O (30 mL) and aq pH 7 buffer (3 
mL). The layers were separated and the aqueous layer extracted with Et2O (2 x 30 mL). The 
combined organic extracts were washed with 10% aq Na2S2O3 (2 x 10 mL) and brine (10 mL), 
dried over Na2SO4 with added hexanes, filtered and concentrated. The residue was analyzed 
by 1H-NMR spectroscopy to assess reaction diastereoselectivity (d.r. ≥ 95:05). Column 
chromatography (gradient elution, 6% → 6.5% EtOAc in hexanes) afforded diol 73 (0.31 g, 
70% yield, two steps) as a white foam. [α] D25  +1.0° (c = 1.2, CH2Cl2); IR (neat) 3498 (br), 
3068, 3036, 2932, 2864, 1712, 1459, 1380, 1253, 1202, 1175, 1098, 1008, 982, 837, 775, 733, 
698 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.34–7.21 (m, 25H, ArH), 4.73 (d, J = 12.0 Hz, 1H, 
one of –OCH2Ph), 4.70 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.70 (d, J = 11.9 Hz, 1H, one 
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of –OCH2Ph), 4.66 (m, 2H, –OCH2Ph), 4.61 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.52 (d, J 
= 11.9 Hz, 1H, one of –OCH2Ph), 4.49 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.45 (m, 2H, –
OCH2Ph), 4.28 (ddd, J = 11.6, 7.0, 2.5 Hz, 1H, C33-H), 4.25 (m, J = 7.0, 6.0 Hz, 1H), 4.22 (m, 
1H), 4.21 (m, J = 5.1, 5.1 Hz, 1H, C39-H), 4.18–4.16 (m, 2H), 4.03–3.98 (m, 2H), 3.98–3.92 
(m, 3H), 3.91 (m, 1H, C31-H), 3.88 (m, 1H, C8-H), 3.82 (dd, J = 8.9, 4.9 Hz, 1H, C34-H), 3.79 
(dd, J = 8.9, 1.9 Hz, 1H, C35-H), 3.69 (m, 1H), 3.66 (d, J = 1.9 Hz, 1H, C36-H), 3.60 (m, J = 
1.6 Hz, 1H), 3.59 (m, J = 9.8 Hz, 1H), 3.54 (m, J = 7.2, 2.8 Hz, 2H), 3.40 (dd, J = 6.2, 2.6 Hz, 
1H, C9-H), 3.33 (dd, J = 9.1, 5.3 Hz, 1H, one of C3-H), 3.14 (dd, J = 9.1, 7.4 Hz, 1H, one of 
C3-H), 2.88 (dd, J = 19.6, 6.6 Hz, 1H, one of C38-H), 2.83 (dd, J = 19.5, 5.4 Hz, 1H, one of 
C38-H), 2.39 (m, J = 6.8, 6.6, 2.5 Hz, 1H, C10-H), 1.94–1.80 (m, 4H), 1.80–1.57 (m, 8H), 1.52 
(m, J = 1.9 Hz, 1H), 1.48–1.20 (m, 16H, C40–47-H2), 1.48–1.20 (m, 5H), 1.44 (s, 3H, one of 
CH3), 1.39 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3), 1.37 (s, 
3H, one of CH3), 1.35 (s, 3H, one of CH3), 1.31 (s, 3H, one of CH3), 1.24 (s, 3H, one of CH3), 
1.16 (ddd, J = 13.3, 8.0, 5.6 Hz, 1H), 1.07 (m, 18H, –SiCH(CH3)2), 1.07 (m, 3H, –
SiCH(CH3)2), 1.04 (ddd, J = 13.3, 6.3, 2.2 Hz, 1H), 0.99–0.97 (m, J = 6.9 Hz, 6H, two of –
CH(CH3)), 0.96 (t, J = 8.0 Hz, 9H, –SiCH2CH3), 0.92–0.81 (m, 12H, four of –CH(CH3)), 0.88 
(s, 9H, one of C(CH3)3), 0.88 (t, J = 7.1 Hz, 3H, C48-H3), 0.86 (s, 9H, one of C(CH3)3), 0.84 
(s, 9H, one of C(CH3)3), 0.83 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.73 (d, J = 6.9 Hz, 3H, one of 
–CH(CH3)), 0.70–0.58 (m, J = 7.9, 7.8 Hz, 6H, –SiCH2CH3), 0.43 (q, J = 8.0 Hz, 6H, –
SiCH2CH3), 0.07 (s, 3H, one of SiCH3), 0.03 (s, 3H, one of SiCH3), 0.03 (s, 3H, one of 
SiCH3), 0.01 (s, 3H, one of SiCH3), –0.03 (s, 3H, one of SiCH3), –0.13 (s, 3H, one of SiCH3); 
13C-NMR (125 MHz, CDCl3) δ 211.8, 139.8, 138.8, 138.8, 137.9, 137.7, 128.5, 128.4, 128.3, 
128.3, 128.2, 128.1, 128.0, 127.8, 127.4, 127.4, 127.4, 127.3, 127.3, 127.0, 107.5, 98.3, 98.3, 
97.2, 80.9, 79.6, 78.9, 78.5, 77.2, 75.9, 75.9, 75.8, 75.5, 75.0, 74.8, 74.0, 73.6, 73.3, 73.0, 
72.8, 72.8, 72.5, 71.5, 71.5, 71.0, 69.9, 69.7, 68.2, 67.3, 67.2, 48.7, 45.1, 42.5, 40.8, 40.7, 
39.2, 39.1, 38.6, 37.9, 32.7, 32.4, 31.9, 31.9, 31.3, 30.6, 30.4, 30.1, 30.0, 29.8, 29.6, 29.6, 
29.3, 28.6, 27.1, 27.0, 26.0, 26.0, 25.9, 25.8, 25.2, 22.7, 20.7, 20.1, 19.8, 19.3, 18.2, 18.2, 
18.2, 18.0, 18.0, 14.1, 12.7, 11.0, 9.5, 9.0, 8.9, 6.9, 6.8, 5.1, 4.6, 4.5, –3.7, –3.8, –4.2, –4.4, –
4.5, –4.7; HRMS (ESI-TOF) m/z calcd for C139H242NaO22Si6 [M+Na]+: 2454.6326, found: 
2454.6361. 
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(2S,3R,4R,5S,6S,8S,10R,12R,13S,14R,15S,16S,18R,19S,20R,21R,22R,23S,24R,25R,27R,29
S)-2,3,4,24,30-Pentakis(benzyloxy)-13,15,19,21,23,27,29-heptamethyl-1-
((2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxy-6-((R)-2-hydroxyundecyl)tetrahydro-2H-pyran-2-
yl)triacontan-5,6,8,10,12,14,16,18,20,22,25-undecaol (74). To a solution of ketone 73 (70 
mg, 29 µmol, 1.0 equiv) in 1:1 CH3CN/CH2Cl2 (1 mL, 0.03 M wrt 73) at 0 °C was added 
dropwise a solution of fluorosilicic acid (H2SiF6) in H2O (~60 µL, 20–25 wt. %). The reaction 
mixture was stirred at 0 °C for 0.5 h, then warmed to rt and stirred for 12 h, carefully 
quenched with two small spatula tips full of NaHCO3 (s), stirred vigorously for an additional 
1 h, and filtered through Celite. The filter cake was rinsed with 1:1 EtOAc/CH3OH (20 mL 
total), and the filtrate concentrated. Pipette column chromatography (gradient elution, 2.5% 
→ 3% → 3.5% CH3OH in CH2Cl2) afforded lactol 74 (0.034 g, 58% yield) as a clear, 
colorless oil. [α] D24  –9.0° (c = 0.61, CH3OH); IR (neat) 3377 (br), 3062, 3032, 2926, 2855, 
1455, 1383, 1327, 1274, 1209, 1155, 1094, 1068, 1030, 970, 850, 736, 699 cm–1; 1H-NMR 
(600 MHz, CD3OD) δ 7.46–7.20 (m, 25H, ArH), 4.88 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 
4.84 (d, J = 10.7 Hz, 1H, one of –OCH2Ph), 4.77 (d, J = 11.3 Hz, 1H, one of –OCH2Ph), 4.71 
(d, J = 10.5 Hz, 1H, one of –OCH2Ph), 4.67 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.60 (d, J 
= 11.4 Hz, 1H, one of –OCH2Ph), 4.50 (d, J = 11.4 Hz, 2H, two of –OCH2Ph), 4.45 (m, 2H, 
two of –OCH2Ph), 4.32 (m, J = 8.8 Hz, 1H), 4.08–4.00 (m, 4H), 3.99–3.95 (m, 3H), 3.97 (m, 
1H, C31-H), 3.91 (m, J = 9.1, 1.2 Hz, 1H), 3.88–3.83 (m, 2H), 3.86 (m, 1H, C33-H), 3.84 (dd, J 
= 9.5, 3.2 Hz, 1H, C35-H), 3.80 (m, J = 8.6, 2.1 Hz, 1H), 3.65 (m, J = 9.4, 1.9 Hz, 1H), 3.65 
(d, J = 3.4 Hz, 1H, C36-H), 3.47 (dd, J = 9.5, 9.4 Hz, 1H, C34-H), 3.34 (dd, J = 9.2, 5.3 Hz, 
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1H, one of C3-H), 3.32 (m, J = 4.4, 1.8 Hz, 1H), 3.23 (dd, J = 9.2, 6.6 Hz, 1H, one of C3-H), 
3.20 (m, J = 9.4 Hz, 1H), 2.54 (ddd, J = 10.0, 10.0, 2.4 Hz, 1H, one of C32-H), 2.25 (m, J = 
7.0, 6.6, 6.3 Hz, 1H, C10-H), 2.03 (dd, J = 14.5, 2.0 Hz, 1H, one of C38-H), 2.01–1.97 (m, 1H), 
1.99 (ddd, J = 10.0, 7.2, 7.1 Hz, 1H, one of C32-H), 1.83 (m, J = 6.6, 6.2 Hz, 1H, one of C4-
H), 1.82–1.73 (m, 4H), 1.69–1.38 (m, 14H), 1.58 (dd, J = 14.4, 10.8 Hz, 1H, one of C38-H), 
1.34–1.23 (m, 14H, C41–47-H2), 0.95–0.92 (m, J = 7.0, 6.9 Hz, 15H, five of –CH(CH3)), 0.88 
(t, J = 7.0 Hz, 3H, C48-H3), 0.81 (d, J = 7.0 Hz, 3H, one of –CH(CH3)), 0.74 (d, J = 6.9 Hz, 
3H, one of –CH(CH3)); 13C-NMR (125 MHz, CD3OD) δ 140.5, 140.2, 140.0, 140.0, 139.5, 
130.0, 129.4, 129.4, 129.3, 129.3, 129.2, 128.9, 128.8, 128.7, 128.5, 128.5, 128.4, 99.9, 84.6, 
81.7, 81.5, 80.0, 78.9, 77.0, 76.7, 76.7, 76.1, 76.1, 75.9, 75.6, 74.7, 74.3, 74.0, 74.0, 74.0, 
73.2, 72.5, 71.8, 71.8, 71.4, 70.7, 70.5, 69.8, 68.7, 45.5, 43.0, 43.0, 43.0, 42.6, 42.6, 42.1, 
40.1, 40.0, 39.7, 39.2, 37.2, 36.7, 33.1, 32.1, 32.1, 31.0, 30.9, 30.9, 30.6, 28.7, 26.8, 23.8, 
21.3, 18.9, 14.5, 13.7, 11.5, 9.5, 6.5, 6.2; HRMS (ESI-TOF) m/z calcd for C88H136NaO22 
[M+Na]+: 1567.9415, found: 1567.9435. 
 
(2S,4R,6R,7R,8S,9R,10R,11R,12S,13R,15S,16S,17R,18S,19R,21R,23S,25S,26S,27R,28R,29
S)-2,4,8,10,12,16,18-Heptamethyl-30-((2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxy-6-((R)-2-
hydroxyundecyl)tetrahydro-2H-pyran-2-yl)triacontane-
1,6,7,9,11,13,15,17,19,21,23,25,26,27,28,29-hexadecaol (1). To a solution of pentabenzyl 
ether 74 (12 mg, 7.7 µmol, 1.0 equiv) in 6:1 dioxane/H2O (0.31 mL, 25 mM wrt 74) at rt was 
added palladium black (~10 mg). The reaction mixture was purged with hydrogen for 1 min, 
stirred vigorously for 12 h, then recharged with additional catalyst at this time and 
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approximately every 12 h thrice after (total palladium black added: ~50 mg). The reaction 
mixture was stirred at rt for 20 h, then filtered through Celite. The filter cake was rinsed with 
1:1 THF/CH3OH (15 mL total), and the filtrate concentrated. Reversed-phase C18 column 
chromatography (gradient elution, 5% → 100% CH3CN in H2O; eluted 50% → 70%) afforded 
aflastatin A C3–C48 degradation lactol 1 (4.5 mg, 53% yield) as a white solid. [α] D25  +7.2° (c 
= 0.29, 3:1 CH3OH/THF); IR (neat) 3319 (br), 2923, 2858, 1571, 1452, 1321, 1277, 1158, 
1092, 973, 848 cm–1; 1H-NMR (600 MHz, C5D5N) δ 7.00 (d, J = 4.5 Hz, 1H, C35-OH), 6.81 
(d, J = 5.0 Hz, 1H, C34-OH), 6.69 (d, J = 4.7 Hz, 1H, C27-OH), 6.52 (d, J = 6.7 Hz, 1H, C27-
OH), 6.47 (br s, 1H, one of –OH), 6.43–6.39 (m, 2H, two of –OH), 6.35–6.31 (m, 2H, two of 
–OH), 6.30–6.21 (m, 5H, five of –OH), 6.10–6.05 (m, 3H, three of –OH), 5.98–5.92 (m, 3H, 
three of –OH), 5.87 (dd, J = 5.3, 5.3 Hz, 1H, C3-OH), 5.03 (m, J = 5.4 Hz, 1H, C29-H), 4.97 
(m, J = 6.7 Hz, 1H, C31-H), 4.85 (ddd, J = 9.8, 9.7, 2.9 Hz, 1H, C33-H), 4.76 (dd, J = 9.4, 3.2 
Hz, 1H, C35-H), 4.72 (m, 1H, C39-H), 4.68 (m, J = 8.8, 8.2 Hz, 1H, C27-H), 4.62 (m, 1H, C25-
H), 4.61 (m, 1H, C17-H), 4.58 (dd, J = 5.6, 1.8 Hz, 1H, C30-H), 4.51–4.46 (m, 2H, C15-H and 
C23-H), 4.48 (d, J = 3.1 Hz, 1H, C36-H), 4.43 (m, J = 8.8, 3.7 Hz, 1H, C21-H), 4.38 (dd, J = 
9.4, 9.4 Hz, 1H, C34-H), 4.32 (m, 1H, C11-H), 4.30 (m, 1H, C28-H), 4.29 (m, 1H, C8-H), 4.12 
(m, J = 8.9 Hz, 1H, C13-H), 4.06 (m, J = 9.7 Hz, 1H, C19-H), 4.00 (dd, J = 4.7, 4.1 Hz, 1H, C9-
H), 3.80 (m, J = 10.4, 4.8 Hz, 1H, one of C3-H), 3.61 (m, J = 10.4, 6.7 Hz, 1H, one of C3-H), 
3.21 (ddd, J = 13.6, 7.2, 2.8 Hz, 1H, one of C32-H), 2.73 (m, J = 13.3 Hz, 1H, one of C38-H), 
2.60 (m, J = 12.9 Hz, 1H, one of C26-H), 2.56 (ddd, J = 13.8, 10.1, 6.4 Hz, 1H, one of C32-H), 
2.31 (m, J = 6.4 Hz, 1H, C10-H), 2.21 (m, J = 9.4, 6.7, 5.7 Hz, 1H, C18-H), 2.16 (m, 1H, one of 
C26-H), 2.15 (m, 1H, C6-H), 2.14 (dd, J = 14.4, 10.6 Hz, 1H, one of C38-H), 2.08 (m, 1H, C12-
H), 2.08–2.01 (m, 4H, one of C16-H, one of C22-H, and C24-H2), 1.99 (m, 1H, C4-H), 1.96 (m, 
1H, one of C16-H), 1.95 (m, 1H, C14-H), 1.87 (m, 1H, C20-H), 1.86 (m, 1H, one of C22-H), 
1.83 (m, J = 6.9, 5.4 Hz, 1H, one of C7-H), 1.77 (m, J = 7.6, 6.0 Hz, 1H, one of C5-H), 1.74 
(m, J = 8.1, 5.9 Hz, 1H, one of C7-H), 1.65 (m, 1H, one of C40-H), 1.57–1.44 (m, 2H, one of 
C40-H, and one of C41-H), 1.35 (m, 1H, one of C41-H), 1.31–1.10 (m, 10H, C42–46-H2), 1.27 (d, 
J = 6.9 Hz, 3H, C51-H3), 1.24 (d, J = 7.0 Hz, 3H, C53-H3), 1.22 (m, 2H, C47-H2), 1.20 (d, J = 
7.0 Hz, 3H, C55-H3), 1.10 (d, J = 6.7 Hz, 3H, C49-H3), 1.06 (d, J = 6.6 Hz, 3H, C50-H3), 1.05 
(m, 1H, one of C5-H), 0.97 (d, J = 6.9 Hz, 3H, C54-H3), 0.83 (t, J = 7.1 Hz, 3H, C48-H3), 0.80 
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(d, J = 6.7 Hz, 3H, C52-H3); 13C-NMR (125 MHz, C5D5N) δ 100.1 (C37), 81.6 (C13), 78.9 
(C11), 78.8 (C19), 78.0 (C9), 77.1 (C15), 76.3 (C21), 76.1 (C28), 75.1 (C36), 74.2 (C30), 
74.0 (C17), 73.3 (C34), 72.9 (C35), 72.3 (C27), 71.7 (C33), 71.4 (C29), 71.3 (C25), 71.0 
(C31), 70.7 (C23), 69.5 (C8), 69.0 (C39), 67.3 (C3), 45.7 (C16), 42.8 (C38), 42.7 (C18), 42.7 
(C22), 42.4 (C7), 42.1 (C26), 41.6 (C5), 39.6 (C40), 39.5 (C20), 39.5 (C14), 38.8 (C12), 38.1 
(C10), 37.4 (C32), 37.0 (C24), 34.0 (C4), 32.1 (C46), 30.1 (C44), 29.9 (C43), 29.8 (C42), 
29.6 (C45), 27.9 (C6), 25.9 (C41), 22.9 (C47), 21.7 (C50), 18.7 (C49), 14.3 (C48), 13.2 
(C52), 11.7 (C54), 8.3 (C51), 6.4 (C53), 6.1 (C55); HRMS (ESI-TOF) m/z calcd for 
C53H106NaO22 [M+Na]+: 1117.7068, found: 1117.7111. 
 
(2S,3R,4R,5S,6S,8S,10R,12R,13S,14R,15S,16S,18R,19S,20R,21R,22R,23S,24R,25R,27R,29
S)-2,3,4,24,30-Pentakis(benzyloxy)-13,15,19,21,23,27,29-heptamethyl-1-
((2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-((R)-2-hydroxyundecyl)-6-methoxytetrahydro-2H-
pyran-2-yl)triacontan-5,6,8,10,12,14,16,18,20,22,25-undecaol (89). To a solution of lactol 
74 (34 mg, 22 µmol, 1.0 equiv) in CH3OH (1.1 mL, 20 mM wrt 74) at rt was added Dowex® 
50WX8 hydrogen form ion-exchange resin (0.22 g, 10 mg/µmol 74, 200–400 mesh). The 
reaction mixture was stirred at 30 °C for 2 d, then filtered through Celite. The filter cake was 
rinsed with 1:1 CH2Cl2/CH3OH (15 mL total), and the filtrate concentrated. Pipette column 
chromatography (gradient elution, 4.5% → 5% → 6% CH3OH in CH2Cl2) afforded lactol 
methyl ether 89 (0.013 g, 39% yield) as a clear, colorless oil. [α] D25  +0.30° (c = 0.67, 
CH3OH); IR (neat) 3379 (br), 3036, 2926, 2854, 1454, 1384, 1331, 1207, 1105, 1066, 976, 
847, 735, 698 cm–1; 1H-NMR (600 MHz, CD3OD) δ 7.43–7.21 (m, 25H, ArH), 4.85 (d, J = 
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11.0 Hz, 1H, one of –OCH2Ph), 4.79 (d, J = 10.8 Hz, 1H, one of –OCH2Ph), 4.75 (d, J = 11.0 
Hz, 1H, one of –OCH2Ph), 4.74 (d, J = 10.8 Hz, 1H, one of –OCH2Ph), 4.66 (d, J = 11.3 Hz, 
1H, one of –OCH2Ph), 4.60 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.55 (d, J = 11.4 Hz, 1H, 
one of –OCH2Ph), 4.49 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.45 (m, 2H, two of –
OCH2Ph), 4.25 (m, J = 7.9 Hz, 1H), 4.06 (m, J = 4.4, 4.1, 3.5 Hz, 1H), 4.02 (m, J = 4.8, 3.5 
Hz, 1H), 4.01 (m, J = 2.6 Hz, 1H), 3.99–3.94 (m, J = 8.3, 6.9, 4.2 Hz, 3H), 3.97 (m, 1H, C31-
H), 3.91 (m, 1H), 3.90 (d, J = 3.7 Hz, 1H, C36-H), 3.88–3.84 (m, J = 6.3, 2.5 Hz, 2H), 3.79 
(m, J = 2.1 Hz, 1H), 3.78 (dd, J = 9.5, 3.7 Hz, 1H, C35-H), 3.69 (m, J = 6.6, 1.8 Hz, 1H), 3.65 
(m, J = 9.6, 1.8 Hz, 1H), 3.48 (dd, J = 9.5, 9.4 Hz, 1H, C34-H), 3.42 (ddd, J = 9.2, 9.2, 2.2 Hz, 
1H, C33-H), 3.35 (m, J = 8.2, 1.4 Hz, 1H), 3.33 (dd, J = 9.2, 4.0 Hz, 1H, one of C3-H), 3.31 
(m, 1H), 3.23 (dd, J = 9.2, 6.6 Hz, 1H, one of C3-H), 3.07 (s, 3H, –OCH3), 2.57 (m, J = 12.1, 
8.5 Hz, 1H, one of C32-H), 2.25 (m, J = 7.0, 6.9, 6.7 Hz, 1H, C10-H), 1.97 (ddd, J = 14.4, 4.7, 
2.6 Hz, 1H), 1.93 (ddd, J = 14.1, 9.2, 3.7 Hz, 1H, one of C32-H), 1.90–1.73 (m, 6H), 1.84 (m, 
1H, one of C4-H), 1.71–1.39 (m, 14H), 1.38–1.24 (m, 14H, C41–47-H2), 0.95–0.92 (m, J = 7.2 
Hz, 15H, five of –CH(CH3)), 0.89 (t, J = 7.0 Hz, 3H, C48-H3), 0.81 (d, J = 6.9 Hz, 3H, one of 
–CH(CH3)), 0.74 (d, J = 6.7 Hz, 3H, one of –CH(CH3)); 13C-NMR (125 MHz, CD3OD) δ 
140.5, 140.1, 140.0, 140.0, 139.7, 129.7, 129.4, 129.3, 129.3, 129.3, 129.2, 129.2, 129.0, 
128.7, 128.7, 128.6, 128.5, 128.5, 128.5, 103.4, 84.6, 82.1, 81.7, 80.2, 78.8, 77.0, 77.0, 76.7, 
76.2, 76.0, 76.0, 75.6, 75.4, 74.3, 74.0, 74.0, 72.9, 72.5, 72.2, 72.1, 71.9, 71.8, 70.8, 70.5, 
68.8, 68.1, 48.5, 45.3, 43.0, 43.0, 43.0, 42.6, 42.0, 40.2, 40.0, 39.7, 39.2, 39.0, 37.2, 36.8, 
33.1, 32.4, 32.1, 30.8, 30.8, 30.7, 30.5, 28.7, 26.6, 23.7, 21.3, 18.9, 14.5, 13.7, 11.5, 9.5, 6.5, 
6.2; HRMS (ESI-TOF) m/z calcd for C89H138NaO22 [M+Na]+: 1581.9572, found: 1581.9502. 
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(2S,4R,6R,7R,8S,9R,10R,11R,12S,13R,15S,16S,17R,18S,19R,21R,23S,25S,26S,27R,28R,29
S)-2,4,8,10,12,16,18-Heptamethyl-30-((2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-((R)-2-
hydroxyundecyl)-6-methoxytetrahydro-2H-pyran-2-yl)triacontane-
1,6,7,9,11,13,15,17,19,21,23,25,26,27,28,29-hexadecaol (46a). To a solution of pentabenzyl 
ether 89 (13 mg, 8.3 µmol, 1.0 equiv) in 6:1 dioxane/H2O (0.33 mL, 25 mM wrt 89) at rt was 
added palladium black (~10 mg). The reaction mixture was purged with hydrogen for 1 min, 
stirred vigorously for 12 h, then recharged with additional catalyst at this time and 
approximately every 12 h thrice after (total palladium black added: ~50 mg). The reaction 
mixture was stirred at rt for 20 h, then filtered through Celite. The filter cake was rinsed with 
1:1 THF/CH3OH (15 mL total), and the filtrate concentrated. Reversed-phase C18 column 
chromatography (gradient elution, 30% → 90% CH3CN in H2O; eluted 45% → 60%) afforded 
aflastatin A C3–C48 degradation lactol methyl ether 46a (6.8 mg, 74% yield) as a white solid. 
[α] D24  +14.0° (c = 0.65, CH3OH); IR (neat) 3353 (br), 2925, 2858, 1444, 1382, 1318, 1209, 
1108, 1034, 968, 848 cm–1; 1H-NMR (600 MHz, C5D5N) δ 6.89 (d, J = 3.5 Hz, 1H, one of –
OH), 6.63 (d, J = 4.4 Hz, 1H, one of –OH), 6.49 (d, J = 3.5 Hz, 1H, C39-OH), 6.46 (br s, 1H, 
one of –OH), 6.41 (br s, 1H, one of –OH), 6.38 (d, J = 4.7 Hz, 1H, one of –OH), 6.31–6.23 
(m, 4H, four of –OH), 6.20 (d, J = 6.9 Hz, 1H, C35-OH), 6.12 (d, J = 4.5 Hz, 1H, C31-OH), 
6.11–6.04 (m, 4H, four of –OH), 5.99 (d, J = 4.4 Hz, 1H, C29-OH), 5.96–5.92 (m, 2H, two of 
–OH), 5.87 (dd, J = 5.3, 5.0 Hz, 1H, C3-OH), 4.96 (m, J = 3.8 Hz, 1H, C29-H), 4.93 (m, J = 
2.3 Hz, 1H, C31-H), 4.67 (d, J = 3.7 Hz, 1H, C36-H), 4.67 (m, J = 3.2 Hz, 1H, C27-H), 4.64 (m, 
1H, C25-H), 4.62 (m, J = 8.2 Hz, 1H, C17-H), 4.56 (dd, J = 9.1, 3.5 Hz, 1H, C35-H), 4.52–4.46 
(m, J = 2.8 Hz, 3H, C15-H, C23-H and C30-H), 4.42 (m, J = 6.7 Hz, 1H, C21-H), 4.34 (m, J = 
7.0 Hz, 1H, C28-H), 4.32 (dd, J = 9.5, 9.4 Hz, 1H, C34-H), 4.31 (m, J = 8.6 Hz, 1H, C11-H), 
4.28 (m, 1H, C8-H), 4.23 (ddd, J = 9.3, 9.1, 2.5 Hz, 1H, C33-H), 4.19 (m, J = 5.9, 5.7, 4.6 Hz, 
1H, C39-H), 4.12 (m, J = 8.5 Hz, 1H, C13-H), 4.05 (m, J = 9.8 Hz, 1H, C19-H), 4.00 (m, J = 
4.4, 4.0 Hz, 1H, C9-H), 3.80 (ddd, J = 10.2, 5.1, 4.6 Hz, 1H, one of C3-H), 3.61 (ddd, J = 10.1, 
6.7, 5.2 Hz, 1H, one of C3-H), 3.35 (s, 3H, C56-H3), 3.17 (ddd, J = 14.1, 6.4, 2.5 Hz, 1H, one 
of C32-H), 2.60 (m, J = 14.1 Hz, 1H, one of C26-H), 2.49 (ddd, J = 14.1, 8.5, 6.4 Hz, 1H, one 
of C32-H), 2.45 (dd, J = 15.3, 9.3 Hz, 1H, one of C38-H), 2.30 (m, J = 6.5 Hz, 1H, C10-H), 2.21 
(m, 1H, C18-H), 2.20 (m, J = 14.9 Hz, 1H, one of C38-H), 2.17 (m, 1H, one of C26-H), 2.15 (m, 
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J = 6.9 Hz, 1H, C6-H), 2.08 (m, 1H, C12-H), 2.07–2.00 (m, 3H, one of C16-H, one of C22-H, 
and one of C24-H), 2.00–1.92 (m, 4H, C4-H, C14-H, one of C16-H, and one of C24-H), 1.87 (m, 
1H, C20-H), 1.85 (m, 1H, one of C22-H), 1.83 (m, J = 6.7, 5.1 Hz, 1H, one of C7-H), 1.77 (m, J 
= 7.5, 6.3 Hz, 1H, one of C5-H), 1.75 (m, J = 7.9, 6.0 Hz, 1H, one of C7-H), 1.67 (m, 1H, one 
of C40-H), 1.63–1.53 (m, 2H, one of C40-H, and one of C41-H), 1.47 (m, 1H, one of C41-H), 
1.32–1.14 (m, 10H, C42–46-H2), 1.28 (d, J = 6.9 Hz, 3H, C51-H3), 1.24 (d, J = 6.9 Hz, 3H, C53-
H3), 1.22 (m, 2H, C47-H2), 1.19 (d, J = 6.9 Hz, 3H, C55-H3), 1.10 (d, J = 6.7 Hz, 3H, C49-H3), 
1.06 (d, J = 6.7 Hz, 3H, C50-H3), 1.04 (m, 1H, one of C5-H), 0.97 (d, J = 6.7 Hz, 3H, C54-H3), 
0.83 (t, J = 7.0 Hz, 3H, C48-H3), 0.80 (d, J = 6.9 Hz, 3H, C52-H3); 13C-NMR (125 MHz, 
C5D5N) δ 103.3 (C37), 81.6 (C13), 78.9 (C11), 78.9 (C19), 78.0 (C9), 77.1 (C15), 76.3 (C21), 
76.3 (C28), 75.5 (C30), 74.0 (C17), 73.1 (C36), 72.8 (C33), 72.6 (C35), 72.4 (C34), 72.2 
(C27), 71.5 (C29), 71.1 (C25), 70.9 (C31), 70.9 (C23), 69.5 (C8), 67.3 (C3), 66.9 (C39), 47.8 
(C56), 45.8 (C16), 42.8 (C18), 42.8 (C22), 42.4 (C7), 42.1 (C26), 41.6 (C5), 39.5 (C20), 39.5 
(C14), 39.4 (C38), 39.4 (C40), 38.8 (C12), 38.1 (C10), 37.6 (C32), 37.0 (C24), 34.0 (C4), 
32.1 (C46), 30.0 (C44), 30.0 (C43), 29.8 (C42), 29.5 (C45), 27.9 (C6), 26.0 (C41), 22.9 
(C47), 21.7 (C50), 18.7 (C49), 14.3 (C48), 13.2 (C52), 11.7 (C54), 8.3 (C51), 6.4 (C53), 6.1 
(C55); HRMS (ESI-TOF) m/z calcd for C54H108NaO22 [M+Na]+: 1131.7225, found: 
1131.7209. 
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S)-2,4,8,10,12,16,18-Heptamethyl-30-((2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-((R)-2-
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1,6,7,9,11,13,15,17,19,21,23,25,26,27,28,29-hexadecaol (46b). To a solution of lactol methyl 
ether 46a (6.8 mg, 6.1 µmol, 1.0 equiv) in CD3OD (1.5 mL, 4.0 mM wrt 46a) at rt was added 
Dowex® 50WX8 hydrogen form ion-exchange resin (~1 mg, 200–400 mesh). The reaction 
mixture stood at rt for 18 h, then was filtered through Celite. The filter cake was rinsed with 
1:1 CH2Cl2/CH3OH (15 mL total), and the filtrate concentrated. Reversed-phase C18 column 
chromatography (gradient elution, 5% → 100% CH3CN in H2O; eluted 50% → 65%) afforded 
aflastatin A C3–C48 degradation lactol trideuteriomethyl ether 46b (5.4 mg, 79% yield) as a 
white solid. [α] D24  +12.6° (c = 0.34, CH3OH); IR (neat) 3331 (br), 2922, 2857, 1457, 1437, 
1314, 1159, 1107, 1061, 969, 848 cm–1; 1H-NMR (600 MHz, C5D5N) δ 6.90 (br s, 1H, one of 
–OH), 6.63 (br s, 1H, one of –OH), 6.49 (br s, 1H, one of –OH), 6.45 (br s, 1H, one of –OH), 
6.41 (br s, 1H, one of –OH), 6.37 (br s, 1H, one of –OH), 6.30–6.21 (m, 4H, four of –OH), 
6.19 (br s, 1H, one of –OH), 6.11 (br s, 1H, one of –OH), 6.10–6.02 (m, 4H, four of –
OH), 5.96 (br s, 1H, one of –OH), 5.95–5.91 (m, 2H, two of –OH), 5.90 (br s, 1H, one of –
OH), 4.97 (m, J = 2.5 Hz, 1H, C29-H), 4.92 (m, J = 2.6 Hz, 1H, C31-H), 4.67 (d, J = 3.7 Hz, 
1H, C36-H), 4.67 (m, 1H, C27-H), 4.64 (m, J = 4.2, 3.7 Hz, 1H, C25-H), 4.62 (m, J = 7.0 Hz, 
1H, C17-H), 4.57 (dd, J = 9.1, 3.5 Hz, 1H, C35-H), 4.52–4.45 (m, 3H, C15-H, C23-H and C30-H), 
4.42 (m, J = 8.6 Hz, 1H, C21-H), 4.34 (m, J = 8.3 Hz, 1H, C28-H), 4.31 (dd, J = 9.2, 9.1 Hz, 
1H, C34-H), 4.31 (m, 1H, C11-H), 4.28 (m, J = 4.1, 4.0 Hz, 1H, C8-H), 4.23 (m, J = 10.8, 5.1 
Hz, 1H, C33-H), 4.18 (m, J = 10.7, 5.9 Hz, 1H, C39-H), 4.11 (m, J = 8.7 Hz, 1H, C13-H), 4.05 
(m, J = 9.5 Hz, 1H, C19-H), 4.00 (m, J = 4.4, 4.1 Hz, 1H, C9-H), 3.79 (m, J = 10.3, 4.8 Hz, 
1H, one of C3-H), 3.60 (m, J = 10.4, 6.7 Hz, 1H, one of C3-H), 3.17 (ddd, J = 11.4, 3.4, 2.8 
Hz, 1H, one of C32-H), 2.59 (m, J = 13.8 Hz, 1H, one of C26-H), 2.49 (ddd, J = 14.0, 7.5, 6.4 
Hz, 1H, one of C32-H), 2.44 (dd, J = 15.2, 9.4 Hz, 1H, one of C38-H), 2.30 (m, J = 6.1 Hz, 1H, 
C10-H), 2.21 (m, 1H, C18-H), 2.20 (m, J = 15.2 Hz, 1H, one of C38-H), 2.16 (m, 1H, one of 
C26-H), 2.14 (m, J = 7.2 Hz, 1H, C6-H), 2.08 (m, 1H, C12-H), 2.07–2.00 (m, 3H, one of C16-H, 
one of C22-H, and one of C24-H), 2.00–1.92 (m, 4H, C4-H, C14-H, one of C16-H, and one of 
C24-H), 1.87 (m, 1H, C20-H), 1.85 (m, 1H, one of C22-H), 1.83 (m, J = 6.7, 5.4 Hz, 1H, one of 
C7-H), 1.76 (m, J = 7.6, 6.0 Hz, 1H, one of C5-H), 1.74 (m, J = 7.9, 7.2, 6.4 Hz, 1H, one of 
C7-H), 1.67 (m, 1H, one of C40-H), 1.62–1.53 (m, 2H, one of C40-H, and one of C41-H), 1.47 
(m, 1H, one of C41-H), 1.32–1.13 (m, 10H, C42–46-H2), 1.28 (d, J = 7.0 Hz, 3H, C51-H3), 1.23 
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(d, J = 6.7 Hz, 3H, C53-H3), 1.22 (m, 2H, C47-H2), 1.19 (d, J = 6.9 Hz, 3H, C55-H3), 1.10 (d, J 
= 6.7 Hz, 3H, C49-H3), 1.06 (d, J = 6.6 Hz, 3H, C50-H3), 1.04 (m, 1H, one of C5-H), 0.97 (d, J 
= 6.7 Hz, 3H, C54-H3), 0.83 (t, J = 7.1 Hz, 3H, C48-H3), 0.80 (d, J = 6.9 Hz, 3H, C52-H3); 13C-
NMR (125 MHz, C5D5N) δ 103.2 (C37), 81.6 (C13), 78.8 (C11), 78.7 (C19), 77.9 (C9), 77.1 
(C15), 76.2 (C21), 76.2 (C28), 75.4 (C30), 73.9 (C17), 73.0 (C36), 72.7 (C33), 72.6 (C35), 
72.3 (C34), 72.2 (C27), 71.5 (C29), 71.1 (C25), 70.9 (C31), 70.8 (C23), 69.5 (C8), 67.2 (C3), 
66.9 (C39), 45.7 (C16), 42.7 (C18), 42.7 (C22), 42.3 (C7), 42.1 (C26), 41.6 (C5), 39.5 (C20), 
39.5 (C14), 39.3 (C38), 39.3 (C40), 38.8 (C12), 38.1 (C10), 37.5 (C32), 36.9 (C24), 34.0 
(C4), 32.0 (C46), 30.0 (C44), 29.9 (C43), 29.8 (C42), 29.5 (C45), 27.8 (C6), 26.0 (C41), 22.9 
(C47), 21.6 (C50), 18.6 (C49), 14.2 (C48), 13.2 (C52), 11.6 (C54), 8.3 (C51), 6.4 (C53), 6.1 
(C55); HRMS (ESI-TOF) m/z calcd for C54H105D3NaO22 [M+Na]+: 1134.7413, found: 
1134.7407. 
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Chapter 
4 
Synthesis of Aflastatin A 
 
I. Installation of the Tetramic Acid 
 Our asymmetric syntheses of the aflastatin A (AsA) C3–C48 degradation fragments 
allowed us to confirm the stereochemical revision of AsA. Having achieved this objective, we 
finally turned our attention to the synthesis of the natural product itself. Unlike its C3–C48 
degradation fragments, AsA is capped by a D-alanine-based tetramic acid moiety.1 We 
therefore focused on developing a method for its installation. 
 Our first retrosynthesis plan for AsA (1) involved disconnection at C2–C3 to produce 
tetramic acid derivative 2 and C3–C48 aldehyde fragment 3 (Scheme 4.1).2 We planned to 
install the tetramic acid by Wittig or Horner-Wadsworth-Emmons reaction as late in the 
synthesis as possible because we expected the C5’ stereocenter to be readily epimerizable.1b 
  
                                                
(1)  For reviews of tetramic acid natural products, see: (a) Schobert, R.; Schlenk, A. Bioorg. Med. Chem. 2008, 
16, 4203–4221; (b) Royles, B.J.L. Chem. Rev. 1995, 95, 1981–2001. 
(2)  Young, J.M. Studies Toward the Synthesis of Aflastatin A. Ph.D. Thesis, Harvard University, 2008. 
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Scheme 4.1. Retrosynthesis plan for aflastatin A (1). 
 
 Precedent for this transformation was borne out of the syntheses of streptolydigin and 
the tirandamycins by the laboratories of Boeckman,3 DeShong,4 and Schlessinger.5 In a 
separate yet closely related example, Rosen and coworkers made disubstituted (E) alkene 6 by 
addition of the potassium dianion of chiral tetramic acid phosphonate 4 to unsaturated 
aldehyde 5 (eq 1).6 Fortunately, additions to aliphatic aldehydes under the same conditions 
were also known.5a However, the reaction of 2-methylated phosphonates such as 2 to produce 
trisubstituted (E) alkenes warranted investigation, so we embarked upon its synthesis. 
 
                                                
(3)  (a) Boeckman, R.K., Jr.; Thomas, A.J. J. Org. Chem. 1982, 47, 2823–2824; (b) Boeckman, R.K., Jr.; 
Starrett, J.E., Jr.; Nickell, D.G.; Sum, P.-E. J. Am. Chem. Soc. 1986, 108, 5549–5559; (c) Boeckman, R.K., 
Jr.; Potenza, J.C.; Enholm, E.J. J. Org. Chem. 1987, 52, 469–472. 
(4)  (a) DeShong, P.; Ramesh, S.; Elango, V.; Perez, J.J. J. Am. Chem. Soc. 1985, 107, 5219–5224; (b) 
Shimshock, S.J.; Waltermire, R.E.; DeShong, P. J. Am. Chem. Soc. 1991, 113, 8791–8796.  
(5)  (a) Schlessinger, R.H.; Bebernitz, G.R. J. Org. Chem. 1985, 50, 1344–1346; (b) Schlessinger, R.H.; 
Bebernitz, G.R.; Lin, P. J. Am. Chem. Soc. 1985, 107, 1777–1778; (c) Schlessinger, R.H.; Graves, D.D. 
Tetrahedron Lett. 1987, 28, 4385–4388. 
(6)  Rosen, T.; Fernandes, P.B.; Marovich, M.A.; Shen, L.; Mao, J.; Pernet, A.G. J. Med. Chem. 1989, 32, 
1062–1069. 
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 The synthesis of tetramic acid phosphonate 27 began with the preparation of N-methyl-
D-alanine ethyl ester (9) in five steps from D-alanine (Scheme 4.2).8 Reductive opening of 
oxazolidinone 79 was followed by ethylation of the nascent carboxylate to produce N-
methylated alanine derivative 8. Deprotection provided N-methyl amino ester 9 as a dilute 
solution in dichloromethane for immediate use since it was prone to self-dimerization. 
Scheme 4.2. Synthesis of N-methyl-D-alanine ethyl ester (9). 
 
Reagents and conditions: (a) CbzCl, Na2CO3, dioxane, H2O, 0 °C to rt; (b) HO(CH2O)nH, CSA, PhMe, 90 °C, 
94% (2 steps); (c) Et3SiH, TFA, CH2Cl2, 84%; (d) EtI, K2CO3, DMF, rt to 50 °C, 51%; (e) H2, Pd/C, CH2Cl2, rt. 
 The synthesis of tetramic acid phosphonate 2 was then completed in five steps from 
2,2,6-trimethyl-4H-1,3-dioxin-4-one (10) (Scheme 4.3).2,8 Methylation, phosphination, and 
oxidative workup provided phosphonate 1110 in moderate overall yield. Cycloelimination of 
dioxinone 11 and capture of ethanethiol by the resultant acylketene intermediate11 afforded β-
ketothioester 1212 in excellent yield. Amide bond formation13 and modified Lacey-Dieckmann 
cyclization14 of β-ketoamide 13 produced tetramic acid phosphonate 2 in good overall yield. 
                                                
(7)  The syntheses of tetramic acid phosphonate 2 and model tetramic acid 15 (vide infra) were performed as a 
collaboration between Dr. Joseph M. Young and David A. Thaisrivongs. 
(8)  Thaisrivongs, D.A. Synthesis of the C5'–C2 and C36–C48 Subunits of Aflastatin A. A.B. Thesis, Harvard 
University, 2007. 
(9)  Aurelio, L.; Box, J.S.; Brownlee, R.T.C.; Hughes, A.B.; Sleebs, M.M. J. Org. Chem. 2003, 68, 2652–2667. 
(10)  (a) Boeckman, R.K., Jr.; Kamenecka, T.M.; Nelson, S.G.; Pruitt, J.R.; Barta, T.E. Tetrahedron Lett. 1991, 
32, 2581–2584; (b) Boeckman, R.K., Jr.; Barta, T.E.; Nelson, S.G. Tetrahedron Lett. 1991, 32, 4091–4094; 
(c) Roush, W.R.; Brown, B.B. J. Org. Chem. 1993, 58, 2162–2172. 
(11)  (a) Clemens, R.J.; Hyatt, J.A. J. Org. Chem. 1985, 50, 2431–2435; (b) Sakaki, J.; Kobayashi, S.; Sato, M.; 
Kaneko, C. Chem. Pharm. Bull. 1990, 38, 2262–2264. 
(12)  (a) Hayashi, Y.; Narasaka, K. Chem. Lett. 1998, 313–314; (b) Hayashi, Y.; Kanayama, J.; Yamaguchi, J.; 
Shoji, M. J. Org. Chem. 2002, 67, 9443–9448. 
(13)  Kim, H.-O.; Olsen, R.K.; Choi, O.-S. J. Org. Chem. 1987, 52, 4531–4536. 
(14)  (a) Lacey, R.N.; J. Chem. Soc. 1954, 850–854; (b) Bloomer, J.L.; Kappler, F.E. J. Chem. Soc., Perkin 
Trans. I 1976, 1485–1491. 
NH3
O
O
Me
D-Ala
94%
a,b
O
N
Me
5' 5'O Cbz
7
NEtO
O
Me
5'
42%
c,d
Me
Cbz
8
NHEtO
O
Me
5'
e
Me
9
 133 
Scheme 4.3. Synthesis of tetramic acid phosphonate 2. 
 
Reagents and conditions: (a) LDA, MeI, THF, –78 °C to 0 °C, 60%; (b) LiHMDS, (EtO)2PCl, rt; aq H2O2, PhH, 
0 °C, 59%; (c) EtSH, PhMe, 111 °C, 95%; (d) CuI, Et3N, CH2Cl2, rt, 84% (2 steps from 8); (e) Cs2CO3, THF, rt, 
98%. 
 Our attempted addition of the potassium dianion of chiral tetramic acid phosphonate 2 
to piperonal (14) resulted in decomposition (eq 2).2,8 Several other bases were then screened 
(NaH/nBuLi, LDA, and Ba(OH)2), but resulted in little to no reactivity, even at elevated 
temperatures. We attributed the lack of reactivity to the reduced kinetic acidity of 
phosphonate 2. Deprotonation of the H2 proton is attenuated by minimization of allylic strain 
between the C2 stereocenter and tetramic acid ring. 
 
 Although desirable, one-step installation of the tetramic acid was infeasible. As an 
alternative, Ley and coworkers reported a reliable three-step procedure for installing tetramic 
acids via olefination, amide bond formation, and cyclization.15 Accordingly, addition of the 
sodium dianion of thioester phosphonate 12 to piperonal (14) produced the desired 
trisubstituted (E)-alkene 16 in very good yield and excellent E:Z selectivity (Scheme 4.4). 
                                                
(15)  (a) Ley, S.V.; Smith, S.C.; Woodward, P.R. Tetrahedron Lett. 1988, 29, 5829–5832; (b) Ley, S.V.; Smith, 
S.C.; Woodward, P.R. Tetrahedron 1992, 48, 1145–1174; (c) Burke, L.T.; Dixon, D.J.; Ley, S.V.; 
Rodríguez, F. Org. Lett. 2000, 2, 3611–3613. 
O O
MeMe
O Me
35%
a,b
10
O O
MeMe
O
11
P
Me
O
OEt
OEt11
95%
c O O
12
P
Me
O
OEt
OEt1EtS
12
Me
OH
NMe
O
O
Me
P
O
2
2
4' OEt
OEt
98%
eEtO
O
Me
5'
Me
O O
P
Me
O
OEt
OEt1N
13
84%
dEtO
O
Me
5'
Me
NH
9
3'
no reactivity or
decomposition
(2)
Me
OH
NMe
O
O
Me
P
O
2
5'
2'
OEt
OEt
2
Me
OH
NMe
O
O
Me
3
5'
2'
15
2
H
O
O
O
O
O3
t-BuOK, NaH/nBuLi,
LDA, or Ba(OH)2
14
 134 
Addition13 of amine 9 to thioester 16 was followed by modified Lacey-Dieckmann 
cyclization15b of β-ketoamide 17 to complete the synthesis of model tetramic acid 157 in good 
overall yield. 
Scheme 4.4. Synthesis of model tetramic acid 15. 
 
Reagents and conditions: (a) piperonal (14), NaH, THF, 0 °C to rt, 83%, E : Z > 99:01; (b) CuI, Et3N, CH2Cl2, rt, 
81%; (c) nBu4NF, THF, rt, 83%. 
 We then attempted to subject more elaborate model aldehydes 18 and 1916 to this 
reaction sequence. 17  Unfortunately, addition of various metal dianions of thioester 
phosphonate 12 to these aldehydes resulted in epimerization of the C4 methyl stereocenter (eq 
3). Throughout our screen of strong bases, aldehyde epimerization was accompanied by 
variable levels of conversion and E:Z selectivity. Although mild deprotonation of 
phosphonate 12 by Ba(OH)218 curtailed epimerization, we only observed trace amounts of 
desired product. From these experiments we determined that phosphonates requiring double 
deprotonation for reactivity were incompatible with aldehydes bearing epimerizable α-
stereocenters, and therefore would not be appropriate for our synthesis of AsA. 
                                                
(16)  Precursors to model aldehydes 18 and 19 were previously synthesized by Dr. Joseph M. Young. See: Ref. 2. 
(17)  Application of the Ley protocol to model aldehydes 18 and 19 was attempted by the author in collaboration 
with Dr. Egmont Kattnig. 
(18)  (a) Alvarez Ibarra, C.; Arias, S.; Fernández, M.J.; Sinisterra, J.V. J. Chem. Soc., Perkin Trans. II 1989, 
503–508; (b) Paterson, I.; Yeung, K.-S.; Smaill, J.B. Synlett 1993, 774–776. 
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 Ultimately, we found recourse in a three-step procedure developed by Boeckman, 
Jones and their respective coworkers.19 Although the overall transformations are similar to 
Ley's protocol15 (Scheme 4.5), olefination occurs under milder conditions and requires single 
deprotonation of dioxenone phosphonate 11.10b,20 Subsequently, amide formation occurs not 
by addition of an amine to a thioester, but rather by cycloelimination of dioxinone 24 and 
capture of amine 9 by the resultant acylketene intermediate to produce common β-ketoamide 
23.21 Both strategies then generate the highly polar and readily epimerizable tetramic acid 25 
in a final cyclization step. 
Scheme 4.5. Ley and Boeckman procedures for tetramic acid installation. 
 
                                                
(19)  (a) Boeckman, R.K., Jr.; Weidner, C.H.; Perni, R.B.; Napier, J.J. J. Am. Chem. Soc. 1989, 111, 8036–8037; 
(b) Jones, R.C.F.; Tankard, M. J. Chem. Soc., Perkin Trans. I 1991, 240–241. 
(20)  (a) Boeckman, R.K., Jr.; Shao, P.; Wrobleski, S.T.; Boehmler, D.J.; Heintzelman, G.R.; Barbosa, A.J. J. 
Am. Chem. Soc. 2006, 128, 10572–10588; (b) Yoshinari, T.; Ohmori, K.; Schrems, M.G.; Pfaltz, A.; 
Suzuki, K. Angew. Chem., Int. Ed. 2010, 49, 881–885. 
(21)  Sato, M.; Ogasawara, H.; Komatsu, S.; Kato, T. Chem. Pharm. Bull. 1984, 32, 3848–3856. 
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 For the cycloelimination step, Jones and Tankard demonstrated that the reactant amino 
esters could be generated in situ from their corresponding hydrochloride salts.19b As such, we 
took this opportunity to synthesize a more stable form of amino ester 9, namely its 
hydrochloride salt 9•HCl, 22  in three steps from N-Cbz-D-alanine (26) (Scheme 4.6). 
Methylation,23 ethyl ester formation,8 and reductive removal of the Cbz protecting group 
under anhydrous acidic conditions produced the hydrochloride salt of N-methyl-D-alanine 
ethyl ester (9•HCl) in excellent overall yield. 
Scheme 4.6. Synthesis of N-Me-D-Ala-OEt•HCl (9•HCl). 
 
Reagents and conditions: (a) MeI, NaH, THF, 0 °C to rt, 91%, Ref. 23a; (b) EtI, K2CO3, DMF, 0 °C to rt, 91%; 
(e) H2, Pd/C, AcCl, EtOH, rt, quant. 
 With both dioxinone phosphonate 11 (Scheme 4.3) and ammonium salt 9•HCl in hand, 
we applied Boeckman's protocol19 to the synthesis of model tetramic acid 32 (Scheme 4.7).24 
Addition of the lithium anion of phosphonate 11 to model aldehyde 19 in the presence of 
HMPA10b,20 produced trisubstituted (E)-alkene 29 as a single isomer in excellent yield and 
without epimerization of the C4 methyl stereocenter. Next, cycloelimination19b of dioxinone 
29 in the presence of ammonium salt 9•HCl and molecular sieves (and the absence of 
exogenous base) led to the formation of β-ketoamide 30 in very good yield. Then, Lacey-
Dieckmann cyclization14 was induced by potassium trimethylsilanolate, rather than potassium 
                                                
(22)  The synthesis of the corresponding methyl ester was achieved by Dr. Egmont Kattnig. The synthesis of 
ammonium salt 9•HCl represents the culminative work of David A. Thaisrivongs, Dr. Peter H. Fuller, and 
the author. 
(23)  (a) Trouche, N.; Wieckowski, S.; Sun, W.; Chaloin, O.; Hoebeke, J.; Fournel, S.; Guichard, G. J. Am. 
Chem. Soc. 2007, 129, 13480–13492; (b) Stodulski, M.; Mlynarski, J. Tetrahedron: Asymmetry 2008, 19, 
970–975. 
(24)  The synthesis of tetramic acid 31 was first performed by Dr. Egmont Kattnig, and then modified by Dr. 
Peter H. Fuller. The synthesis of tetramate salt 32•Et2NH was performed in collaboration with Dr. Fuller. 
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tert-butoxide,14b to cleanly produce tetramic acid 31 in good yield. As before, removal of the 
acetonide and silyl protecting groups was achieved with hexafluorosilicic acid,25 proceeded 
with concomitant lactonization, and ultimately furnished model 3-acyltetramic acid 32. 
Importantly, both the cyclization and deprotection steps proceeded without appreciable 
epimerization of the C5' stereocenter. 
Scheme 4.7. Synthesis of model tetramic acid 32. 
 
Reagents and conditions: (a) phosphonate 11, LDA, THF, –78 °C to 0 °C; HMPA, –78 °C; aldehyde 19, –78 °C 
to rt, 95%, E:Z > 95:05; (b) 4 Å MS, PhMe, 110 °C, 82%; (c) KOTMS, TMSOH, THF, 0 °C, 79%; (d) aq H2SiF6, 
MeCN, CH2Cl2, 0 °C to rt; (e) Et2NH, MeOH, rt. 
 After completing the synthesis of model tetramic acid 32, we compared its NMR 
spectroscopic data to that reported by the isolation group for AsA.26  Acknowledging the 
obvious stereochemical and structural differences in the C8–C9 diol and C10–C15 
                                                
(25)  (a) Pilcher, A.S.; Hill, D.K.; Shimshock, S.J.; Waltermire, R.E.; DeShong, P. J. Org. Chem. 1992, 57, 
2492–2495; (b) Pilcher, A.S.; Shimshock, S.J. J. Org. Chem. 1993, 58, 5130–5134. 
(26) (a) Sakuda, S.; Ono, M.; Furihata, K.; Nakayama, J.; Suzuki, A.; Isogai, A. J. Am. Chem. Soc. 1996, 118, 
7855–7856; (b) Ono, M.; Sakuda, S.; Suzuki, A.; Isogai, A. J. Antibiotics 1997, 50, 111–118; (c) Ono, M.; 
Suzuki, A.; Isogai, A.; Sakuda, S. Production Aflastatin A from Streptomyces sp., A Pharmaceutical 
Composition and Methods of Use. U.S. Patent 5,773,263, June 30, 1998. 
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polypropionate regions, respectively, we were still disappointed by the general disagreement 
of data sets in the seemingly removed N1'–C6'/C1–C3 enoyltetramate region. Additionally, 
we observed significant line broadening of resonances in the carbon NMR spectrum of model 
tetramic acid 32 due to rotameric and tautomeric equilibria.27 At this point in time we realized 
that the isolation group purified AsA under basic conditions, and reported spectral data 
corresponding not to the free tetramic acid but its corresponding diethylamine salt.26b,c 
Unfortunately, conversion of model tetramic acid 32 to diethylammonium tetramate 
32•Et2NH did not completely resolve chemical shift discrepancies in the C1–C3 enoyl region. 
 To resolve this issue, we undertook the synthesis of AsA tetramic acid degradation 
fragment 38 (Scheme 4.8).28 Parikh-Doering oxidation29 of C3 carbinol 3330 and reaction10b,20 
of resultant aldehyde 34 with dioxinone phosphonate 11 provided trisubstituted (E)-alkene 35 
as a single isomer in good yield over two steps. Cycloelimination19b of dioxinone 35 in the 
presence of ammonium salt 9•HCl led to the formation of β-ketoamide 36 in excellent yield. 
Modified Lacey-Dieckmann cyclization14 was followed by silyl group removal25 to furnish 
degradation fragment 38. The free tetramic acid was then converted to its corresponding 
diethylamine salt 38•Et2NH. 
 Comparison of our NMR spectroscopic data for diethylammonium tetramate 
38•Et2NH to that reported by the isolation group for the naturally derived tetramic acid 
                                                
(27)  (a) Yamaguchi, T.; Saito, K.; Tsujimoto, T.; Yuki, H. Bull. Chem. Soc. Jpn. 1976, 49, 1161–1162; (b) Saito, 
K.; Yamaguchi, T. Bull. Chem. Soc. Jpn. 1978, 51, 651–652; (c) Saito, K.; Yamaguchi, T. J. Chem. Soc., 
Perkin Trans. II 1979, 1605–1609; (d) Steyn, P.S.; Wessels, P.L. Tetrahedron Lett. 1978, 19, 4707–4710; 
(d) Nolte, M.J.; Steyn, P.S.; Wessels, P.L. J. Chem. Soc., Perkin Trans. I 1980, 1057–1065; (e) Steyn, P.S.; 
Wessels, P.L. S. Afr. J. Chem. 1980, 33, 120; (f) Jeong, Y.-C.; Moloney, M.G. J. Org. Chem. 2011, 76, 
1342–1354 and references therein. 
(28)  The synthesis of degradation fragment 38•Et2NH was performed by the author. 
(29)  Parikh, J.R.; Doering, W.v.E. J. Am. Chem. Soc. 1967, 89, 5505–5507. 
(30)  A precursor to carbinol 33 was previously synthesized by Dr. Joseph M. Young. See: Ch. 2. 
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degradation fragment 3826a,b revealed a spectroscopic match save those resonances 
corresponding to the diethylammonium cation. Since naturally derived degradation fragment 
38 was also purified under basic conditions, we concluded that the data tabulated by the 
isolation group for naturally derived AsA tetramic acid degradation fragment 38 should in fact 
be attributed to its derivative diethylammonium tetramate salt 38•Et2NH. 
Scheme 4.8. Synthesis of degradation fragments 38 and 38•Et2NH. 
 
Reagents and conditions: (a) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C; (b) phosphonate 11, LDA, 
THF, –78 °C to 0 °C; HMPA, –78 °C; aldehyde 34, –78 °C to rt, E:Z > 95:05. 74% (2 steps); (c) 4 Å MS, PhMe, 
110 °C, 97%; (d) KOTMS, TMSOH, THF, 0 °C; (e) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt; (f) Et2NH, MeOH, rt. 
 In the end, our synthesis of tetramate 38•Et2NH and its spectroscopic match to 
naturally derived tetramic acid degradation fragment 38 confirmed the absolute 
stereochemical assignment of the C5' stereocenter.31 When taken together with our syntheses 
of the AsA C3–C48 degradation fragments, we confirmed both the revised stereochemical 
assignment and full absolute configuration of AsA.32  
  
                                                
(31)  Ikeda, H.; Matsumori, N.; Ono, M.; Suzuki, A.; Isogai, A.; Nagasawa, H.; Sakuda, S. J. Org. Chem. 2000, 
65, 438–444. 
(32)  Sakuda, S.; Matsumori, N.; Furihata, K.; Nagasawa, H. Tetrahedron Lett. 2007, 48, 2527–2531. 
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II. Revised Synthesis of the C27–C48 Aldehyde 
 Having found a suitable method for installing the tetramic acid moiety, we embarked 
upon the synthesis of AsA (1) and its diethylamine salt. Our final retrosynthesis plan33 for 
AsA (1) involved disconnections at C2–C3 and C3'–C4' to produce C3–C48 aldehyde 39, as 
well as two tetramic acid precursors: the hydrochloride salt of N-methyl-D-alanine ethyl ester 
(9•HCl), and dioxinone phosphonate 11 (Scheme 4.9). In turn, we envisioned aldehyde 39 to 
arise from the diastereoselective aldol addition of C3–C26 ketone 40 to C27–C48 aldehyde 
41.33 We took this opportunity to revise the original synthesis of C27–C48 aldehyde 41 in 
order to reduce the number of protecting group manipulation steps.34 
Scheme 4.9. Retrosynthesis plan for aflastatin A (1). 
 
 Our synthesis of C27–C48 aldehyde 41 began with the preparation of C27–C31 
                                                
(33)  Kattnig, E. An Aldol Approach Toward Aflastatin A – Synthesis of the C3–C48 Polyol. Postdoctoral Report, 
Harvard University, 2011. 
(34)  The revised synthesis of C27–C48 aldehyde 41 was performed by the author. 
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aldehyde 46 from dibenzylglucopyranoside 4235 in five steps (Scheme 4.10). Iodination36 and 
silylation produced pyranoside 43 in excellent overall yield. Zinc-mediated fragmentation37 
and in situ reduction produced enol 44, which in turn was silylated and oxidatively cleaved, 
ultimately furnishing C27–C31 aldehyde 45 in 86% overall yield. 
Scheme 4.10. Synthesis of C27–C31 aldehyde 45. 
 
Reagents and conditions: (a) PPh3, I2, imidazole, PhMe, MeCN, rt, 97%; (b) TBSCl, imidazole, CH2Cl2, 0 °C to 
rt, quant.; (c) Zn, THF, H2O, ))), 45 °C; NaBH4, 0 °C, 88%; (d) TESCl, imidazole, CH2Cl2, 0 °C to rt, 98%; (e) 
O3, py, CH2Cl2, MeOH, –78 °C; PPh3, –78 °C to rt, 94%. 
 Our synthesis of C27–C48 aldehyde 41 continued with the stereoselective allylation of 
syn α,β-bisalkoxy aldehyde 45 (Scheme 4.11). Although both α- and β-oxygen substituents 
were available for chelation,38 the rate of reaction of allylmagnesium bromide with the five-
membered chelate39 was significantly faster, 40 producing homoallylic alcohol 46 in 95% yield 
as a single diastereomer (d.r. ≥ 95:05). Acryloylation41 of the nascent C31 carbinol, and ring-
                                                
(35)  Français, A.; Urban, D.; Beau, J.-M. Angew. Chem., Int. Ed. 2007, 46, 8662–8665. 
(36)  (a) Garegg, P.J.; Samuellson, B. J. Chem. Soc., Perkin Trans. I. 1980, 2866–2869; (b) Garegg, P.J.; 
Johansson, R.; Ortega, C.; Samuellson, B. J. Chem. Soc., Perkin Trans. I. 1982, 681–683. 
(37)  Skaanderup, P.R.; Hyldtoft, L.; Madsen, R. Monatsh. Chem. 2002, 133, 467–472. 
(38)  The possibility of bicyclic chelates involving the aldehyde carbonyl and both oxygen substituents cannot be 
ruled out. See: (a) Charette, A.B.; Mellon C.; Rouillard, L.; Malenfant, E. Pure Appl. Chem. 1992, 64, 
1925–1931; (b) Charette, A.B.; Mellon C.; Rouillard, L.; Malenfant, E. Synlett 1993, 81–82. 
(39)  (a) Cram, D.J.; Abd Elhafez, F.A. J. Am. Chem. Soc. 1952, 74, 5828–5835; (b) Cram, D.J.; Kopecky, K.R. 
J. Am. Chem. Soc. 1959, 81, 2748–2755; (c) Cram, D.J.; Leitereg, T.H. J. Am. Chem. Soc. 1968, 90, 4019–
4026. 
(40)  For examples that suggest five-membered magnesium chelates react much faster than six-membered 
chelates, see: (a) Frye, S.V.; Eliel, E.L.; Cloux, R. J. Am. Chem. Soc. 1987, 109, 1862–1863; (b) Williams, 
D.R.; Klingler, F.D. Tetrahedron Lett. 1987, 28, 869–872; (c) Keck, G.E.; Andrus, M.B.; Romer, D.R. J. 
Org. Chem. 1991, 56, 417–420; (d) Burgess, K.; Chaplin, D.A. Tetrahedron Lett. 1992, 33, 6077–6080. 
(41)  Tanaka, A.; Suzuki, H.; Yamashita, K. Agric. Biol. Chem. 1989, 53, 2253–2256. 
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closing metathesis42 of the intermediate diene then furnished unsaturated lactone 47.  
Scheme 4.11. Synthesis of C27–C35 aldehyde 52. 
 
Reagents and conditions: (a) MgBr2•OEt2, allylMgBr, CH2Cl2, Et2O, PhMe, –78 °C, 92%, dr ≥ 95:05; (b) acrylic 
pivalic anhydride, EtN(iPr)2, DMAP, THF, PhH, rt, 98%; (c) (Ph3P)2Cl2Ru=CHPh, PhH, 65 °C, 69%; (d) RuCl3, 
CeCl3•7H2O, NaIO4, EtOAc, MeCN, H2O, 0 °C, dr ≥ 95:05; (e) Me2C(OMe)2, PPTS, acetone, 35 °C, 65% (2 
steps); (f) LiBH4, H2O, THF, 0 °C to rt, 91%; (g) TBDPSCl, imidazole, DMF, 0 °C, 92%; (h) BnBr, NaH, 
nBu4NI, DMF, –20 °C to –5 °C, 92%; (i) nBu4NF, AcOH, THF, rt, 93%; (j) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, 
–30 °C to –20 °C, 94%. 
 Stereoselective dihydroxylation 43 , 44  proceeded with concomitant removal of the 
primary TES ether to give triol 48 as a single diastereomer. Acetonide formation and 
protection of the C27 carbinol as its 2-methoxy-2-propyl (MOP) ether45 produced lactone 49 
in good yield over two steps. Reduction to diol 50, selective protection of the primary carbinol, 
                                                
(42)  Schwab, P.; France, M.B.; Ziller, J.W.; Grubbs, R.H. Angew. Chem. 1995, 107, 2179–2181; Angew. Chem., 
Int. Ed. 1995, 34, 2039–2041. 
(43)  (a) Plietker, B.; Niggemann, M. J. Org. Chem. 2005, 70, 2402–2405; (b) Plietker, B. Synthesis 2005, 2453–
2472. 
(44)  For examples of the diastereoselective dihydroxylation of related α,β-unsaturated δ-lactones using Upjohn 
conditions (OsO4, NMO), see: (a) Ghosh, A.K.; Kim, J.-H. Tetrahedron Lett. 2003, 44, 3967–3969; (b) 
Ramachandran, P.V.; Prabhudas, B.; Chandra, J.S.; Reddy, M.V.R. J. Org. Chem. 2004, 69, 6294–6304; 
(c) Bhaket, P.; Stauffer, C.S.; Datta, A. J. Org. Chem. 2004, 69, 8594–8601. 
(45)  For one of the earliest examples of using a 2-methoxy-2-propyl (MOP) ether as a carbinol protecting group, 
see: Kluge, A.F.; Untch, K.G.; Fried, J.H. J. Am. Chem. Soc. 1972, 94, 7827–7832. 
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and benzylation yielded disilyl ether 51. Selective removal of the TBDPS ether and 
oxidation29 of the resultant carbinol ultimately provided C27–C35 aldehyde 52 in 10 steps and 
32% overall yield from aldehyde 45. 
 With a more efficient route to aldehyde 52 in hand, the synthesis of the C27–C48 
fragment 41 was nearly complete. Addition46 of the corresponding (E) enolate of ketone 53 to 
aldehyde 52 produced the desired anti-Felkin product 54 in moderate yield and good 
diastereoselection (Scheme 4.12). Silylation of the C35 carbinol and selective cleavage of the 
primary MOP ether were then accomplished in one pot. Oxidation29 of the resultant C27 
carbinol completed the synthesis of C27–C48 aldehyde 41 in good overall yield and 21 linear 
steps from methyl α-D-(+)-glucopyranoside. 
Scheme 4.12. Synthesis of C27–C48 aldehyde 41. 
 
Reagents and conditions: (a) ketone 53, Cy2BCl, Me2NEt, pentane, 0 °C to rt; aldehyde 52, Et2O, –78 °C to –
25 °C, dr = 85:15, 57%; (b) TESOTf, 2,6-lutidine, CH2Cl2, 0 °C; aq H2SO4, 83%; (c) SO3•Py, EtN(iPr)2, DMSO, 
CH2Cl2, –30 °C to –20 °C, 95%. 
III. Completion of the Synthesis of Aflastatin A47 
 Having completed the syntheses of both the C3–C26 and C27–C48 fragments, we 
ventured forward with the synthesis of C3–C48 aldehyde 58 (Scheme 4.13). Satisfyingly, 
chelate-controlled addition of ketone 40 to aldehyde 41 under our soft enolization conditions33 
                                                
(46)  (a) Glorius, F. Development of α-Oxygenated Aldol Methodology and Progress Towards the Synthesis of 
Aflastatin A. Postdoctoral Report, Harvard University, 2001; (b) Evans, D.A.; Glorius, F.; Burch, J.D. Org. 
Lett. 2005, 7, 3331–3335. 
(47)  The synthesis of AsA 1 and its diethylamine salt 1•Et2NH was performed by the author. 
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delivered the desired β-hydroxy ketone with excellent diastereoselection. We immediately 
reduced the aldol adduct48 under Prasad's conditions49, to afford 1,3-syn diol 55 as a single 
diastereomer in good overall yield. Both steps were completely chemoselective and 
eliminated the need to mask the C37 carbonyl. 
Scheme 4.13. Synthesis of C3–C48 aldehydes 58. 
 
Reagents and conditions: (a) MgBr2•OEt2, PMP, CH2Cl2, –5 °C, d.r. = 95:05; (b) Et2BOMe, NaBH4, THF, 
MeOH, –78 °C to –55 °C; aq H2O2, aq NaOH, MeOH, 0 °C, dr ≥ 95:05, 70% (2 steps); (c) H2, Pd black, THF, 
dioxane, H2O, rt, 93%; (d) TMSCl, py, CH2Cl2, 0 °C to rt; (e) PPTS, CH2Cl2, iPrOH, 0 °C; Et3N, 87% (2 steps); 
(f) SO3•Py, EtN(iPr)2, DMSO, CH2Cl2, –30 °C to –20 °C. 
 Our synthesis of C3–C48 aldehyde 58 continued with the hydrogenolysis of 
pentabenzyl ether 55 to produce heptaol 56. We removed all the benzyl protecting groups in 
                                                
(48)  We observed that the intermediate aldol adduct is subject to retro-aldolization on silica gel. For higher 
overall yields of diol 55, we performed the aldol addition and reduction in tandem before purification. 
(49)  Chen, K.-M.; Hardtmann, G.E.; Prasad, K.; Repič, O; Shapiro, M.J. Tetrahedron Lett. 1987, 28, 155–158. 
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advance of installing the tetramic acid because hydrogenation of the C2–C3 alkene of 
enoyltetramic acids under similar conditions (H2/Pd) was known.50 Persilylation of heptaol 56 
was then attempted and produced an inseparable yet inconsequential mixture of 
hexakistrimethylsilyl ethers. We believe persilylation of the C27–C31 pentaol was incomplete, 
unselective, and potentially complicated by 1,2-silyl migration of the C28 TBS ether.51,52 
Unfortunately, this mixture of differentially silylated material complicated spectral analyses 
and persisted until global deprotection. Nevertheless, the C3 carbinol was selectively 
desilylated and oxidized29,53 to afford a mixture of C3–C48 aldehydes best represented by 
structure 58. 
 With C3–C48 aldehydes 58 in hand, we installed the tetramic acid moiety according to 
Boeckman's three-step method.19 Addition of the lithium anion of dioxinone phosphonate 11 
to aldehydes 58 in the presence of HMPA10b,20 provided trisubstituted (E) alkenes 59 in 
moderate yield over two steps (Scheme 4.14). Cycloelimination19b of dioxinones 59 in the 
presence of ammonium salt 9•HCl led to the formation of β-ketoamides 60 in good yield.  
  
                                                
(50)  (a) Jones, R.C.F.; Pillainayagam, T.A. Synlett 2004, 2815–2817; (b) Schlenk, A.; Diestel, R.; Sasse, F.; 
Schobert, R. Chem. Eur. J. 2010, 16, 2599–2604. 
(51)  Mulzer, J.; Schöllhorn, B. Angew. Chem., Int. Ed. 1990, 29, 431–432. 
(52)  We believe regioisomers are formed in this step due to the inconsequential 1,2-migration of the tert-
butyldimethylsilyl (TBS) group(s) at C28 and/or (less likely) C8. 
(53)  Selective oxidation of the C3 carbinol may also be achieved with TEMPO as catalytic oxidant, but we 
observed that aldehydes 58 were more prone to decomposition during workup. See: De Luca, L.; 
Giacomelli, G.; Porcheddu, A. Org. Lett. 2001, 3, 3041–3043. 
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Scheme 4.14. Synthesis of β-ketoamides 60. 
 
Reagents and conditions: (a) phosphonate 11, LDA, THF, –78 °C to 0 °C; HMPA, –78 °C; aldehydes 58, –78 °C 
to rt, E:Z > 95:05, 59% (2 steps); (b) 4 Å MS, PhMe, 110 °C, 69%. 
 Modified Lacey-Dieckmann cyclization14 of β-ketoamides 60 was then induced by 
potassium trimethylsilanolate and produced tetramic acids 61 without appreciable elimination 
of the C39 silyl ether (Scheme 4.15). Removal of the acetonide and silyl protecting groups25 
converged the isomer mixture of tetramic acids and completed the synthesis of AsA (1). The 
free tetramic acid was converted to its corresponding diethylammonium salt 1•Et2NH upon 
purification. 
 Spectroscopic data for diethylammonium tetramate 1•Et2NH was identical in all 
respects (1H-NMR, 13C-NMR, IR, HRMS) to those reported by the isolation group for the 
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naturally derived AsA salt.26 The optical rotation of the synthetic material ([α] D26  –2.8° (c = 
0.55, DMSO)) was also in agreement with that reported for the naturally derived sample    
([α] D19  –2.6° (c = 0.545, DMSO)). 
Scheme 4.15. Synthesis of the diethylamine salt of AsA (1•Et2NH). 
 
Reagents and conditions: (a) KOTMS, TMSOH, THF, 0 °C; (b) aq H2SiF6, MeCN, CH2Cl2, 0 °C to rt; Et2NH, 
MeOH, H2O, rt (purification), 36% (2 steps). 
 Herein we have described the asymmetric synthesis of aflastatin A (1) in 32 linear 
steps and 0.69% overall yield from methacrolein, and in 91 total steps from commercially 
available starting materials. Our synthesis features several complex diastereoselective 
fragment couplings, including an anti-Felkin-selective α-oxygenated aldol reaction, two trityl-
catalyzed Felkin-selective aldol additions, and two chelate-controlled/soft enolization-based 
aldol couplings. We hope our work involving oxygenated enolates, trityl catalysis, and soft 
enolization with magnesium clearly demonstrates the reliability of these methods in complex 
settings, as well as their potential applicability to the large-scale production of chiral building 
blocks for stereoselective organic synthesis. 
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IV. Graphical Summary of the Total Synthesis of Aflastatin A 
Synthesis of the C3–C26 Ketone 
Synthesis of C8–C15 Aldehyde 75 
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Synthesis of C3–C15 Aldehyde 9354,55 
 
  
                                                
(54)  Dunn, T.B. Synthesis of the C21–C40 Fragment of Azaspiracid-1. Ph.D. Thesis, Harvard University, 2005 
and references cited therein. 
(55)  (a) Ref. 54; (b) Rambaud, M.; Bakasse, M.; Duguay, G.; Villieras, J. Synthesis 1988, 564–566. 
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Synthesis of C16–C26 Enolsilane 11356 
  
                                                
(56)  (a) Chan, T.-H.; Brownbridge, P. J. Chem. Soc., Chem. Commun. 1979, 578–579; (b) Brownbridge, P.; 
Chan, T.-H.; Brook, M.A.; Kang, G.J. Can. J. Chem. 1983, 61, 688–693. 
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Synthesis of C3–C26 Ketone 40 
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Synthesis of the C27–C48 Aldehyde 
Synthesis of C36–C48 Ketone 53 
 
Synthesis of C27–C31 Aldehyde 45 
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Synthesis of C27–C48 Aldehyde 41 
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Alternative Synthesis of the C27–C48 Aldehyde 
Synthesis of C27–C35 Aldehyde 15657,58 
 
                                                
(57)  Hirth, G.; Walther, W. Helv. Chim. Acta 1985, 68, 1863–1871. 
(58)  Hubschwerlen, C.; Specklin, J.-L.; Higelin, J. Org. Synth. 1995, 72, 1–5. 
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Synthesis of C3–C48 Aldehydes 58 
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Syntheses of Dioxinone Phosphonate 11 and Ammonium Salt 9•HCl 
 
Synthesis of β-Ketoamides 60 
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Synthesis of Aflastatin A (1) and its Diethylamine Salt (1•Et2NH) 
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IV. Experimental Section 
Spectroscopic Data for Tetramic Acid Degradation Fragment 38•Et2NH 
 
Diethylammonium (1Z,2E,4S,6R)-1-((R)-1,5-dimethyl-2,4-dioxopyrrolidin-3-ylidene)-8-
hydroxy-2,4,6-trimethyloct-2-en-1-olate (38•Et2NH). White solid; 1H-NMR (600 MHz, 
CD3OD) δ 5.69 (d, J = 9.8 Hz, 1H, C3-H), 3.59 (ddd, J = 10.8, 6.6, 6.6 Hz, 1H, one of C8-H2), 
3.54 (ddd, J = 11.0, 6.7, 6.6 Hz, 1H, one of C8-H2), 3.46 (q, J = 6.7 Hz, 1H, C5'-H), 3.02 (q, J 
= 7.3 Hz, 4H, NCH2CH3), 2.85 (s, 3H, C7'-H3), 2.66–2.63 (m, 1H, C4-H), 1.83 (d, J = 1.2 Hz, 
3H, C9-H3), 1.71–1.68 (m, 1H, C6-H), 1.50–1.46 (m, J = 6.7, 6.6 Hz, 1H, one of C7-H2), 1.38–
1.31 (m, J = 7.0, 6.7 Hz, 2H, one of C5-H2, and one of C7-H2), 1.27 (t, J = 7.3 Hz, 6H, 
NCH2CH3), 1.26 (d, J = 7.3 Hz, 3H, C6'-H3), 1.12 (ddd, J = 13.3, 9.1, 4.4 Hz, 1H, one of C5-
H2), 0.99 (d, J = 6.6 Hz, 3H, C10-H3), 0.90 (d, J = 6.6 Hz, 3H, C11-H3); 13C-NMR (125 MHz, 
CD3OD) δ 196.0 (C4'), 195.7 (C1), 175.8 (C2'), 143.2 (C3), 137.0 (C2), 101.0 (C3'), 61.8 
(C5'), 60.9 (C8), 46.2 (C5), 43.4 (NCH2CH3), 41.8 (C7), 31.7 (C4), 28.3 (C6), 26.9 (C7'), 21.1 
(C10), 20.4 (C11), 16.3 (C6'), 13.6 (C9), 11.6 (NCH2CH3); HRMS (ESI-TOF) m/z calcd for 
C17H28NO4 [M+H]+: 310.2013, found: 310.2015. 
 
Synthesis of the C27–C35 Aldehyde 
 
(2S,3R,4R,5S,6S)-4,5-Bis(benzyloxy)-6-(iodomethyl)-2-methoxytetrahydro-2H-pyran-3-ol 
(127). To a solution of diol 42 (9.8 g, 26 mmol, 1.0 equiv), imidazole (5.4 g, 79 mmol, 3.0 
equiv), and triphenylphosphine (10.7 g, 40.7 mmol, 1.55 equiv) in 2:1 PhMe/MeCN (131 mL, 
0.2 M wrt 42) at rt was added iodine (10 g, 39 mmol, 1.5 equiv) in three portions. The 
reaction mixture was stirred at rt for 3 h, quenched with brine (100 mL), and then diluted with 
H2O (10 mL) and Et2O (50 mL). The layers were separated and the aqueous layer extracted 
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with Et2O (3 x 100 mL). The combined organic extracts were dried over Na2SO4 with added 
hexanes, filtered and concentrated. Column chromatography (gradient elution, 5:1 → 4:1 → 
3:1 hexanes/EtOAc) afforded iodide 127 (12.3 g, 97% yield) as a white solid. [α]
€ 
D
25  +95.4° (c 
= 2.3, CH2Cl2); IR (neat) 3424 (br), 3029, 2924, 1497, 1453, 1399, 1361, 1325, 1214, 1192, 
1140, 1087, 1046, 733, 696 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.39–7.30 (m, 10H, ArH), 
4.95 (d, J = 11.0 Hz, 1H, one of –OCH2Ph), 4.94 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.84 
(d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.78 (d, J = 3.8 Hz, 1H, C27-H), 4.72 (d, J = 11.0 Hz, 
1H, one of –OCH2Ph), 3.80 (dd, J = 9.2, 8.9 Hz, 1H, C29-H), 3.71 (ddd, J = 8.8, 8.6, 3.8 Hz, 
1H, C28-H), 3.51 (dd, J = 10.5, 2.6 Hz, 1H, one of C32-H), 3.48 (ddd, J = 9.1, 6.4, 2.6 Hz, 1H, 
C31-H), 3.48 (s, 3H, –OCH3), 3.36 (dd, J = 9.2, 8.9 Hz, 1H, C30-H), 3.32 (dd, J = 10.5, 6.3 Hz, 
1H, one of C32-H), 2.16 (d, J = 8.6 Hz, 1H, C28-OH); 13C-NMR (125 MHz, CDCl3) δ 138.4, 
137.9, 128.5, 128.5, 127.9, 127.9, 127.8, 99.3, 82.8, 81.2, 75.4, 75.3, 73.1, 69.7, 55.5, 7.3; 
HRMS (ESI-TOF) m/z calcd for C21H25INaO5 [M+Na]+: 507.06389, found: 507.06416. 
 
(((2S,3R,4S,5S,6S)-4,5-Bis(benzyloxy)-6-(iodomethyl)-2-methoxytetrahydro-2H-pyran-3-
yl)oxy)(tert-butyl)dimethylsilane (43). To a solution of carbinol 127 (12.3 g, 25.3 mmol, 1.0 
equiv) and imidazole (3.5 g, 51 mmol, 2.0 equiv) in CH2Cl2 (25 mL, 1.0 M wrt 127) at 0 °C 
was added tert-butylchlorodimethylsilane (5.7 g, 38 mmol, 1.5 equiv). The reaction mixture 
was stirred at 0 °C for 2 h, slowly warmed to rt over 2 h, stirred at rt for 8 h, quenched at 0 °C 
with brine (40 mL), and diluted with Et2O (150 mL) and H2O (20 mL). The layers were 
separated and the organic layer washed with 1:1 H2O/brine (2 x 50 mL), dried over Na2SO4 
with added hexanes, filtered and concentrated. Column chromatography (gradient elution, 3% 
→ 4% → 5% EtOAc in hexanes) afforded silyl ether 43 (15.2 g, quant. yield) as a clear, 
colorless oil. [α] D23  +56.1° (c = 2.9, CH2Cl2); IR (neat) 3064, 3032, 2929, 2857, 1455, 1360, 
1254, 1196, 1151, 1090, 1051, 1000, 862, 838, 778, 735, 698 cm–1; 1H-NMR (600 MHz, 
C6D6) δ 7.32 (m, 2H, ArH), 7.20–7.05 (m, 8H, ArH), 4.95 (d, J = 11.6 Hz, 1H, one of –
OCH2Ph), 4.85 (d, J = 11.3 Hz, 1H, one of –OCH2Ph), 4.74 (d, J = 11.6 Hz, 1H, one of –
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OCH2Ph), 4.57 (m, 1H, C27-H), 4.56 (d, J = 11.3 Hz, 1H, one of –OCH2Ph), 4.03 (ddd, J = 
9.1, 9.1, 2.2 Hz, 1H, C29-H), 3.77 (ddd, J = 9.4, 3.6, 1.8 Hz, 1H, C28-H), 3.47 (ddd, J = 6.6, 
2.3, 1.6 Hz, 1H, C31-H), 3.33 (dd, J = 9.2, 1.6 Hz, 1H, C30-H), 3.30 (dd, J = 10.5, 2.5 Hz, 1H, 
one of C32-H), 3.20 (s, 3H, –OCH3), 3.12 (dd, J = 10.6, 6.5 Hz, 1H, one of C32-H), 0.93 (s, 
9H, C(CH3)3), 0.03 (s, 3H, one of SiCH3), –0.02 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, 
C6D6) δ 139.4, 138.8, 128.5, 128.5, 128.4, 127.9, 127.8, 127.5, 127.5, 100.5, 82.5, 82.1, 75.5, 
75.2, 74.6, 70.0, 55.3, 25.9, 18.2, 8.0, –4.5, –4.6; HRMS (ESI-TOF) m/z calcd for 
C27H39INaO5Si [M+Na]+: 621.15036, found: 621.14896. 
 
(2S,3S,4R)-3,4-Bis(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-1-ol (44). To a 
solution of iodide 43 (3.7 g, 6.2 mmol, 1.0 equiv) in 9:1 THF/H2O (77 mL, 0.08 M wrt 43) at 
rt was added preactivated zinc dust59 (4.0 g, 62 mmol, 10 equiv). The reaction mixture was 
sonicated at 40–45 °C for 3 h, then cooled to 0 °C and charged with sodium borohydride (0.77 
g, 20 mmol, 3.3 equiv) in six portions over 1 h. The resulting suspension was stirred at 0 °C 
for an additional 15 min, slowly quenched with 1 M NaHSO4 (40 mL), diluted with Et2O (40 
mL), warmed to rt, and filtered through Celite. The filter cake was rinsed with Et2O (3 x 50 
mL) and sat. aq NH4Cl (3 x 50 mL). The layers were separated and the aqueous layer 
extracted with Et2O (3 x 150 mL). The combined organic extracts were dried over Na2SO4 
with added hexanes, filtered and concentrated. Column chromatography (gradient elution, 6% 
→ 7% → 8% → 9% EtOAc in hexanes) afforded carbinol 44 (2.4 g, 88% yield) as a clear, 
colorless oil. [α] D23  –12.1° (c = 1.1, CH2Cl2); IR (neat) 3466 (br), 3072, 3032, 2931, 2861, 
1461, 1396, 1361, 1253, 1209, 1055, 928, 834, 776, 735, 697 cm–1; 1H-NMR (600 MHz, 
CDCl3) δ 7.36–7.28 (m, 10H, two of ArH), 5.94 (ddd, J = 17.4, 10.4, 7.3 Hz, 1H, C31-H), 5.31 
(dd, J = 17.4, 0.8 Hz, 1H, one of C32-H), 5.29 (dd, J = 10.5, 0.8 Hz, 1H, one of C32-H), 4.71 
(d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.68 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.64 (d, J 
= 11.7 Hz, 1H, one of –OCH2Ph), 4.38 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.09 (ddd, J = 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(59)  Hyldtoft, L.; Madsen, R. J. Am. Chem. Soc. 2000, 122, 8444–8452. 
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7.3, 3.8, 0.7 Hz, 1H, C30-H), 3.76 (ddd, J = 5.7, 4.8, 4.5 Hz, 1H, C28-H), 3.67 (ddd, J = 11.7, 
5.7, 5.2 Hz, 1H, one of C27-H), 3.59 (ddd, J = 11.7, 7.5, 4.2 Hz, 1H, one of C27-H), 3.52 (dd, J 
= 5.9, 3.9 Hz, 1H, C29-H), 2.37 (dd, J = 7.3, 5.8 Hz, 1H, C27-OH), 0.88 (s, 9H, C(CH3)3), 0.05 
(s, 3H, one of SiCH3), 0.01 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, CDCl3) δ 138.3, 
137.9, 135.7, 128.3, 128.3, 128.1, 128.1, 127.6, 118.1, 82.6, 79.3, 74.3, 72.6, 70.6, 64.0, 25.8, 
18.0, –4.7, –4.7; HRMS (ESI-TOF) m/z calcd for C26H38NaO4Si [M+Na]+: 465.24316, found: 
465.24360. 
 
(S)-5-((1S,2R)-1,2-Bis(benzyloxy)but-3-en-1-yl)-8,8-diethyl-2,2,3,3-tetramethyl-4,7-dioxa-
3,8-disiladecane (128). To a solution of carbinol 44 (6.0 g, 14 mmol, 1.0 equiv) and 
imidazole (1.4 g, 20 mmol, 1.5 equiv) in CH2Cl2 (14 mL, 1.0 M wrt 44) at 0 °C was added 
chlorotriethylsilane (2.7 mL, 16 mmol, 1.2 equiv). The reaction mixture was stirred at 0 °C 
for 2 h, slowly warmed to rt over 2 h, stirred at rt for 7 h, quenched at 0 °C with sat. aq NH4Cl 
(50 mL), and diluted with 1:1 hexanes/Et2O (150 mL) and H2O (10 mL). The layers were 
separated and the organic layer washed sequentially with sat. aq NH4Cl and 1:1 H2O/brine (50 
mL each), dried over Na2SO4, filtered and concentrated. Column chromatography (gradient 
elution, 2% → 2.5% → 3% EtOAc in hexanes) afforded silyl ether 128 (7.4 g, 98% yield) as a 
clear, colorless oil. [α] D24  –12.9° (c = 2.3, CH2Cl2); IR (neat) 3066, 3031, 2955, 2934, 2877, 
1455, 1251, 1087, 1005, 961, 928, 836, 808, 777, 731, 697 cm–1; 1H-NMR (600 MHz, CDCl3) 
δ 7.37–7.27 (m, 10H, two of ArH), 5.92 (ddd, J = 17.3, 10.4, 7.6 Hz, 1H, C31-H), 5.30 (dd, J 
= 17.4, 0.8 Hz, 1H, one of C32-H), 5.27 (m, J = 10.4 Hz, 1H, one of C32-H), 4.77 (d, J = 11.7 
Hz, 1H, one of –OCH2Ph), 4.68 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.63 (d, J = 11.7 Hz, 
1H, one of –OCH2Ph), 4.38 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.13 (dd, J = 7.5, 5.0 Hz, 
1H, C30-H), 3.86 (ddd, J = 6.7, 4.4, 4.0 Hz, 1H, C28-H), 3.79 (dd, J = 10.4, 3.8 Hz, 1H, one of 
C27-H), 3.60 (dd, J = 10.4, 6.7 Hz, 1H, one of C27-H), 3.49 (dd, J = 4.7, 4.7 Hz, 1H, C29-H), 
0.95 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.87 (s, 9H, C(CH3)3), 0.58 (q, J = 7.9 Hz, 6H, –
SiCH2CH3), 0.05 (s, 3H, one of SiCH3), –0.01 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, 
OBn
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CDCl3) δ 138.9, 138.4, 136.4, 128.2, 128.1, 128.1, 128.1, 127.4, 127.4, 117.8, 82.3, 79.9, 
74.2, 74.2, 70.7, 64.3, 25.9, 18.1, 6.8, 4.4 –4.1, –4.9; HRMS (ESI-TOF) m/z calcd for 
C32H52NaO4Si2 [M+Na]+: 579.32963, found: 579.33115. 
 
(2S,3S,4S)-2,3-Bis(benzyloxy)-4-((tert-butyldimethylsilyl)oxy)-5-
((triethylsilyl)oxy)pentanal (45). To a solution of alkene 128 (7.4 g, 13 mmol, 1.0 equiv) in 
1:1 CH2Cl2/MeOH (0.27 L, 0.05 M wrt 128) at –78 °C was added pyridine (11 mL, 0.13 mol, 
10 equiv). The reaction mixture was bubbled with ozone until it turned blue, purged with 
oxygen until the color faded, quenched dropwise with a solution of triphenylphosphine (4.2 g, 
16 mmol, 1.2 equiv) in 1:1 CH2Cl2/MeOH (66 mL, 0.24 M wrt PPh3), slowly warmed to rt 
over 1.5 h, stirred at rt for 9 h, concentrated, and azeotroped with PhH (2 x 50 mL). Column 
chromatography (gradient elution, 2% → 3% → 4% EtOAc in hexanes) afforded aldehyde 45 
(6.9 g, 94% yield) as a clear, colorless oil. [α] D21  –25.6° (c = 3.0, CH2Cl2); IR (neat) 3065, 
3032, 2954, 2933, 2878, 1733 (s), 1456, 1362, 1252, 1121, 1088, 1006, 959, 837, 779, 734, 
698 cm–1; 1H-NMR (600 MHz, CDCl3) δ 9.68 (d, J = 1.8 Hz, 1H, C31-H), 7.36–7.28 (m, 10H, 
ArH), 4.72 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.65 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.63 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.55 (d, J = 11.8 Hz, 1H, one of –
OCH2Ph), 4.09 (dd, J = 4.7, 1.2 Hz, 1H, C30-H), 3.91 (ddd, J = 6.5, 5.3, 3.5 Hz, 1H, C28-H), 
3.83 (dd, J = 10.6, 3.5 Hz, 1H, one of C27-H), 3.81 (dd, J = 5.3, 4.7 Hz, 1H, C29-H), 3.67 (dd, 
J = 10.6, 6.5 Hz, 1H, one of C27-H), 0.96 (t, J = 8.2 Hz, 9H, –SiCH2CH3), 0.86 (s, 9H, 
C(CH3)3), 0.59 (q, J = 8.2 Hz, 6H, –SiCH2CH3), 0.04 (s, 3H, one of SiCH3), –0.01 (s, 3H, one 
of SiCH3); 13C-NMR (125 MHz, CDCl3) δ 202.0, 137.8, 137.2, 128.4, 128.33, 128.27, 128.1, 
128.0, 127.8, 83.4, 80.1, 73.9, 73.25, 73.18, 63.6, 25.8, 18.0, 6.8, 4.3, –4.5, –5.0; HRMS (ESI-
TOF) m/z calcd for C31H50KO5Si2 [M+K]+: 597.28284, found: 597.28060. 
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(4S,5R,6S,7S)-5,6-Bis(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-8-((triethylsilyl)oxy)oct-
1-en-4-ol (46). To a solution of aldehyde 45 (6.9 g, 12 mmol, 1.0 equiv) in CH2Cl2 (0.25 L, 
0.05 M wrt 45) at 0 °C was added a freshly prepared solution of MgBr2•OEt2 in 2:1 
Et2O/PhMe (74 mL, 0.67 M, 50 mmol, 4.0 equiv). The reaction mixture was stirred at 0 °C for 
5 min, cooled to –78 °C, and then charged dropwise with a freshly prepared60 solution of 
allylmagnesium bromide in Et2O (44 mL, 0.42 M, 19 mmol, 1.5 equiv). The reaction mixture 
was stirred at –78 °C for 2 h, charged with additional allylmagnesium bromide (15 mL, 0.42 
M in Et2O, 6.2 mmol, 0.5 equiv), stirred at –78 °C for an additional 1.5 h, then briefly warmed 
to 0 °C and quenched with sat. aq NH4Cl (100 mL). The biphasic mixture was diluted with 
H2O (50 mL) and CH2Cl2 (50 mL) and warmed to rt. The layers were separated and the 
aqueous layer extracted with CH2Cl2 (2 x 150 mL). The combined organic extracts were dried 
over Na2SO4, filtered and concentrated. The residue was analyzed by 1H-NMR spectroscopy 
to assess reaction diastereoselectivity (d.r. ≥ 95:05). Column chromatography (gradient 
elution, 3% → 4% → 5% EtOAc in hexanes) afforded homoallylic carbinol 46 (6.9 g, 92% 
yield) as a clear, colorless oil. [α] D22  –11.8° (c = 1.4, CH2Cl2); IR (neat) 3452 (br), 3067, 
3032, 2955, 2879, 1459, 1412, 1362, 1252, 1093, 1006, 917, 837, 808, 777, 733, 698 cm–1; 
1H-NMR (600 MHz, C6D6) δ 7.32 (m, J = 7.6 Hz, 2H, two of ArH), 7.28 (m, J = 7.6 Hz, 2H, 
two of ArH), 7.16–7.13 (m, 4H, four of ArH), 7.10–7.05 (m, J = 7.6, 7.1 Hz, 2H, two of 
ArH), 5.94 (dddd, J = 17.0, 10.6, 7.7, 6.5 Hz, 1H, C33-H), 5.07 (ddd, J = 15.9, 1.8, 1.1 Hz, 
1H, one of C33a-H), 5.05 (d, J = 10.5 Hz, 1H, one of C33a-H), 4.88 (d, J = 11.2 Hz, 1H, one of 
–OCH2Ph), 4.73 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.68 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.58 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.14 (ddd, J = 7.0, 4.1, 4.1 Hz, 1H, 
C28-H), 4.04 (dd, J = 10.3, 4.1 Hz, 1H, one of C27-H), 4.02 (dddd, J = 8.2, 6.5, 5.9, 2.3 Hz, 
1H, C31-H), 4.00 (dd, J = 7.3, 4.1 Hz, 1H, C29-H), 3.84 (dd, J = 10.3, 7.1 Hz, 1H, one of C27-
H), 3.78 (dd, J = 7.3, 2.3 Hz, 1H, C30-H), 2.44 (ddddd, J = 14.1, 6.5, 6.5, 1.8, 1.2 Hz, 1H, one 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(60)  Benson, R.E.; McKusick, B.C. Org. Synth. 1958, 38, 78–84. 
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of C32-H), 2.36 (ddddd, J = 14.1, 7.7, 6.4, 1.2, 1.2 Hz, 1H, one of C32-H), 2.24 (d, J = 8.8 Hz, 
1H, C28-OH), 1.03 (s, 9H, C(CH3)3), 1.00 (t, J = 8.2 Hz, 9H, –SiCH2CH3), 0.60 (q, J = 8.2 Hz, 
6H, –SiCH2CH3), 0.20 (s, 3H, one of SiCH3), 0.13 (s, 3H, one of SiCH3); 13C-NMR (125 
MHz, C6D6) δ 139.3, 139.2, 135.9, 128.5, 128.3, 128.1, 127.9, 127.7, 117.1, 81.2, 80.8, 75.1, 
74.8, 74.5, 71.2, 64.6, 39.7, 26.2, 18.5, 7.1, 4.8, –3.8, –4.5; HRMS (ESI-TOF) m/z calcd for 
C34H56NaO5Si2 [M+Na]+: 623.35585, found: 623.35554. 
 
(4S,5R,6S,7S)-5,6-Bis(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-8-((triethylsilyl)oxy)oct-
1-en-4-yl acrylate (132). To a solution of homoallylic carbinol 46 (1.2 g, 2.0 mmol, 1.0 
equiv) in THF (9.8 mL, 0.2 M wrt 46) at room temperature was added EtN(iPr)2 (1.4 mL, 7.8 
mmol, 4.0 equiv), DMAP (60 mg, 0.49 mmol, 0.25 equiv), and a freshly prepared solution of 
acrylic pivalic anhydride in PhH (2.9 mL, 2.0 M, 5.9 mmol, 3.0 equiv). The resulting 
suspension was stirred at room temperature for 12 h, then charged with additional EtN(iPr)2 
(1.4 mL, 7.8 mmol, 4.0 equiv), DMAP (60 mg, 0.49 mmol, 0.25 equiv), and acrylic pivalic 
anhydride (2.9 mL, 2.0 M, 5.9 mmol, 3.0 equiv). The reaction mixture was stirred for an 
additional 9 h, quenched with sat. aq NaHCO3 (20 mL), and diluted with 1:1 hexanes/Et2O (80 
mL) and H2O (5 mL). The layers were separated and the aqueous layer extracted with 1:1 
hexanes/Et2O (2 x 75 mL). The combined organic extracts were dried over Na2SO4 with added 
hexanes, filtered and concentrated. Column chromatography (gradient elution, 1% → 1.5% 
EtOAc in hexanes) afforded acrylate ester 132 (1.3 g, 98% yield) as a clear, colorless oil. [α]
D
22  –17.4° (c = 2.3, CH2Cl2); IR (neat) 3066, 3032, 2954, 2880, 1726 (s), 1638, 1460, 1406, 
1359, 1295, 1260, 1190, 1089, 1008, 921, 837, 807, 777, 734, 698 cm–1; 1H-NMR (600 MHz, 
CDCl3) δ 7.37–7.26 (m, 10H, ArH), 6.41 (dd, J = 17.3, 1.5 Hz, 1H, one of C34a-H), 6.16 (dd, J 
= 17.3, 10.2 Hz, 1H, C34-H), 5.81 (dd, J = 10.2, 1.5 Hz, 1H, one of C34a-H), 5.67 (dddd, J = 
17.0, 10.0, 7.7, 7.0 Hz, 1H, C33-H), 5.25 (ddd, J = 7.1, 5.3, 4.1 Hz, 1H, C31-H), 5.00 (m, J = 
1.2 Hz, 2H, C33a-H2), 4.79 (d, J = 11.2 Hz, 1H, one of –OCH2Ph), 4.75 (d, J = 11.7 Hz, 1H, 
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one of –OCH2Ph), 4.72 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.67 (d, J = 11.1 Hz, 1H, one 
of –OCH2Ph), 3.92 (dd, J = 5.9, 4.1 Hz, 1H, C30-H), 3.90 (ddd, J = 6.5, 5.3, 3.5 Hz, 1H, C28-
H), 3.77 (dd, J = 10.0, 5.3 Hz, 1H, one of C27-H), 3.72 (dd, J = 5.9, 3.5 Hz, 1H, C29-H), 3.55 
(dd, J = 10.0, 6.5 Hz, 1H, one of C27-H), 2.41–2.33 (m, J = 14.1, 7.6, 7.1, 7.0, 5.3, 1.1 Hz, 2H, 
C32-H2), 0.91 (s, 9H, C(CH3)3), 0.90 (t, J = 8.2 Hz, 9H, –SiCH2CH3), 0.52 (q, J = 8.2 Hz, 6H, 
–SiCH2CH3), 0.11 (s, 3H, one of SiCH3), 0.09 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, 
CDCl3) δ 165.6, 138.7, 138.4, 133.7, 130.8, 128.5, 128.3, 128.2, 127.9, 127.54, 127.47, 117.8, 
78.7, 78.3, 74.6, 73.8, 73.3, 72.9, 63.7, 35.6, 26.0, 18.2, 6.8, 4.3, –3.9, –4.7; HRMS (ESI-
TOF) m/z calcd for C37H59O6Si2 [M+H]+: 655.3845, found: 655.3819. 
 
(S)-6-((1R,2S,3S)-1,2-Bis(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-4-
((triethylsilyl)oxy)butyl)-5,6-dihydro-2H-pyran-2-one (47). To a degassed solution of diene 
132 (1.3 g, 1.9 mmol, 1.0 equiv) in PhH (0.13 L, 0.015 M wrt 132) at room temperature was 
added ruthenium catalyst 166 (79 mg, 96 µmol, 0.05 equiv). The reaction mixture was purged 
with argon for 5 min, stirred at 65 °C for 8 h, then recharged with additional catalyst (79 mg, 
96 µmol, 0.05 equiv) at this time and approximately every 12 h thrice after (total catalyst 166 
added: 0.25 equiv). The reaction mixture was stirred at 65 °C for an additional 8 h, cooled to 
room temperature, concentrated to half volume, diluted with 9:1 hexanes/EtOAc (0.13 L) and 
filtered through a silica gel plug (4 cm). The filter cake was rinsed with 9:1 hexanes/EtOAc 
(0.5 L), and the filtrate concentrated. Column chromatography (gradient elution, 9:1 → 8:1 → 
7:1 hexanes/EtOAc) afforded lactone 47 (0.83 g, 69% yield) as a pale brown oil contaminated 
with ruthenium-based impurities (<5%). A sufficient quantity of this material was repurified 
by column chromatography to produce a clear, colorless oil for characterization. [α] D22  –59.8° 
(c = 2.3, CH2Cl2); IR (neat) 3064, 3032, 2954, 2885, 1733 (s), 1496, 1460, 1384, 1248, 1089, 
957, 837, 813, 778, 738, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.36–7.26 (m, 10H, ArH), 
6.71 (ddd, J = 9.4, 6.4, 2.3 Hz, 1H, C33-H), 5.95 (dd, J = 9.4, 2.3 Hz, 1H, C34-H), 4.81 (d, J = 
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11.7 Hz, 1H, one of –OCH2Ph), 4.77 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.71 (d, J = 11.8 
Hz, 1H, one of –OCH2Ph), 4.70 (ddd, J = 12.9, 4.1, 4.1 Hz, 1H, C31-H), 4.68 (d, J = 11.7 Hz, 
1H, one of –OCH2Ph), 3.97 (ddd, J = 5.9, 4.1, 3.6 Hz, 1H, C28-H), 3.86 (dd, J = 5.9, 4.1 Hz, 
1H, C29-H), 3.84 (dd, J = 5.9, 4.1 Hz, 1H, C30-H), 3.74 (dd, J = 10.6, 3.5 Hz, 1H, one of C27-
H), 3.64 (dd, J = 10.6, 5.9 Hz, 1H, one of C27-H), 2.39 (dddd, J = 18.2, 12.9, 2.4, 2.3 Hz, 1H, 
one of C32-H), 1.82 (ddd, J = 18.2, 6.5, 4.1 Hz, 1H, one of C32-H), 0.94 (t, J = 8.0 Hz, 9H, –
SiCH2CH3), 0.89 (s, 9H, C(CH3)3), 0.57 (q, J = 8.0 Hz, 6H, –SiCH2CH3), 0.08 (s, 3H, one of 
SiCH3), 0.05 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, CDCl3) δ 163.8, 145.2, 138.3, 
138.2, 128.4, 128.3, 128.2, 127.7, 127.6, 121.0, 78.6, 78.4, 78.2, 75.0, 73.7, 73.5, 64.1, 25.9, 
25.8, 18.1, 6.8, 4.3, –4.3, –4.7; HRMS (ESI-TOF) m/z calcd for C35H55O6Si2 [M+H]+: 
627.3532, found: 627.3526. 
 
(3R,4R,6S)-6-((1R,2S,3S)-1,2-Bis(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-4-
hydroxybutyl)-3,4-dihydroxytetrahydro-2H-pyran-2-one (48). To a bright yellow 
suspension of NaIO4 (0.76 g, 3.5 mmol, 1.5 equiv) and CeCl3•7H2O (88 mg, 0.24 mmol, 0.1 
equiv) in deionized H2O (1.1 mL, 3⅓ M wrt NaIO4) at 0 °C was added EtOAc (3.0 mL, 1.2 M 
wrt NaIO4), MeCN (3.5 mL, 1.0 M wrt NaIO4), and an aqueous solution of RuCl3 (0.12 mL, 
0.1 M, 12 µmol, 0.005 equiv). The bilayer suspension was stirred at 0 °C for 2 min, then 
charged slowly dropwise with a solution of unsaturated lactone 47 (1.5 g, 2.4 mmol, 1.0 
equiv) in EtOAc (3.0 mL, 0.5 M overall wrt 47) over 1 min (with 1.0 mL and 0.7 mL rinses). 
The reaction mixture was vigorously stirred at 0 °C for 40 min, charged with Na2SO4 (2.4 g), 
then filtered through Na2SO4 with EtOAc rinses (0.3 L total) into a separatory funnel 
containing sat. aq Na2SO3 (50 mL) and 1:1 H2O/brine (100 mL). The layers were separated 
and the aqueous layer extracted with EtOAc (4 x 0.1 L). The combined organic extracts were 
dried over Na2SO4 with added hexanes (0.18 L) and filtered through a silica gel plug (4 cm). 
The filter cake was rinsed with 4:1 hexanes/EtOAc (0.25 L), then 1:2 hexanes/EtOAc (1 L), 
and the latter filtrate concentrated to afford crude triol 48 as a pale yellow solid contaminated 
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with aldehyde byproduct (~9%). [α]
€ 
D
24  –0.06° (c = 2.3, CH2Cl2); IR (neat) 3444 (br), 3065, 
3032, 2954, 2930, 2883, 2858, 1735 (s), 1497, 1455, 1390, 1362, 1253, 1200, 1115, 1048, 
938, 837, 779, 735, 698 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.35–7.28 (m, 10H, ArH), 5.07 
(ddd, J = 11.7, 4.1, 1.7 Hz, 1H, C31-H), 4.94 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.77 (d, J 
= 11.7 Hz, 1H, one of –OCH2Ph), 4.67 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.58 (d, J = 
11.8 Hz, 1H, one of –OCH2Ph), 4.26 (m, 1H, C33-H), 4.03 (m, J = 2.9 Hz, 1H, C34-H), 3.99 
(dd, J = 8.2, 4.1 Hz, 1H, C29-H), 3.92 (ddd, J = 4.7, 4.1, 4.1 Hz, 1H, C28-H), 3.77 (ddd, J = 
11.1, 7.6, 3.5 Hz, 1H, one of C27-H), 3.73 (dd, J = 8.2, 1.7 Hz, 1H, C30-H), 3.71 (ddd, J = 
11.1, 4.7, 4.7 Hz, 1H, one of C27-H), 3.40 (s, 1H, C34-OH), 2.64 (s, 1H, C33-OH), 2.10 (dd, J = 
7.6, 4.7 Hz, 1H, C27-OH), 2.08 (dddd, J = 14.1, 11.7, 2.4, 2.3 Hz, 1H, one of C32-H), 1.90 
(ddd, J = 14.0, 4.1, 4.1 Hz, 1H, one of C32-H), 0.88 (s, 9H, C(CH3)3), 0.06 (s, 6H, Si(CH3)2); 
13C-NMR (125 MHz, CDCl3) δ 173.7, 138.1, 137.9, 128.4, 128.1, 128.0, 127.8, 127.7, 79.8, 
79.4, 76.9, 75.3, 74.4, 72.1, 70.5, 66.1, 63.1, 30.0, 25.8, 18.0, –4.8, –4.9; HRMS (ESI-TOF) 
m/z calcd for C29H42NaO8Si [M+Na]+: 569.2541, found: 569.2558. 
 
(3aR,6S,7aR)-6-((1R,2S,3S)-1,2-Bis(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-4-((2-
methoxypropan-2-yl)oxy)butyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyran-
4(6H)-one (49). To a solution of crude triol 48 (theoretical 1.3 g, 2.4 mmol, 1.0 equiv) in 2:1 
acetone/2,2-dimethoxypropane (47 mL, 0.05 M wrt 48) at rt was added PPTS (59 mg, 0.24 
mmol, 0.1 equiv). The reaction mixture was stirred at 35 °C for 12 h, quenched with NaHCO3 
(s) (~0.1 g), stirred vigorously for an additional 30 min at rt, and filtered through Celite. The 
filter cake was rinsed with EtOAc (75 mL total), and the filtrate concentrated. Column 
chromatography (gradient elution, 18% → 20% → 25% EtOAc in hexanes) afforded 
acetonide 49 (1.0 g, 65% yield, two steps) as a clear, colorless oil. [α] D24  +2.2° (c = 2.1, 
CH2Cl2); IR (neat) 3062, 3030, 2988, 2934, 2893, 2858, 1751 (s), 1459, 1377, 1261, 1211, 
1156, 1114, 1077, 1049, 930, 834, 779, 738, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.35–
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7.26 (m, 10H, ArH), 4.92 (ddd, J = 10.6, 2.9, 2.4 Hz, 1H, C31-H), 4.87 (d, J = 11.1 Hz, 1H, 
one of –OCH2Ph), 4.74 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.68 (d, J = 11.8 Hz, 1H, one 
of –OCH2Ph), 4.63 (d, J = 11.2 Hz, 1H, one of –OCH2Ph), 4.55 (ddd, J = 7.0, 4.1, 3.5 Hz, 1H, 
C33-H), 4.50 (d, J = 7.1 Hz, 1H, C34-H), 4.01 (ddd, J = 6.4, 4.1, 3.5 Hz, 1H, C28-H), 3.92 (dd, 
J = 7.1, 4.1 Hz, 1H, C29-H), 3.80 (dd, J = 7.1, 2.9 Hz, 1H, C30-H), 3.60 (dd, J = 10.0, 3.5 Hz, 
1H, one of C27-H), 3.50 (dd, J = 10.0, 6.5 Hz, 1H, one of C27-H), 3.18 (s, 3H, –OCH3), 2.01 
(ddd, J = 14.6, 10.5, 4.1 Hz, 1H, one of C32-H), 1.75 (ddd, J = 14.7, 2.9, 2.4 Hz, 1H, one of 
C32-H), 1.46 (s, 3H, one of CH3), 1.32 (s, 3H, one of CH3), 1.31 (s, 6H, two of CH3), 0.89 (s, 
9H, C(CH3)3), 0.09 (s, 3H, one of Si(CH3)2), 0.05 (s, 3H, one of Si(CH3)2); 13C-NMR (125 
MHz, CDCl3) δ 167.9, 138.4, 138.0, 128.4, 128.3, 128.2, 127.8, 127.7, 127.6, 110.4, 99.9, 
80.0, 79.3, 75.2, 74.8, 74.0, 72.8, 72.1, 71.5, 62.0, 48.6, 30.4, 26.1, 26.0, 24.42, 24.40, 23.8, 
18.3, –4.3, –4.8; HRMS (ESI-TOF) m/z calcd for C36H54NaO9Si [M+Na]+: 681.3429, found: 
681.3412. 
 
(2S,3R,4S,5S)-3,4-Bis(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-1-((4R,5S)-5-
(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-6-((2-methoxypropan-2-yl)oxy)hexan-
2-ol (50). To a solution of lactone 49 (1.0 g, 1.5 mmol, 1.0 equiv) in THF (15 mL, 0.10 M wrt 
49) at 0 °C was added H2O (44 µL, 2.5 mmol, 1.6 equiv) and LiBH4 (50 mg, 1.1 mmol, 1.5 
equiv). The reaction mixture was slowly warmed to rt o/n (12 h total stir time), then recooled 
to 0 °C, quenched with 1 M aq NaOH (15 mL), stirred vigorously at rt for 1 h, and diluted 
with Et2O (75 mL). The layers were separated and the organic layer washed sequentially with 
H2O and brine (10 mL each). The combined aqueous layers were extracted with Et2O (3 x 50 
mL), and the combined organic extracts were dried over Na2SO4 with added hexanes, filtered 
and concentrated. Column chromatography (gradient elution, 5:2 → 2:1 → 3:2 
hexanes/EtOAc + 1% Et3N) afforded diol 50 (0.92 g, 91% yield) as a clear, colorless oil. [α]
€ 
D
23  –7.8° (c = 2.3, CH2Cl2); IR (neat) 3456 (br), 3060, 3029, 2987, 2934, 2883, 1460, 1374, 
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1252, 1215, 1078, 1051, 835, 778, 738, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.37–7.26 
(m, 10H, ArH), 4.84 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.75 (d, J = 11.7 Hz, 1H, one of 
–OCH2Ph), 4.68 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.62 (d, J = 11.2 Hz, 1H, one of –
OCH2Ph), 4.14 (ddd, J = 9.3, 5.9, 4.7 Hz, 1H, C33-H), 4.03 (ddd, J = 7.1, 5.9, 4.7 Hz, 1H, C34-
H), 4.02 (ddd, J = 7.6, 4.1, 3.5 Hz, 1H, C28-H), 3.98 (dddd, J = 8.8, 4.7, 4.1, 2.9 Hz, 1H, C31-
H), 3.82 (dd, J = 7.1, 4.1 Hz, 1H, C29-H), 3.63 (dd, J = 10.0, 3.0 Hz, 1H, one of C27-H), 3.62 
(dd, J = 7.6, 2.9 Hz, 1H, C30-H), 3.47 (ddd, J = 11.2, 7.1, 4.1 Hz, 1H, one of C35-H), 3.44 (dd, 
J = 10.0, 7.6 Hz, 1H, one of C27-H), 3.42 (ddd, J = 11.2, 7.6, 4.7 Hz, 1H, one of C35-H), 3.17 
(s, 3H, –OCH3), 3.07 (d, J = 4.7 Hz, 1H, C31-OH), 1.90 (dd, J = 7.6, 4.1 Hz, 1H, C35-OH), 
1.78 (ddd, J = 14.0, 9.4, 8.8 Hz, 1H, one of C32-H), 1.49 (ddd, J = 14.1, 4.2, 4.1 Hz, 1H, one 
of C32-H), 1.44 (s, 3H, one of CH3), 1.32 (s, 3H, one of CH3), 1.31 (s, 3H, one of CH3), 1.30 
(s, 3H, one of CH3), 0.89 (s, 9H, C(CH3)3), 0.09 (s, 3H, one of Si(CH3)2), 0.04 (s, 3H, one of 
Si(CH3)2); 13C-NMR (125 MHz, CDCl3) δ 138.6, 138.4, 128.5, 128.31, 128.30, 128.0, 127.7, 
127.6, 108.3, 99.9, 80.4, 80.0, 77.8, 75.6, 74.7, 73.9, 72.4, 69.8, 62.0, 61.5, 48.4, 32.3, 28.1, 
25.9, 25.4, 24.4, 24.4, 18.2, –4.3, –4.8; HRMS (ESI-TOF) m/z calcd for C36H58NaO9Si 
[M+Na]+: 685.3742, found: 685.3736. 
 
(2S,3R,4S,5S)-3,4-Bis(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-1-((4R,5S)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-6-((2-methoxypropan-2-
yl)oxy)hexan-2-ol (133). To a solution of diol 50 (1.7 g, 2.6 mmol, 1.0 equiv) and imidazole 
(0.26 g, 3.8 mmol, 1.5 equiv) in DMF (13 mL, 0.20 M wrt 50) at 0 °C was added tert-
butylchlorodiphenylsilane (0.80 mL, 3.1 mmol, 1.2 equiv). The reaction mixture was stirred at 
0 °C for 6 h, quenched with sat. aq NaHCO3 (25 mL), and diluted with 1:1 hexanes/Et2O (0.1 
L) and H2O (15 mL). The layers were separated and the aqueous layer extracted with 1:1 
hexanes/Et2O (3 x 75 mL). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated. Column chromatography (gradient elution, 9% → 10% → 12% EtOAc in 
hexanes) afforded silyl ether 133 (2.1 g, 92% yield) as a clear, colorless oil. [α] D23  +0.21° (c = 
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2.9, CH2Cl2); IR (neat) 3543 (br), 3062, 3031, 2990, 2932, 2888, 2857, 1468, 1430, 1370, 
1251, 1214, 1112, 1082, 1056, 831, 777, 737, 701 cm–1; 1H-NMR (600 MHz, C6D6) δ 7.78–
7.72 (m, J = 3.5 Hz, 4H, ArH), 7.31 (m, J = 7.0, 5.3 Hz, 4H, ArH), 7.21–7.18 (m, J = 6.5, 4.1 
Hz, 6H, ArH), 7.11 (m, J = 7.0, 1.2 Hz, 4H, ArH), 7.04 (m, J = 7.6, 1.2 Hz, 2H, ArH), 4.88 
(d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.74 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.68 (d, J 
= 11.7 Hz, 1H, one of –OCH2Ph), 4.66 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.39 (dddd, J = 
11.4, 4.7, 4.7, 2.9 Hz, 1H, C31-H), 4.34 (ddd, J = 7.6, 3.5, 3.5 Hz, 1H, C34-H), 4.20 (ddd, J = 
8.2, 5.9, 2.3 Hz, 1H, C33-H), 4.19–4.14 (m, J = 7.0, 5.9, 2.9 Hz, 2H, C28-H and C29-H), 3.97 
(dd, J = 10.0, 3.5 Hz, 1H, one of C35-H), 3.89 (dd, J = 7.0, 2.9 Hz, 1H, C30-H), 3.81 (dd, J = 
10.6, 5.9 Hz, 1H, one of C27-H), 3.78 (dd, J = 11.1, 7.0 Hz, 1H, one of C27-H), 3.73 (dd, J = 
10.0, 7.6 Hz, 1H, one of C35-H), 3.17 (d, J = 4.7 Hz, 1H, C31-OH), 3.14 (s, 3H, –OCH3), 2.13 
(ddd, J = 14.1, 11.2, 8.2 Hz, 1H, one of C32-H), 1.95 (ddd, J = 14.1, 4.7, 2.3 Hz, 1H, one of 
C32-H), 1.34 (s, 3H, one of CH3), 1.31 (s, 3H, one of CH3), 1.29 (s, 3H, one of CH3), 1.21 (s, 
3H, one of CH3), 1.13 (s, 9H, C(CH3)3), 1.08 (s, 9H, C(CH3)3), 0.24 (s, 3H, one of Si(CH3)2), 
0.21 (s, 3H, one of Si(CH3)2); 13C-NMR (125 MHz, C6D6) δ 139.5, 139.4, 136.0, 135.9, 133.8, 
133.7, 130.1, 130.0, 128.5, 128.3, 128.14, 128.12, 128.09, 128.06, 127.9, 127.61, 127.59, 
108.5, 100.1, 80.9, 80.5, 78.5, 77.0, 74.7, 74.4, 73.4, 70.9, 63.2, 62.9, 48.3, 33.2, 28.1, 27.1, 
26.3, 25.6, 24.7, 24.6, 19.4, 18.6, –3.8, –4.4; HRMS (ESI-TOF) m/z calcd for C52H76NaO9Si2 
[M+Na]+: 923.4920, found: 923.4888. 
 
(S)-3,3,8,8,9,9-Hexamethyl-6-((1S,2R,3S)-1,2,3-tris(benzyloxy)-4-((4R,5S)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butyl)-2,4,7-trioxa-8-
siladecane (51). To a solution of carbinol 133 (2.1 g, 2.3 mmol, 1.0 equiv) in DMF (12 mL, 
0.20 M wrt 133) at –20 °C was added sodium hydride (0.28 g, 60 wt% mineral oil dispersion, 
7.0 mmol, 3.0 equiv). The suspension was stirred at –20 °C for 15 min, then charged with 
benzyl bromide (0.42 mL, 3.5 mmol, 1.5 equiv) and tetrabutylammonium iodide (86 mg, 0.23 
mmol, 0.1 equiv). The reaction mixture was stirred between –20 °C and –5 °C for 6 h, briefly 
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warmed to 0 °C, then quenched with sat. aq NaHCO3 (50 mL), and diluted with 1:1 
hexanes/Et2O (0.15 L) and H2O (50 mL). The layers were separated and the aqueous layer 
extracted with 1:1 hexanes/Et2O (3 x 0.1 L). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated. Column chromatography (gradient elution, 6% → 8% → 
9% EtOAc in hexanes) afforded benzyl ether 51 (2.1 g, 92% yield) as a clear, colorless oil. 
[α]
€ 
D
25  –0.42° (c = 2.0, CH2Cl2); IR (neat) 3069, 3031, 2988, 2933, 2890, 2858, 1456, 1429, 
1378, 1252, 1213, 1110, 1082, 1052, 832, 778, 736, 700 cm–1; 1H-NMR (600 MHz, C6D6) 
δ 7.83–7.79 (m, 4H, ArH), 7.38 (m, J = 7.0 Hz, 2H, ArH), 7.33 (m, J = 7.1 Hz, 2H, ArH), 
7.22–7.17 (m, 8H, ArH), 7.16–7.02 (m, 15H, ArH), 4.81 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.79 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.75 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.68 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.67 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.57 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.41 (ddd, J = 10.5, 5.8, 2.4 Hz, 1H, 
C33-H), 4.30 (ddd, J = 7.6, 4.1, 3.5 Hz, 1H, C28-H), 4.19 (ddd, J = 8.2, 4.1, 4.1 Hz, 1H, C31-H), 
4.17–4.13 (m, J = 4.7, 4.1, 4.1 Hz, 2H, C29-H and C30-H), 4.08 (ddd, J = 5.9, 5.8, 5.3 Hz, 1H, 
C34-H), 4.01 (dd, J = 10.0, 3.6 Hz, 1H, one of C27-H), 3.85 (dd, J = 10.6, 5.9 Hz, 1H, one of 
C35-H), 3.79 (dd, J = 10.5, 5.3 Hz, 1H, one of C35-H), 3.67 (dd, J = 10.0, 7.6 Hz, 1H, one of 
C27-H), 3.08 (s, 3H, –OCH3), 2.36 (ddd, J = 14.1, 8.2, 2.4 Hz, 1H, one of C32-H), 2.18 (ddd, J 
= 14.1, 10.5, 3.5 Hz, 1H, one of C32-H), 1.46 (s, 3H, one of CH3), 1.28 (s, 3H, one of CH3), 
1.26 (s, 6H, two of CH3), 1.16 (s, 9H, C(CH3)3), 1.07 (s, 9H, C(CH3)3), 0.25 (s, 3H, one of 
Si(CH3)2), 0.21 (s, 3H, one of Si(CH3)2); 13C-NMR (125 MHz, C6D6) δ 139.5, 139.41, 139.38, 
136.1, 136.0, 133.9, 133.8, 130.0, 128.5, 128.4, 128.3, 128.07, 128.06, 127.91, 127.86, 
127.59, 127.56, 108.0, 100.0, 79.9, 78.7, 78.6, 76.8, 74.3, 74.0, 73.9, 73.1, 71.9, 63.6, 63.4, 
48.3, 30.7, 28.4, 27.1, 26.4, 25.6, 24.62, 24.60, 19.5, 18.6, –3.7, –4.2; HRMS (ESI-TOF) m/z 
calcd for C59H82NaO9Si2 [M+Na]+: 1013.5390, found: 1013.5355. 
 
((4S,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S)-2,3,4-tris(benzyloxy)-5-((tert-
butyldimethylsilyl)oxy)-6-((2-methoxypropan-2-yl)oxy)hexyl)-1,3-dioxolan-4-yl)methanol 
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(134). To a solution of silyl ether 51 (0.70 g, 0.70 mmol, 1.0 equiv) in THF (14 mL, 0.05 M 
wrt 51) at rt was added dropwise a pre-mixed solution of glacial acetic acid (40 µL, 0.70 
mmol, 1.0 equiv) and tetrabutylammonium fluoride in THF (0.77 mL, 1.0 M, 0.77 mmol, 1.1 
equiv). The reaction mixture was stirred at rt for 15 h, quenched with sat. aq NaHCO3 (15 
mL), and diluted with 1:1 hexanes/Et2O (40 mL) and H2O (5 mL). The layers were separated 
and the aqueous layer extracted with 1:1 hexanes/Et2O (3 x 30 mL). The combined organic 
extracts were dried over Na2SO4 with added hexanes, filtered and concentrated. Column 
chromatography (gradient elution, 20% → 22% → 24% EtOAc in hexanes + 1% Et3N) 
afforded carbinol 134 (0.49 g, 93%) as a clear, colorless oil. [α] D22  –12.5° (c = 1.8, CH2Cl2); 
IR (neat) 3468 (br), 3063, 3032, 2988, 2934, 2886, 2858, 1497, 1458, 1378, 1252, 1214, 
1082, 1051, 964, 835, 778, 735, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.38–7.27 (m, 15H, 
ArH), 4.74 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.71 (d, J = 12.4 Hz, 1H, one of –
OCH2Ph), 4.69 (d, J = 11.2 Hz, 1H, one of –OCH2Ph), 4.68 (d, J = 11.7 Hz, 1H, one of –
OCH2Ph), 4.61 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.56 (d, J = 11.1 Hz, 1H, one of –
OCH2Ph), 4.06 (ddd, J = 7.6, 4.7, 3.6 Hz, 1H, C28-H), 3.95 (ddd, J = 9.4, 5.9, 4.1 Hz, 1H, C33-
H), 3.90 (dd, J = 4.7, 4.1 Hz, 1H, C30-H), 3.84 (dd, J = 4.6, 4.2 Hz, 1H, C29-H), 3.76 (m, J = 
5.9, 5.8 Hz, 1H, C31-H), 3.73 (m, J = 7.0, 4.1 Hz, 1H, C34-H), 3.71 (dd, J = 10.0, 3.6 Hz, 1H, 
one of C27-H), 3.39 (dd, J = 10.0, 7.6 Hz, 1H, one of C27-H), 3.38 (m, J = 12.0, 7.1 Hz, 1H, 
one of C35-H), 3.32 (br m, J = 10.5 Hz, 1H, one of C35-H), 3.13 (s, 3H, –OCH3), 1.81 (ddd, J 
= 14.1, 5.9, 4.1 Hz, 1H, one of C32-H), 1.76 (br s, 1H, C35-OH), 1.71 (ddd, J = 14.1, 9.4, 5.8 
Hz, 1H, one of C32-H), 1.43 (s, 3H, one of CH3), 1.29 (s, 3H, one of CH3), 1.25 (s, 6H, two of 
CH3), 0.92 (s, 9H, C(CH3)3), 0.10 (s, 3H, one of Si(CH3)2), 0.06 (s, 3H, one of Si(CH3)2); 13C-
NMR (125 MHz, CDCl3) δ 138.6, 138.41, 138.39, 128.5, 128.3, 128.2, 128.0, 127.9, 127.6, 
127.54, 127.53, 107.9, 99.8, 78.8, 77.7, 77.5, 76.3, 74.0, 73.8, 73.3, 72.2, 72.0, 62.8, 61.6, 
48.3, 30.0, 28.2, 26.0, 25.3, 24.39, 24.37, 18.2, –4.1, –4.6; HRMS (ESI-TOF) m/z calcd for 
C43H68NO9Si [M+NH4]+: 770.46579, found: 770.46677. 
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(4R,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S)-2,3,4-tris(benzyloxy)-5-((tert-
butyldimethylsilyl)oxy)-6-((2-methoxypropan-2-yl)oxy)hexyl)-1,3-dioxolane-4-
carbaldehyde (52). To a solution of carbinol 134 (0.12 g, 0.16 mmol, 1.0 equiv) and 
EtN(iPr)2 (83 µL, 0.48 mmol, 3.0 equiv) in CH2Cl2 (0.46 mL, 0.35 M wrt 134) and DMSO (80 
µL, 2.0 M wrt 134) at –30 °C was added a solution of SO3•py (76 mg, 0.48 mmol, 3.0 equiv) 
in DMSO (0.37 mL, 1.3 M wrt SO3•py). The reaction mixture was stirred between –30 °C and 
–20 °C for 1 h, then quenched with brine (8 mL), Et2O (40 mL) and H2O (2 mL). The layers 
were separated and the organic layer washed sequentially with 1 M aq NaHSO4 (10 mL), sat. 
aq NaHCO3 (10 mL), and 1:1 H2O/brine (2 x 10 mL). The organic layer was then dried over 
Na2SO4 with added hexanes, filtered and concentrated. Column chromatography (gradient 
elution, 15% → 20% EtOAc in hexanes) afforded aldehyde 52 (0.11 g, 94% yield) as a clear, 
colorless oil. [α] D24  –12.0° (c = 2.6, CH2Cl2); IR (neat) 3067, 3031, 2989, 2934, 2887, 2857, 
1734 (s), 1497, 1458, 1378, 1253, 1214, 1157, 1081, 1052, 963, 834, 778, 735, 699 cm–1; 1H-
NMR (600 MHz, CDCl3) δ 9.42 (d, J = 3.0 Hz, 1H, C35-H), 7.39–7.27 (m, 15H, ArH), 4.74 
(d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.73 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.68 (d, J 
= 10.0 Hz, 1H, one of –OCH2Ph), 4.66 (d, J = 11.2 Hz, 1H, one of –OCH2Ph), 4.62 (d, J = 
11.8 Hz, 1H, one of –OCH2Ph), 4.54 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.18 (ddd, J = 
8.8, 7.0, 4.1 Hz, 1H, C33-H), 4.07 (ddd, J = 7.7, 4.7, 3.0 Hz, 1H, C28-H), 3.88 (dd, J = 5.3, 3.5 
Hz, 1H, C30-H), 3.81 (ddd, J = 5.9, 5.9, 5.3 Hz, 1H, C31-H), 3.78 (dd, J = 4.7, 3.5 Hz, 1H, C29-
H), 3.74 (dd, J = 7.0, 2.9 Hz, 1H, C34-H), 3.73 (dd, J = 9.9, 2.9 Hz, 1H, one of C27-H), 3.38 
(dd, J = 10.0, 7.6 Hz, 1H, one of C27-H), 3.14 (s, 3H, –OCH3), 1.94 (ddd, J = 14.1, 5.9, 4.1 
Hz, 1H, one of C32-H), 1.21 (ddd, J = 14.7, 8.8, 5.9 Hz, 1H, one of C32-H), 1.54 (s, 3H, one of 
CH3), 1.30 (s, 3H, one of CH3), 1.28 (s, 3H, one of CH3), 1.26 (s, 3H, one of CH3), 0.92 (s, 
9H, C(CH3)3), 0.11 (s, 3H, one of Si(CH3)2), 0.06 (s, 3H, one of Si(CH3)2); 13C-NMR (125 
MHz, CDCl3) δ 201.6, 138.5, 138.3, 138.2, 128.5, 128.3, 128.2, 128.10, 128.08, 127.62, 
127.60, 127.56, 110.2, 99.8, 81.7, 78.6, 77.3, 75.51, 75.46, 73.7, 73.2, 72.2, 71.8, 62.9, 48.3, 
30.9, 27.6, 26.0, 25.2, 24.4 (2C), 18.1, –4.2, –4.6; HRMS (ESI-TOF) m/z calcd for 
C43H62NaO9Si [M+Na]+: 773.4055, found: 773.4047. 
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Synthesis of the C27–C48 Aldehyde 
 
(5S,8R)-5-((S)-((4S,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S)-2,3,4-tris(benzyloxy)-5-((tert-
butyldimethylsilyl)oxy)-6-((2-methoxypropan-2-yl)oxy)hexyl)-1,3-dioxolan-4-
yl)(hydroxy)methyl)-3,3-diethyl-10,10,11,11-tetramethyl-8-nonyl-4,9-dioxa-3,10-
disiladodecan-6-one (54). To a solution of ketone 53 (0.12 g, 0.27 mmol, 2.1 equiv) and 
EtNMe2 (58 µL, 0.53 mmol, 4.2 equiv) in pentane (1.3 mL, 0.2 M wrt 53) at 0 °C was added 
Cy2BCl (61 µL, 0.28 mmol, 2.2 equiv). The enolization mixture was stirred at 0 °C for 20 
min, then stirred at rt for 16 h, then cooled to –78 °C and charged slowly dropwise with a 
solution of aldehyde 52 (0.11 g, 0.15 mmol, 1.0 equiv) in Et2O (0.24 mL, 0.3 M wrt 52) over 
1 min (with 0.20 mL rinse). The reaction mixture was stirred at –78 °C for 45 min, slowly 
warmed to –40 °C over 0.5 h, stirred at –40 °C for 4 h, slowly warmed to –25 °C over 2 h, 
stirred at –25 °C for 10 h, then quenched at 0 °C with aq pH 7 buffer (3 mL), MeOH (3 mL), 
Et2O (30 mL) and 30% aq H2O2 (1 mL). The biphasic mixture was stirred vigorously at 0 °C 
for 1 h, then at rt for 1 h. The layers were separated and the aqueous layer extracted with Et2O 
(2 x 30 mL). The combined organic extracts were washed with 10% aq Na2S2O3 (2 x 15 mL) 
and brine (15 mL), dried over Na2SO4 with added hexanes, filtered and concentrated. The 
residue was analyzed by 1H-NMR spectroscopy to assess reaction diastereoselectivity (d.r. = 
85:15). Column chromatography (gradient elution, 3% → 4% → 5% EtOAc in hexanes) 
afforded aldol adduct 54 (0.10 g, 57% yield) as a clear, colorless oil. [α] D23  –7.6° (c = 2.3, 
CH2Cl2); IR (neat) 3558 (br), 3064, 3031, 2954, 2929, 2856, 1721 (s), 1497, 1467, 1379, 
1253, 1212, 1086, 1052, 1004, 967, 835, 776, 732, 697 cm–1; 1H-NMR (600 MHz, C6D6) 
δ 7.41 (m, J = 8.2 Hz, 2H, two of ArH), 7.39 (m, J = 7.7 Hz, 2H, two of ArH), 7.36 (m, J = 
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7.6 Hz, 2H, two of ArH), 7.24–7.18 (m, 6H, six of ArH), 7.13–7.09 (m, 3H, three of ArH), 
4.82 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.79 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.78 
(d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.73 (d, J = 11.8 Hz, 1H, one of –OCH2Ph), 4.65 (d, J 
= 11.7 Hz, 1H, one of –OCH2Ph), 4.58 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.54 (dddd, J = 
6.5, 5.9, 5.3, 5.2 Hz, 1H, C39-H), 4.49 (ddd, J = 10.0, 7.1, 2.9 Hz, 1H, C33-H), 4.31 (m, J = 7.0 
Hz, 1H, C34-H), 4.30 (ddd, J = 7.6, 3.5, 3.0 Hz, 1H, C28-H), 4.25 (d, J = 8.2 Hz, 1H, C36-H), 
4.15–4.13 (m, J = 6.5, 5.3, 4.7 Hz, 2H, C30-H and C31-H), 4.10 (dd, J = 4.7, 3.5 Hz, 1H, C29-
H), 4.01 (dd, J = 9.9, 3.0 Hz, 1H, one of C27-H), 3.85 (dd, J = 8.8, 8.2 Hz, 1H, C35-H), 3.66 
(dd, J = 10.0, 7.6 Hz, 1H, one of C27-H), 3.21 (dd, J = 18.2, 5.3 Hz, 1H, one of C38-H), 3.08 
(s, 3H, –OCH3), 2.89 (dd, J = 18.2, 6.5 Hz, 1H, one of C38-H), 2.53 (d, J = 8.8 Hz, 1H, C35-
OH), 2.50 (ddd, J = 14.1, 10.0, 4.1 Hz, 1H, one of C32-H), 2.36 (ddd, J = 14.1, 6.5, 2.9 Hz, 
1H, one of C32-H), 1.82–1.76 (m, J = 13.5, 5.9, 4.7 Hz, 1H, one of C40-H), 1.65–1.60 (m, J = 
13.5, 5.9, 5.3 Hz, 1H, one of C40-H), 1.57–1.45 (m, 2H, C41-H2), 1.38 (s, 3H, one of CH3), 
1.37–1.22 (m, 12H, C42–47-H2), 1.263 (s, 3H, one of CH3), 1.257 (s, 3H, one of CH3), 1.22 (s, 
3H, one of CH3), 1.07 (s, 9H, C(CH3)3), 1.02 (s, 9H, C(CH3)3), 1.01 (t, J = 7.9 Hz, 9H, –
SiCH2CH3), 0.90 (t, J = 7.1 Hz, 3H, C48-H3), 0.67 (q, J = 7.8 Hz, 6H, –SiCH2CH3), 0.25 (s, 
3H, one of SiCH3), 0.22 (s, 3H, one of SiCH3), 0.20 (s, 3H, one of SiCH3), 0.18 (s, 3H, one of 
SiCH3); 13C-NMR (125 MHz, C6D6) δ 209.2, 139.3 (3C), 128.6, 128.5, 128.4, 128.3, 128.1, 
128.0, 127.9, 127.7, 127.64, 127.59, 107.9, 100.0, 79.8, 79.4, 78.7, 76.9, 75.7, 74.5, 74.1, 
73.9, 72.9, 72.1, 72.0, 68.3, 63.4, 48.2, 46.4, 38.0, 32.3, 31.1, 30.2, 30.1, 30.0, 29.7, 27.0, 
26.4, 26.2, 25.5, 24.62, 24.60, 24.56, 23.1, 18.5, 18.3, 14.3, 7.0, 5.1, –3.8, –4.20, –4.21, –4.5; 
HRMS (ESI-TOF) m/z calcd for C68H120NaO12Si3 [M+NH4]+: 1226.81128, found: 1226.81179. 
 
(5R,8S,9S)-9-((4R,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S)-2,3,4-tris(benzyloxy)-5-((tert-
butyldimethylsilyl)oxy)-6-hydroxyhexyl)-1,3-dioxolan-4-yl)-11,11-diethyl-2,2,3,3-
tetramethyl-5-nonyl-8-((triethylsilyl)oxy)-4,10-dioxa-3,11-disilatridecan-7-one (135). To a 
solution of carbinol 54 (0.10 g, 83 µmol, 1.0 equiv) and 2,6-lutidine (39 µL, 0.33 mmol, 4.0 
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equiv) in CH2Cl2 (0.41 mL, 0.2 M wrt 54) at 0 °C was added TESOTf (28 µL, 0.12 mmol, 1.5 
equiv). The reaction mixture was stirred between 0 °C and 10 °C for 3 h, charged with 
additional TESOTf (19 µL, 83 µmol, 1.0 equiv), stirred between 0 °C and 10 °C for 1 h, then 
quenched with 1 M aq H2SO4 (1 mL) and Et2O (2 mL). The biphasic mixture was stirred 
vigorously at 0 °C for 1 h, then diluted with H2SO4 (6 mL) and Et2O (40 mL), and the layers 
were separated. The organic layer was washed sequentially with sat. aq NaHCO3 and brine (6 
mL each), dried over Na2SO4 with added hexanes, filtered and concentrated. Column 
chromatography (gradient elution, 3% → 4% EtOAc in hexanes) afforded diol 135 (86 mg, 
83% yield) as a clear, colorless oil. [α] D25  +19.6° (c = 1.8, CH2Cl2); IR (neat) 3510 (br), 3065, 
3031, 2930, 2857, 1711 (s), 1461, 1408, 1378, 1252, 1219, 1098, 1061, 1008, 836, 776, 732, 
699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.32–7.20 (m, 15H, ArH), 4.80 (d, J = 11.1 Hz, 1H, 
one of –OCH2Ph), 4.66 (m, 2H, –OCH2Ph), 4.63 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.56 
(d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.50 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.28 (ddd, 
J = 11.1, 5.0, 3.1 Hz, 1H, C33-H), 4.22 (dddd, J = 6.0, 5.7, 5.6, 5.4 Hz, 1H, C39-H), 3.98 (ddd, 
J = 4.1, 4.0, 3.5 Hz, 1H, C31-H), 3.92 (dd, J = 4.4, 4.0 Hz, 1H, C30-H), 3.91 (dd, J = 6.0, 5.0 
Hz, 1H, C29-H), 3.84 (m, J = 5.3, 5.0 Hz, 1H, C28-H), 3.84 (dd, J = 8.8, 5.0 Hz, 1H, C34-H), 
3.77 (dd, J = 8.9, 1.9 Hz, 1H, C35-H), 3.69 (ddd, J = 11.3, 8.2, 3.1 Hz, 1H, one of C27-H), 3.67 
(d, J = 1.9 Hz, 1H, C36-H), 3.56 (ddd, J = 11.4, 5.1, 4.7 Hz, 1H, one of C27-H), 2.89 (dd, J = 
19.6, 6.7 Hz, 1H, one of C38-H), 2.82 (dd, J = 19.6, 5.3 Hz, 1H, one of C38-H), 1.78 (dd, J = 
8.1, 4.7 Hz, 1H, C27-OH), 1.75 (ddd, J = 13.0, 11.1, 4.2 Hz, 1H, one of C32-H), 1.71 (m, J = 
13.0, 2.8 Hz, 1H, one of C32-H), 1.48–1.22 (m, 16H, C40–47-H2), 1.42 (s, 3H, one of CH3), 1.26 
(s, 3H, one of CH3), 0.97 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.89 (s, 9H, one of C(CH3)3), 0.88 
(t, 3H, C48-H3), 0.87 (s, 9H, one of C(CH3)3), 0.84 (t, J = 8.0 Hz, 9H, –SiCH2CH3), 0.70–0.57 
(m, J = 7.8, 7.5, 7.3 Hz, 6H, –SiCH2CH3), 0.43 (q, J = 7.9 Hz, 6H, –SiCH2CH3), 0.08 (s, 3H, 
one of SiCH3), 0.04 (s, 3H, one of SiCH3), 0.01 (s, 3H, one of SiCH3), –0.01 (s, 3H, one of 
SiCH3); 13C-NMR (125 MHz, CDCl3) δ 211.9, 138.8, 138.6, 138.3, 128.4, 128.2, 128.2, 
128.2, 128.0, 127.5, 127.4, 127.4, 127.3, 107.7, 78.8, 78.6, 78.5, 77.5, 76.1, 75.3, 74.1, 73.9, 
73.5, 73.3, 71.4, 67.3, 64.2, 48.7, 37.9, 31.9, 30.4, 29.8, 29.6, 29.6, 29.3, 28.7, 26.0, 25.9, 
25.9, 25.2, 22.7, 18.1, 18.0, 14.1, 6.9, 6.8, 5.3, 5.1, 5.0, 4.5, –4.5, –4.5, –4.7, –4.7; HRMS 
(ESI-TOF) m/z calcd for C70H122NaO11Si4 [M+Na]+: 1273.7956, found: 1273.7948. 
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(2R,3S,4R,5S)-3,4,5-Tris(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)-6-((4R,5R)-5-
((5S,6S,9R)-3,3-diethyl-11,11,12,12-tetramethyl-9-nonyl-7-oxo-6-((triethylsilyl)oxy)-4,10-
dioxa-3,11-disilatridecan-5-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)hexanal (41). To a solution 
of carbinol 135 (0.24 g, 0.19 mmol, 1.0 equiv) and EtN(iPr)2 (0.10 mL, 0.58 mmol, 3.0 equiv) 
in CH2Cl2 (0.55 mL, 0.35 M wrt 135) and DMSO (0.11 mL, 1.8 M wrt 135) at –30 °C was 
added a solution of SO3•py (0.092 g, 0.58 mmol, 3.0 equiv) in DMSO (0.44 mL, 1.3 M wrt 
SO3•py). The reaction mixture was stirred between –30 °C and –20 °C for 1.5 h, quenched 
with brine (15 mL), then diluted with Et2O (40 mL) and H2O (1 mL). The layers were 
separated and the organic layer washed sequentially with 1 M aq NaHSO4 (15 mL), sat. aq 
NaHCO3 (15 mL), and 1:1 H2O/brine (2 x 15 mL). The organic layer was then dried over 
Na2SO4 with added hexanes, filtered and concentrated. Column chromatography (gradient 
elution, 1% → 1.5% → 2% EtOAc in hexanes) afforded aldehyde 41 (0.23 g, 95% yield) as a 
clear, colorless oil. [α] D26  +11.9° (c = 2.2, CH2Cl2); IR (neat) 3066, 3031, 2927, 2872, 1731 
(s), 1714 (s), 1455, 1416, 1380, 1252, 1220, 1143, 1097, 1061, 1026, 979, 950, 894, 837, 777, 
729, 699 cm–1; 1H-NMR (600 MHz, CDCl3) δ 9.74 (s, 1H, C27-H), 7.33–7.18 (m, 15H, ArH), 
4.68 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.63 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.61 
(d, J = 11.6 Hz, 1H, one of –OCH2Ph), 4.47 (d, J = 11.4 Hz, 1H, one of –OCH2Ph), 4.46 (d, J 
= 11.0 Hz, 1H, one of –OCH2Ph), 4.32 (d, J = 11.1 Hz, 1H, one of –OCH2Ph), 4.25 (dddd, J = 
5.7, 5.7, 5.7, 5.7 Hz, 1H, C39-H), 4.22 (ddd, J = 11.4, 5.0, 2.1 Hz, 1H, C33-H), 4.08 (dd, J = 
5.9, 3.7 Hz, 1H, C29-H), 3.97 (d, J = 5.7 Hz, 1H, C28-H), 3.88 (dd, J = 5.6, 3.7 Hz, 1H, C30-H), 
3.84 (dd, J = 9.1, 5.1 Hz, 1H, C34-H), 3.79 (m, 1H, C31-H), 3.78 (dd, J = 9.1, 2.0 Hz, 1H, C35-
H), 3.70 (d, J = 2.1 Hz, 1H, C36-H), 2.90 (dd, J = 19.6, 6.4 Hz, 1H, one of C38-H), 2.85 (dd, J 
= 19.6, 5.6 Hz, 1H, one of C38-H), 1.87 (ddd, J = 13.9, 3.7, 1.6 Hz, 1H, one of C32-H), 1.75 
(ddd, J = 13.8, 11.9, 5.0 Hz, 1H, one of C32-H), 1.48–1.27 (m, 16H, C40–47-H2), 1.41 (s, 3H, 
one of CH3), 1.27 (s, 3H, one of CH3), 0.97 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.89 (t, J = 7.0 
Hz, 3H, C48-H3), 0.88 (s, 9H, one of C(CH3)3), 0.88 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.88 (s, 
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9H, one of C(CH3)3), 0.71–0.59 (m, J = 8.1, 7.9, 7.8 Hz, 6H, –SiCH2CH3), 0.43 (q, J = 7.9 Hz, 
6H, –SiCH2CH3), 0.09 (s, 3H, one of SiCH3), 0.06 (s, 3H, one of SiCH3), 0.02 (s, 3H, one of 
SiCH3), –0.10 (s, 3H, one of SiCH3); 13C-NMR (125 MHz, CDCl3) δ 211.9, 200.6, 138.7, 
138.0, 137.7, 128.7, 128.6, 128.4, 128.3, 128.2, 128.0, 127.7, 127.5, 127.4, 107.6, 80.9, 78.8, 
78.4, 77.0, 76.9, 76.7, 75.3, 74.9, 73.7, 73.7, 72.1, 67.3, 48.7, 37.9, 31.9, 31.0, 29.8, 29.6, 
29.6, 29.3, 28.6, 26.1, 25.9, 25.8, 25.2, 22.7, 18.3, 18.0, 14.1, 6.9, 6.8, 5.1, 4.5, –4.5, –4.6, –
4.7, –5.5; HRMS (ESI-TOF) m/z calcd for C70H120NaO11Si4 [M+Na]+: 1271.7800, found: 
1271.7846. 
 
Synthesis of Aflastatin A 
 
(5R,8S,9S)-9-((4R,5R)-2,2-Dimethyl-5-((2S,3R,4S,5S,6S,8R,10R)-2,3,4-tris(benzyloxy)-11-
((4R,5S,6S)-6-((S)-1-((4S,6R)-6-((S)-1-((4R,5R,6R)-6-((2S,3R,4R,6R,8S)-3,9-
bis(benzyloxy)-4-((tert-butyldimethylsilyl)oxy)-6,8-dimethylnonan-2-yl)-2,2,5-trimethyl-
1,3-dioxan-4-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2,2,5-trimethyl-1,3-dioxan-4-
yl)-5-((tert-butyldimethylsilyl)oxy)-6,8-dihydroxy-10-((triisopropylsilyl)oxy)undecyl)-1,3-
dioxolan-4-yl)-11,11-diethyl-2,2,3,3-tetramethyl-5-nonyl-8-((triethylsilyl)oxy)-4,10-dioxa-
3,11-disilatridecan-7-one (55). To a solution of aldehyde 41 (0.23 g, 0.18 mmol, 1.0 equiv) 
and ketone 40 (0.24 g, 0.20 mmol, 1.1 equiv) in CH2Cl2 (1.3 mL, 0.14 M wrt 41) at –5 °C was 
added freshly prepared MgBr2•OEt2 (0.38 g, 1.5 mmol, 8.0 equiv). The resulting suspension 
was stirred at –5 °C for 10 min, then charged dropwise with 1,2,2,6,6-pentamethylpiperidine 
(83 µL, 0.46 mmol, 2.5 equiv). The reaction mixture was stirred at –5 °C for 7 min, then 
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rapidly quenched with pre-chilled sat. aq NaHCO3 (3 mL). The biphasic mixture was stirred 
vigorously at rt for 10 min, then diluted with Et2O (30 mL), H2O (10 mL) and sat. aq NaHCO3 
(15 mL). The layers were separated and the aqueous layer extracted with CH2Cl2 (2 x 30 mL). 
The combined organic extracts were washed sequentially with sat. aq NH4Cl (2 x 20 mL) and 
brine (15 mL), dried over Na2SO4, filtered, concentrated and azeotroped with PhH (2 x 2 mL) 
to afford crude aldol adduct 163 as a clear, pale yellow oil that was used without further 
purification. 
To a solution of crude aldol adduct 163 (theoretical 0.44 g, 0.18 mmol, 1.0 equiv) in 4:1 
THF/MeOH (1.8 mL, 0.1 M wrt 163) at –78 °C was added dropwise a solution of 
diethylmethoxyborane in THF (0.20 mL, 1.0 M, 0.20 mmol, 1.1 equiv). The reaction mixture 
was stirred at –78 °C for 2.5 h, then charged with sodium borohydride (21 mg, 0.55 mmol, 3.0 
equiv) in one portion. The reaction mixture was slowly warmed to –55 °C over 0.5 h, stirred 
at –55 °C for 20 h, quenched with a pre-mixed mixture of 1 M aq NaOH (1 mL) and 30% aq 
H2O2 (0.4 mL), then diluted with 4:1 THF/MeOH (1 mL). The heterogeneous mixture was 
stirred vigorously at 0 °C for 1.5 h, then diluted with Et2O (30 mL) and aq pH 7 buffer (3 
mL). The layers were separated and the aqueous layer extracted with Et2O (2 x 30 mL). The 
combined organic extracts were washed with 10% aq Na2S2O3 (2 x 10 mL) and brine (10 mL), 
dried over Na2SO4 with added hexanes, filtered and concentrated. The residue was analyzed 
by 1H-NMR spectroscopy to assess reaction diastereoselectivity (d.r. ≥ 95:05). Column 
chromatography (gradient elution, 6% → 6.5% EtOAc in hexanes) afforded diol 55 (0.31 g, 
70% yield, two steps) as a white foam. [α] D25  +1.0° (c = 1.2, CH2Cl2); IR (neat) 3498 (br), 
3068, 3036, 2932, 2864, 1712, 1459, 1380, 1253, 1202, 1175, 1098, 1008, 982, 837, 775, 733, 
698 cm–1; 1H-NMR (600 MHz, CDCl3) δ 7.34–7.21 (m, 25H, ArH), 4.73 (d, J = 12.0 Hz, 1H, 
one of –OCH2Ph), 4.70 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.70 (d, J = 11.9 Hz, 1H, one 
of –OCH2Ph), 4.66 (m, 2H, –OCH2Ph), 4.61 (d, J = 11.7 Hz, 1H, one of –OCH2Ph), 4.52 (d, J 
= 11.9 Hz, 1H, one of –OCH2Ph), 4.49 (d, J = 11.9 Hz, 1H, one of –OCH2Ph), 4.45 (m, 2H, –
OCH2Ph), 4.28 (ddd, J = 11.6, 7.0, 2.5 Hz, 1H, C33-H), 4.25 (m, J = 7.0, 6.0 Hz, 1H), 4.22 (m, 
1H), 4.21 (m, J = 5.1, 5.1 Hz, 1H, C39-H), 4.18–4.16 (m, 2H), 4.03–3.98 (m, 2H), 3.98–3.92 
(m, 3H), 3.91 (m, 1H, C31-H), 3.88 (m, 1H, C8-H), 3.82 (dd, J = 8.9, 4.9 Hz, 1H, C34-H), 3.79 
(dd, J = 8.9, 1.9 Hz, 1H, C35-H), 3.69 (m, 1H), 3.66 (d, J = 1.9 Hz, 1H, C36-H), 3.60 (m, J = 
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1.6 Hz, 1H), 3.59 (m, J = 9.8 Hz, 1H), 3.54 (m, J = 7.2, 2.8 Hz, 2H), 3.40 (dd, J = 6.2, 2.6 Hz, 
1H, C9-H), 3.33 (dd, J = 9.1, 5.3 Hz, 1H, one of C3-H), 3.14 (dd, J = 9.1, 7.4 Hz, 1H, one of 
C3-H), 2.88 (dd, J = 19.6, 6.6 Hz, 1H, one of C38-H), 2.83 (dd, J = 19.5, 5.4 Hz, 1H, one of 
C38-H), 2.39 (m, J = 6.8, 6.6, 2.5 Hz, 1H, C10-H), 1.94–1.80 (m, 4H), 1.80–1.57 (m, 8H), 1.52 
(m, J = 1.9 Hz, 1H), 1.48–1.20 (m, 16H, C40–47-H2), 1.48–1.20 (m, 5H), 1.44 (s, 3H, one of 
CH3), 1.39 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3), 1.37 (s, 
3H, one of CH3), 1.35 (s, 3H, one of CH3), 1.31 (s, 3H, one of CH3), 1.24 (s, 3H, one of CH3), 
1.16 (ddd, J = 13.3, 8.0, 5.6 Hz, 1H), 1.07 (m, 18H, –SiCH(CH3)2), 1.07 (m, 3H, –
SiCH(CH3)2), 1.04 (ddd, J = 13.3, 6.3, 2.2 Hz, 1H), 0.99–0.97 (m, J = 6.9 Hz, 6H, two of –
CH(CH3)), 0.96 (t, J = 8.0 Hz, 9H, –SiCH2CH3), 0.92–0.81 (m, 12H, four of –CH(CH3)), 0.88 
(s, 9H, one of C(CH3)3), 0.88 (t, J = 7.1 Hz, 3H, C48-H3), 0.86 (s, 9H, one of C(CH3)3), 0.84 
(s, 9H, one of C(CH3)3), 0.83 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.73 (d, J = 6.9 Hz, 3H, one of 
–CH(CH3)), 0.70–0.58 (m, J = 7.9, 7.8 Hz, 6H, –SiCH2CH3), 0.43 (q, J = 8.0 Hz, 6H, –
SiCH2CH3), 0.07 (s, 3H, one of SiCH3), 0.03 (s, 3H, one of SiCH3), 0.03 (s, 3H, one of 
SiCH3), 0.01 (s, 3H, one of SiCH3), –0.03 (s, 3H, one of SiCH3), –0.13 (s, 3H, one of SiCH3); 
13C-NMR (125 MHz, CDCl3) δ 211.8, 139.8, 138.8, 138.8, 137.9, 137.7, 128.5, 128.4, 128.3, 
128.3, 128.2, 128.1, 128.0, 127.8, 127.4, 127.4, 127.4, 127.3, 127.3, 127.0, 107.5, 98.3, 98.3, 
97.2, 80.9, 79.6, 78.9, 78.5, 77.2, 75.9, 75.9, 75.8, 75.5, 75.0, 74.8, 74.0, 73.6, 73.3, 73.0, 
72.8, 72.8, 72.5, 71.5, 71.5, 71.0, 69.9, 69.7, 68.2, 67.3, 67.2, 48.7, 45.1, 42.5, 40.8, 40.7, 
39.2, 39.1, 38.6, 37.9, 32.7, 32.4, 31.9, 31.9, 31.3, 30.6, 30.4, 30.1, 30.0, 29.8, 29.6, 29.6, 
29.3, 28.6, 27.1, 27.0, 26.0, 26.0, 25.9, 25.8, 25.2, 22.7, 20.7, 20.1, 19.8, 19.3, 18.2, 18.2, 
18.2, 18.0, 18.0, 14.1, 12.7, 11.0, 9.5, 9.0, 8.9, 6.9, 6.8, 5.1, 4.6, 4.5, –3.7, –3.8, –4.2, –4.4, –
4.5, –4.7; HRMS (ESI-TOF) m/z calcd for C139H242NaO22Si6 [M+Na]+: 2454.6326, found: 
2454.6361. 
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(5R,8S,9S)-9-((4R,5R)-5-((2S,3R,4S,5S,6S,8R,10R)-5-((tert-Butyldimethylsilyl)oxy)-11-
((4R,5S,6S)-6-((S)-1-((4S,6R)-6-((S)-1-((4R,5S,6S)-6-((2R,3R,4R,6R,8S)-4-((tert-
butyldimethylsilyl)oxy)-3,9-dihydroxy-6,8-dimethylnonan-2-yl)-2,2,5-trimethyl-1,3-
dioxan-4-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2,2,5-trimethyl-1,3-dioxan-4-yl)-
2,3,4,6,8-pentahydroxy-10-((triisopropylsilyl)oxy)undecyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)-11,11-diethyl-2,2,3,3-tetramethyl-5-nonyl-8-((triethylsilyl)oxy)-4,10-dioxa-3,11-
disilatridecan-7-one (56). To a solution of pentabenzyl ether 55 (0.11 g, 45 µmol, 1.0 equiv) 
in THF (0.30 mL, 0.15 M wrt 55) and 6:1 dioxane/H2O (0.15 mL, 0.30 M wrt 55) at rt was 
added palladium black (~10 mg). The reaction mixture was purged with hydrogen for 1 min, 
stirred vigorously for 6 h, then recharged with additional catalyst at this time and 
approximately every 6 h thrice after (total palladium black added: ~50 mg). The reaction 
mixture was stirred at rt for 6 h, then filtered through Celite. The filter cake was rinsed with 
THF (35 mL total), and the filtrate concentrated. Column chromatography (gradient elution, 
1% → 1.5% EtOH in CH2Cl2) afforded heptaol 56 (84 mg, 93% yield) as a clear, colorless 
glass. [α] D23  –5.1° (c = 2.1, CH2Cl2); IR (neat) 3448 (br), 2932, 2864, 1716, 1462, 1380, 1254, 
1201, 1096, 1057, 1007, 981, 885, 837, 776, 743, 678 cm–1; 1H-NMR (500 MHz, CDCl3) 
δ 4.44 (m, 1H), 4.36 (m, J = 11.7, 4.9 Hz, 1H), 4.25 (m, J = 5.4, 4.4 Hz, 1H), 4.21 (m, J = 5.9, 
5.4 Hz, 1H, C39-H), 4.17–4.11 (m, 3H), 4.11–3.94 (m, 4H), 3.94–3.83 (m, 4H), 3.78–3.64 (m, 
6H), 3.64–3.55 (m, 3H), 3.49 (dd, J = 10.5, 5.1 Hz, 1H), 3.42–3.37 (m, J = 9.8, 8.3 Hz, 2H, 
C3-H2), 3.22 (m, J = 3.9 Hz, 1H), 2.92 (dd, J = 19.5, 5.4 Hz, 1H, one of C38-H), 2.81 (dd, J = 
19.5, 5.9 Hz, 1H, one of C38-H), 2.08 (m, J = 9.8 Hz, 1H, C3-OH), 1.93–1.81 (m, 6H), 1.79–
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1.68 (m, 5H), 1.65 (m, J = 7.3, 7.3 Hz, 1H), 1.62–1.47 (m, 6H), 1.47 (s, 3H, one of CH3), 
1.45–1.22 (m, 16H, C40–47-H2), 1.43 (s, 3H, one of CH3), 1.38 (s, 3H, one of CH3), 1.36 (m, 
1H), 1.36 (m, 1H, one of C5-H), 1.36 (s, 3H, one of CH3), 1.34 (s, 3H, one of CH3), 1.34 (s, 
3H, one of CH3), 1.27 (s, 3H, one of CH3), 1.25 (s, 3H, one of CH3), 1.07 (m, 21H, –
SiCH(CH3)2, and –SiCH(CH3)2), 1.03 (d, J = 6.8 Hz, 3H, one of –CH(CH3)), 0.98 (m, 1H, one 
of C5-H), 0.95 (t, J = 7.8 Hz, 18H, –SiCH2CH3), 0.95 (d, J = 7.8 Hz, 3H, one of –CH(CH3)), 
0.92 (d, J = 6.3 Hz, 3H, one of –CH(CH3)), 0.92 (d, J = 6.3 Hz, 3H, one of –CH(CH3)), 0.89 
(s, 18H, two of C(CH3)3), 0.87 (t, 3H, C48-H3), 0.86 (d, 3H, one of –CH(CH3)), 0.86 (s, 9H, 
one of C(CH3)3), 0.80 (d, J = 6.8 Hz, 3H, one of –CH(CH3)), 0.67 (d, J = 5.9 Hz, 3H, one of –
CH(CH3)), 0.70–0.58 (m, J = 7.8, 7.3 Hz, 12H, –SiCH2CH3), 0.11 (s, 9H, three of SiCH3), 
0.10 (s, 3H, one of SiCH3), 0.06 (s, 3H, one of SiCH3), 0.02 (s, 3H, one of SiCH3); 13C-NMR 
(125 MHz, CDCl3) δ 212.0, 108.1, 98.4, 98.2, 97.1, 79.1, 78.4, 75.8, 75.8, 75.0, 74.8, 74.7, 
74.5, 73.5, 73.4, 73.3, 72.4, 71.3, 70.8, 70.5, 69.9, 69.5, 68.5, 68.2, 68.2, 67.2, 48.4, 43.9, 
41.9, 41.9, 41.2, 40.0, 39.9, 39.2, 38.5, 37.8, 36.3, 33.3, 33.1, 32.9, 31.9, 31.8, 30.3, 30.0, 
29.8, 29.7, 29.6, 29.5, 29.3, 28.4, 26.8, 25.9, 25.8, 25.8, 25.8, 25.1, 22.6, 20.8, 20.1, 19.7, 
19.2, 18.1, 18.0, 18.0, 18.0, 17.1, 14.1, 12.7, 10.9, 9.3, 9.2, 9.1, 6.8, 6.8, 5.1, 4.7, 4.7, –3.4, –
4.2, –4.4, –4.6, –4.6, –4.7; HRMS (ESI-TOF) m/z calcd for C104H213O22Si6 [M+H]+: 
1982.41586, found: 1982.41308. 
 
Primary carbinols 57. To a solution of heptaol 56 (0.10 g, 51 µmol, 1.0 equiv) and pyridine 
(58 µL, 0.72 mmol, 14 equiv) in CH2Cl2 (0.86 mL, 60 mM wrt 56) at 0 °C was added 
chlorotrimethylsilane (65 µL, 0.51 mmol, 10 equiv). The reaction mixture was stirred at 0 °C 
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for 2 h, slowly warmed to rt over 2 h, stirred at rt for 2 d, quenched at 0 °C with H2O (1 mL), 
and diluted with Et2O (3 mL). The layers were separated and the aqueous layer extracted with 
9:1 hexanes/EtOAc (5 x 2 mL). The combined organic extracts were filtered through a silica 
gel plug (4 cm), and the filter cake rinsed with 9:1 hexanes/EtOAc (50 mL). The filtrate was 
concentrated, then azeotroped with PhH (3 x 5 mL) to afford a crude mixture of regioisomeric 
hexakistrimethylsilyl ethers 164 as a clear, colorless oil that was used without further 
purification. 
To a solution of crude trimethylsilyl ethers 164 (theoretical 0.13 g, 51 µmol, 1.0 equiv) in 4:1 
CH2Cl2/iPrOH (1.3 mL, 0.04 M wrt 164) at 0 °C was added PPTS (0.13 mg, 0.51 µmol, 0.01 
equiv). The reaction mixture was stirred at 0 °C for 2 h, quenched with Et3N (0.1 mL), stirred 
while warming to rt over 5 min, and filtered through a silica gel plug (4 cm). The filter cake 
was rinsed with 9:1 hexanes/EtOAc (50 mL), and the filtrate concentrated. Column 
chromatography (gradient elution, 3% → 3.5% → 4% EtOAc in hexanes) afforded a mixture 
of primary carbinols 57 (0.10 g, 87% yield, two steps) as a white foam. [α] D23  –7.8° (c = 2.6, 
CH2Cl2); IR (neat) 3509 (br), 2955, 1718, 1463, 1379, 1252, 1201, 1094, 1056, 978, 840, 775, 
746, 679 cm–1; partial list of resonances: 1H-NMR (600 MHz, CDCl3) δ 4.23–4.15 (m, J = 
11.2, 2.9 Hz, 2H), 4.21 (m, J = 5.9, 5.8, 5.3 Hz, 1H, C39-H), 4.18–4.15 (m, J = 11.2, 2.9 Hz, 
2H), 3.89 (m, 1H), 3.84–3.76 (m, 3H), 3.75–3.65 (m, 4H), 3.63 (dd, J = 4.7, 3.5 Hz, 1H), 
3.58–3.48 (m, 7H), 3.34 (ddd, J = 10.6, 7.0, 4.1 Hz, 1H), 2.91–2.83 (m, J = 6.5, 5.3 Hz, 2H, 
C38-H2), 2.70 (d, J = 8.3 Hz, 1H, CH-OH), 2.17–2.15 (m, 1H), 1.43 (s, 3H, one of CH3), 1.41 
(s, 3H, one of CH3), 1.38 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3), 1.35 (s, 3H, one of 
CH3), 1.34 (s, 3H, one of CH3), 1.28 (s, 3H, one of CH3), 1.21 (s, 3H, one of CH3), 1.06 (m, 
21H, –SiCH(CH3)2, 0.962 (t, J = 7.9 Hz, 9H, –SiCH2CH3), 0.958 (t, J = 7.9 Hz, 9H, –
SiCH2CH3), 0.91 (s, 9H, one of C(CH3)3), 0.89 (d, J = 7.0 Hz, 3H, one of –CH(CH3)), 0.89 (s, 
9H, one of C(CH3)3), 0.87 (d, J = 7.1 Hz, 3H, one of –CH(CH3)), 0.87 (d, J = 7.0 Hz, 3H, one 
of –CH(CH3)), 0.86 (d, 3H, one of –CH(CH3)), 0.86 (s, 9H, one of C(CH3)3), 0.85 (d, J = 7.1 
Hz, 3H, one of –CH(CH3)), 0.78 (d, J = 7.0 Hz, 3H, one of –CH(CH3)), 0.70 (d, J = 7.0 Hz, 
3H, one of –CH(CH3)), 0.70–0.58 (m, 12H, –SiCH2CH3), 0.15 (s, 9H, one of –Si(CH3)3), 0.14 
(s, 9H, one of –Si(CH3)3), 0.11 (s, 9H, one of –Si(CH3)3), 0.10 (s, 9H, one of –Si(CH3)3), 0.08 
(s, 9H, one of –Si(CH3)3); 13C-NMR (125 MHz, CDCl3) δ 211.8, 106.9, 98.5, 98.2, 97.2, 78.4, 
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78.3, 77.6, 77.3, 77.0, 76.2, 76.0, 75.1, 73.5, 73.2, 73.1, 72.5, 71.5, 70.6, 70.4, 68.1 (3C), 
67.4, 67.3, 66.8, 48.9, 46.0, 41.8 (2C), 40.2, 39.6, 39.3, 38.6, 37.9, 34.8, 33.0, 31.9, 31.83, 
31.80, 30.4, 30.1, 30.0, 29.8, 29.63, 29.59, 29.3, 28.8, 27.1, 26.1, 26.0, 25.9, 25.8, 25.2, 22.7, 
20.9, 20.2, 20.0, 19.4, 18.4, 18.34, 18.30, 18.1, 18.0, 17.7, 14.1, 12.9, 11.1, 9.5, 8.9, 6.9, 5.2, 
4.7, 1.35, 1.34, 0.95, 0.91, 0.78, –3.5 (2C), –4.0, –4.6, –4.7, –4.8; HRMS (ESI-TOF) m/z 
calcd for C119H252NaO22Si11 [M+Na]+: 2364.58752, found: 2364.59544. 
 
Dioxinones 59. To a solution of carbinols 57 (73 mg, 30 µmol, 1.0 equiv) and EtN(iPr)2 (16 
µL, 91 µmol, 3.0 equiv) in CH2Cl2 (0.43 mL, 0.07 M wrt 57) and DMSO (0.10 mL, 0.3 M wrt 
57) at –30 °C was added a solution of SO3•py (14 mg, 91 µmol, 3.0 equiv) in DMSO (0.30 
mL, 0.3 M wrt SO3•py). The reaction mixture was stirred between –30 °C and –20 °C for 1.5 
h, charged with an additional solution of SO3•py (14 mg, 91 µmol, 3.0 equiv) in DMSO (0.10 
mL, 0.9 M wrt SO3•py), stirred for an additional 3 h, quenched with brine (8 mL), then diluted 
with Et2O (40 mL) and H2O (1 mL). The layers were separated and the organic layer washed 
sequentially with 1 M aq NaHSO4 (8 mL), sat. aq NaHCO3 (8 mL), and 1:1 H2O/brine (2 x 8 
mL). The organic layer was then dried over Na2SO4 with added hexanes, filtered and 
concentrated. Benzene was added during concentration to prevent decomposition. Column 
chromatography (gradient elution, 2% → 3% EtOAc in hexanes) afforded a mixture of 
aldehydes 58 as a clear, colorless oil that was slightly wet with benzene. 
To a solution of dioxinone phosphonate 11 (27 mg, 91 µmol, 3.0 equiv) in THF (0.45 mL, 0.2 
M wrt 11) at –78 °C was added a freshly prepared solution of LDA in THF (0.18 mL, 0.5 M, 
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91 µmol, 3.0 equiv). The reaction mixture was slowly warmed to 0 °C over 1.5 h, stirred at 0 
°C for 30 min, then recooled to –78 °C and charged with HMPA (0.10 mL, 0.3 M wrt 58). 
The reaction mixture was stirred at –78 °C for 45 min, charged with a solution of aldehydes 
58 (theoretical 73 mg, 30 µmol, 1.0 equiv) in THF (0.15 mL, 0.20 M wrt 58), slowly warmed 
to 0 °C over 3 h, stirred at 0 °C for 3 h, quenched with brine (1 mL), then diluted with Et2O (3 
mL) and H2O (0.2 mL). The biphasic mixture was directly filtered through a silica gel plug (4 
cm), the filter cake rinsed with 9:1 hexanes/EtOAc (50 mL), and the filtrate concentrated. 
Column chromatography (gradient elution, 3% → 3.5% → 4% EtOAc in hexanes) afforded a 
mixture of dioxinones 59 (44 mg, 59% yield, two steps) as a white foam. [α] D22  +2.5° (c = 2.2, 
CH2Cl2); IR (neat) 3506 (br), 2956, 2877, 1736, 1639, 1597, 1462, 1378, 1252, 1202, 1096, 
1058, 1010, 978, 839, 776, 746, 678 cm–1; partial list of resonances: 1H-NMR (600 MHz, 
CDCl3) δ 6.14 (d, J = 10.0 Hz, 1H, C3-H), 5.40 (s, 1H, C3'-H), 4.21–4.15 (m, 2H), 4.20 (m, J 
= 5.9, 5.8, 5.3 Hz, 1H, C39-H), 4.12–4.06 (m, 2H), 3.92–3.87 (m, 1H), 3.86–3.75 (m, 3H), 
3.69–3.65 (m, 4H), 3.59–3.44 (m, 7H), 2.91–2.83 (m, 2H, C38-H2), 2.70 (d, J = 8.2 Hz, 1H, 
CH-OH), 2.70–2.66 (m, 1H, C4-H), 2.17–2.11 (m, 1H), 1.82 (s, 3H, C2-CH3), 1.70 (s, 6H, two 
of CH3), 1.43 (s, 3H, one of CH3), 1.41 (s, 3H, one of CH3), 1.37 (s, 3H, one of CH3), 1.36 (s, 
3H, one of CH3), 1.35 (s, 3H, one of CH3), 1.33 (s, 3H, one of CH3), 1.27 (s, 3H, one of CH3), 
1.21 (s, 3H, one of CH3), 1.05 (m, 21H, –SiCH(CH3)2, 0.99 (d, J = 6.4 Hz, 3H, –C4(CH3)), 
0.97 (d, 3H, one of –CH(CH3)), 0.96 (t, J = 7.9 Hz, 18H, –SiCH2CH3), 0.90 (s, 9H, one of 
C(CH3)3), 0.87 (d, J = 7.1 Hz, 3H, one of –CH(CH3)), 0.86 (s, 9H, one of C(CH3)3), 0.85 (s, 
9H, one of C(CH3)3), 0.84 (d, J = 7.1 Hz, 3H, one of –CH(CH3)), 0.82 (d, J = 7.1 Hz, 3H, one 
of –CH(CH3)), 0.78 (d, J = 7.1 Hz, 3H, one of –CH(CH3)), 0.69 (d, J = 6.4 Hz, 3H, one of –
CH(CH3)), 0.70–0.58 (m, 12H, –SiCH2CH3), 0.15 (s, 9H, one of –Si(CH3)3), 0.14 (s, 9H, one 
of –Si(CH3)3), 0.11 (s, 9H, one of –Si(CH3)3), 0.08 (s, 18H, two of –Si(CH3)3); 13C-NMR (125 
MHz, CDCl3) δ 211.9, 165.8, 162.4, 143.5, 125.7, 106.9, 105.9, 98.5, 98.2, 97.2, 91.4, 78.4, 
78.3, 77.6, 77.5, 77.0, 76.8, 76.1, 76.0, 75.1, 73.5, 73.1, 73.0, 72.4, 71.5, 70.6, 70.4, 68.1, 
67.4, 67.3, 66.8, 48.8, 46.0, 45.3, 40.7, 40.2, 39.6, 39.3, 38.6, 37.9, 36.6, 32.8, 31.9, 31.8, 
31.7, 30.6, 30.4, 30.1, 30.0, 29.8, 29.63, 29.59, 29.3, 28.8, 28.4, 27.6, 26.9, 26.2, 26.1, 26.0, 
25.9, 25.8, 25.7, 25.4, 25.2, 24.7, 24.6, 23.3, 22.7, 21.2, 20.3, 20.2, 20.0, 19.4, 18.4, 18.34, 
18.30, 18.2, 18.02, 18.00, 14.1, 12.9, 12.3, 11.1, 9.5, 8.9, 8.8, 6.9, 5.2, 4.7, 1.39, 1.35, 0.94, 
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0.76 (2C), –3.5 (2C), –4.1, –4.6, –4.7, –4.8; HRMS (ESI-TOF) m/z calcd for C127H264NO24Si11 
[M+NH4]+: 2495.69248, found: 2495.68105. 
 
β-Ketoamides 60. A mixture of dioxinones 59 (12 mg, 4.7 µmol, 1.0 equiv), aminium 
chloride 9•HCl (13 mg, 75 µmol, 16 equiv), and 4 Å molecular sieves (25 mg, 1:1 mass ratio 
wrt 59 + 9•HCl) was azeotroped with 1:1 CH2Cl2/PhH (3 x 1 mL) in a 0.5 dram vial. The 
reaction vessel was charged with PhMe (94 µL, 50 mM wrt 59), sealed with Teflon tape and 
parafilm, then heated to 110 °C for 7 h. The reaction mixture was cooled to rt, diluted with 
9:1 CH2Cl2/MeOH (0.5 mL), and filtered through a silica gel plug (4 cm). The filter cake was 
rinsed with 9:1 CH2Cl2/MeOH (30 mL), and the filtrate concentrated. Column 
chromatography (gradient elution, 0.5% → 0.75% → 1% EtOAc in hexanes) afforded a 
mixture of β-ketoamides 60 (8.5 mg, 69% yield) as a clear, colorless oil. These β-ketoamides 
60 existed as a complex mixture of rotamers and tautomers. partial list of resonances: 1H-
NMR (600 MHz, CDCl3) δ 6.57–6.28 (3 x d, J = 10.0 Hz, 1H, C3-H), 2.95–2.84 (3 x s, 3H, N-
CH3), 2.91–2.83 (m, 2H, C38-H2), 2.75–2.68 (m, 1H, C4-H), 2.70 (d, J = 8.2 Hz, 1H, CH-OH), 
1.82 (s, 3H, C2-CH3); 13C-NMR (125 MHz, CDCl3) δ 211.9, 195.1, 171.7, 168.0, 150.8, 135.2, 
106.9, 98.5, 98.2, 97.2. 
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Aflastatin A diethylamine salt (1•Et2NH). To a solution of β-ketoamides 60 (19 mg, 7.4 
µmol, 1.0 equiv) in 1:1 THF/TMSOH (0.37 mL, 0.02 M wrt 60) at 0 °C was added KOTMS 
(2.3 mg, 16 µmol, 2.2 equiv). The reaction mixture was stirred at 0 °C for 2.5 h, charged with 
additional KOTMS (9.5 mg, 74 µmol, 10 equiv), then stirred for an additional 45 min. The 
reaction mixture was quenched at 0 °C with AcOH (8 µL, 15 µmol, 20 equiv), warmed to rt 
and stirred for 30 min, diluted with 19:1 CH2Cl2/CH3OH (1 mL), and filtered through a silica 
gel plug (4 cm). The filter cake was rinsed with 19:1 CH2Cl2/CH3OH (30 mL), and the filtrate 
concentrated to afford a mixture of tetramic acids 61 as a pale reddish orange solid. 
To a solution of tetramic acids 61 (theoretical 19 mg, 7.4 µmol, 1.0 equiv) in 3:2 CH2Cl2/ 
CH3CN (0.5 mL, 15 mM wrt 61) at 0 °C was added dropwise a solution of fluorosilicic acid 
(H2SiF6) in H2O (~60 µL, 20–25 wt. %). The reaction mixture was diluted with CH3CN (0.4 
mL), then immediately warmed to rt and stirred for 1 d. The reaction mixture was quenched 
with TMSOMe (0.5 mL), stirred for 15 min, then filtered through Celite, and the filter cake 
rinsed with 4:1 CH2Cl2/CH3OH (100 mL total). The filtrate was concentrated, triturated with 
THF (5 x 0.3 mL), and azeotroped with 1% Et2NH in CH3OH (3 x 5 mL). Purification by 
reversed-phase HPLC (gradient elution, 65% → 80% CH3OH in H2O + 0.5% Et2NH, 20 min 
runtime) on a C18 column (Capcell Pak C18 UG, 5 µm, 120 Å, 250 mm x 10 mm) and 
lyophilization afforded the diethylamine salt of aflastatin A (1•Et2NH) (3.6 mg, 36% yield, 
two steps) as a white solid. [α] D26  –2.80° (c = 0.55, DMSO); IR (neat) 3321 (br), 2924, 2853, 
1600, 1450, 1379, 1314, 1209, 1154, 1065, 968, 843 cm–1; 1H-NMR (600 MHz, DMSO-d6) 
δ 6.13 (br s, 1H, C37-OH), 5.42 (d, J = 9.9 Hz, 1H, C3-H), 5.28 (br s, 1H, C25-OH), 5.27 (br s, 
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1H, C13-OH), 5.19 (br s, 1H, C11-OH), 5.02 (br s, 1H, C8-OH), 4.85 (br s, 1H, C39-OH), 4.80 
(br s, 1H, C15-OH), 4.79 (br s, 1H, C23-OH), 4.75 (br s, 1H, C21-OH), 4.72 (br s, 1H, C17-OH), 
4.71 (br s, 1H, C27-OH), 4.64 (br s, 1H, C34-OH), 4.62 (br s, 1H, C28-OH), 4.60 (br s, 1H, C19-
OH), 4.49 (br s, 1H, C36-OH), 4.42 (br s, 1H, C9-OH), 4.40 (br s, 1H, C35-OH), 4.17 (br s, 2H, 
C30-OH and C31-OH), 4.15 (br s, 1H, C29-OH), 3.90 (m, 1H, C17-H), 3.87 (m, 1H, C25-H), 3.86 
(m, 2H, C15-H and C39-H), 3.85 (m, 2H, C29-H and C31-H), 3.79 (m, 1H, C21-H), 3.76 (m, 1H, 
C23-H), 3.69 (m, J = 7.6 Hz, 1H, C13-H), 3.68 (m, 1H, C11-H), 3.64 (m, J = 7.6 Hz, 1H, C8-H), 
3.62 (m, J = 7.0 Hz, 2H, C27-H and C33-H), 3.56 (m, J = 7.1 Hz, 1H, C35-H), 3.44 (m, 2H, C19-
H and C30-H), 3.39 (m, 1H, C36-H), 3.26 (m, 2H, C9-H and C28-H), 3.24 (q, J = 6.4 Hz, 1H, 
C5'-H), 3.17 (dd, J = 9.4, 9.4 Hz, 1H, C34-H), 2.70 (s, 3H, C7'-H3), 2.53 (m, 1H, C4-H), 2.05 
(m, J = 10.6, 7.1 Hz, 1H, one of C32-H), 1.88 (m, 1H, C6-H), 1.83 (m, 1H, one of C26-H), 1.82 
(m, J = 12.9 Hz, 1H, one of C38-H), 1.81 (m, 1H, C10-H), 1.69 (s, 3H, C49-H3), 1.66 (m, 1H, 
C14-H), 1.65 (m, 1H, C18-H), 1.61 (m, J = 8.2, 7.6 Hz, 2H, C12-H, and one of C16-H), 1.56 (m, 
1H, one of C24-H), 1.55–1.50 (m, 3H, C20-H and C22-H2), 1.46 (m, 1H, one of C32-H), 1.41 
(dd, J = 14.1, 10.5 Hz, 1H, one of C38-H), 1.40 (m, 1H, one of C24-H), 1.33 (m, 2H, one of C5-
H, and one of C26-H), 1.30 (m, 3H, one of C16-H, and C40-H2), 1.28–1.18 (m, 14H, C41–47-H2), 
1.25 (m, 2H, C7-H2), 1.12 (d, J = 7.0 Hz, 3H, C6'-H3), 0.94 (m, 1H, one of C5-H), 0.88 (d, J = 
6.4 Hz, 3H, C50-H3), 0.85–0.83 (m, 9H, C48-H3, C52-H3, and C51-H3), 0.81 (d, J = 6.5 Hz, 3H, 
C54-H3), 0.78 (d, J = 6.4 Hz, 3H, C56-H3), 0.68 (d, J = 7.0 Hz, 3H, C55-H3), 0.64 (d, J = 6.5 Hz, 
3H, C53-H3); 13C-NMR (125 MHz, DMSO-d6) δ 193.3 (C4'), 191.8 (C1), 173.5 (C2'), 138.8 
(C3), 135.0 (C2), 98.4 (C37), 98.2 (C3'), 79.0 (C13), 76.2 (C19), 75.8 (C11), 74.9 (C9), 74.5 
(C15), 74.3 (C28), 73.5 (C21), 73.0 (C36), 72.4 (C30), 71.2 (C34), 70.7 (C35), 70.2 (C17), 
70.1 (C33), 69.7 (C27), 69.3 (C29), 68.6 (2C, C25 and C31), 67.9 (C23), 67.5 (C39), 67.2 
(C8), 59.4 (C5'), 44.7 (C5), 44.5 (C24), 42.7 (C7), 41.8 (C18, C22 or C38), 41.7 (C18, C22 or 
C38), 41.6 (C18, C22 or C38), 41.0 (C26), 38.25 (C12, C14, C20 or C40), 38.21 (C12, C14, 
C20 or C40), 38.1 (C12, C14, C20 or C40), 38.0 (C12, C14, C20 or C40), 37.1 (C10), 35.8 
(C32), 34.8 (C16), 31.3 (C46), 29.8 (C4), 29.2 (C42), 29.1 (C43 or C44), 29.0 (C43 or C44), 
28.7 (C45), 26.3 (C7'), 26.2 (C6), 24.9 (C41), 22.1 (C47), 21.4 (C50), 20.7 (C51), 15.9 (C6'), 
14.0 (C48), 13.4 (C49), 12.8 (C53), 10.5 (C55), 8.7 (C52), 6.4 (C54), 5.8 (C56); HRMS (ESI-
TOF) m/z calcd for C62H115NNaO24 [M+Na]+: 1280.77012, found: 1280.77464. 
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Stereochemical Proof by Mosher’s Ester Analysis 
Homoallylic alcohol 46 
 
3.73
3.53
3.70
3.52
+0.03
+0.01
δS (ppm) δR (ppm) Δδ = δS – δRH
C27-H2
4.02 3.96 +0.06C28-H
3.63 3.60 +0.03C29-H
3.91 3.91 0.00C30-H
4.71
4.61
4.65
4.49
+0.06
+0.12
PhCH2O
2.42
2.22
2.47
2.31
–0.05
–0.09
C32-H
5.59 5.68 –0.09C33-H
4.96
4.90
5.03
4.98
–0.07
–0.08
C34-H
4.66
4.61
4.56
4.56
+0.10
+0.05
PhCH2O
L2
L3
OBn
46
OBnTBSO
TESO 27 31
OH
0.90
0.09
0.08
0.90
0.09
0.08
0.00
0.00
0.00
TBS
0.87
0.48
0.88
0.50
–0.01
–0.02
TES
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Appendix 
1 
Spectral Data Comparisons 
 
General Key to Tables 
a Spectra of naturally derived aflastatin A (AsA) C3–C48 degradation polyol ("1a") were acquired in 
pyridine-d5 at 150 MHz (13C-NMR) or 600 MHz (1H-NMR): H. Ikeda, N. Matsumori, M. Ono, A. 
Suzuki, A. Isogai, H. Nagasawa, S. Sakuda, J. Org. Chem. 2000, 65, 438–444. 
b Spectra of synthetic aflastatin A (AsA) C3–C48 degradation polyol (1a), AsA C3–C48 degradation 
lactol methyl ethers 1b and 1c, model C27–C48 lactols 2a/2d–2h, and model C27–C48 lactol 
methyl ethers 2b and 2c were acquired in pyridine-d5 at 125 MHz (13C-NMR) or 600 MHz (1H-
NMR). 
c These values were corrected from those reported in 2000: S. Sakuda, N. Matsumori, K. Furihata, H. 
Nagasawa, Tetrahedron Lett. 2007, 48, 2527–2531. 
e Spectra of naturally derived blasticidin A (BcA) C3–C47 degradation polyol (3a) were acquired in 
pyridine-d5 at 125 MHz (13C-NMR) or 500 MHz (1H-NMR): S. Sakuda, H. Ikeda, T. Nakamura, 
R. Kawachi, T. Kondo, M. Ono, M. Sakurada, H. Inagaki, R. Ito, H. Nagasawa, J. Antibiotics 
2000, 53, 1378–1384. 
  Atoms for BcA degradation polyol 3a and BcA degradation lactol methyl ether 3b have been 
renumbered so that they correlate to AsA polyol 2. Only data for the structurally homologous 
lactol region is shown. 
g Spectra of naturally derived aflastatin A (AsA) diethylamine salt (4•Et2NH) were acquired in DMSO-
d6 at 125 MHz (13C-NMR) or 500 MHz (1H-NMR): (a) Sakuda, S.; Ono, M.; Furihata, K.; 
Nakayama, J.; Suzuki, A.; Isogai, A. J. Am. Chem. Soc. 1996, 118, 7855–7856; (b) Ono, M.; 
Sakuda, S.; Ikeda, H.; Furihata, K.; Nakayama, J.; Suzuki, A.; Isogai, A. J. Antibiotics 1998, 51, 
1019–1028. 
h Spectra of synthetic aflastatin A (AsA) diethylamine salt (4•Et2NH) were acquired in DMSO-d6 at 
125 MHz (13C-NMR) or 600 MHz (1H-NMR). 
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Table 1. Contrast Between 13C-NMR Data for Naturally Derived and Synthetic Aflastatin A 
(AsA) C3–C48 Degradation Polyols 1a.d 
 
AsA # 
 
Natural “1a”a Synthetic 1ab AsA # 
 
Natural “1a”a Synthetic 1ab 
3 
 
67.2 67.3 28 
 
76.2c 76.1 
    
29 
 
71.5 71.4 
4 
 
34.0 34.0 30 
 
75.4 74.2 
5 
 
41.6 41.6 31 
 
70.9 71.0 
    
32 
 
37.5 37.4 
6 
 
27.8 27.9 
    7 
 
42.3 42.4 33 
 
72.8 71.7 
    
34 
 
72.3 73.3 
8 
 
69.5 69.5 35 
 
72.6 72.9 
9 
 
77.9 78.0 36 
 
71.5 75.1 
10 
 
38.1 38.1 37 
 
103.2 100.1 
11 
 
78.8 78.9 38 
 
39.3 42.8 
12 
 
38.8 38.8 
    13 
 
81.6 81.6 39 
 
66.9 69.0 
14 
 
39.3 39.5 40 
 
39.3 39.6 
15 
 
77.1 77.1 
    16 
 
45.7 45.7 41 
 
26.0 25.9 
        17 
 
73.9 74.0 42 
 
29.8 29.8 
18 
 
42.7 42.7 43 
 
30.0 29.9 
19 
 
78.8 78.8 44 
 
30.0 30.1 
20 
 
39.5 39.5 45 
 
29.5 29.6 
21 
 
76.2 76.3 46 
 
32.0 32.1 
22 
 
42.7 42.7 47 
 
22.9 22.9 
    
48 
 
14.2 14.3 
23 
 
70.8 70.7 49 
 
18.6 18.7 
24 
 
36.9 37.0 50 
 
21.7 21.7 
    
51 
 
8.3 8.3 
25 
 
71.1c 71.3 52 
 
13.2 13.2 
26 
 
42.1 42.1 53 
 
6.4 6.4 
    
54 
 
11.6 11.7 
27 
 
72.2c 72.3 55 
 
6.1 6.1 
d Tabulated values in grey are |Δδ| ≥ ±1 ppm.   
O C9H19
Me Me OH
HO
Me
HO HO
Me
HO
Me Me
HO HO
Me
HO HO HO HO
OH
HO
OH
HO
H OH
HO OHOH
3 7 11 15 19 23 27 31 39
35
HO
OH
|Δδ| ≥ ±1 ppm
Aflastatin A (AsA) C3–C48 Degradation Polyol (1a)
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Table 2. Contrast Between 1H-NMR Data for Naturally Derived and Synthetic Aflastatin A 
(AsA) C3–C48 Degradation Polyols 1a.d 
 
AsA # 
 
Natural “1a”a Synthetic 1ab AsA # 
 
Natural “1a”a Synthetic 1ab 
3 
 
3.80 3.80 28 
 
4.34c 4.30 
  
3.61 3.61 29 
 
4.96 5.03 
4 
 
1.98 1.99 30 
 
4.49 4.58 
5 
 
1.78 1.77 31 
 
4.92 4.97 
  
1.04 1.05 32 
 
3.17 3.21 
6 
 
2.14 2.15 
  
2.49 2.56 
7 
 
1.84 1.83 33 
 
4.24 4.85 
  
1.75 1.74 34 
 
4.32 4.38 
8 
 
4.29 4.29 35 
 
4.56 4.76 
9 
 
4.00 4.00 36 
 
4.64 4.48 
10 
 
2.31 2.31 37 
   11 
 
4.32 4.32 38 
 
2.45 2.14 
12 
 
2.08 2.08 
  
2.19 2.73 
13 
 
4.12 4.12 39 
 
4.18 4.72 
14 
 
1.97 1.95 40 
 
1.67 1.65 
15 
 
4.49 4.48 
  
1.59 1.51 
16 
 
2.04 2.04 41 
 
1.59 1.51 
  
1.95 1.96 
  
1.48 1.35 
17 
 
4.61 4.61 42 
 
1.25 1.16 
18 
 
2.19 2.21 43 
 
1.19 1.16 
19 
 
4.05 4.06 44 
 
1.19 1.16 
20 
 
1.86 1.87 45 
 
1.19 1.16 
21 
 
4.42 4.43 46 
 
1.19 1.16 
22 
 
2.04 2.04 47 
 
1.23 1.22 
  
1.86 1.86 48 
 
0.83 0.83 
23 
 
4.49 4.48 49 
 
1.10 1.10 
24 
 
2.05 2.03 50 
 
1.07 1.06 
  
1.98 2.03 51 
 
1.28 1.27 
25 
 
4.67 4.62 52 
 
0.81 0.80 
26 
 
2.59 2.60 53 
 
1.23 1.24 
  
2.14 2.16 54 
 
0.97 0.97 
27 
 
4.67c 4.68 55 
 
1.19 1.20 
d Tabulated values in grey are |Δδ| ≥ ±0.1 ppm.  
O C9H19
Me Me OH
HO
Me
HO HO
Me
HO
Me Me
HO HO
Me
HO HO HO HO
OH
HO
OH
HO
H OH
HO OHOH
3 7 11 15 19 23 27 31 39
35
HO
OH
|Δδ| ≥ ±0.1 ppm
Aflastatin A (AsA) C3–C48 Degradation Polyol (1a)
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Table 3. Contrast Between NMR Data for Naturally Derived and Synthetic Aflastatin A 
(AsA) C3–C48 Degradation Polyols 1a, and Model C27–C48 Lactol 2a.d 
 
   13C-NMR    1H-NMR  
AsA # 
 
Natural “1a”a Synthetic 1ab Model 2ab 
 
Natural “1a”a Synthetic 1ab Model 2ab 
27  72.2c 72.3 64.6  4.67c 4.68 4.33 
28 
 
76.2c 76.1 72.9 
 
4.34c 4.30 4.61 
29 
 
71.5 71.4 73.5 
 
4.96 5.03 4.72 
30 
 
75.4 74.2 73.7 
 
4.49 4.58 4.61 
31 
 
70.9 71.0 71.6 
 
4.92 4.97 5.00 
32 
 
37.5 37.4 37.5 
 
3.17 3.21 3.22 
 
  
  
 
2.49 2.56 2.58 
33 
 
72.8 71.7 71.6 
 
4.24 4.85 4.89 
34 
 
72.3 73.3 73.8 
 
4.32 4.38 4.41 
35 
 
72.6 72.9 72.9 
 
4.56 4.76 4.79 
36 
 
71.5 75.1 75.2 
 
4.64 4.48 4.50 
37 
 
103.2 100.1 100.2 
  
  
38 
 
39.3 42.8 42.6 
 
2.45 2.14 2.15 
 
  
  
 
2.19 2.73 2.75 
39 
 
66.9 69.0 69.0 
 
4.18 4.72 4.76 
40 
 
39.3 39.6 39.6 
 
1.67 1.65 1.64 
 
  
  
 
1.59 1.51 1.53 
41 
 
26.0 25.9 25.8 
 
1.59 1.51 1.51 
 
  
  
 
1.48 1.35 1.36 
42 
 
29.8 29.8 29.8 
 
1.25 1.16 1.14 
43 
 
30.0 29.9 29.9 
 
1.19 1.16 1.14 
44 
 
30.0 30.1 30.1 
 
1.19 1.16 1.14 
45 
 
29.5 29.6 29.6 
 
1.19 1.16 1.14 
46 
 
32.0 32.1 32.1 
 
1.19 1.16 1.14 
47 
 
22.9 22.9 22.9 
 
1.23 1.22 1.21 
48 
 
14.2 14.3 14.3 
 
0.83 0.83 0.83 
d With respect to synthetic 1a, tabulated values in grey are |Δδ| ≥ ±1 ppm (13C-NMR) or |Δδ| ≥ ±0.1 
ppm (1H-NMR).  
HO
Aflastatin A (AsA) C3–C48 Degradation Polyol (1a)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
C27–C48 Model Lactol 2a
HO
OH
3127
HO 35
OH
C9H19
OH
O 39H OH
HO
OH
OH
HO
1H-NMR: |Δδ| ≥ ±0.1 ppm
13C-NMR: |Δδ| ≥ ±1 ppm
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Table 4. Contrast Between 13C-NMR Data for Naturally Derived Aflastatin A (AsA) C3–C48 
Degradation Polyol 1a, and Model C27–C48 Lactols 2a/2d–2h.d 
 
AsA # 
 
Natural “1a”a Model 2ab Model 2db Model 2eb Model 2fb Model 2gb Model 2hb 
27  72.2c 64.6 64.6 64.6 64.5 64.6 64.5 
28 
 
76.2c 72.9 74.1 73.2 73.9 74.0 73.6 
29 
 
71.5 73.5 73.3 74.0 74.2 73.5 75.8 
30 
 
75.4 73.7 74.8 73.3 73.5 74.0 73.8 
31 
 
70.9 71.6 72.4 69.9 70.6 71.6 71.5 
32 
 
37.5 37.5 37.3 38.5 35.7 37.2 37.6 
 
  
      
33 
 
72.8 71.6 72.9 71.1 69.3 67.3 70.7 
34 
 
72.3 73.8 72.9 73.0 72.1 73.1 77.1 
35 
 
72.6 72.9 73.1 76.1 72.5 74.4 73.1 
36 
 
71.5 75.2 74.2 74.0 74.3 71.8 77.8 
37 
 
103.2 100.2 100.3 100.2 100.1 100.8 99.8 
38 
 
39.3 42.6 45.3 44.8 43.8 45.7 43.8 
 
  
      
39 
 
66.9 69.0 67.6 67.9 68.2 67.8 68.3 
40 
 
39.3 39.6 39.1 39.0 39.2 38.9 39.2 
 
  
      
41 
 
26.0 25.8 26.2 26.2 25.8 26.0 25.8 
 
  
      
42 
 
29.8 29.8 29.8 29.8 29.8 29.8 29.8 
43 
 
30.0 29.9 30.0 30.0 29.9 29.9 29.9 
44 
 
30.0 30.1 30.0 30.0 30.0 30.1 30.1 
45 
 
29.5 29.6 29.6 29.6 29.5 29.6 29.5 
46 
 
32.0 32.1 32.1 32.1 32.0 32.1 32.0 
47 
 
22.9 22.9 22.9 22.9 22.9 22.9 22.9 
48 
 
14.2 14.3 14.3 14.3 14.2 14.3 14.2 
d With respect to naturally derived "1a", tabulated values in grey are |Δδ| ≥ ±1 ppm. 
  
HO
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HO 35
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C9H19
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O 39H OH
HO
OH
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HO 35
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OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
AsA Model Lactol 2a epi-C39 Lactol 2d epi-C33–C37 Lactol 2e
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Table 5. Contrast Between 1H-NMR Data for Naturally Derived Aflastatin A (AsA) C3–C48 
Degradation Polyol 1a, and Model C27–C48 Lactols 2a/2d–2h.d 
 
AsA # 
 
Natural “1a”a Model 2ab Model 2db Model 2eb Model 2fb Model 2gb Model 2hb 
27  4.67c 4.33 4.31 4.32 4.32 4.32 4.32 
28 
 
4.34c 4.61 4.54 4.55 4.59 4.59 4.58 
29 
 
4.96 4.72 4.56 4.64 4.48 4.67 4.70 
30 
 
4.49 4.61 4.43 4.91 4.68 4.52 4.58 
31 
 
4.92 5.00 4.83 4.90 4.85 4.92 4.95 
32 
 
3.17 3.22 3.07 3.11 2.96 3.09 3.21 
 
 
2.49 2.58 2.53 2.32 2.69 2.51 2.51 
33 
 
4.24 4.89 4.87 5.04 5.07 4.91 4.90 
34 
 
4.32 4.41 4.42 4.38 4.44 3.86 3.94 
35 
 
4.56 4.79 4.88 4.30 4.56 4.70 4.59 
36 
 
4.64 4.50 4.59 4.58 4.38 3.91 3.91 
37 
  
      
38 
 
2.45 2.15 2.48 2.38 2.64 2.45 2.67 
 
 
2.19 2.75 2.62 2.70 2.04 2.16 2.06 
39 
 
4.18 4.76 4.59 4.55 4.69 4.58 4.69 
40 
 
1.67 1.64 1.75 1.74 1.62 1.67 1.63 
 
 
1.59 1.53 1.60 1.60 1.48 1.54 1.50 
41 
 
1.59 1.51 1.60 1.60 1.48 1.54 1.50 
 
 
1.48 1.36 1.46 1.44 1.33 1.42 1.38 
42 
 
1.25 1.14 1.15 1.15 1.15 1.16 1.14 
43 
 
1.19 1.14 1.15 1.15 1.15 1.16 1.14 
44 
 
1.19 1.14 1.15 1.15 1.15 1.16 1.14 
45 
 
1.19 1.14 1.15 1.15 1.15 1.16 1.14 
46 
 
1.19 1.14 1.15 1.15 1.15 1.16 1.14 
47 
 
1.23 1.21 1.19 1.19 1.20 1.20 1.20 
48 
 
0.83 0.83 0.82 0.82 0.82 0.82 0.82 
d With respect to naturally derived "2", tabulated values in grey are |Δδ| ≥ ±0.1 ppm. 
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Table 6. Contrast Between NMR Data for Naturally Derived Aflastatin A (AsA) C3–C48 
Degradation Polyol 1a, and Model C27–C48 Lactol Methyl Ethers 2b and 2c.d 
 
   13C-NMR    1H-NMR  
AsA # 
 
Natural “1a”a Model 2bb Model 2cb 
 
Natural “1a”a Model 2bb Model 2cb 
27  72.2c 64.7 64.6  4.67c 4.35 4.35 
28 
 
76.2c 73.9 73.9 
 
4.34c 4.65 4.65 
29 
 
71.5 73.6 73.6 
 
4.96 4.68 4.68 
30 
 
75.4 74.3 74.3 
 
4.49 4.52 4.52 
31 
 
70.9 71.3 71.3 
 
4.92 4.94 4.94 
32 
 
37.5 37.5 37.5 
 
3.17 3.20 3.20 
 
  
  
 
2.49 2.50 2.50 
33 
 
72.8 72.8 72.8 
 
4.24 4.26 4.26 
34 
 
72.3 72.4 72.4 
 
4.32 4.33 4.33 
35 
 
72.6 72.7 72.6 
 
4.56 4.58 4.58 
36 
 
71.5 73.1 73.1 
 
4.64 4.68 4.68 
37 
 
103.2 103.3 103.3 
  
  
38 
 
39.3 39.4 39.4 
 
2.45 2.46 2.46 
 
  
  
 
2.19 2.23 2.22 
39 
 
66.9 67.0 66.9 
 
4.18 4.19 4.19 
40 
 
39.3 39.4 39.4 
 
1.67 1.68 1.68 
 
  
  
 
1.59 1.60 1.60 
41 
 
26.0 26.0 26.0 
 
1.59 1.60 1.58 
 
  
  
 
1.48 1.48 1.48 
42 
 
29.8 29.8 29.8 
 
1.25 1.23 1.23 
43 
 
30.0 30.0 30.0 
 
1.19 1.17 1.17 
44 
 
30.0 30.0 30.0 
 
1.19 1.17 1.17 
45 
 
29.5 29.5 29.5 
 
1.19 1.17 1.17 
46 
 
32.0 32.1 32.1 
 
1.19 1.17 1.17 
47 
 
22.9 22.9 22.9 
 
1.23 1.21 1.21 
48  14.2 14.2 14.2  0.83 0.82 0.82 
–OMe  n/a 47.9 n/a  n/a 3.37 n/a 
d With respect to naturally derived "2", tabulated values in grey are |Δδ| ≥ ±0.5 ppm (13C-NMR) or |Δδ| 
≥ ±0.05 ppm (1H-NMR).  
C27–C48 Model
Lactol Trideuteriomethyl
Ether 2c, R = CD3
HO
Aflastatin A (AsA) C3–C48 Degradation Polyol (1a)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
HO
OH
3127
HO 35
OH
C9H19
OH
O 39H OR
HO
OH
OH
HO
13C-NMR: |Δδ| ≥ ±0.5 ppm 1H-NMR: |Δδ| ≥ ±0.05 ppm
HO
OH
3127
HO 35
OH
C9H19
OH
O 39H OR
HO
OH
OH
HO
C27–C48 Model
Lactol Methyl Ether
2b, R = CH3
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Table 7. Comparison of 13C-NMR Data for Aflastatin A (AsA) C3–C48 Degradation Polyols 
1a and Blasticidin A (BcA) Degradation Polyol 3a.d 
 
AsA # Natural “1a”a Natural 3af Synthetic 1ab AsA # Natural “1a”a Natural 3af Synthetic 1ab 
3 67.2 
 
67.3 28 76.2c 76.1 76.1 
    
29 71.5 71.3 71.4 
4 34.0 
 
34.0 30 75.4 74.2 74.2 
5 41.6 
 
41.6 31 70.9 70.7 71.0 
    
32 37.5 37.5 37.4 
6 27.8 
 
27.9 
    7 42.3 
 
42.4 33 72.8 71.7 71.7 
    
34 72.3 73.4 73.3 
8 69.5 
 
69.5 35 72.6 72.9 72.9 
9 77.9 
 
78.0 36 71.5 75.1 75.1 
10 38.1 
 
38.1 37 103.2 100.1 100.1 
11 78.8 
 
78.9 38 39.3 42.9 42.8 
12 38.8 
 
38.8 
    13 81.6 
 
81.6 39 66.9 69.1 69.0 
14 39.3 
 
39.5 40 39.3 39.6 39.6 
15 77.1 
 
77.1 
    16 45.7 
 
45.7 41 26.0 25.9 25.9 
        17 73.9 
 
74.0 42 29.8 
 
29.8 
18 42.7 
 
42.7 43 30.0 
 
29.9 
19 78.8 
 
78.8 44 30.0 
 
30.1 
20 39.5 
 
39.5 45 29.5 
 
29.6 
21 76.2 70.8 76.3 46 32.0 
 
32.1 
22 42.7 45.7 42.7 47 22.9 
 
22.9 
    
48 14.2 
 
14.3 
23 70.8 70.7 70.7 49 18.6 
 
18.7 
24 36.9 45.7 37.0 50 21.7 
 
21.7 
    
51 8.3 
 
8.3 
25 71.1c 71.3 71.3 52 13.2 
 
13.2 
26 42.1 42.2 42.1 53 6.4 
 
6.4 
    
54 11.6 
 
11.7 
27 72.2c 72.2 72.3 55 6.1 
 
6.1 
d Tabulated values in grey are |Δδ| ≤ ±0.3 ppm.  
HO
Aflastatin A (AsA) C3–C48 Degradation Polyol (1a)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
HO
Blasticidin A (BcA) Degradation Polyol (3a)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me
HO HO HO HO HO
Me
2319 C10H21
OH
O 39H OH
HO
OH
OH
HO
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Table 8. Comparison of 1H-NMR Data for Aflastatin A (AsA) C3–C48 Degradation Polyols 
1a and Blasticidin A (BcA) Degradation Polyol 3a.d 
 
AsA # Natural “1a”a Natural 3af Synthetic 1ab AsA # Natural “1a”a Natural 3af Synthetic 1ab 
3 3.80 
 
3.80 28 4.34c 4.30 4.30 
 
3.61 
 
3.61 29 4.96 5.03 5.03 
4 1.98 
 
1.99 30 4.49 4.57 4.58 
5 1.78 
 
1.77 31 4.92 4.98 4.97 
 
1.04 
 
1.05 32 3.17 3.21 3.21 
6 2.14 
 
2.15 
 
2.49 2.55 2.56 
7 1.84 
 
1.83 33 4.24 4.85 4.85 
 
1.75 
 
1.74 34 4.32 4.39 4.38 
8 4.29 
 
4.29 35 4.56 4.76 4.76 
9 4.00 
 
4.00 36 4.64 4.48 4.48 
10 2.31 
 
2.31 37 
   11 4.32 
 
4.32 38 2.45 2.14 2.14 
12 2.08 
 
2.08 
 
2.19 2.74 2.73 
13 4.12 
 
4.12 39 4.18 4.72 4.72 
14 1.97 
 
1.95 40 1.67 1.66 1.65 
15 4.49 
 
4.48 
 
1.59 1.52 1.51 
16 2.04 
 
2.04 41 1.59 1.54 1.51 
 
1.95 
 
1.96 
 
1.48 1.54 1.35 
17 4.61 
 
4.61 42 1.25 1.18 1.16 
18 2.19 
 
2.21 43 1.19 1.18 1.16 
19 4.05 
 
4.06 44 1.19 
 
1.16 
20 1.86 
 
1.87 45 1.19 
 
1.16 
21 4.42 4.48 4.43 46 1.19 
 
1.16 
22 2.04 1.89 2.04 47 1.23 
 
1.22 
 
1.86 1.89 1.86 48 0.83 
 
0.83 
23 4.49 4.52 4.48 49 1.10 
 
1.10 
24 2.05 2.02 2.03 50 1.07 
 
1.06 
 
1.98 2.02 2.03 51 1.28 
 
1.27 
25 4.67 4.62 4.62 52 0.81 
 
0.80 
26 2.59 2.60 2.60 53 1.23 
 
1.24 
 
2.14 2.15 2.16 54 0.97 
 
0.97 
27 4.67c 4.66 4.68 55 1.19 
 
1.20 
d Tabulated values in grey are |Δδ| ≤ ±0.03 ppm.  
HO
Aflastatin A (AsA) C3–C48 Degradation Polyol (1a)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
HO
Blasticidin A (BcA) Degradation Polyol (3a)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me
HO HO HO HO HO
Me
2319 C10H21
OH
O 39H OH
HO
OH
OH
HO
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Table 9. Comparison of 13C-NMR Data for Naturally Derived Aflastatin A (AsA) C3–C48 
Degradation Polyol 1a, Blasticidin (BcA) Degradation Lactol Methyl Ether 3b, and Aflastatin 
A (AsA) C3–C48 Degradation Lactol Methyl Ethers 1b and 1c.d 
 
AsA # Natural “1a”a Natural 3be Synthetic 1bb Synthetic 1cb 
3 67.2 
 
67.3 67.2 
    
 
4 34.0 
 
34.0 34.0 
5 41.6 
 
41.6 41.6 
    
 
6 27.8 
 
27.9 27.8 
7 42.3 
 
42.4 42.3 
    
 
8 69.5 
 
69.5 69.5 
9 77.9 
 
78.0 77.9 
10 38.1 
 
38.1 38.1 
11 78.8 
 
78.9 78.8 
12 38.8 
 
38.8 38.8 
13 81.6 
 
81.6 81.6 
14 39.3 
 
39.5 39.5 
15 77.1 
 
77.1 77.1 
16 45.7 
 
45.8 45.7 
    
 
17 73.9 
 
74.0 73.9 
18 42.7 
 
42.8 42.7 
19 78.8 
 
78.9 78.7 
20 39.5 
 
39.5 39.5 
21 76.2 
 
76.3 76.2 
22 42.7 
 
42.8 42.7 
    
 
23 70.8 
 
70.9 70.8 
24 36.9 
 
37.0 36.9 
    
 
25 73.1f 71.2 71.1 71.1 
26 42.1 42.1 42.1 42.1 
    
 
27 72.2c 72.2 72.2 72.2 
28 76.2c 76.2 76.3 76.2 
HO
Aflastatin A (AsA) C3–C48 Degradation Polyols
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OR
HO
OH
OH
HO
Blasticidin A (BcA) Degradation Lactol Methyl Ether (3b)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me
HO HO HO HO HO
Me
2319 C10H21
OH
O 39H OMe
HO
OH
OH
HO
Lactol 1a,
Lactol Methyl Ether 1b,
Lactol Trideuteriomethyl Ether 1c,
R = H
R = Me
R = CD3
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Table 9 (Continued). Comparison of 13C-NMR Data for Naturally Derived Aflastatin A 
(AsA) C3–C48 Degradation Polyol 1a, Blasticidin (BcA) Degradation Lactol Methyl Ether 
3b, and Aflastatin A (AsA) C3–C48 Degradation Lactol Methyl Ethers 1b and 1c.d 
 
AsA # Natural “1a”a Natural 3be Synthetic 1bb Synthetic 1cb 
29 71.5 71.5 71.5 71.5 
30 75.4 75.4 75.5 75.4 
31 70.9 70.8 70.9 70.9 
32 37.5 37.6 37.6 37.5 
     
33 72.8 72.8 72.8 72.7 
34 72.3 72.4 72.4 72.3 
35 72.6 72.6 72.6 72.6 
36 71.5f 73.1 73.1 73.0 
37 103.2 103.3 103.3 103.2 
38 39.3 39.4 39.4 39.3 
     
39 66.9 66.9 66.9 66.9 
40 39.3 39.4 39.4 39.3 
     
41 26.0  26.0 26.0 
     
42 29.8  29.8 29.8 
43 30.0  30.0 29.9 
44 30.0  30.0 30.0 
45 29.5  29.5 29.5 
46 32.0  32.1 32.0 
47 22.9  22.9 22.9 
48 14.2  14.3 14.2 
49 18.6  18.7 18.6 
50 21.7  21.7 21.6 
51 8.3  8.3 8.3 
52 13.2  13.2 13.2 
53 6.4  6.4 6.4 
54 11.6  11.7 11.6 
55 6.1  6.1 6.1 
56 n/a 47.8 47.8 n/a 
 
d All tabulated values (except those shaded in grey) are |Δδ| ≤ ±0.2 ppm. 
f Values shaded in grey correspond to those originally reported in 2000. In 2007, the chemical shift of 
C25 was revised from 73.1 ppm to 71.1 ppm. However, we believe the chemical shift of 71.5 ppm 
originally reported for C36 should instead be revised to 71.1 ppm. Then, the data for these two 
atoms should be switched. We noted a similar switch of NMR data for C27 and C28 in the 2007 
paper (see note c).  
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Table 10. Comparison of 1H-NMR Data for Naturally Derived Aflastatin A (AsA) C3–C48 
Degradation Polyol 1a, Blasticidin (BcA) Degradation Lactol Methyl Ether 3b, and Aflastatin 
A (AsA) C3–C48 Degradation Lactol Methyl Ethers 1b and 1c.d 
 
AsA # Natural “1a”a Natural 3be Synthetic 1bb Synthetic 1cb 
3 3.80 
 
3.80 3.79 
 
3.61 
 
3.61 3.60 
4 1.98 
 
1.98 1.98 
5 1.78 
 
1.77 1.76 
 
1.04 
 
1.04 1.04 
6 2.14 
 
2.15 2.14 
7 1.84 
 
1.83 1.83 
 
1.75 
 
1.75 1.74 
8 4.29 
 
4.28 4.28 
9 4.00 
 
4.00 4.00 
10 2.31 
 
2.30 2.30 
11 4.32 
 
4.31 4.31 
12 2.08 
 
2.08 2.08 
13 4.12 
 
4.12 4.11 
14 1.97 
 
1.96 1.96 
15 4.49 
 
4.50 4.49 
16 2.04 
 
2.04 2.03 
 
1.95 
 
1.96 1.96 
17 4.61 
 
4.62 4.62 
18 2.19 
 
2.21 2.21 
19 4.05 
 
4.05 4.05 
20 1.86 
 
1.87 1.87 
21 4.42 
 
4.42 4.42 
22 2.04 
 
2.04 2.03 
 
1.86 
 
1.85 1.85 
23 4.49 
 
4.50 4.49 
24 2.05 
 
2.04 2.03 
 
1.98 
 
1.98 1.98 
25 4.67f 4.63 4.64 4.64 
26 2.59 2.16 2.60 2.59 
 
2.14 2.16 2.17 2.16 
27 4.67c 4.68 4.67 4.67 
28 4.34c 4.33 4.34 4.34 
HO
Aflastatin A (AsA) C3–C48 Degradation Polyols
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OR
HO
OH
OH
HO
Blasticidin A (BcA) Degradation Lactol Methyl Ether (3b)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me
HO HO HO HO HO
Me
2319 C10H21
OH
O 39H OMe
HO
OH
OH
HO
Lactol 1a,
Lactol Methyl Ether 1b,
Lactol Trideuteriomethyl Ether 1c,
R = H
R = Me
R = CD3
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Table 10 (Continued). Comparison of 1H-NMR Data for Naturally Derived Aflastatin A 
(AsA) C3–C48 Degradation Polyol 1a, Blasticidin (BcA) Degradation Lactol Methyl Ether 
3b, and Aflastatin A (AsA) C3–C48 Degradation Lactol Methyl Ethers 1b and 1c.d 
 
AsA # Natural “1a”a Natural 3be Synthetic 1bb Synthetic 1cb 
29 4.96 4.97 4.96 4.97 
30 4.49 4.50 4.50 4.49 
31 4.92 4.93 4.93 4.92 
32 3.17 3.18 3.17 3.17 
 2.49 2.49 2.49 2.49 
33 4.24 4.21 4.23 4.23 
34 4.32 4.31 4.32 4.31 
35 4.56 4.56 4.56 4.57 
36 4.64f 4.66 4.67 4.67 
37     
38 2.45 2.44 2.45 2.44 
 2.19 2.22 2.20 2.20 
39 4.18 4.18 4.19 4.18 
40 1.67 1.68 1.67 1.67 
 1.59 1.58 1.59 1.58 
41 1.59  1.59 1.60 
 1.48  1.47 1.47 
42 1.25  1.24 1.24 
43 1.19  1.19 1.18 
44 1.19  1.19 1.18 
45 1.19  1.19 1.18 
46 1.19  1.19 1.18 
47 1.23  1.22 1.22 
48 0.83  0.83 0.83 
49 1.10  1.10 1.10 
50 1.07  1.06 1.06 
51 1.28  1.28 1.28 
52 0.81  0.80 0.80 
53 1.23  1.24 1.23 
54 0.97  0.97 0.97 
55 1.19  1.19 1.19 
56 n/a 3.35 3.35 n/a 
 
d All tabulated values are |Δδ| ≤ ±0.03 ppm. 
f As with the 13C-NMR data (see Table S9), we believe that the resonances assigned to H25 and H36 
(shaded in grey) should be switched. We noted a similar switch of NMR data for H27 and H28 in 
the 2007 paper (see note c). 
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Table 11. Comparison of 13C-NMR Data for Naturally Derived and Synthetic Aflastatin A 
(AsA) Diethylamine Salt 4•Et2NH. 
 
AsA # 
 
Nat. 4•Et2NHg Syn. 4•Et2NHh AsA # 
 
Nat. 4•Et2NHg Syn. 4•Et2NHh 
1  191.5 191.8 29-OH    
2  135.2 135.0 30  72.5 72.4 
3 
 
139.3 138.8 30-OH    
4 
 
29.9 29.8 31  68.6 68.6 
5  44.8 44.7 31-OH    
6  26.1 26.2 32  35.8 35.8 
7  42.8 42.7 33  70.2 70.1 
8  67.2 67.2 34  71.2 71.2 
8-OH    34-OH    
9  75.0 74.9 35  70.7 70.7 
9-OH    35-OH    
10  37.1 37.1 36  73.0 73.0 
11  75.8 75.8 36-OH    
11-OH    37  98.4 98.4 
12  38.1 38.0 37-OH    
13  78.9 79.0 38  41.6 41.8 
13-OH    39  67.5 67.5 
14  38.1 38.1 39-OH    
15  74.5 74.5 40  38.1 38.2 
15-OH    41  24.9 24.9 
16  34.9 34.8 42  29.2 29.2 
17  70.4 70.2 43  29.0 29.0 
17-OH    44  29.0 29.1 
18  41.6 41.7 45  28.7 28.7 
19  76.2 76.2 46  31.3 31.3 
19-OH    47  22.1 22.1 
20  38.1 38.2 48  13.9 14.0 
21  73.5 73.5 49  13.3 13.4 
21-OH    50  21.5 21.4 
22  41.6 41.6 51  20.8 20.7 
23  67.9 67.9 52  8.7 8.7 
23-OH    53  12.8 12.8 
24  44.5 44.5 54  6.4 6.4 
25  68.6 68.6 55  10.6 10.5 
25-OH    56  5.8 5.8 
26  41.0 41.0 2'  173.4 173.5 
27  69.7 69.7 3'  98.1 98.2 
27-OH    4'  192.6 193.3 
28  74.3 74.3 5'  59.4 59.4 
28-OH    6'  15.9 15.9 
29  69.4 69.3 7'  26.3 26.3 
HO
OH
HO
C9H1939
OH
OH
HO
Me Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
7
3
11 15 2319
Me
O
NMe
O
O
Me
2' O
HO
H OH
OH
OH
35
27 31
Et2NH2
Aflastatin A (AsA) Diethylamine Salt (4•Et2NH)
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Table 12. Comparison of 1H-NMR Data for Naturally Derived and Synthetic Aflastatin A 
(AsA) Diethylamine Salt 4•Et2NH. 
 
AsA # 
 
Nat. 4•Et2NHg Syn. 4•Et2NHh AsA # 
 
Nat. 4•Et2NHg Syn. 4•Et2NHh 
1    29-OH  4.12 4.15 
2    30  3.45 3.44 
3 
 
5.45 5.42 30-OH  4.17 4.17 
4 
 
2.54 2.53 31  3.83 3.85 
5  1.34, 0.93 1.33, 0.94 31-OH  4.12 4.17 
6  1.90 1.88 32  2.06, 1.48 2.05, 1.46 
7  1.26 1.25 33  3.62 3.62 
8  3.64 3.64 34  3.18 3.17 
8-OH  n/a 5.02 34-OH  n/a 4.64 
9  3.26 3.26 35  3.56 3.56 
9-OH  n/a 4.42 35-OH  n/a 4.40 
10  1.81 1.81 36  3.41 3.39 
11  3.71 3.68 36-OH  4.45 4.49 
11-OH  5.20 5.19 37    
12  1.62 1.61 37-OH  6.11 6.13 
13  3.67 3.69 38  1.82, 1.42 1.82, 1.41 
13-OH  5.26 5.27 39  3.89 3.86 
14  1.67 1.66 39-OH  4.75 4.85 
15  3.85 3.86 40  1.30 1.30 
15-OH  4.79 4.80 41  1.23 1.23 
16  1.60, 1.30 1.61, 1.30 42  1.23 1.23 
17  3.91 3.90 43  1.23 1.23 
17-OH  4.71 4.72 44  1.23 1.23 
18  1.65 1.65 45  1.23 1.23 
19  3.46 3.44 46  1.23 1.23 
19-OH  4.57 4.60 47  1.23 1.23 
20  1.53 1.53 48  0.84 0.84 
21  3.81 3.79 49  1.67 1.69 
21-OH  4.76 4.75 50  0.88 0.88 
22  1.53 1.53 51  0.85 0.85 
23  3.79 3.76 52  0.84 0.84 
23-OH  4.73 4.79 53  0.64 0.64 
24  1.55, 1.39 1.56, 1.40 54  0.81 0.81 
25  3.87 3.87 55  0.68 0.68 
25-OH  5.24 5.28 56  0.79 0.78 
26  1.85, 1.35 1.83, 1.33 2'    
27  3.63 3.62 3'    
27-OH  4.66 4.71 4'    
28  3.25 3.26 5'  3.20 3.24 
28-OH  4.59 4.62 6'  1.11 1.12 
29  3.82 3.85 7'  2.68 2.70 
HO
OH
HO
C9H1939
OH
OH
HO
Me Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
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3
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Appendix 
2 
1H- and 13C-NMR Spectra  
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Chapter 3 
Compound 78. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OI
H OMe
OBn
BnO OH
2731
78 (600 MHz, CDCl3)
78 (125 MHz, CDCl3)
OI
H OMe
OBn
BnO OH
2731
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Compound 79. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
OBnOH
HO 27
31
79 (600 MHz, C6D6)
79 (125 MHz, C6D6)
OBn
OBnOH
HO 27
31
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Compound 63. 
 
 
 
 
  
ppm0 01122334455667788
ppm0 05050100100150150200200
OBn
OBn
31
O
O
27
Me Me
63 (600 MHz, CDCl3)
OBn
OBn
31
O
O
27
Me Me
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Compound 80. 
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OBn
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O
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Me Me
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O
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H
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O
27
Me Me
80 (125 MHz, C6D6)
O
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Compound 64. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
OBn
31O
O
27
Me Me
OH
33a
64 (600 MHz, CDCl3)
OBn
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O
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Me Me
OH
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64 (125 MHz, CDCl3)
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Compound 81. 
 
 
 
 
  
ppm0 011223344556677889
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OBn
OBn
31O
O
27
Me Me
O
O
33a
34a
81 (600 MHz, CDCl3)
OBn
OBn
31O
O
27
Me Me
O
O
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34a
81 (125 MHz, CDCl3)
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Compound 65. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
OBn
31O
O
27
Me Me
O
O
35
65 (600 MHz, CDCl3)
OBn
OBn
31O
O
27
Me Me
O
O
35
65 (125 MHz, CDCl3)
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Compound 82. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
OBn
31O
O
27
Me Me
O
O
35
OH
OH
82 (600 MHz, CDCl3)
OBn
OBn
31O
O
27
Me Me
O
O
35
OH
OH
82 (125 MHz, CDCl3)
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Compound 66. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
OBn
31O
O
27
Me Me
O
O
35
O
O
Me
Me
66 (600 MHz, CDCl3)
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O
27
Me Me
O
O
35
O
O
Me
Me
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Compound 83. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
BnO
31O
O
27
Me Me
OH O
O
OH35
Me
Me
83 (600 MHz, C6D6)
OBn
BnO
31O
O
27
Me Me
OH O
O
OH35
Me
Me
83 (125 MHz, C6D6)
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Compound 84. 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
BnO
31O
O
27
Me Me
OH O
O
OTBDPS35
Me
Me
84 (600 MHz, CDCl3)
OBn
BnO
31O
O
27
Me Me
OH O
O
OTBDPS35
Me
Me
84 (125 MHz, CDCl3)
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Compound 61. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
61 (600 MHz, C6D6)
BnO
31O
O
27
Me Me
OBn O
O
OTBDPS35
Me
Me
OBn
61 (125 MHz, C6D6)
BnO
31O
O
27
Me Me
OBn O
O
OTBDPS35
Me
Me
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Compound 85. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
85 (600 MHz, CDCl3)
BnO
31O
O
27
Me Me
OBn O
O
OH35
Me
Me
OBn
85 (125 MHz, CDCl3)
BnO
31O
O
27
Me Me
OBn O
O
OH35
Me
Me
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Compound 67. 	  
	  	  
	  	   	  
ppm0 01122334455667788991010
ppm0 05050100100150150200200
OBn
67 (600 MHz, CDCl3)
BnO
31O
O
27
Me Me
OBn O
O
H35
Me
Me
O
OBn
67 (125 MHz, CDCl3)
BnO
31O
O
27
Me Me
OBn O
O
H35
Me
Me
O
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Compound 68. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
68 (600 MHz, CDCl3)
BnO
31O
O
27
Me Me
OBn O
O
35
Me
Me
OH O
C9H1939
OTBS
OTES
OBn
68 (125 MHz, CDCl3)
BnO
31O
O
27
Me Me
OBn O
O
35
Me
Me
OH O
C9H1939
OTBS
OTES
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Compound 69. 
 	  
	  	  
	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
69 (600 MHz, C6D6)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESHO
HO
TES
OBn
69 (125 MHz, C6D6)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESHO
HO
TES
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Compound 86. 
 
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
86 (600 MHz, C6D6)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESHO
AcO
TES
OBn
86 (125 MHz, C6D6)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESHO
AcO
TES
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Compound 70. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
70 (600 MHz, CDCl3)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
AcO
TES
OBn
70 (100 MHz, CDCl3)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
AcO
TES
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Compound 87. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
87 (600 MHz, CDCl3)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
HO
TES
OBn
87 (125 MHz, CDCl3)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
HO
TES
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Compound 71. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
71 (600 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
H
TES
O
OBn
71 (125 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
H
TES
O
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Compound 73. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
73 (600 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OH
Me
BnO
Me
OH
O
OBn
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
TIPS
TBS
73 11 15 2319
OBn
73 (125 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OH
Me
BnO
Me
OH
O
OBn
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
TIPS
TBS
73 11 15 2319
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Compound 74. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
BnO
74 (600 MHz, CD3OD)
OBn
3127
BnO 35
OH
HO
Me
BnO
Me
HO
OH
BnO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
BnO
74 (125 MHz, CD3OD)
OBn
3127
BnO 35
OH
HO
Me
BnO
Me
HO
OH
BnO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
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Compound 1.	  	  
	  	  
	  	   	  
ppm0 0112233445566778899
ppm0 05050100100150150200200
    X 
PhH MeCN 
  H2O 
    X 
HO
1 (600 MHz, C5D5N)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
HO
1 (125 MHz, C5D5N)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OH
HO
OH
OH
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Compound 89.	  	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
BnO
89 (600 MHz, CD3OD)
OBn
3127
BnO 35
OH
HO
Me
BnO
Me
HO
OH
BnO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OMe
HO
OH
OH
BnO
89 (125 MHz, CD3OD)
OBn
3127
BnO 35
OH
HO
Me
BnO
Me
HO
OH
BnO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OMe
HO
OH
OH
	   231 
Compound 46a.	  	  
	  	  
	  	   	  
ppm0 0112233445566778899
ppm0 05050100100150150200200
  PhH 
      PhH 
        H2O 
HO
46a (600 MHz, C5D5N)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OMe
HO
OH
OH
HO
46a (125 MHz, C5D5N)
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OMe
HO
OH
OH
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Compound 46b.	  	  
	  	  
	  	   	  
ppm0 0112233445566778899
ppm0 05050100100150150200200
    X 
  H2O 
HO
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OCD3
HO
OH
OH
46b (600 MHz, C5D5N)
HO
OH
3127
HO 35
OH
HO
Me
HO
Me
HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
73 11 15 2319 C9H19
OH
O 39H OCD3
HO
OH
OH
46b (125 MHz, C5D5N)
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Comparison of the 1H-NMR Spectrum Reported for 1a to Our Spectra for 46ab and 46b. 
Sakuda "1" (600 MHz, C5D5N) 
 
Evans 46a (600 MHz, C5D5N) 
 
Evans 46b (600 MHz, C5D5N) 
 
a Reproduced from: H. Ikeda, N. Matsumori, M. Ono, A. Suzuki, A. Isogai, H. Nagasawa, S. Sakuda, 
J. Org. Chem. 2000, 65, 438–444. 
b Arrow (→) points at resonance corresponding to the methyl group (C56-H3) of lactol methyl ether 
46a. 
ppm1 1223344556677889
ppm1 1223344556677889
PhH 
H2O 
H2O 
→ 
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Comparison of the 13C-NMR Spectrum Reported for 1a to Our Spectra for 46ab and 46b. 
Sakuda "1" (150 MHz, C5D5N) 
 
Evans 46a (125 MHz, C5D5N) 
 
Evans 46b (125 MHz, C5D5N) 
 
a Reproduced from: H. Ikeda, N. Matsumori, M. Ono, A. Suzuki, A. Isogai, H. Nagasawa, S. Sakuda, 
J. Org. Chem. 2000, 65, 438–444. 
b Arrow (→) points at resonance corresponding to the methyl group (C-56) of lactol methyl ether 46a. 
ppm0 05050100100150
ppm0 05050100100150
PhH 
   X 
→ 
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Chapter 4 
Compound 38•Et2NH. 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
Me
O
NMe
O
O
Me
3
Me Me
7 OH
38•Et2NH (600 MHz, CD3OD)
5'
2'
Et2NH2
Me
O
NMe
O
O
Me
3
Me Me
7 OH
38•Et2NH (125 MHz, CD3OD)
5'
2'
Et2NH2
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Compound 127. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OI
H OMe
OBn
BnO OH
2731
127 (600 MHz, CDCl3)
127 (125 MHz, CDCl3)
OI
H OMe
OBn
BnO OH
2731
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Compound 43. 
 
 
 
 
  
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OI
H OMe
OBn
BnO OTBS
2731
43 (600 MHz, C6D6)
43 (125 MHz, C6D6)
OI
H OMe
OBn
BnO OTBS
2731
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Compound 44. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
BnOTBSO
HO 27
31
44 (600 MHz, CDCl3)
44 (125 MHz, CDCl3)
OBn
BnOTBSO
HO 27
31
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Compound 128. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
BnOTBSO
TESO 27
31
128 (600 MHz, CDCl3)
128 (125 MHz, CDCl3)
OBn
BnOTBSO
TESO 27
31
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Compound 45. 
 
 
 
 
 
  
ppm0 01122334455667788991010
ppm0 05050100100150150200200
OBn
45 (600 MHz, CDCl3)
H
BnOTBSO
TESO 27 31
O
OBn
45 (125 MHz, CDCl3)
H
BnOTBSO
TESO 27 31
O
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Compound 46. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
46 (600 MHz, C6D6)
BnOTBSO
TESO 27 31
OH
OBn
46 (125 MHz, C6D6)
BnOTBSO
TESO 27 31
OH
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Compound 132. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
132 (600 MHz, CDCl3)
BnOTBSO
TESO 27 31
O
O
OBn
132 (125 MHz, CDCl3)
BnOTBSO
TESO 27 31
O
O
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Compound 47. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
47 (600 MHz, CDCl3)
BnOTBSO
TESO 27 31
O
O
35
OBn
47 (125 MHz, CDCl3)
BnOTBSO
TESO 27 31
O
O
35
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Compound 48. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
48 (600 MHz, CDCl3)
BnOTBSO
TESO 27 31
O
O
35 OH
OH
OBn
48 (125 MHz, CDCl3)
BnOTBSO
TESO 27 31
O
O
35 OH
OH
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Compound 49. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
49 (600 MHz, CDCl3)
BnOTBSO
MOPO 27 31
O
O
35
O
O
Me
Me
OBn
49 (125 MHz, CDCl3)
BnOTBSO
MOPO 27 31
O
O
35
O
O
Me
Me
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Compound 50. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
50 (600 MHz, CDCl3)
BnO
31
OH O
O
OH35
Me
MeTBSO
MOPO 27
OBn
50 (125 MHz, CDCl3)
BnO
31
OH O
O
OH35
Me
MeTBSO
MOPO 27
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Compound 133. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
133 (600 MHz, C6D6)
BnO
31
OH O
O
OTBDPS35
Me
MeTBSO
MOPO 27
OBn
133 (125 MHz, C6D6)
BnO
31
OH O
O
OTBDPS35
Me
MeTBSO
MOPO 27
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Compound 51. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
51 (600 MHz, C6D6)
BnO
31
OBn O
O
OTBDPS35
Me
MeTBSO
MOPO 27
OBn
51 (125 MHz, C6D6)
BnO
31
OBn O
O
OTBDPS35
Me
MeTBSO
MOPO 27
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Compound 134. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
134 (600 MHz, CDCl3)
BnO
31
OBn O
O
OH35
Me
MeTBSO
MOPO 27
OBn
134 (125 MHz, CDCl3)
BnO
31
OBn O
O
OH35
Me
MeTBSO
MOPO 27
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Compound 52. 
 
 
 
 
 
  
ppm0 011223344556677889910
ppm0 05050100100150150200200
OBn
52 (600 MHz, CDCl3)
BnO
31
OBn O
O
H35
Me
MeTBSO
MOPO 27
O
OBn
52 (125 MHz, CDCl3)
BnO
31
OBn O
O
H35
Me
MeTBSO
MOPO 27
O
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Compound 54. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
54 (600 MHz, C6D6)
BnO
31
OBn O
O
35
Me
MeTBSO
MOPO 27
OH O
C9H19
OTBS
OTES
39
OBn
54 (125 MHz, C6D6)
BnO
31
OBn O
O
35
Me
MeTBSO
MOPO 27
OH O
C9H19
OTBS
OTES
39
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Compound 135. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
135 (600 MHz, CDCl3)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
HO
TES
OBn
135 (125 MHz, CDCl3)
BnO
31
27
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
HO
TES
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Compound 41. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
41 (600 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
H
TES
O
OBn
41 (125 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
H
TES
O
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Compound 55. 	  
	  	  
	  	   	  
ppm0 011223344556677889
ppm0 05050100100150150200200
OBn
55 (600 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OH
Me
BnO
Me
OH
O
OBn
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
TIPS
TBS
73 11 15 2319
OBn
55 (125 MHz, CDCl3)
BnO
3127
OBn O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OH
Me
BnO
Me
OH
O
OBn
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
TIPS
TBS
73 11 15 2319
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Compound 56. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OH
56 (500 MHz, CDCl3)
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OH O
O
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Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OH
Me
HO
Me
OH
O
OH
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
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TBS
73 11 15 2319
OH
56 (125 MHz, CDCl3)
HO
3127
OH O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OH
Me
HO
Me
OH
O
OH
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
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TBS
73 11 15 2319
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Compound 57. 
 
 
 
 
 
  
ppm0 011223344556677889
ppm0 05050100100150150200200
OH
57, R = TMS
(600 MHz, CDCl3)
RO
3127
OR O
O
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Me
Me
O O
C9H1939
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OTESTBSO
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OR
Me
HO
Me
OR
O
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Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
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TBS
73 11 15 2319
OH
57, R = TMS
(125 MHz, CDCl3)
RO
3127
OR O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OR
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HO
Me
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O
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Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
TIPS
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73 11 15 2319
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Compound 59. 
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ppm0 05050100100150150200200
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O O
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OR
O
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O O O O O O O
MeMe MeMe MeMe
Me Me
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TBS
7
3
11 15 2319
Me
OO
O
MeMe
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2'
59, R = TMS
(600 MHz, CDCl3)
OH
RO
3127
OR O
O
35
Me
Me
O O
C9H1939
OTBS
OTESTBSO
TES
OR
Me Me
OR
O
OR
Me Me Me
O O O O O O O
MeMe MeMe MeMe
Me Me
TIPS
TBS
7
3
11 15 2319
Me
OO
O
MeMe
3'
2'
59, R = TMS
(125 MHz, CDCl3)
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Compound 60. 
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ppm0 05050100100150150200200
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O O
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OR
Me Me
OR
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OR
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O O O O O O O
MeMe MeMe MeMe
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7
3
11 15 2319
Me
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N
Me
Me
O
EtO 2'4'
60, R = TMS (600 MHz, CDCl3)
OH
RO
3127
OR O
O
35
Me
Me
O O
C9H1939
OTBS
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Me Me
OR
O
OR
Me Me Me
O O O O O O O
MeMe MeMe MeMe
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7
3
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N
Me
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O
EtO 2'4'
60, R = TMS (125 MHz, CDCl3)
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Compound 1•Et2NH. 
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3
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OH
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HO
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OH
OH
HO
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HO
OH
HO
Me Me Me
HO HO HO HO HO HO HO
Me Me
7
3
11 15 2319
Me
O
NMe
O
O
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2' O
HO
H OH
OH
OH
35
1•Et2NH (125 MHz, DMSO-d6)
Et2NH2
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Comparison of the 1H-NMR Spectrum Reported for 1•Et2NHa to Our Spectrum. 
Sakuda 1•Et2NH (500 MHz, DMSO-d6) 
 
Evans 1•Et2NH (500 MHz, DMSO-d6) 
 
 
a Reproduced from: (a) Ono, M.; Sakuda, S.; Suzuki, A.; Isogai, A. J. Antibiotics 1997, 50, 111–118; 
(b) Ono, M.; Suzuki, A.; Isogai, A.; Sakuda, S. Production Aflastatin A from Streptomyces sp., A 
Pharmaceutical Composition and Methods of Use. U.S. Patent 5,773,263, June 30, 1998. 
ppm0.5 0.51.01.01.51.52.02.02.52.53.03.03.53.54.04.04.54.55.05.05.55.56.06.06.56.57.0
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Comparison of the 13C-NMR Spectrum Reported for 1•Et2NHa to Our Spectrum. 
Sakuda 1•Et2NH (125 MHz, DMSO-d6) 
 
Evans 1•Et2NH (125 MHz, DMSO-d6) 
 
 
a Reproduced from: (a) Ono, M.; Sakuda, S.; Suzuki, A.; Isogai, A. J. Antibiotics 1997, 50, 111–118; 
(b) Ono, M.; Suzuki, A.; Isogai, A.; Sakuda, S. Production Aflastatin A from Streptomyces sp., A 
Pharmaceutical Composition and Methods of Use. U.S. Patent 5,773,263, June 30, 1998. 
  
ppm0 05050100100150150200200
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Comparison of the IR Spectrum Reported for 1•Et2NHa to Our Spectrum. 
Sakuda 1•Et2NH (KBr) 
 
Evans 1•Et2NH (NaCl) 
 
 
a Reproduced from: (a) Ono, M.; Sakuda, S.; Suzuki, A.; Isogai, A. J. Antibiotics 1997, 50, 111–118; 
(b) Ono, M.; Suzuki, A.; Isogai, A.; Sakuda, S. Production Aflastatin A from Streptomyces sp., A 
Pharmaceutical Composition and Methods of Use. U.S. Patent 5,773,263, June 30, 1998. 
